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INTRODUCTION
Colorectal cancer (CRC) is the third most common type of cancer worldwide, and the 2nd 
most lethal of all cancers [1]. Approximately 1.2 million new cases are diagnosed each year 
and more than 600,000 annual deaths are estimated to occur worldwide [1]. Around 50% 
of patients with CRC present with localized disease (stage I-II), about 25% with locoregional 
advanced-stage disease (stage III), and the remainder with metastases in distant organs (stage 
IV) [2-4]. Approximately 30% of patients with stage I-III disease develop recurrent disease 
after initial treatment [5, 6]; among patients with stage IV CRC, up to 65% have relapsed 
disease after treatment with curative intent [7-13]. Thirty years ago, stage IV colorectal 
cancers were answered with nihilism in terms of curative treatment options [14]. Today, 
indications for local, curative treatment are ever expanding. Liver resection is considered 
to be the optimal treatment for isolated colorectal liver metastases (CRLM) with 5-year 
survival rates up to 60% in selected patients [15, 16]. Until recently, only 10-20% of patients 
were considered suitable for attempted curative resection [15, 17]. Due to improvements in 
surgical technique, the acceptance of smaller resection margins, the introduction of more 
effective systemic chemotherapy, the use of portal vein embolization (VPE), radio frequency 
ablation (RFA) and stereotactic body radiation (STBR) more patients become eligible for 
liver surgery. Importantly, not all patients with colorectal liver metastases benefit as much 
from surgery and/or systemic therapies, which emphasizes the need for “tailored” treatment 
strategies.
Traditionally, a tailor is a person who makes, repairs, or alters clothing, professionally. 
The term “tailor” took on its modern sense in the 18th century [18]. “Tailoring” classically 
referred to a set of specific hand and machine sewing and pressing techniques that are 
unique to the construction of clothing. The term evolved, in the United Kingdom traditional 
tailoring is called “bespoke tailoring” [18]. The term “bespoke” in fashion is reserved for 
individually patterned clothing, in contrast with mass-manufactured “ready-to-wear”. With 
the multifaceted clinical and molecular characteristics of colorectal cancer, the emergence 
of “individualized” or “tailored” therapies became apparent the past decade. “One-size fits 
nobody” may be as true in fashion as it is in cancer treatment.
This thesis describes studies aimed at optimizing and thus tailor treatment strategies for the 
individual patient with colorectal liver metastases. Aims were to:
 - Conduct a multicenter randomized controlled trial to assess the effect of neo-adjuvant  
  chemotherapy in high-risk resectable patients;
 - Evaluate and improve logistics of multicenter randomized trials in the Netherlands in general;
 - Identify and evaluate new biomarkers in order to improve patient selection for various  
  treatment modalities (prognostic/predictive markers);
 - Optimize patient referral for surgery and assessment of resectability for patients with CRLM;
 - Assess and improve the value of surveillance after curative treatment for colorectal cancer;
PART i | Introduction
11
PART I: MULTICENTER CLINICAL TRIALS ON COLORECTAL LIVER METASTASES IN THE 
NETHERLANDS
In patients with primarily resectable colorectal liver metastases, administration of systemic 
therapies is not standard of care in the Netherlands due to limited evidence supporting such 
a strategy. Until today it remains unknown whether chemotherapy in these patients impact 
overall survival. In 2013, the EORTC 40983 randomized trial (EPOC trial) published its mature 
results, which showed that 12 courses of perioperative chemotherapy only impact disease-
free survival and not overall survival after resection of CRLM [19, 20]. Due to strict inclusion 
criteria this landmark study mainly included patients with a relatively low oncological risk 
profile. Consequently, patients with a high-risk profile who might benefit the most from 
chemotherapy may be underrepresented in these studies. Oncological risk is captured in 
various clinical risk scores, generally expressing tumor load. The CRS according to Fong 
et al. is the most widely used and validated score, able to distinguish between high- and 
low-risk patients in terms of survival outcomes [21, 22]. Chapter 1 describes the protocol 
and rationale for the randomized controlled CHARISMA trial, aimed at assessing the impact 
of neo-adjuvant chemotherapy in addition to resection of CRLM in high-risk patients, 
specifically.
For patients with multi-organ oligo-metastases of colorectal cancer, local treatment may 
lead to superior overall survival in selected patients, as compared to palliative systemic 
treatments [23-25]. For more advanced disease there seems to be no role for local treatment, 
and palliative systemic therapies are currently standard of care for this group of patients. 
There are no prospective data on efficacy of local treatment for patients with multi-
organ colorectal cancer. Chapter 2 reports on the safety and feasibility of the multicenter 
randomized ORCHESTRA trial. In this trial, patients with multi-organ metastases of CRC are 
randomized for palliative systemic treatment, versus palliative treatment with additional 
maximal tumor debulking.
In the field of research, one of the most powerful designs is the randomized controlled trial 
(RCT). RCTs have had an enormous influence on the evaluation of interventions since the 
first of its kind in the 1940s [26]. The configuration and management of trials have evolved 
significantly since, and RCTs have become the “gold standard” for the comparative assessment 
of therapies. Large multicenter trials involve substantial complexity as a consequence 
of regulatory guidelines, financial investment and administrative burdens, even without 
taking into account trial inclusion and follow-up time [27-36]. The feasibility of RCTs can be 
facilitated by standardized and sensible regulatory and logistical guidelines. In chapter 3, 
the current thesis depicts the complex logistic, administrative, legal, ethical and financial 
landscape associated with the initiation of 2 oncological multicenter randomized trials in the 
Netherlands.
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PART II: PROGNOSTIC AND PREDICTIVE FACTORS AFTER SURGERY FOR  
COLORECTAL LIVER METASTASES
A substantial number of patients develop recurrent disease after liver surgery for CRLM, with 
an associated high mortality rate, underlining the need for prognostic biomarkers [7, 37, 38]. 
Such prognostic biomarkers may allow a more personalized treatment strategy (predictive 
biomarkers). In recent years, several clinicopathological prognostic variables in patients with 
CRLM have been identified predicting the risk of relapse or death after a metastasectomy 
[39]. These variables have been integrated in various clinical risk scores (CRS) [21, 39-42]. As 
mentioned earlier, the CRS according to Fong et al. is the most widely used and validated 
score, able to distinguish between high risk and low risk patients in terms of survival 
outcomes [21]. In chapter 4 the predictive value of this CRS is assessed in relation to overall 
survival benefit from neo-adjuvant systemic chemotherapy, which formed the basis for the 
CHARISMA study protocol (chapter 1 of this book). Part of Fong’s CRS is the lymph node 
status of the primary colorectal tumor. As the CRS was established before adjuvant therapies 
for node positive colon cancer became standard of care, the prognostic value of primary 
nodal status was re-assessed in the era of adjuvant chemotherapy for stage III colon cancer 
[43] (chapter 5). 
For patients with resectable CRLM, no biomarkers exist that impact clinical management. 
Classic clinical variables are far from perfect in predicting patient outcome. New staging 
systems (i.e. biomarkers) are urgently needed to optimize treatment [44, 45]. Unravelling 
biological properties characterising tumours may be pivotal to designing these individualised 
therapies, based on biological predictors of outcome rather than or in addition to clinical 
predictors. Various groups have established molecular subtypes in primary cancers with 
distinct biology, predictive and prognostic value [46-49] [50, 51]. Biological markers may 
improve patient selection for (neo-) adjuvant therapies in addition to surgical management 
or intensive surveillance schemes. The current thesis describes clinical, histopathological 
and genetic biomarker research. In chapter 6, the prognostic value of C-Reactive Protein 
(CRP) post-liver resection was assessed. Chapter 7 describes a study aimed at identifying 
a prognostic biomarker at mRNA level. Chapter 8 represents a protocol for reliably scoring 
three distinct histopathological growth patterns of CRLM with prognostic power. In chapter 
9, the predictive capacity of these growth patterns is assessed in terms of overall survival 
impact of chemotherapy in addition to surgery.
PART III: SURGICAL MANAGEMENT OF COLORECTAL LIVER METASTASES
In patients with colorectal liver metastases, surgery offers superior survival outcomes and 
the only potential for cure [15-17, 25, 52]. Therefore surgery, if technically possible, is the gold 
standard treatment modality for patients with liver-only metastases although no randomized 
controlled trials have been conducted on the subject. Undertaking such a trial has been 
argued to be unethical by some in the field [14]. Thus, in chapter 10 a case-matched analysis 
was performed in patients with liver-only CRC metastases, treated with surgery or systemic 
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therapy alone.
Based on current evidence on outcome after surgery for CRLM, all patients should be 
considered for resection. At present, metastasectomy is considered if there is an expected 
functional liver remnant of at least 20-30%, if liver resection is anatomically feasible in 
relation to vascular and biliary structures, and if no unresectable extrahepatic metastases 
are present. Despite the definition of resectability, the decision of CRLM being amenable for 
surgery varies even between dedicated hepatobilliary surgeons [53-55]. For various types of 
cancer (esophageal, gastric and lung), significant inter-hospital and interregional differences 
exist for application of curative (local) treatment [56-58]. In Sweden, this has already been 
established for CRLM, with significant variations in selection for liver surgery based on 
hospital type, region, gender, and age [59]. Chapter 11 investigated potential Dutch inter-
hospital and regional differences in utilization of surgery for CRLM, and assessment of 
resectability by specialist liver surgeons.
After curative treatment, 30% of patients with stage I–III and up to 65% of patients with 
stage IV CRC develop recurrent disease [5-13]. Historically, CRC patients are routinely offered 
surveillance in order to detect disease recurrence at an early, asymptomatic stage, with the 
intention of treating these recurrences with curative intent and improving survival. To date, 
controversy continues to surround the yield of any surveillance after curative treatment. There 
exists great variance in surveillance protocols between hospitals all around the world [60-
63]. In chapter 12 the need of surveillance for patients after resected CRLM and a prolonged 
disease free interval was assessed, aiming to identify subgroups that may be excluded from 
follow-up at some stage after surgery. Chapter 13 sets out a rigorous review of literature on 
surveillance after curative treatment of stage I-IV CRC, and reflects on its utility.
PART IV: DISCUSSION AND FUTURE PERSPECTIVES, SUMMARY AND APPENDICES
The final chapters 14, 15 and 16 of this thesis provide a general summary and a discussion 
with future perspectives in the field of management of colorectal liver metastases. In chapter 
17 the appendices are published, including a list op publications, acknowledgements and a 
section about the author.
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ABSTRACT
BACKGROUND
Efforts to improve the outcome of liver surgery by combining curative resection with 
chemotherapy have failed to demonstrate definite overall survival benefit. This may partly 
be due to the fact that these studies often involve strict inclusion criteria. Consequently, 
patients with a high-risk profile as characterized by Fong’s Clinical Risk Score (CRS) are 
often underrepresented in these studies. Conceptually, this group of patients might benefit 
the most from chemotherapy. The present study evaluates the impact of neo-adjuvant 
chemotherapy in high-risk patients with primary resectable colorectal liver metastases, 
without extrahepatic disease. Our hypothesis is that adding neo-adjuvant chemotherapy 
to surgery will provide an improvement in overall survival (OS) in patients with a high-risk 
profile.
METHODS/DESIGN
CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to 
either surgery alone (standard treatment, arm A) or to 6 cycles of neo-adjuvant oxaliplatin-
based chemotherapy, followed by surgery (arm B). Patients must be ≥ 18 years of age with 
liver metastases of histologically confirmed primary colorectal carcinoma. Patients with 
extrahepatic metastases are excluded. Liver metastases must be deemed primarily resectable. 
Only patients with a CRS of 3-5 are eligible. The primary study endpoint is OS. Secondary 
endpoints are progression free survival (PFS), quality of life, morbidity of resection, treatment 
response on neo-adjuvant chemotherapy, and whether CEA levels can predict treatment 
response.
DISCUSSION
CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer 
to the question if adding neo-adjuvant chemotherapy to surgery will improve OS in a well-
defined high-risk patient group with colorectal liver metastases.
TRIAL REGISTRATION
The CHARISMA is registered at European Union Clinical Trials Register (EudraCT), number: 
2013-004952-39.
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BACKGROUND
COLORECTAL LIVER METASTASES: SURGICAL TREATMENT
Colorectal cancer (CRC) is one of the leading causes of cancer death. It is in the top 3 most 
commonly diagnosed cancers, with over 1.2 million new cases and over 600,000 deaths 
estimated to have occurred in 2008 worldwide [1]. In approximately 20% of patients distant 
metastases are present at time of diagnosis [2]. The liver is the most common metastatic site. 
Approximately 50% of patients with early-stage disease will eventually develop colorectal 
liver metastases (CRLM) [3, 4]. 
When metastases of CRC patients are restricted to the liver, possible curative treatment can 
be obtained by surgical resection. Complete surgical resection of CRLM improves 5-year 
survival rates to around 35-60% in selected patients [5-8].  However in only 10-20% of 
patients surgical resection of CRLM is feasible. Although surgery for CRLM provides the only 
potential for cure, cancer relapse is a common phenomenon, with a recurrence rate of up to 
50% in the first 2 years after surgery [9].
CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES
Initially, systemic treatment with 5-fluoruracil based regimens was standard of care in CRLM, 
improving OS from 6 to 10-12 months. The development of chemotherapeutic agents 
such as oxaliplatin and irinotecan has subsequently improved OS to a median of up to 24 
months. Sequential treatment with all available cytotoxic agents, as well as the introduction 
of Epidermal Growth Factor receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) 
binding monoclonal antibodies have further increased overall survival [10-13]. 
The high relapse rate after curative resection of CRLM, and the efficacy of modern systemic 
treatment in the metastatic setting, have prompted investigators to perform numerous studies 
to evaluate the potential role of systemic chemotherapy combined with liver resection. The 
purpose of both adjuvant and neo-adjuvant chemotherapy is to treat microscopic disease 
that is not addressed by surgery. This microscopic disease may be promoting the high 
relapse rate that is observed after liver surgery [9]. Notably, current literature suggests that 
timing of additional chemotherapy (adjuvant vs. neo-adjuvant) seems to have no influence 
on outcome [14]. The role of perioperative chemotherapy in case of resectable CRLM was 
established in a randomized controlled trial [15]. In the mature OS analysis of this trial there 
was no significant effect on OS after a median follow up of 7 years [16]. 
STRATIFICATION BY CLINICAL RISK SCORE
In the past, several clinical risk scores for the outcome of patients with CRLM have been 
published [7, 17-25]. In 1999, Fong et al. described the most widely used CRS [19]. This 
prognostic scoring system has been verified by independent investigators [26]. Several 
authors have proposed the concept of stratification by CRS in relation to the effects of a 
multimodal treatment strategy on OS. These authors suggest that patients with a high-
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risk score have a worse prognosis and might therefore benefit more from chemotherapy 
compared to patients with a low risk score [27-29]. 
These findings have prompted others and ourselves to retrospectively evaluate data on 
patients who have undergone liver resection for CRLM in the last decade with and without 
chemotherapy, stratified by CRS according to the Fong-criteria [30, 31].
As described earlier, efforts to improve outcome of liver surgery by combining the resection 
with chemotherapy have failed to demonstrate definite OS benefit. This may partly be due to 
the fact that these studies often involve strict study protocol inclusion criteria. Consequently, 
patients with a high clinical risk score - which might benefit the most from chemotherapy - 
are often underrepresented in these studies. Since genuine survival benefit has not yet been 
demonstrated, could this low impact of chemotherapy on survival then be explained by the 
relatively low risk profile of the patients included in these trials?
STUDY AIM AND HYPOTHESIS
The CHARISMA randomized clinical trial will evaluate the effect on OS of neo-adjuvant 
chemotherapy in patients with primary resectable CRLM and a CRS (Fong) of 3-5, thereby 
bearing a poor prognosis. The primary aim of this study is to compare OS in patients with 
resectable liver metastases randomized for treatment with chemotherapy, consisting of 
capecitabine and oxaliplatin (XELOX), followed by surgery versus surgery alone. 
We hypothesize that neo-adjuvant chemotherapy will provide an improvement in OS in 
this high-risk patient group. Secondary endpoints in this study will be progression free 
survival (PFS), quality of life as assessed by QLQ-30 and MFI questionnaires, response to 
chemotherapy, morbidity of surgery and resection rate, and whether carcinoembryonic 
antigen (CEA) can predict for treatment response, PFS, and OS. 
METHODS/DESIGN
Patients with CRLM and a high CRS will be evaluated for inclusion by the local multidisciplinary 
team meeting. In this meeting, at least two surgeons with expertise in liver surgery should 
be present. In case of doubt, the imaging can be sent to a central expert panel. Patients are 
eligible for randomization if, in the opinion of a local expert panel, radical resection of the 
CRLM (R0-resection) is feasible.
Patients will be randomized 1:1 to either (figure 1):
 • Arm A:   
 Surgery of the liver metastases
 • Arm B:   
 Neo-adjuvant oxaliplatin-based chemotherapy followed by surgery of the liver 
 metastases
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Figure 1. Study flowchart
STUDY POPULATION
INCLUSION CRITERIA
Age ≥ 18 years, ECOG performance status 0-1. Histologically confirmed primary colorectal 
carcinoma. Radiological confirmed and primary resectable CRLM. CRS of 3-5 (Fong). 
Adequate bone marrow, liver and renal functions. 
Before any study related procedure will be pursued, written informed consent must be given 
according to ICH/GCP and national/local regulations.
Figure 1:  
Study flowchart 
 
 
 
 
Inclusion 
Baseline QoL (QlQ-C30, MFI) 
Randomization 
- Within 2 weeks of diagnosis 
 
Baseline QoL (QlQ-C30, MFI) 
Follow-up 
1st visit after surgery (2-4 weeks after operation):  Surgical complications assessment 
 
1st and 2nd year after surgery:    Every 3 months: CEA levels, ECOG performance status, CT scan 
QoL questionnaires (QLQ-C30, MFI, up to 1 year after completion) 
 
Arm B 
1. Neoadjuvant chemotherapy (6 x Xelox) 
- Within 2 weeks after randomisation  
- Within 4 weeks after last CT scan 
- Assessment after 3 and 6 cycles: CT-scan 
- Assessment after 6 cycles: Toxicity, ECOG performance status,  
laboratory analysis incl. CEA-level, QoL questionnaires (QLQ-C30, MFI) 
    
Arm A 
Surgery 
 
- Within 4 weeks after randomisation 
- Within 6 weeks after last CT scan 
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EXCLUSION CRITERIA
Adjuvant chemotherapy for colorectal carcinoma given < 6 months prior to detection of 
the liver metastases. Prior non-colorectal malignancies, except for basal or squamous cell 
carcinoma of the skin, or patients with carcinoma in situ of the cervix. Extrahepatic colorectal 
metastases. Locally advanced rectal cancer in situ requiring long-course pre-operative 
chemoradiotherapy. Major surgical procedures < 4 weeks prior to randomization. Pregnancy. 
History of psychiatric disability. Clinically significant cardiovascular disease. Uncontrolled 
hypertension. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption 
syndrome, or inability to take oral medication. Known peripheral neuropathy. Organ 
allografts requiring immunosuppressive therapy. Serious, non-healing wound, ulcer, or 
bone fracture. Current or recent use of full-dose oral anticoagulants or thrombolytic agents 
for therapeutic purposes. Chronic treatment with corticosteroids. Serious intercurrent 
infections. Current or recent treatment with another investigational drug or participation in 
another investigational study. Psychological, familial, sociological or geographical conditions 
hampering compliance to the study protocol and follow-up schedule. 
ASSESSMENT OF OPERABILITY
All patients have to be screened by their treating surgeon for fitness to undergo liver surgery. 
In case of doubt, formal anesthetic assessment is mandatory prior to randomization.
ASSESSMENT OF RESECTABILITY
Prior to resection of the CRLM, an expert panel must review imaging of patients enrolled in 
this study in order to determine resectability. Resectability is defined as the possibility to 
achieve R0 resection. The liver remnant should comprise a portal vein, a hepatic artery, and a 
bile duct, one of the three main hepatic veins. The liver remnant should have sufficient liver 
function and 2 segments free of metastases at the time of resection.
If these prerequisites cannot be met, radiofrequency ablation (RFA) is allowed to obtain 
resectability. However, RFA may only be used in combination with liver resection if the 
number of lesions to be treated with RFA does not exceed 3 and the largest diameter of 
these lesions is less than 3 cm.
THERAPEUTIC REGIMEN OF PATIENTS ARM A
Patients should preferably be randomized within 2 weeks of the definitive diagnosis of CRLM. 
Patients allocated to Arm A should have their surgery within 4 weeks after randomization 
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and within 6 weeks after the last CT scan. Adjuvant chemotherapy after R0 resection is not 
allowed. Protocol therapy ends following the liver resection.
THERAPEUTIC REGIMEN OF PATIENTS ARM B
Patients in Arm B will receive 6 cycles of XELOX. Oxaliplatin will be administered in a 130 
mg/m2 dose, Capecitabine in a 1000 mg/m2 dose. Patients should preferably be randomized 
within 2 weeks of the definitive diagnosis of CRLM. Patients allocated to Arm B should start 
neo-adjuvant chemotherapy within 2 weeks after randomization and within 4 weeks after 
the last CT scan. Treatment evaluation will occur after the 3rd and 6th chemotherapy cycle. In 
the case of progressive disease (PD) after the 3rd cycle, a resectability check will take place. If 
patients remained resectable, they will be planned for surgery within 4-6 weeks after completion 
of the 4th cycle. If patients are assessed to be irresectable, they will go off study protocol. 
After the last day of chemotherapy exposure, resection should take place at least 4 weeks, but 
at maximum 6 weeks later. Treatment evaluation can take place according to local hospital 
procedures, but should at least consist of a CT scan of the thorax/abdomen and CEA level. 
Adjuvant chemotherapy after R0 resection is not allowed. Protocol therapy ends following 
the liver resection.
ENDPOINT
PRIMARY ENDPOINT
Primary endpoint of the study will be OS, calculated from the date of randomization to the 
date of death of the patient, from any cause. Patients still alive at the date of last contact will 
be censored.
SECONDARY ENDPOINTS
PFS will be defined from the date of randomization to the first event defined as local/distant 
recurrence or progression or death from any cause.
CRITERIA OF EVALUATION
Progressive or recurrent disease can be detected by imaging modalities (e.g. CT scan). A rise 
in serum tumor marker (e.g. CEA) is insufficient. In case of doubt, histological biopsy can 
provide definitive proof of progression/recurrence. Response to neo-adjuvant chemotherapy 
will be evaluated by CT scan using RECIST 1.1 criteria [32]. To evaluate the well being of 
patients the European Organization for Research and Treatment of Cancer Quality of Life 
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questionnaire (EORTC QoL) will be used. The EORTC QLQ-C30 is generally used to assess QoL 
of cancer patients; additionally the Multifactorial Fatigue Index (MFI) will be used. Toxicity 
will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. Surgical complications will be defined according to the standard classification 
of surgical complications [33]. Postoperative mortality will be defined as any death during 
hospitalization or within 30 days from surgery. Complication and post-operative mortality 
rates will be securely monitored and documented.
STATISTICAL CONSIDERATIONS
SAMPLE SIZE AND ACCRUAL
On the basis of retrospective data, we expect the hazard ratio (HR) for arm B to be 0.60. 
For the detection of a HR of 0.60 for the chemotherapy arm and with an expected 5-year 
OS of 25% in arm A, with two-sided significance level α = 0.05 and power 1 - β = 0.8, 126 
deaths have to be reported before the final analysis will take place. This number of events is 
expected to be reached after the recruitment of 224 patients with an average accrual rate of 
56 patients per year, and an additional follow up of 2 years. A HR = 0.60 corresponds to an 
increase of 5-year OS of 43% in arm B.  
RANDOMIZATION
Eligible patients should be registered after written informed consent and before start of 
treatment (based on inclusion/exclusion criteria). Patients will be randomized for surgery 
versus neo-adjuvant chemotherapy followed by surgery in a 1:1 design. During randomization 
patients will be stratified by center, CRS score and status of primary tumor (still in situ vs. 
resected) with a minimization procedure, ensuring balance within each stratum and overall 
balance. 
STATISTICAL ANALYSIS PLAN
The main analysis addressing the primary endpoint is planned after 126 events. No interim 
analysis is planned. 
ETHICS
The study has ethical approval from the Erasmus MC medical-ethical committee. The study 
will be conducted in accordance with the ethical principles of the Declaration of Helsinki, the 
ICH-GCP Guidelines, the EU Clinical Trial Directive (2001/20/EG), and applicable regulatory 
requirements. The local investigator is responsible for the proper conduct of the study at the 
study site. 
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DISCUSSION
Currently, multimodal treatment is not incorporated in the standard of care for primary 
resectable colorectal liver metastases. To date, no definite evidence exists favoring 
administration of (neo) adjuvant chemotherapy in CRLM in addition to surgery. Considering 
the retrospective observations that pre-selection of patients by clinical prognostic 
characteristics may define a patient population expected to benefit from chemotherapy, CRS 
stratification provides the base for this randomized controlled trial. 
Preceding studies of peri-operative chemotherapy combined with liver surgery often 
engaged strict study protocol inclusion criteria. Consequently, patients with a high CRS - 
which might benefit the most from chemotherapy - are often underrepresented in these 
studies. Possibly, this low impact of chemotherapy on survival could be explained by the 
relatively low risk profile of the patients included in these trials. Recently, two reports on 
patients with relatively low risk for recurrence have been published. Adam et al. performed 
an analysis of the LiverMetSurvey database on patients with solitary, metachronous, 
primarily resectable metastases. These patients have particularly favorable tumor biology 
and a low CRS. The authors concluded that these patients do not benefit from preoperative 
chemotherapy [34]. A recent systematic review of the literature by Lehmann et al. concludes 
that routine use of neo-adjuvant chemotherapy for patients with clearly resectable lesions 
limited to the liver is not recommended due to a lack of benefit on survival [35].
As mentioned before, several authors have proposed the concept of stratification by CRS 
with regard to the effects of systemic therapy. Tomlinson et al. demonstrated on actual 10-
year survivors of liver surgery for CRLM that patients with a low CRS had a cure rate of 21% 
and that patients with a high CRS had a cure rate of 10% [27]. They suggest that this finding 
may be used to identify patients who might benefit from neo-adjuvant chemotherapy [27]. 
In a large, non-randomized study by Parks et al., adjuvant therapy did seem to improve OS 
[28]. In this study, patients with a high CRS had more benefit from adjuvant therapy than 
patients with a low CRS, again suggesting a role for CRS when considering chemotherapy.
These reports have stimulated others and our own unit to retrospectively evaluate data 
on patients that underwent liver resection for CRLM in the last decade with and without 
chemotherapy, stratified by CRS according to the Fong-criteria [19]. Rahbari et al. have 
evaluated the role of adjuvant chemotherapy in a cohort of 316 patients, of whom 43% 
were high-risk according to the “Memorial Sloan-Kettering Cancer Center CRS” (CRS>2). They 
found that adjuvant chemotherapy had a profound impact on OS in the high-risk population 
(HR=0.40), whereas in low-risk patients HR=0.90 [31]. In a recent manuscript by Hirokawa et 
al. similar results are described with de use of adjuvant chemotherapy [36]. In our population 
of patients that underwent resection for CRLM in Rotterdam (N=365), we have focused on 
neo-adjuvant chemotherapy. In this study, a pronounced improvement in OS was found in 
high-risk patients receiving neo-adjuvant chemotherapy versus no chemotherapy (median 
67 months vs. 33 months, HR=0.55 [95% CI 0.35-0.84], p=0.006). This difference was absent 
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in the low-risk group (median 65 months vs. 56 months, HR=0.89 [95% CI 0.57-1.40], p=0.62) 
[30]. Notably, these studies were retrospective and non-randomized. The sample size 
calculation of the present study is based on these retrospective data. 
In a recent editorial by Jarnagin et al. it is suggested that future trials should strongly 
consider stratification by some scoring system [29], given the results of the retrospective 
studies as mentioned above. Our study will evaluate patients with resectable CRLM without 
extra hepatic disease and a CRS of 3-5 thereby bearing a poor prognosis. The primary aim of 
this study is to compare OS rates of patients with resectable liver metastases randomized for 
treatment with chemotherapy consisting of capecitabine and oxaliplatin (XELOX) followed 
by surgery, versus surgery alone. We hypothesize that adding neo-adjuvant chemotherapy 
to surgical resection of CRLM will provide an improvement in OS in patients with a high-
risk profile. As secondary objectives we will study PFS, quality of life, treatment response on 
neoadjuvant chemotherapy, morbidity of surgery and resection rate, and whether CEA can 
predict for treatment response, PFS, and OS. 
LIST OF ABBREVIATIONS
CEA  = Carcinoembryonic antigen
CRC  =  Colorectal cancer
CRLM  = Colorectal liver metastases
CRS  = Clinical risk score
ECOG  = Eastern cooperative oncology group 
OS  =  Overall survival
PFS  =  Progression free survival
RCT  = Randomized controlled trial 
RFA  = Radiofrequency ablation
XELOX  = Chemotherapy consisting of capecitabine and oxaliplatin
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ABSTRACT
BACKGROUND
For selected patients with oligometastatic colorectal cancer (mCRC), local treatment of 
metastases is standard of care based on retrospective reports showing long-term survival 
rates. Local treatment of metastases is technically feasible in an increasing number of 
patients with multi-organ mCRC. It is unknown if patients with extensive disease (multi-
organ) will benefit from tumor debulking when added to first line palliative chemotherapy. 
The ORCHESTRA trial (NCT01792934) was designed to prospectively evaluate overall survival 
(OS) benefit from tumor debulking in patients with multi-organ mCRC. 
METHODS
Patients with multi-organ mCRC were eligible if >80% tumor debulking was deemed feasible 
by resection, radiotherapy and/or thermal ablative therapy. All patients received oxaliplatin 
based chemotherapy ± bevacizumab. In case of stable disease or response at first evaluation 
(9 weeks), patients were randomized to continuation of chemotherapy or tumor debulking 
followed by chemotherapy. If patient withdrawal after randomization was <10%, the study 
was deemed feasible. Study continuation was based on the interim report on safety and 
feasibility after inclusion of 100 (of 478) patients. 
RESULTS
Patients were randomized to the standard (N = 43) or intervention arm (N = 45). No patients 
withdrew after randomization. In 13.3% of patients debulking was not performed due to 
progressive disease (N = 5) or death (N = 1) prior to local treatment. Two patients had no 
lesions left to treat, 37 patients underwent tumor debulking. In 15 locally treated patients 
(40%) 21 serious adverse events related to debulking were reported. Postoperative 90-
day mortality was 2.7% (N = 1). Chemotherapy was resumed in 89% of patients, median 
chemotherapy-free interval was 12.5 weeks (6-34) and 79% completed (the equivalent of ) 
8 cycles CAP(OX). 
CONCLUSIONS
Tumor debulking is feasible and safe and does not prohibit administration of palliative 
chemotherapy in the majority of patients with multi-organ mCRC. The ORCHESTRA trial will 
continue accrual to determine whether tumor debulking will lead to  > 6 months OS benefit 
while maintaining quality of life.
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BACKGROUND
In the current multidisciplinary approach of stage IV metastatic colorectal cancer (mCRC), 
local treatment of oligometastases is increasingly performed. Large series of selected 
patients with liver-only metastases treated with complete surgical resection suggest that 
this approach improves 5-year survival rates to around 30-60%, and offer the only potential 
for cure [1-4]. Application of techniques such as radiofrequency or microwave ablation (RFA, 
MWA) and stereotactic ablative radiotherapy (SABR) potentially increases feasibility of local 
treatment of metastases.  
For selected patients with oligometastatic colorectal cancer (mCRC), local treatment of 
metastases is standard of care based on retrospective reports showing long-term survival 
rates [5, 6]. Treatment options with curative intent are generally not available for patients 
with extensive hepatic and/or extrahepatic mCRC. These patients primarily receive palliative 
systemic treatment consisting of combination chemotherapy with agents targeting VEGF or 
EGFR. So far, reports on the benefit of local treatment for multi-organ metastases of CRC have 
major limitations, including being small, non-randomized, single-center and retrospective. It 
is unknown if patients with extensive disease will benefit from tumor debulking when added 
to first line palliative systemic therapy. In ovarian cancer, irradical but maximal resection 
of tumor lesions induces an overall survival benefit [7]. As a consequence, some clinicians 
suggest that maximal tumor debulking for metastatic disease may also benefit colorectal 
cancer patients [8], although there exists no evidence for such management. The benefit 
from local treatment of multi-organ metastases for these patients should be evaluated 
prospectively. Published retrospective reports were hampered by selection bias [5, 6]. The 
current manuscript reports the safety and feasibility of the ORCHESTRA trial (NCT01792934), 
a multicenter randomized trial, designed to prospectively evaluate overall survival (OS) 
benefit from tumor debulking by resection, radiotherapy and/or thermal ablative therapy in 
patients with multi-organ mCRC based on the first 100 included patients. The ORCHESTRA 
trial incorporates both systemic and local therapy in the experimental arm and combines 
local treatment modalities to pursue maximal tumor debulking. The trial aims to improve 
overall survival of patients with multi-organ mCRC by maximal tumor debulking after 
induction chemotherapy by at least six months. 
The current report focused on feasibility of patient accrual, randomization, withdrawal after 
randomization, safety of the local treatment procedures in this patient population and the 
ability to administer adequate palliative systemic treatment in the intervention arm, being 
the current evidence based treatment regimen [9].
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METHODS
The ‘ORCHESTRA’ trial is a randomized multicenter clinical trial for patients with multi-organ 
mCRC, comparing the combination of chemotherapy and maximal tumor debulking versus 
chemotherapy alone. 
Written informed consent was obtained from all patients included. Patients were 18 years or 
older and had an indication for first line palliative systemic therapy for mCRC. They all had an 
ECOG performance status of 0-2 and adequate bone marrow, liver and renal function.
Patients with extensive multi-organ mCRC were eligible, as specified in table 1 below. Tumor 
debulking by a combination of resection, radiotherapy or thermal ablative therapy was 
deemed feasible by a multidisciplinary team, including a specialist in surgical oncology, 
radiotherapy, radiology and medical oncology.
Table 1: Main eligibility criteria
ORCHESTRA Eligible patients
Patients with CRC metastases in ≥ 2 different organs if at least
>1 extrahepatic metastases or
>5 hepatic metastases not located to one lobe or
either a positive para-aortal lymph nodes or celiac lymph nodes or adrenal
metastases or pleural carcinomatosis or peritoneal carcinomatosis
NB The primary tumor is excluded as metastatic site
Feasible radical tumor debulking. Incomplete tumor debulking is allowed only if at least 80% of metastases 
can be treated.
Patients who underwent prior local treatment were not excluded. Prior (adjuvant) systemic 
therapy should have been completed more than 6 months at diagnosis of extrahepatic 
metastatic disease. Comprehensive in and exclusion criteria are available at clinicaltrials.gov.
Clinical data on medical history, tumor characteristics and treatment were entered in a web 
based electronic case record form, prospectively.
All patients received 5-FU/oxaliplatin based systemic therapy ± bevacizumab at physician 
discretion. Systemic therapy consisted of orally administered capecitabine 1000 mg/m2 
twice a day for two weeks and oxaliplatin 130 mg/m2 intravenous (CAPOX) on day 1 in a 
3-week cycle or comparable intravenous regimen consisting of oxaliplatin 85 mg/m2 on 
day 1 and 400 mg/ m2 LV followed by 400 mg/m2 5-FU bolus and 2400 mg/m2 continuous 
infusion over 46 hours (modified FOLFOX6) of each 2-week cycle. Bevacizumab was added at 
physician discretion as intravenous infusion over 30-90 minutes on day 1 (in CAPOX regimen 
a 7.5 mg/kg 3-weekly, in FOLFOX regimen biweekly 5 mg/kg). The FOLFOX regimen could be 
combined with biweekly bevacizumab, 5 mg/kg). First evaluation of response was scheduled 
after 3 cycles of CAPOX(B) or 4 cycles of FOLFOX(B) by CT scan of thorax and abdomen. 
Response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST 
Chapter 2 | Safety and Feasibility of the ORCHESTRA Trial
41
2
1.1) [10]. Follow up scans were done at least every 3 months. 
In case of stable disease or response, patients were randomized to continuation of systemic 
therapy (standard arm A) or tumor debulking (intervention arm B) followed by systemic 
therapy. 
Patients who were randomized in the intervention arm, with stable disease at evaluation, first 
continued systemic therapy (3 x CAPOX or 4 x FOLFOX ± bevacizumab) followed by debulking 
if disease remained stable. Bevacizumab was omitted the chemotherapy cycle prior to tumor 
debulking. A definitive local treatment plan was determined by a multidisciplinary team 
based on the most recent evaluation scan. Patients were referred to a hospital with adequate 
local treatment expertise as appropriate.
Adverse events (AE) were documented according to Common Terminology Criteria for 
Adverse Events (CTCAE version 4.03) and documented to be related to systemic therapy, 
local therapy or not related. If related to systemic therapy only AE’s > grade 2 were entered 
in the eCRF. All AE’s related to local treatment were documented and furthermore graded 
according to Clavien Dindo [11]. Serious Adverse Events (SAE) are adverse events that resulted 
in death, were life-threatening, required inpatient hospitalization or caused prolongation 
of existing hospitalization, resulted in persistent or significant disability/incapacity, or 
required intervention to prevent permanent impairment or damage. SAE’s were reported to 
the competent authority within 7 days. Safety reports were drawn up and evaluated by an 
independent Data Safety Monitoring Board after inclusion of 25, 50 and 100 patients. Study 
continuation was based on the interim report on safety and feasibility after inclusion of 100 
(of 478) patients.
A total of 478 patients are anticipated to be included to randomize 382 patient and meet the 
primary endpoint of an overall survival benefit of > 6 months (power 80%, type I error rate 
5%). The study was deemed feasible if less than 10% of patients would withdraw from the 
study after randomization, after 20% of patients have been randomized (N=76). 
The primary endpoint of the current randomized trial is overall survival counting from the 
date of study inclusion to the date of death. Secondary endpoints include progression free 
survival and quality of life, as well as evaluation of potential biomarkers such as CEA, MiRNA, 
(phospho)proteomics, Platelet derived RNA and genetic profiles.  
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Figure  1.  Study protocol flow chart
RESULTS
Between May 2013 and May 2015 the first 100 patients were included in 16 of 32 participating 
Dutch hospitals that are part of the Dutch colorectal cancer group (DCCG). During the first 
year, 6 centers were open and they included 5 patients, increasing to 30 centers in 2016 
including 60 patients in one year. Currently over 200 patients are included (figure 2).
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Figure 2. Included patients
 
Patients had a median age of 65 (range 30-78) years and 67% were male. Seventy-one percent had 
a primary tumor (either resected or in situ) located on the left side and approximately two-third of 
the population presented with synchronous metastatic disease. In 72 patients the primary tumor 
was previously resected and 34 patients also had prior local treatment of metastases. 
In 35 patients more than 2 organs were involved in metastatic disease (up to 5 organs involved). 
Patients had a median of 6 metastatic lesions ranging from 2 to 18 lesions or diffuse disease. 
Twenty-six patients had less than 5 lesions, 43 patients had 5-10 lesions, and 31 patients 
had more than 10 or diffuse (peritoneal) disease. There were no significant differences in 
baseline characteristics between arm A and arm B prior to start of chemotherapy including 
baseline CEA and LDH values (see table 2). Liver metastases were present in 81 patients, 50 
patients had lung metastasis, and 57 had distant lymph node metastases (from which 34 
were located at poor prognostic site) [5]. Peritoneal disease was present in 33 patients, and 
respectively 7, 5 and 3 patients had bone, adrenal gland or skin/subcutaneous metastases.
All but one patients were treated with CAPOX (± bevacizumab (62%)), one patient was 
treated with FOLFOX, 3 more patients switched to FOLFOX during the course of the study 
due to capecitabine toxicity.
Results: 
Between May 2013 and May 2015 the first 100 patients were included in 16 of 32 
participating Dutch hospitals that are part of the Dutch colorectal cancer group (DCCG). During the 
first year, 6 centers were open and they included 5 patients, increasing to 30 centers in 2016 
including 60 patients in one year. Currently over 200 patients are included (figure 2). 
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Patients had a median age of 65 (range 30-78) years and 67% were male. Seventy-one 
percent had a primary tumor (either resected or in situ) located on the left side and approximately 
two-third of the population presented with synchronous metastatic disease. In 72 patients the 
primary tumor was previously resected and 34 patients also had prior local treatment of metastases.  
In 35 patients more than 2 organs wer  involved in metastatic disease (up to 5 organs 
involved). Patients had a median of 6 metastatic lesions ranging from 2 to 18 lesions or diffuse 
disease.  Twenty-six patients had less than 5 lesions, 43 patients had 5-10 lesions, and 31 patients 
had more than 10 or diffuse (peritoneal) disease. There were no significant differences in baseline 
characteristics between arm A and arm B prior to start of chemotherapy including baseline CEA and 
LDH val es (s e t ble 2). Liver metastases were pres nt in 81 patients, 50 patients had lung 
metastasis, and 57 had distant lymph node metastases (from which 34 were located at poor 
prognostic site) [5]. Peritoneal disease was present in 33 patients, and respectively 7, 5 and 3 
patients had bone, adren l gland or skin/subcutaneous metastases. 
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Table 2: Baseline characteristics
Parameter Total
(N = 100)
Arm A   (%)
(N = 43)
Arm B  (%)
(N = 45)
P value
Gender - Male 67 29 (67%) 31 (69%) 0.88
Age <65 51 25 (58%) 21 (47%) 0.28
Synchronous metastases 63 30 (70%) 26 (58%) 0.24
Left sided primary tumor 71 26 (60%) 35 (78) 0.08
Primary in situ 28 29 (67%) 33 (73) 0.55
Number of metastases 0.89
<5 26 11 (26%) 10 (22)
5-10 43 18 (42%) 21 (47)
>10 or diffuse 31 14 (33%) 14 (31)
Number of organs involved 0.35
2 65 29 (67%) 26 (58%)
>2 35 14 19
CEA  >5 ug/l 78 31 (79%) 37 (84%) 0.18
LDH normal level 77 37 (86%) 34 (65%) 0.28
Prior tumor treatments
Prior (neo-) adjuvant chemo 19 34 (79%) 35 (78%) 0.88
Prior chemoradiation 14 4 (9%) 8 (17%) 0.25
Previous local treatment 34 26 (60%) 33 (73%) 0.20
Systemic therapy
Chemotherapy 0.30
CAPOX 97 42 (98%) 45 (100%)
FOLFOX 1 1 0
Bevacizumab 62 25 (58%) 30 (67%) 0.41
Completed equivalent of 8 cycles CAP(OX) 30 (70%) 29 (64%) 0.65
Number of cycles CAPOX 11 (median) range 3-36
9 (median) 
range 4-31 0.42
Response at first evaluation 0.59
CR 1 0 (0%) 1 (2%)
PR 41 21 (48%) 20 (44%)
SD 46 22 (51%) 24 (53%)
PD 3 - -
Prior to randomization, two patients went off study due to toxicity of systemic treatment, 
two patients died and five patients withdrew consent prior to starting or during the first 
cycles systemic therapy (no reason specified). Three patients had progressive disease and 
were not randomized per protocol. Eighty-eight patients were randomized to the standard 
(N=43) or intervention arm (N=45). No one withdrew after randomization (see figure 3).
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Figure 3.  Simplified flowchart/consort diagram 
ARM B - DEBULKING
In 13.3% of 45 patients randomized for local treatment, debulking was not performed due to 
progressive disease (N=5) or death (N=1) prior to local treatment (figure 2). Two patients, who 
had stable disease at randomization, progressed during the following courses of systemic 
therapy and debulking was not performed as per protocol. Two other patients showed 
progressive disease awaiting local treatment (one patient with a newly diagnosed brain 
metastasis, one patient with progressive liver metastases rendering debulking unfeasible). 
In one patient extensive peritoneal disease became apparent per-operatively, for which 
debulking was not feasibly, and the operation was terminated without treatment of any 
metastases. One patient died in a motor vehicle accident just prior to local treatment. On 
imaging prior to debulking, two patients had near complete response, with lesions too small 
to treat after systemic therapy.
In 37 of 45 allocated patients, debulking was performed. In 38% of patients debulking was 
performed with one single modality, the other patients required combined modalities. 
Eleven percent was treated by three modalities (surgery, RFA and radiotherapy). Four patients 
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Arm B - Debulking 
In 13.3% of 45 patients randomized for local treatment, debulking was not performed due to 
progressive disease (N=5) or death (N=1) prior to local treatment (figure 2). Two patients, who had 
stable disease at randomization, progressed during the following courses of systemic therapy and 
debulking was not performed as per protocol. Two other patients showed progressive disease 
awaiting local treat ent (one patient with a newly diagnosed brain metastasis, one patient with 
progressive liver metastases rendering debulking unf asible). In one patient extensive peritoneal 
disease became apparent per-operativ ly, for which debulking was ot feasibly, and the operation 
was terminated without treatment of any metastases. One patient died in a motor vehicle accident 
just prior to local treatment. On imaging prior to debulking, two patients had near complete 
response, with lesions too small to treat after systemic therapy. 
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required a second elective admission for second stage debulking. In 31 patients, debulking 
of >80 % of metastatic lesions was realized. These results are summarized in table 3. 
Table 3: Debulking
Arm B N = 45
ASA classification Median 2  (range 1-3)
Debulking performed N = 37 (82%)
More than 80% treated N = 31 (69%) 
Number of modalities
    1 
2
3
Median 2 (range 1-3)
N = 14
N = 19
N = 4
Total in-hospital local treatment days Median 14 (range 1-50)
Systemic therapy resumed after local treatment N = 33 (89%)
≥8 cycles capox or 12 folfox administered N = 26 (78.8%)
Chemotherapy free interval in weeks Median 12.5 (range 6-34)
ARM B – TREATMENT IMPACT
The total duration of hospital admission in days was median 9 days (range 1-50). This included 
elective hospital admission, unplanned readmissions (in 7 patients), radiotherapy sessions 
and/or percutaneous RFA sessions. In 7 (16%) patients a colostomy was created as part of 
the debulking procedure. In 5 patients with liver metastases hemihepatectomy was needed 
as part of debulking. Radiotherapy was administered in an outpatient setting. Patients had a 
median of 6 radiotherapy sessions (range 2-27).
A total of 77 severe adverse events (SAE’s) were reported in all 100 patients, from which 32 
occurred prior to randomization, 17 in arm A and 28 in arm B. In arm A, 6 SAE’s were related 
to systemic therapy and 11 were not related to treatment. Of the SAE’s in arm B, 1 was related 
to systemic therapy, and 21 were related to local treatment (in 15 patients = 40%, see tables 
5A). The SAE’s included infections, hepatobiliary and respiratory disorders and 16% did not 
resolve in 30 days (N=6). 
In the intervention arm, 32 adverse events (AE’s) related to debulking were reported (in 19 
patients). Eleven of these AE’s were ≥ grade 3 according to Clavien Dindo (see table 5B). 
Postoperative 90-day mortality was 2.7% (N = 1; hepatic failure).
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Table 5A: Serious adverse events related to tumor debulking procedures 
Serious adverse events 
(According to CTCAE 4.03)
N = 21 (%)
Cardiac disorders 1 (5%)
Gastrointestinal disorders 3 (14.3)
Hepatobiliary disorders 5 (23.8)
Infections and infestations 5 (23.8)
Procedural complications 2 (9.5)
Renal and urinary disorders 1 (4.8)
Respiratory, thoracic and mediastinal disorders 4 (19)
Table 5B: Adverse events of debulking procedures ≥ grade 3 according to Clavien Dindo
Clavien Dindo Grade Complication
Grade 3 Presacral abscess
Urinary anastomotic leak
Wound aces
Pleural effusion
Colonic perforation
Abdominal sepsis
Biliary anastomotic leak/duct leak (3x)
Grade 4 Ileus
Grade 5 Liver failure
Chemotherapy could be resumed in 89% of patients in arm B. The four patients who did 
not resume chemotherapy all had stable disease at randomization and therefore completed 
7 cycles of CAPOX prior to debulking (see figure 1). One patient could not restart due to 
complications of debulking, and one due to progressive disease. In the other 2 patients, the 
treating physician did not restart because the patients had no evaluable disease left and 
no symptoms to palliate after debulking had taken place. Altogether, 83% of patients who 
underwent debulking completed (the equivalent of ) 8 cycles of CAP(OX). In general, 70% 
of patients in arm A and 64% of patients in arm B (p = 0.65) completed the equivalent of 8 
cycles of CAP(OX), and there was no difference in median number of cycles administered 
between study arms (see table 1). The median chemotherapy-free interval was 12.5 weeks 
(range 6-34) after completion of the last pre-local treatment cycle of systemic therapy. The 
chemotherapy-free interval between the last debulking event and restart was median 5 
weeks (range 1-24).
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DISCUSSION
The current report demonstrated that it is feasible and safe to prospectively include and 
randomize patients with metastasized colorectal cancer (mCRC) for palliative systemic 
treatment and extensive tumor debulking in addition to palliative systemic treatment. 
Setting up an oncological trial of this kind and enrolling patients in 32 different hospitals in 
the Netherlands is a major challenge. Data in this manuscript show that at initiation patient 
inclusion was characterized by a “start up phase”, with low patient accrual. This probably 
reflects initial unfamiliarity with the logistic implications of the trial protocol and the 
challenge of getting multidisciplinary consensus on feasibility of tumor debulking. Obtaining 
study approval in participating hospitals requires different procedures within each individual 
institute in the Netherlands [12], also causing a delay in inclusion. Commitment and close 
collaboration of specialists in multidisciplinary teams was needed in all participating centers. 
As shown, the ORCHESTRA protocol is currently implemented in 32 general and academic 
hospitals. If the ORCHESTRA trial has clinical implications in the future, the current study 
objectified its feasibility in various centers.
Although some patients withdrew from study participation, no one withdrew after 
randomization due to potential dissatisfaction with the treatment arm they were randomized 
to. Three patients developed disease progression in the interval between chemotherapy and 
resection (6.7%), and were excluded from local treatment. The incidence was lower in our 
study as compared to scarce reports in literature (6.7% versus 25% respectively) [13].
It remains challenging to plan all needed local treatment modalities in such a way that 
patients have sufficient time to recover without delaying systemic treatment. To prevent 
tumor progression and poor oncological outcome we aimed for a short chemotherapy-free 
interval. The interval reported in the current study was 12.5 weeks after the last cycle, and 5 
weeks after last debulking modality. Literature on the impact of prolonged chemotherapy-free 
intervals on overall survival is scarce [14]. For patients undergoing two-stage hepatectomy 
for colorectal liver metastases, the interval between pre- and postoperative chemotherapy 
was median 18.7 weeks [14]. The interval between surgery and resuming chemotherapy 
within 10 weeks seemed to have positive predictive value on survival. In comparison, the 
current protocol seems safe. 
Although the chemotherapy-free interval was 12.5 weeks in the intervention arm, there 
was no significant difference in the total amount of cycles of systemic therapy administered 
between the study arms. A comparable proportion of patients completed at least 8 cycles of 
capox(±B) (or the equivalent in FOLFOX) in both treatment arms.
Another important factor in terms of safety and feasibility is the actual process of tumor 
debulking. This is an intensive process, with important treatment burden for the patients 
involved. Inevitably, serious adverse events occurred, with hospitalization up to 50 days for 
an individual patient. The morbidity and mortality of local treatments performed (2.7%) 
compares to surgical literature [15]. Patients randomized in arm B that underwent debulking 
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after 7 cycles of systemic therapy, due to stable disease at first evaluation did not have more 
SAE’s related to the procedures despite having had more chemotherapy. 
The current data show that tumor debulking is feasible and safe and does not prohibit 
administration of palliative systemic therapy in the majority of patients with mCRC. This study 
addresses a topical issue in everyday practice of multidisciplinary colorectal cancer care with 
a study design compatible with current treatment options, enabling the results to be readily 
implemented in treatment practice. Besides the reported adverse events, collected data on 
quality of life will then contribute largely to the decision whether it is worthwhile to offer 
this treatment strategy to patients with multi organ metastatic CRC. The ORCHESTRA trial 
will continue accrual to determine whether the primary aim of  >6 months overall survival 
benefit of additional tumor debulking will be met.
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ABSTRACT
BACKGROUND
Large multicentre randomised controlled trials (RCTs) in the Netherlands are increasingly 
being impeded by major differences between local approval procedures. However, no 
national agenda exists as yet to improve this situation. The existence of major local differences 
in processing time and documentation required has been reported previously but little 
is known about the costs incurred and whether or not specific certifications and research 
contracts are mandatory. The current study evaluated these aspects of local procedures for 
obtaining approval of two oncological multicentre RCTs.
METHODS
All local procedures for obtaining approval of two randomised clinical trials were evaluated: 
the CAIRO5 and CHARISMA trials initiated by the Dutch Colorectal Cancer Group (DCCG). We 
objectified time between approval by the Medical Ethics Review Committee (METC) and final 
approval by the Board of Directors (RvB), the type and number of documents needed, and 
costs charged.
RESULTS
The median time interval between the approval by the central Medical Ethics Committee 
for participation of a local centre and the final approval for local feasibility by the Board of 
Directors of a participating centre was 90 days (range 4-312). The number of documents 
required for the procedure per centre ranged from 6-20. The charged costs by participating 
centres for the procedure ranged from €0-€1750, and amounted to €8575 for all procedures 
combined. The majority of the centres charged no costs.
CONCLUSION
The procedures for obtaining approval for local feasibility of participating centres in 
multicentre clinical trials in the Netherlands demonstrate a large variety in duration, content 
and costs. This is an obstacle for conducting clinical research efficiently and cost-effectively. 
Uniform regulations are urgently needed.
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INTRODUCTION
Prospective randomised trials are considered the best instrument to test the effectiveness 
of medical interventions and are therefore at the core of ‘evidence-based’ healthcare. Novel 
treatment modalities are currently emerging at increased frequency, which results in a great 
demand for these types of trials [1]. Randomised trials typically involve a large number 
of patients, and therefore the participation of multiple centres. In 2014, 759 multicentre 
studies were assessed by a medical ethical committee (MEC) in The Netherlands, of which 
43% were investigator-initiated studies [2]. The initiation and conduct of these multicentre 
studies require a significant investment of time and financial investment. This is an obstacle 
for investigator-initiated research, which unlike pharmaceutical industry-driven research 
typically has no structural financial and staff support. 
Central medical ethical approval and subsequent local approval of the participating centres 
for feasibility are required before a trial can be initiated. The increasing complexity and 
diversity of the procedure to obtain approval for local feasibility in participating centres 
causes delay and increases costs of initiating trials [3-8]. This hampers the conduct of clinical 
research in The Netherlands [2, 9]. However, objective, raw data regarding these issues are 
scarce [3, 4, 6].  
The so-called ‘Richtlijn Externe Toetsing’ (RET; Guideline for External Assessment) is the Dutch 
guideline in which the protocol is described for the procedure to obtain approval for local 
feasibility by a local centre. The guideline is prepared by the Central Committee on Research 
Involving Human Subjects of the Netherlands (CCMO) [10]. The scope of this directive is 
limited in terms of its absolute, mandatory influence on local levels (individual research 
institutions). The RET is endorsed by the Boards of Directors of University Medical Centres 
(UMC) and the Cooperating Top Clinical Medical Teaching Hospitals (Samenwerkende 
Topklinische opleidingsZiekenhuizen, STZ). These hospitals have expressed their 
endorsement of the RET by signing the so called ‘Institution Statement’ [11, 12]. The RET 
and the Institution Statement contain the following mandatory aspects: 1) to provide a 
signed “research statement” by the local researchers, on behalf of supporting facilities in a 
participating centre for assessment by the central Medical Ethical Committee (MEC) [13]; 2) 
an insurance for subjects of each participating centre; and 3) substantive scientific/medical 
ethical assessment of the study protocol and patient information leaflet may only be done 
by the central MEC and not by individual participating centres. Other aspects of the local 
procedures at the level of a participating centre such as the duration, charges and content 
of the process are not regulated by the CCMO (and the CCMO is not allowed to do so). The 
Institution Statement only stipulates in general that local centres should have efficiently 
organized their applications for participation in multicentre trials [11]. 
The Netherlands ranks internationally among the countries with the highest scientific output, 
in terms of volume and quality [14, 15]. One of the most important parameters that determine 
the success rate of clinical research is the speed by which logistic procedures that are required 
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for study initiation are completed. This is especially true for pharmaceutical industry-initiated 
clinical research, in which pharmaceutical companies monitor the procedural and financial 
parameters of individual countries and centres [9]. In such reports the procedure required for 
obtaining approval for local feasibility is mentioned as a cause of declining attractiveness at an 
international level to carry out multicentre clinical trials in The Netherlands [9]. The feasibility 
of multicentre research can be facilitated by standardization of this procedure. Data from The 
Netherlands and other countries specifically indicate a delay caused by the local feasibility 
procedures, confirming that this procedure is complex and difficult to optimize in terms of 
efficiency and costs [14, 16-24].
In the current study we have evaluated the procedure for obtaining approval for local feasibility 
of the participating centres of two investigator-initiated, multicentre randomised trials of 
the Dutch Colorectal Cancer Group (DCCG): CHARISMA and CAIRO5 [25, 26]. The purpose 
of our evaluation is to provide real-life data on this issue and thereby to contribute to the 
development of a more efficient, less costly and uniform procedure.
METHODS
The CHARISMA and CAIRO5 trial evaluate treatment strategies for patients with colorectal 
liver metastases [25, 26]. The CHARISMA trial was reviewed by the MEC of the Erasmus Medical 
Centre, Rotterdam, The Netherlands, and the CAIRO5 trial by the MEC of the Academic Medical 
Centre, Amsterdam, The Netherlands.
THE PROCEDURE
Figure 1 provides an overview of the full procedure for medical ethical approval and approval 
for local feasibility in participating centres. The time period that was involved in obtaining local 
approval in participating centres was evaluated based on four periods:
 A. The time period starting from the date of central medical ethical approval of the MEC 
  to include a new participating centre in the trial up to the date at which official approval 
  was obtained (local feasibility) from the local board of directors of each participating 
  centre.
 B. The time period between the date of central approval of the MEC to include a 
  participating centre in the trial and the date of submission of the complete file to the 
  board of directors of each participating centre. 
 C.  The time period between the date of submission of the complete file to the board of 
  directors of each participating centre and the date of local approval to start the trial.
 D.  The time period between the date of approval of the board of directors of each 
  participating centre and the date of written confirmation by the coordinating research 
  team that the trial was open for inclusion.
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The procedure for obtaining local approval in each centre was also evaluated according to the 
following: 
	   The number and type of documents required for the local procedures that were 
  requested per centre. We specifically kept track of the obligation to deliver a Clinical 
  Trial Agreement (CTA) and a “Good Clinical Practice (GCP)” certificate or “Basic Rules 
  and Organization for Clinical researchers (BROK)” from the local principal investigator;
	 	Any fees charged by the local MEC/trial bureau for the procedure of obtaining local 
  feasibility approval.
Figure 1: Overview of the procedure for obtaining approval to start a multicentre clinical trial in a 
participating hospital
RESULTS
At the time of this analysis the CHARISMA trial was open in 9 centres and the CAIRO5 trial in 
19 centres.
TIME PERIODS
The median and range of time periods A, B, C and D are displayed in table 1. For primary medical 
ethical review, an initial maximum of 60 weeks is allowed for the Medical Ethical Committee to 
assess a study protocol [27]. Therefore, a 60-day time period was chosen as a reference in our 
analyses. The median time to obtain approval of local feasibility from central medical ethical 
approval (period A) was 90 days, with a range from 4-312 days. Time period A took more than 
60 days in 68% of all procedures. Figure 2 displays the variation in time period A between the 
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CHARISMA and CAIRO5 trials in centres that were open for both trials. Time period B had the 
most impact on total duration of approval (time period A). This period took more than 60 days 
in 46% of all procedures. Time period C took more than 60 days in only 21% of procedures. 
Table 1: The median and range of time periods A, B, C and D (days) of all procedures in both trials and of 
CAIRO5 and CHARISMA trial, respectively.
Time period Days
Median Range
A:
All procedures 90 4-312
CAIRO5 136 4-312
CHARISMA 63 32-217
B:
All procedures 64 2-308
CAIRO5 91 2-308
CHARISMA 60 15-116
C:
All procedures 21 3-178
CAIRO5 21,5 3-178
CHARISMA 17 3-315
D:
All procedures 68 3-351
CAIRO5 113 3-351
CHARISMA 41 9-78
Figure 2: The variation in time period A in 5 centres open for both the CHARISMA and CAIRO5 trial. 
X-axis: centres, Y-axis: time period in days.
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Figure 2: The variation in time period A in 5 centres that were open for both the CHARISMA and 
CAIRO5 trial. X-axis: centres, Y-axis: time period in days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Documents 
 
  The median number of documents that were requested per centre for the procedure was 10 
(range 6-10) and did not differ between CHARISMA and CAIRO5 (range 7-16 and 6-20, respectively). 
A CTA was mandatory in 69% of the centres, and 65% of the centres requested a certificate 
of good clinical practice (GCP). Notification in the curriculum vitae of the local investigator that the 
GCP certificate was obtained was often considered as sufficient. 
In case the local committee demanded that any standard file had to be adjusted it 
predominantly concerned the CTA and/or the patient information leaflet. The type of modifications 
of CTA that were requested differed greatly among centres. Also, local centres often required 
additional documents, such as an estimate of radiological diagnostics or laboratory tests that may or 
may not take place in the context of the trial. Documents that are required by supportive 
departments could cause delay of the procedure. Figure 3 displays the different types of documents 
that were involved in all procedures. 
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DOCUMENTS
The median number of documents that were requested per centre for the procedure was 
10 (range 6-20) and did not differ between CHARISMA and CAIRO5 (range 7-16 and 6-20, 
respectively).
A CTA was mandatory in 69% of the centres, and 65% of the centres requested a certificate of 
good clinical practice (GCP). Notification in the curriculum vitae of the local investigator that 
the GCP certificate was obtained was often considered as sufficient.
In case the local committee demanded that any standard file had to be adjusted it 
predominantly concerned the CTA and/or the patient information leaflet. The type of 
modifications of CTA that were requested differed greatly among centres. Also, local centres 
often required additional documents, such as an estimate of radiological diagnostics or 
laboratory tests that may or may not take place in the context of the trial. Documents that are 
required by supportive departments could cause delay of the procedure. Figure 3 displays 
the different types of documents that were involved in all procedures.
Figure 3: Overview of types of documents that participating centres requested for their local approval 
procedures. X-axis: number of centres, Y-axis: document type. 
* local budget form or other local forms designed by participating centres; Procedures were 
analysed in a total of 23 centres.
 
FEES
The average fee charged for the procedure of obtaining local feasibility was €318, with a 
range of €0-1,750. 62% of the centres charged no costs for the procedure.
For CAIRO5 the mean fees were €226 with a range of €0-1,750, the total fees were €4,075. For 
CHARISMA the mean fee was €500 with a range of € 0-1,750, the total fees were € 4,500. For 
all analysed procedures, an unanticipated budget of €8,575 was needed.
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DISCUSSION
The current analysis demonstrates that the procedure for obtaining approval of local feasibility in 
participating centres to multicentre trials greatly varies in duration, content and financial burden.
In 2012 a new guideline for external validation (RET 2012) was implemented in the Netherlands, 
and this guideline is operational since the 1st of March 2012 [10]. The foremost modification in 
the guideline was the abolition of the ‘’local feasibility statement’’, which implied that a medical-
ethical reassessment of the content of the trial protocol by the local centre should no longer be 
performed. The track for obtaining approval of local feasibility for multicentre research has been 
re-evaluated by research groups and by the CCMO after implementation of the new guideline 
in 2012 [3, 6, 7]. The median time lapse between obtaining approval by the central MEC and 
obtaining approval by the board of directors of the local participating centre was 50 days for 
centres who adhered to the new guideline and 118 days for those who did not [3]. In our study 
the median time lapse of this procedure was 90 days, with a range up to 312 days.
Results from an evaluation by the CCMO showed that within 60 days, 50% of the centrally 
approved studies were opened for inclusion of patients in a participating centre [6, 27, 28]. In our 
study this percentage is 32%. In contrast to central medical ethical reviews of clinical research, the 
procedure for local approval has no time limit.
The time period between the date of submission of the complete file to the board of directors 
of a participating centre and the date of local approval to start the trial is relatively short. An 
explanation for this phenomenon is the introduction of the RET 2012 (abolishment of a double 
review). From a researcher’s perspective however, the delay now occurs between the date 
of central approval of the MEC to include a participating centre in the trial and the date of 
submission of the complete file to the board of directors of a participating centre. In other words: 
it is challenging to submit a complete file by local standards, due to variation in local standards. 
This period cannot be influenced by the RET 2012 or the CCMO, due to autonomy of individual 
participating hospitals. Our study demonstrates that the period of time of the total procedure has 
not been shortened. The CCMO also suggested this in their review [6, 28]. 
Lastly, we observed a delay between the date of final local approval and the date of dispatch of 
the letter by which the trial is officially open for accrual. This is the responsibility of the research 
teams and not of the participating centres or local medical ethical committees, and is not part of 
the RET 2012.
THE PROCEDURE
In 2012 the “research statement” replaced the local feasibility statement. The research 
statement has to be signed by the head of department/healthcare group manager/local 
researcher on behalf of the participating centre [13]. However, departments that are not 
directly involved in the primary care of study patients, i.e. diagnostic departments such as 
radiology, clinical laboratory and pathology, are usually not involved in an early stage of the 
local approval procedure. This often results in a delay at a later stage when these departments 
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are confronted with study procedures that involve their collaboration. The use of a uniform 
procedure involving all departments that is initiated as soon as a local centre shows interest 
and before the research statement is signed, may prevent unnecessary delays.
DOCUMENTS
We observed a large variation among centres in the number and characteristics of documents 
that were requested for local approval. There is no national standard research file in The 
Netherlands for this procedure such as exists for the procedure of central approval by the 
medical ethics committee. 
Handling of the CTA is causing an important delay in the procedure. This was also recognized 
in the evaluation by the CCMO [6, 28]. Of note, not all centres require a CTA. The CTA is a 
frequent cause of time-consuming correspondence between the legal departments of the 
initiating organization/centre and the local centres. In The Netherlands a CTA between the 
initiating party and participating centres is not mandatory by law, and there is no uniformity 
regarding the content of CTA. Several CTA templates are available, however these have been 
drafted by different authorities and show substantial disparities (CCMO [29], STZ-Nefarma-
ACRON-NKI [30]). We observed significant differences among participating centres in the 
items that their legal departments requested to modify within a CTA.  
Because a GCP certificate is legally not mandatory for local investigators, these were not 
always available [31]. Where legislation is not available or multi-interpretable the Dutch 
Federation of University Medical Centres (NFU) academic hospitals together contribute to 
its development. In case of the GCP certificate the NFU urges to make this mandatory [32]. 
Currently, the GCP certificate is a cause for delay. A clear statement on this issue in the CCMO 
guideline would facilitate this process.
FINANCIAL COMPENSATION
Despite the signing of the ‘Institution Statement’ by 8 academic hospitals and 27 
Cooperating Top Clinical Medical Teaching Hospitals [12], 38% of the hospitals charged 
widely varying fees for the procedure of local approval. The Institution Statement only 
mentions that participation in multicentre research should be organized and supported as 
efficiently as possible, and the issue of charges is not mentioned. The observed variation in 
fees is not logical and undesirable, especially for investigator-initiated studies that usually 
have a limited budget. We support a procedure that is free of charges or a procedure with 
transparent and uniform costs, taking the nature of the study into account (investigator- 
versus pharmaceutical industry-initiated).
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CONCLUSION
Great variation exists in the procedures for obtaining approval for local feasibility of 
multicentre research in terms of time, content and costs. These variations are unpredictable 
and form a serious obstacle in conducting scientific clinical research in The Netherlands. Delay 
in the process of initiation of studies decrease the chance of successful accrual of patients and 
thereby endanger their successful completion. This is not acceptable from the perspective 
of patients, researchers and funding bodies. This process is not within the scope of the RET 
2012. Consensus on simplification of the procedure is urgently needed. Collaboration with 
all stakeholders on further standardization, centralization and digitalization of the procedure 
would be of great value. Currently three Dutch cancer research groups, the Dutch Colorectal 
Cancer Group (DCCG), Breast Cancer Research Group (BOOG), Hematology Oncology 
Research group (HOVON), in collaboration with the Dutch Comprehensive Cancer Centre 
(IKNL) and Dutch Cancer Foundation (KWF) are initiating the a national platform (Dutch 
Oncology Research Platform, DORP) which aims among other issues to coordinate and 
create uniformity in logistical procedures in investigator-initiated clinical cancer research in 
The Netherlands.
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ABSTRACT 
AIM 
The combination of surgery and chemotherapy (CTx) is increasingly accepted as an effective 
treatment for patients with colorectal liver metastases (CRLM). However, controversy exists 
whether all patients with resectable CRLM benefit from perioperative CTx. We investigated 
the impact on overall survival (OS) by neo-adjuvant CTx in patients with resectable CRLM, 
stratified by the clinical risk score (CRS) described by Fong et al.   
METHODS 
Patients who underwent surgery for CRLM between January 2000 and December 2009 were 
included. We compared OS of patients with and without neo-adjuvant CTx stratified by the 
CRS. The CRS includes five prognosticators and defines two risk groups: low CRS (0–2) and 
high CRS (3–5).   
RESULTS 
363 patients (64% male) were included, median age 63 years (IQR 57–70). Prior to resection, 
219 patients had a low CRS (neo-adjuvant CTx: N=65) and 144 patients had a high CRS (neo-
adjuvant CTx: N=88). Median follow-up was 47 months (IQR 25–82). In the low CRS group, 
there was no significant difference in median OS between patients with and without CTx (65 
months (95% CI 39–91) vs. 54 months (95% CI 44–64), P = 0.31). In the high CRS group, there 
was a significant difference in OS between patients with and without CTx (46 months (95% 
CI 24–68) vs. 33 month (95% CI 29–37), P=0.004).   
CONCLUSION 
In our series, patients with a high CRS benefit from neo-adjuvant CTx. In patients with a low 
risk profile, neo-adjuvant CTx might not be beneficial.
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INTRODUCTION
Colorectal carcinoma is one of the leading causes of cancer death world-wide, mostly as a 
consequence of metastatic disease [1]. Administration of combined chemotherapy regimens 
improves survival rates of patients with colorectal metastases (CRLM) [2-4]. If metastases 
are confined to the liver, surgical resection is the most effective therapy, providing the only 
potential for cure [5, 6]. However, cancer relapse after curative resection of CRLM is a common 
phenomenon, with recurrence rates up to 50% in the first 2 years [7]. In an attempt to reduce 
these recurrence rates, the combination of liver resection with systemic therapy, either 
pre-, peri- or postoperatively, is increasingly researched. Multiple studies have investigated 
the impact of adjuvant chemotherapy in addition to surgery for CRLM, but have failed to 
show survival benefit [8, 9]. Recently, the mature results of the landmark EORTC 40983 trial, 
studying the impact of perioperative chemotherapy, were published showing no overall 
survival benefit for patients in the chemotherapy group [10, 11]. Therefore, the exact role 
of systemic therapy in combination with resection for CRLM remains unclear. Nonetheless, 
some reports recommend to treat the majority of patients with CRLM with neo-adjuvant 
chemotherapy [12]. 
In order to predict the likelihood of tumour recurrence and survival after resection of 
CRLM, several Clinical Risk Scores (CRS) have been developed [5, 13-18]. The most widely 
used and validated CRS has been described by Fong et al. in 1999 [15]. In this publication, 
5 independently prognostic clinical variables for survival after surgery for CRLM are 
identified. Furthermore, 2 risk groups (high/low) are characterized: patients with a high risk 
profile have significantly worse overall survival rates as compared to patients with a low 
risk profile. Although all CRLM may well be regarded as “high risk”, this CRS may explain, at 
least in part, the relative lack of efficacy of systemic therapy when combined with surgery 
in the metastasized setting. It is not uncommon in other types of malignancies (e.g. breast, 
primary colon) to reserve the use of adjuvant chemotherapy to those patients with the most 
advanced disease (highest risk profile). The present retrospective study aimed to evaluate 
overall survival outcome in patients with and without neo-adjuvant chemotherapy, stratified 
by their clinical risk profile as described by Fong.
PATIENTS AND METHODS 
Between January 2000 and December 2009, all consecutive patients who underwent liver 
resection for CRLM were analysed. Patients were assessed by Fong’s CRS and excluded from the 
analysis if they had missing data to calculate the CRS and/or extrahepatic disease. Calculation 
of the CRS was based on clinical data at diagnosis of CRLM. The clinical prognosticators in 
Fong’s CRS were: (1) node positive status of primary tumour (pathological), (2) disease-free 
interval from the primary to discovery of the liver metastases < 12 months, (3) number of 
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metastases > 1 (radiological), (4) size of the largest metastases > 5 cm (radiological) and (5) 
preoperative CEA level > 200 ng/ml [15]. Each criterion is assigned one point. The prognostic 
value of this scoring system has been verified by independent research groups [19, 20]. We 
identified two risk groups: low risk (CRS 0-2) and high risk (CRS 3-5), in concordance with the 
original study. The rationale for dividing patients in two risk groups was to evaluate whether 
the CRS may play a role in explaining the relative lack of efficacy of chemotherapy when 
combined with surgery in the metastasized setting. 
CHEMOTHERAPY
Erasmus MC Cancer Institute is a tertiary referral hospital for patients with CRLM. In our 
treatment protocol, perioperative chemotherapy is not standard of care for patients 
with CRLM. All patients in this study were assessed by a dedicated liver surgeon in a 
multidisciplinary meeting with respect to resectability before potential administration 
of chemotherapy. Patients in our hospital received neo-adjuvant chemotherapy in case 
of multiple (≥ 4), synchronous metastases. However, a large proportion of patients in this 
study received neo-adjuvant chemotherapy in the referring hospital, after which patients 
are transferred to our unit for liver surgery. The reason for administering one type of 
chemotherapy over another was based on local treatment protocols. All patients received 
a combination of 5-fluorouracil (5-FU)/Capecitabine and Oxaliplatin or Irinotecan, with or 
without Bevacizumab. The response to neo-adjuvant systemic therapy was assessed after 
two or three cycles by CT scan (according to RECIST [21]) and carcinoembryonic antigen 
levels. Further treatment strategy was determined on basis of the tumour response and 
extent of the disease. When the liver metastases were resectable, a laparotomy was planned 
at least three weeks after the last course of neo-adjuvant chemotherapy. Bevacizumab had to 
be excluded from the last course of chemotherapy to ensure an interval of at least six weeks. 
All patients included in this study had resectable CRLM; resectability of liver metastases was 
assessed by a liver surgeon at diagnosis. None of the patients received standard adjuvant 
systemic therapy after liver surgery. 
Patients were included after 2000, as from then on modern chemotherapy and biologicals 
were available. In our unit, the definition of resectability has not changed since 2000 (i.e. 
possibility of an R0 resection, the feasibility of securing vascular in- and outflow as well as 
biliary drainage to the remaining segments, and a future liver remnant of at least 20-30%) 
FOLLOW-UP 
Follow-up after resection of CRLM consisted of clinical examination and measurement of 
CEA every 3 months. Abdominal imaging (ultrasound, CT-thorax-abdomen) was performed 
at 3, 6, 9 and 12 months in the first year, every 6 months the second year and once per year 
thereafter. If recurrent disease occurred, palliative or curative treatment strategies were 
considered by the multidisciplinary team. 
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OUTCOME 
Overall survival (OS) was defined as the interval in months between resection of CRLM and 
death, or the date of last follow-up. Disease-free survival (DFS) was defined as the interval in 
months between resection of CRLM and recurrence, death without recurrence, or date of last 
follow-up without recurrence. 
STATISTICS 
Descriptive values are expressed as median (interquartile range (IQR)). Variables were 
compared by means of chi-square analysis or Fischer’s exact test (depending on the sample 
size) or with the independent Student’s t test or Mann-Whitney U test when appropriate. 
Survival analysis was performed by the Kaplan-Meier method. Comparison between survival 
curves was made by log-rank tests. For the multivariate analysis only parameters with a p 
value < 0.10 in the univariate model were entered in the Cox regression model. The SPSS 
statistical package (version 21.0, Chicago, IL, USA) was used for statistical analysis; a p-value 
of ≤ 0.05 was considered statistically significant. 
RESULTS 
Between January 2000 and December 2009, 442 patients underwent liver resection for 
CRLM. Of these, 77 patients (17%) were excluded due to extrahepatic disease and/or missing 
data for calculation of the CRS. 2 patients were lost to follow-up, leaving 363 patients eligible 
for analysis (42 patients extrahepatic disease, 33 patients missing data and 2 patients with 
both, 2 lost to follow-up). Neo-adjuvant chemotherapy was given in 153 (42%) patients. 51 
patients received adjuvant chemotherapy for primary colorectal cancer (30 patients in the 
low CRS group and 21 patients in the high CRS group, P=0.093). 15 of these patients received 
further neo-adjuvant chemotherapy for liver metastases. 
Neo-adjuvant capecitabine monotherapy was administered in 5 patients and 5-FU/LV 
monotherapy was administered in 3 patients. The majority of patients receiving neo-adjuvant 
chemotherapy received either oxaliplatin-based chemotherapy (88%) or irinotecan-based 
chemotherapy (7%). Sixty-seven patients received concomitant bevacizumab (44%) mostly 
in combination with oxaliplatin (88%). The median number of chemotherapy cycles for all 
patients was 5 (IQR 4-6). The median number of chemotherapy cycles was also 5 (IQR 4-6) in 
patients with a low risk profile and 6 in patients with a high CRS (IQR 4-7). Patient characteristics 
are displayed in tables 1, 2 and 3. Eighty-four patients (23%) had an R1 resection. The numbers 
of R1 resections in patients with and without neo-adjuvant chemotherapy were comparable: 
28% vs. 20% (P=0.09), respectively. An R1 resection occurred more often in patients with a 
high CRS than in patients with a low CRS (38% versus 14%, P<0.001). The median follow-up 
of patients in this study was 47 months (IQR 25-82). Five patients (1.6%) died postoperatively.
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Table 1: Characteristics of patients with a low CRS by neo-adjuvant chemotherapy treatment (CTx)
Variables
Without CTx (N=154)
       value              % or IQR
Without CTx (N=65)
      value              % or IQR P value
All patients (N=219)
      value             % or IQR
Male 95 62% 47 72% 0,133 142
Age median 66 59-72 63 58-70 0,09 65 59-71
Primary tumour
Rectal cancer 70 46% 36 55% 0,179 106 48%
pT-stage
pT3 107 70% 40 62% 0,253 147 67%
pT4 9 6% 7 11% 0,201 16 7%
Positive lymph node (p) 61 40% 46 71% 0,145 80 37%
CEA µg/L
median 15 6-49 16 6-47 0,726 16 6-48
mean 48 37 45
Liver metastases
Synchronous (≤ 3mo) 27 18% 40 62% < 0,001 67 31%
Synchronous (≤ 12mo) 59 38% 50 77% < 0,001 109 50%
Diameter (cm) (r) median 3,2 2,4-4,4 2,6 2-3,8 0,016 3 2-4
Number of metastases (r)
median 1 1-2 2 1-4 < 0,001 1 1-2
Bilobar 22 14% 27 42% < 0,001 49 22%
R1 resection (p) 21 14% 10 16% 0,743 31 14%
p = as objectified by pathologist, r = as objectified by radiologist
Table 2: Characteristics of patients with a high CRS by neo-adjuvant chemotherapy treatment (CTx)
Variables
Without CTx (N=56)
       value              % or IQR
Without CTx (N=88)
      value              % or IQR P value
All patients (N=144)
      value             % or IQR
Male 36 64% 54 61% 0,724 90 63%
Age median 61 57-69 61 56-68 0,397 61 56-68
Primary tumour
Rectal cancer 26 46% 25 28% 0,028 51 35%
pT-stage
pT3 43 77% 73 83% 0,362 116 81%
pT4 6 11% 7 8% 0,573 13 9%
Positive lymph node (p) 49 88% 68 77%  117 81%
CEA µg/L
median 26 8-70 55 8-229 0,246 34 8-202
mean 104 274 208
Liver metastases
Synchronous (≤ 3mo) 27 48% 72 82% < 0,001 99 69%
Synchronous (≤ 12mo) 46 82% 81 92% 0,073 127 88%
Diameter (cm) (r) median 3,5 2-5,5 4,5 3-6 0,033 4 2,5-5,8
Number of metastases (r)
median 3 2-3 4 2-5 0,004 3 2
Bilobar 31 55% 55 63% 0,394 86 60%
R1 resection (p) 21 38% 32 38% 0,949 53 38%
p = as objectified by pathologist, r = as objectified by radiologist
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Table 3: Characteristics of patients by CRS
Variables
CRS low (N=219)
       value              % or IQR
CRS high (N=144)
      value              % or IQR P value
All patients (N=363)
      value             % or IQR
Male 142 65% 90 63% 0,65 232 64%
Age median 65 59-71 61 56-68 0,001 63 57-70
Primary tumour
Rectal cancer 106 48% 51 35% 0,015 157 43%
pT-stage
pT3 147 67% 116 81% 0,005 263 73%
pT4 16 7% 13 9% 0,554 29 8%
Positive lymph node (p) 80 37% 117 81%  < 0,001 197 54%
CEA µg/L
median 16 6-48 34 8-203 < 0,001 19 6-69
mean 45 208 110
Liver metastases
Synchronous (≤ 3mo) 67 31% 99 69% < 0,001 166 46%
Synchronous (≤ 12mo) 109 50% 127 88% < 0,001 236 65%
Diameter (cm) (r) median 3 2-4 4 3-6 < 0,001 3,4 2,2-5
Number of metastases (r)
median 1 1-2 3 2-4 < 0,001 2 1-3
Bilobar 49 22% 86 2-4 < 0,001 135 37%
R1 resection (p) 31 14% 53 38% < 0,001 84 23%
Chemotherapy
Yes 65 30% 88 61% < 0,001 153 42%
Response
CR 5 8% 3 3% 8 5%
PR 40 64% 61 69% 101 67%
SD 18 29% 22 25% 40 27%
PD 0 0 1 1% 1 1%
No 154 70% 56 39% 210 48%
p = as objectified by pathologist, r = as objectified by radiologist
DISEASE FREE SURVIVAL AND RECURRENCE
For patients with neo-adjuvant chemotherapy the median DFS was 12 months (95% 
confidence interval (CI) 9-15) and for patients without chemotherapy it was 13 months 
(95% CI 10-16, P=0.83). In patients with a low CRS there was no difference in the median 
DFS between patients with and without chemotherapy (13 months, 95% CI 9-17) versus 16 
months (95% CI 10-22, P=0.96). The 5-year DFS was 34% versus 27% respectively. In patients 
with a high CRS there was a significant difference in median DFS between patients with and 
without chemotherapy (11 months, 95% CI 7-15) versus 9 months (95% CI 8-10, P=0.02). The 
5-year DFS was 24% versus 9% respectively (Figure 1). 
During follow-up, 266 patients (73%) developed a recurrence. Local treatment was performed 
in 122 patients (47%) (surgery, radiofrequency ablation, stereotactic radiotherapy), 112 
patients (43%) had palliative chemotherapy and 29 patients (11%) received neither 
chemotherapy nor local treatment. Patients treated with neo-adjuvant chemotherapy for 
initial CRLM developed less extrahepatic recurrences (versus hepatic or local) than patients 
treated without CTx (extrahepatic recurrence in patients treated with and without CTx: low 
CRS 46% vs. 67%, P=0,032 and high CRS 40% vs. 71%, P=0,001, respectively). In line with 
these findings, more patients with CTx for initial CRLM were treated with curative intent 
for recurrent disease, again in both risk groups. However, this difference did only reach 
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significance in the high CRS group (curative treatment for recurrent disease in patients 
treated with and without CTx, respectively: low CRS 45% vs. 59%, P=0,109, high CRS 22% vs. 
43%, P=0,015). 
OVERALL SURVIVAL 
For patients with neo-adjuvant chemotherapy the median OS was 57 months (95% CI 40-74) 
and for patients without chemotherapy it was 45 months (95% CI 38-52), P=0.08. In patients 
with a low CRS there was no difference in the median OS between patients with and without 
chemotherapy (65 months, 95% CI 39-91) versus 54 months (95% CI 44-64, HR 0.83, P=0.31). 
The 5-year OS was 52% versus 46% respectively. In patients with a high CRS the median OS 
was significantly higher in patients who received chemotherapy compared with those who 
did not: 46 months (95% CI 24-68), versus 33 months (95% CI 29-37, HR 0.57, P=0.004). The 
5-year OS was 46% versus 20% respectively (Figure 1). 
Excluding all patients with a R1 resection yielded comparable results. In patients with a low 
CRS there was no difference in DFS and OS between patients treated with or without neo-
adjuvant chemotherapy, respectively: DFS 14 (95% CI 8-20) vs. 17 months (95% CI 11-23, 
P=0,880), OS 78 (95% CI 51-105) vs. 57 (95% CI 42-72, HR 0.76, P=0,21). In patients with a 
high CRS there was a significant difference in DFS and OS between patients treated with or 
without neo-adjuvant chemotherapy, respectively: DFS 13 (95% CI 6-20) vs. 8 months (95% 
CI 6-10, P=0,003), OS 68 (95% CI 38-98) vs. 34 months (95% CI 31-37, HR 0.47, P=0,004). 
Figure 1. Low and high CRS in patients with and without neo-adjuvant chemotherapy (CTx): disease 
free survival and overall survival
Figure 1. Low and high CRS in patients with and without neo-adjuvant chemotherapy (CTx): disease 
free survival and overall survival 
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UNIVARIATE AND MULTIVARIATE ANALYSES 
In patients with a low CRS, the univariate analysis showed that 2 factors were prognostic for OS: 
T-stage primary tumour (T4) and positive resection margin (R1). In multivariate analysis these 
factors remained prognostic for OS (Table 4). In patients with a high CRS, 2 factors were prognostic 
for OS in univariate analysis: primary tumour location (colon vs. rectum) and administration 
of neo-adjuvant chemotherapy. In multivariate analysis, only administration of neo-adjuvant 
chemotherapy remained of significant influence on overall survival (Table 4). Excluding patients 
with a R1 resection from the uni- and multivariate analysis generated comparable results. 
Table 4: Univariate and multivariate analysis, overall survival
CRS low (N=219) CRS high (N=144)
Variables
Median
Survival
(95% CI)
Univariate 
HR (95%CI)
P-value*
Multivariate
HR (95% CI)
Median
Survival
(95% CI)
Univariate
HR (95% CI)
P-value*
Multivariate
HR (95% CI)
Gender
Male 63 (49-77) 0,934 (0,666-1,310)
-
41 (33-49) 0,961 (0,648-1,424)
-
Female 49 (36-62) P=0,692 34 (29-39) P=0,841
Age
< 65 59 (47-71) 1,131 (0,816-1,566)
-
37 (31-43) 1,170 (0,786-1,742)
-
> 65 54 (38-70) P=0,460 35 (25-45) P=0,438
Primary tumour
Rectum 57 (42-72) 1,026 (0,742-1,421)
-
34 (28-40) 1,436 (0,969-2,130) 1,340 (0,9-1,995)
Colon 58 (44-72) P=0,875 43 (27-59) 0,072 P=0,149
T-stage
T4 32 (10-54) 2,447 (1,452-4,124) 2,670 (1,575-4,526) 41 (27-55) 1,134 (0,590-2,179)
-
T 1-3 59 (49-69) P=0,001 P < 0,001 37 (31-43) 0,706 
Lymph node
Positive 51 (43-59) 1,279 (0,919-1,779)
-
35 (30-40) 1,429 (0,849-2,406)
-
Negative 65 (51-79) P=0,279 57 (15-99) P=0,179
Liver metastases
Disease free interval
< 12 months 54 (43-65) 0,768 (0,554-1,063)
-
37 (31-43) 1,045 (0,595-1,836)
-
> 12 months 63 (40-86) P=0,112 37 (28-46) P=0,878
Largest size metastases (cm)
> 5 59 (38-80) 1,123 (0,744-1,696)
-
35 (22-48) 1,244 (0,844-1,831)
-
< 5 56 (45-67) P=0,581 39 (33-45) P=0,270
Number metastases
> 1 58 (37-79) 1,087 (0,776-1,524)
-
32 (12-52) 1,214 (0,632-2,331)
-
1 57 (45-69) P=0,627 37 (31-43) P=0,561
CEA level  µg/L
> 200 32 (16-48) 1,606 (0,657-3,924)
-
43 (14-72) 0,916 (0,590-1,420)
-
< 200 58 (48-68) P=0,299 35 (29-41) P=0,916
Tumour distribution
Bilobar 48 (21-75) 1,235 (0,847-1,8)
-
35 (29-41) 1,253 (0,845-1,858)
-
Unilobar 58 (45-71) P=0,272 41 (27-55) P=0,263
Resection margin
R1 43 (22-64) 1,927 (1,256-2,956) 1,837 (1,187-2,842) 41 (31-51) 1,259 (0,848-1,868)
-
R0 61 (47-75) P=0,003 P=0,006 34 (27-41) P=0,259
Chemotherapy
Yes 65 (39-91) 0,825 (0,570-1,195)
-
46 (24-68) 0,572 (0,390-0,841) 0,594 (0,403-0,876)
No 54 (44-64) P=0,309 33 (29-37) P=0,004 P=0,009
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DISCUSSION 
This is the first study to demonstrate (retrospectively) that patients with primary resectable CRLM 
and a high clinical risk profile gain significant overall survival benefit when adding neo-adjuvant 
chemotherapy to resection for metastases. All patients in this study have a potential follow-up of 
at least 5 years, as can be seen by the few censored cases in the Kaplan Meier curves. 
In the last decade, the development of modern chemotherapeutic agents and biologicals has 
significantly improved OS in patients with CRLM [2-4, 22-29]. The success of systemic therapy 
in the palliative setting has prompted studies that evaluated the role of chemotherapy in 
combination with liver resection [9-11, 30]. However, these studies regularly involve strict 
inclusion criteria. Consequently, patients with a high risk profile - who might benefit the most 
from chemotherapy – may be underrepresented in these studies. Since genuine survival 
benefit of multimodal therapies has not yet been demonstrated, could the insignificant 
impact of chemotherapy on overall survival then be explained by the relatively low risk 
profile of patients in these trials?
The present role of perioperative chemotherapy for primary resectable metastases 
was established in a large randomized controlled trial, which compared perioperative 
chemotherapy with surgery alone [10]. The mature overall survival data of this trial were 
recently published; although perioperative chemotherapy improved DFS, no increase in 
overall survival could be objectified after a median follow-up of 8,5 years [11]. This may 
be explained by the fact that at present, recurrences can be adequately treated by means 
of systemic and/or local therapies, as the authors suggest. Additionally, this trial was not 
powered upfront to detect differences in overall survival, as explained by the authors. 
Alternatively, the lack of impact on overall survival might be a result of the fact that patients 
eligible for randomization in the EORTC 40983 trial had a relatively low risk profile. Although 
the study population of the current study is comparable to the population in the EORTC 
trial in general (age 63 vs. 63; male 64% vs. 66%; rectal primary 43% vs. 42%, T3-T4 stage 
73%-8% vs. 70%-13%; positive LN 54% vs. 56%; synchronous 46% vs. 35%; median number 
of lesions 2 vs. 1; median diameter 3 cm vs. the sum of largest diameter 50 mm -33 mm 
after CTx, respectively [10]), uncertainty exists about the exact number of high risk patients 
represented in EORTC 40983. 
Several authors have advocated the concept of stratification by CRS. Tomlinson et al. 
demonstrated in actual 10-year survivors of liver surgery for CRLM that patients with a low 
CRS had a cure rate of 21% versus 10% in patients with a high CRS. They suggest this finding 
may be used to identify patients who might benefit from neo-adjuvant chemotherapy [31]. 
In a large, non-randomized study by Parks et al., adjuvant therapy did seem to improve OS 
after resection of CRLM [32]. In their study, patients with a high CRS had more benefit from 
adjuvant therapy than patients with a low CRS. Subsequently, Rahbari et al. performed a 
similar analysis as in our current study, however, with a different chemotherapy sequence [33]. 
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Instead of neo-adjuvant chemotherapy, they analysed the effect of adjuvant chemotherapy 
in addition to resection of colorectal liver metastases and stratified patients according to 
Fong’s CRS. The outcome has a striking similarity to our results. In patients with a high CRS, 
adjuvant chemotherapy was associated with a marked survival advantage, whereas it was 
of no benefit in patients with a low CRS. Additionally, Adam et al. performed an analysis of 
the LiverMetSurvey database on patients with solitary, metachronous, primarily resectable 
metastases. These patients have favourable tumour biology and a low CRS. The authors 
concluded that these patients do not benefit from preoperative chemotherapy [34]. Finally, 
Sorby et al. demonstrated in an exploratory retrospective analysis of the EORTC 40983 study 
that CEA was the strongest baseline predictive factor for the benefit of perioperative FOLFOX 
[35]. They conclude that moderately and highly elevated CEA serum levels were both 
predictive for the benefit of perioperative chemotherapy; an obvious explanation would 
be that elevated CEA is a surrogate for more advanced disease [35]. Again these results 
suggest a role for CRS’s when considering chemotherapy in addition to surgery for CRLM, 
as delineated in a recently published editorial [36]. Undoubtedly other more sophisticated 
markers may better stratify patients with regard to outcome. However, cellular, proteomic or 
genomic markers are not readily available. 
This study might be biased due to its non-randomized, retrospective, single-centre design. 
However, patients were included from a prospective database and differences in terms of the 
main characteristics did not influence OS. In our current treatment protocol perioperative 
chemotherapy is not considered to be standard of care for patients with CRLM. We consider 
patients for neo-adjuvant chemotherapy in case of initially difficult/irresectable liver 
metastases (ill location) or multiple (≥4) synchronous metastases. This implies that within the 
high CRS group, baseline characteristics differed between patients treated with and without 
neo-adjuvant chemotherapy on basis of number of metastases and time to development of 
metastases (see table 2). Due to our treatment protocol we selected patients with relatively 
unfavorable tumor biology for chemotherapy, even within the high risk group. However, this 
proves the significant overall survival benefit in patients with a high risk profile treated with 
CTx is even more striking. Within the low CRS group on the other hand, patients treated with 
or without chemotherapy had comparable survival rates. Again, patients within this group 
who received neo-adjuvant chemotherapy had significantly worse tumour characteristics 
(see table 1), again (at least partially) generated by our local selection criteria for multimodal 
therapy. Theoretically, these patients might have had poorer survival rates without 
neo-adjuvant chemotherapy. Therefore, this study at best suggests that neo-adjuvant 
chemotherapy will not improve survival in the low CRS group. Other factors might contribute 
to the OS benefit we find in high risk patients receiving neo-adjuvant CTx. Recurrent disease 
was hepatic in most cases for patients treated with neo-adjuvant CTx, in both risk groups (as 
compared to extra-hepatic). More patients receiving neo-adjuvant CTx for initial CRLM were 
treated with curative intent for recurrent disease; this difference only reached significance 
in the high risk group. Whether the location of recurrent disease and possibility to treat 
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recurrent disease with curative intent is a consequence of neo-adjuvant CTx for initial CRLM 
remains unknown. Additional prospective studies are needed to explore the exact role of 
multimodal therapies in patients with a high risk profile. 
Since only patients coming to resection were included in this study, there is a potential bias 
of patients who have progressed under chemotherapy and were therefore not considered 
surgical candidates. This failure to comply with intention to treat principles is inherent to a 
retrospective study. However, progression under chemotherapy treatment is rare - 7% in the 
EORTC 40983 trial [10, 11] – with the availability of effective chemotherapeutics. Therefore 
we suggest that this phenomenon did not have a major impact on our conclusion. Finally, 
patients with a high risk profile might not have received chemotherapy for other reasons 
than pure oncologic risk, such as age and comorbidity.  
The findings of this study have prompted a multicentre randomized controlled trial, 
investigating the effects of neo-adjuvant chemotherapy in high risk patients with resectable 
colorectal liver metastasis as compared to surgery alone (EudraCT number: 2013-004952-39).
CONCLUSION
In this study we demonstrate that stratifying patients with resectable CRLM according to 
their clinical risk profile, as described by Fong et al, could provide a useful tool for selecting 
patients who are most likely to obtain survival benefit from neo-adjuvant chemotherapy. 
Although the indication for neo-adjuvant chemotherapy may not solely be based on overall 
survival benefit, we believe it should be included in the decision making process. 
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ABSTRACT
BACKGROUND
Nodal status of primary colorectal cancer is of prognostic value for survival after resection 
for colorectal liver metastases (CRLM). However, the past decade effective adjuvant 
chemotherapy for lymph node positive primary colon cancer was introduced. This study 
evaluated the prognostic value of primary lymph node status in patients with resectable 
metachronous CRLM in the era of effective systemic therapy.
METHODS
Between January 2000 and December 2011, all consecutive patients undergoing curative 
liver resection for colorectal liver metastases (CRLM) were retrospectively analyzed. Overall 
survival (OS) was analyzed by localization of the primary tumor (colon vs. rectum) and by 
lymph node status (positive vs. negative) of the primary tumor. 
RESULTS
286 patients with metachronous CRLM’s were selected. 5-year OS was similar for colon and 
rectal primaries (42% and 40%, P=0.62). Lymph node positivity was only a prognostic factor 
in rectal primaries (N + 32% vs. N0 49% P=0.04) and not in colon primaries (N+ 42% vs. N0 
41% P=0.99). In multivariate analysis, these results were confirmed.
CONCLUSION
The current study demonstrates that nodal status of primary colon malignancies does not 
have prognostic value in patients undergoing resection for metachronous CRLM. A possible 
explanation might be the administration of effective adjuvant chemotherapy in node 
positive colon cancer.
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INTRODUCTION
Approximately half of patients suffering from colorectal cancer will develop metastases, 
with the liver being prone to distant disease progression. In approximately 20 percent of 
patients with colorectal malignancies, hepatic metastases are found at time of diagnosis, 
while another 30 percent of patients develop metachronous disease [1, 2]. Currently, surgical 
resection of colorectal liver metastases (CRLM) is the most effective therapy, providing the 
only potential for cure. With the contemporary surgical management of CRLM, patients 
experience 40-60 percent 5-year overall survival (OS) [3-7]. However, the management of 
colorectal cancer and CRLM continues to evolve, with modern multimodality therapies 
improving outcome.
Over time, multiple clinical risk scores (CRS) were developed to determine the outcome after 
surgery for CRLM [8-11]. Fong’s CRS is the most widely used and validated [8]. In this CRS, five 
prognostic factors for OS are identified: node positive primary tumor, disease free interval 
<12 months, CEA levels >200µg/L, number of metastases >1 and size of metastases >5 cm. 
Initially, this CRS was designed to select patients who may benefit from CRLM resection. In 
addition, these criteria proved to be useful for stratifying patients in clinical trials. In most 
CRS’s, lymph node positivity of the primary tumor is of prognostic value after surgery for 
CRLM [8, 9, 11].
In the era of effective systemic for colorectal cancer, traditional clinical risk scores as such may 
no longer provide a reliable prognostic tool. In the past two decades treatment strategies 
and surgical techniques for primary colorectal cancer and CRLM has altered significantly. 
Regarding primary colorectal tumors, two major developments have reshaped outcome of 
colorectal cancer patients: 1) the introduction of total mesorectal excision with or without 
neo-adjuvant (chemo-) radiation in rectal cancer [12-14]; and 2) the introduction of effective 
adjuvant chemotherapy in colon cancer [15]. These developments might influence the 
prognostic value of primary-tumor-related clinical variables specifically, such as lymph node 
status. In the Netherlands, adjuvant chemotherapy is reserved for lymph node positive 
primary colon malignancies, in contrast to lymph node positive rectal cancer where no 
adjuvant therapy is administered. Thus, localization of the primary tumor may indirectly 
influence the prognostic value of lymph node status. The purpose of this study is to evaluate 
specifically the prognostic value of nodal status in primary colorectal tumors in the modern 
era of adjuvant systemic chemotherapy.
PATIENTS AND METHODS
Between January 2000 and December 2011, all consecutive patients undergoing resection of 
CRLM in Erasmus MC Cancer Institute, a tertiary referral center, were retrospectively analyzed. 
Only patients with metachronous CRLM were selected. In our database, metachronous 
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disease is characterized by metastases occurring >3 months after diagnosis of primary 
tumor. As we aimed for a study population of patients in which we could test for the possible 
impact of adjuvant chemotherapy on node positive primaries, we needed to exclude all 
synchronous metastases.
Patient characteristics were collected retrospectively from a prospectively maintained 
database. Data in our database comprises: gender, age, primary tumor site, primary tumor 
pathological and lymph node stage (pTN), carcinoembryonic antigen (CEA), interval between 
resection of primary tumor and detection of liver metastases, location, distribution, size and 
number of liver metastases. Furthermore, type of liver surgery, radicality of surgery (R1, R0), 
extrahepatic disease, adjuvant treatment of primary tumor, neo-adjuvant chemotherapy for 
CRLM, and neo-adjuvant (chemo) radiotherapy for primary rectal malignancies were listed. 
In our center, patients with locally advanced rectal cancer have been treated with long 
course scheme neo-adjuvant radiotherapy: 45–50 Gy (in fractions of 1.8–2 Gy) with or 
without chemotherapy (capecitabine 825 mg/m2 twice a day only on radiotherapy days). 
For intermediate-risk rectal cancer, short course neo adjuvant radiotherapy is administered: 
25 Gy (in fractions of 5 Gy). On basis of high age and/or comorbidities, short course pre-
operative radiotherapy was considered. 
Most resections of primary tumors were performed in referring hospitals, as ours is a tertiary 
referral center for liver surgery. Lymph node harvesting during colorectal surgery is, as in many 
other countries, standardized by Dutch guidelines. In the yearly Dutch Surgical Colorectal 
Audit (DSCA), nodal harvesting is delineated as a quality indicator of colorectal cancer care. 
According to the Dutch Institute for Clinical Auditing, at least 10 lymph nodes were analyzed 
by the pathologist in > 91% of patients that underwent surgery for colon cancer nationwide 
[16]. Although resections of primary tumors in our patient cohort generally occurred outside 
our institution, lymph node harvesting was performed in a standardized process resulting in 
a consistent number of nodes analyzed by a pathologist. 
Liver resections were performed by a single or two-stage procedure and included wedge 
resections, segmental resections, hemihepatectomies and radiofrequency ablations (RFA). 
Hepatic parenchymal resection was performed with an ultrasonic surgical aspirator and a 
monopolar coagulator. R0-resections were defined by the absence of microscopic tumor 
invasion of the resection margins, and R1-resections were defined by the presence or 
microscopic tumor invasion of the resection margins.
During follow-up, patients visited the outpatient clinic every 3 months in the first 2 years 
after CRLM resection for clinical examination and CEA-determination. Thereafter, patients 
visited the outpatient clinic every 6 months and were discharged from follow up after 5 years. 
Abdominal imaging (ultrasound, CT of thorax and abdomen) was performed biannually 
during the first 3 years and thereafter annually. If disease recurred, a decision on whether to 
initiate chemotherapy treatment (again) or to perform a second resection was made by the 
multidisciplinary team.
Overall survival (OS) was defined as the interval in months between resection of the first 
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CRLM and death, or the date of last follow-up. 
STATISTICAL ANALYSIS
Descriptive values are expressed as median (interquartile range (IQR)). Categorical data 
are presented as numbers (percentage frequencies). Differences between subgroups 
were compared by the usage of chi-square tests (χ²) or Fisher’s exact tests as appropriate. 
Continuous data with a skewed distribution are displayed as medians and compared with 
the Mann-Whitney U test. Overall survival was calculated by Kaplan-Meier curves and log-
rank tests were used to examine any differences in survival rates. The prognostic value of 
variables was calculated by Cox’s proportional hazard models. For the multivariate analysis 
only parameters with a P-value less than 0.40 in the univariate model were entered in the Cox 
regression model. P-values less than 0.05 were considered significant. All statistical analysis 
was performed by using SPSS version 20.0 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Between January 2000 and December 2011 a total of 623 patients underwent CRLM resection 
with curative intent, of which 293 patients (47%) presented with metachronous CRLM. In 7 
patients primary lymph node status was unknown, leaving 286 patients eligible for analysis. 
The median follow up was 36 months (IQR 21-57). Primary tumor localization was colon in 
165 patients and rectum in 121 patients. A total of 145 patients (51%) had a positive lymph 
node status of the primary tumor.
The baseline patient and tumor characteristics of both primary colon and rectal malignancies 
are outlined in table 1 and 2. In primary colon malignancies, patient- and tumor characteristics 
of patients with liver metastases from a lymph node positive versus lymph node negative 
tumor differed on basis of administration of adjuvant chemotherapy (90% vs. 4%, P<0.001) 
and Fong’s clinical risk profile (high risk: 38% vs. 8%, P<0.001), respectively. Characteristic 
of patients with liver metastases from a primary node positive vs. node negative rectal 
malignancy differed on basis of tumor stage (T3/T4: 87% vs. 53%, P<0.001) adjuvant systemic 
therapy for primary (13% vs. 2%, P=0.02), neo-adjuvant systemic therapy for CRLM (N+ 29% 
vs. N0 14%, P=0.05) and again Fong’s risk profile (high risk 31% vs. 12%, P=0,01), respectively. 
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Table 1: Patient characteristics by primary tumor location
Variable Colon (N=165) Rectum (N=121) P-value All patients (N=286)
Value % or IQR Value % or IQR p Value % or IQR
Male 97 59% 77 64% 0,407  174 61%
Age, median 65 58-73 64 60-69 0,782 64 59-72
Primary tumor
T3/T4 140 86% 85 0,71 0,002 225 80%
Lymph node positive 82 50% 63 52% 0,692 145 51%
Adjuvant CTx 72 45% 9 0,07 <0,001 81 29%
Liver metastases
DFI < 12 months 57 35% 48 40% 0,374 105 37%
Number metastases  > 1 83 50% 53 44% 0,306 136 48%
Diameter metastases > 5 43 26% 31 26% 0,918 74 26%
CEA > 200 μg/L 9 6% 13 11% 0,156 22 9%
Bilobair distribution 52 32% 38 32% 0,984 90 32%
Fong 3-5 37 23% 26 22% 0,801 63 23%
Neo-adjuvant CTx 46 28% 26 22% 0,219 72 25%
ADJUVANT CHEMOTHERAPY IN LYMPH NODE POSITIVE COLON CANCER
Adjuvant chemotherapy (primary) was administered to patients with stage III colon carcinoma 
according to Dutch national guidelines. From 82 node positive primary colon cancers, 69 
patients (90%) were treated with adjuvant chemotherapy. 13 patients with lymph node 
positive colon cancer (16%) did not receive adjuvant chemotherapy. In 5 cases reasons for 
not administering adjuvant chemotherapy were unknown. In the remaining 8 cases reasons 
were: refusal (n=2), complications of surgery (n=2), age (n=1), palliative chemotherapy due 
to irradical resection (n=1), operation primary in 1988 prior to guideline initiation (n=1), 
chronic use of immunosuppressant (n=1). Chemotherapeutic regimens consisted mainly 
of 5FU/LV/Xeloda with or without oxaliplatin. Median number of adjuvant cycles for lymph 
node positive colon carcinoma was 7 (IQR 6-11).
NEO-ADJUVANT CHEMO- (RADIO-) THERAPY FOR LOCALLY ADVANCED RECTAL CANCER
Of all patients with CRLM from a primary rectal malignancy, 30% (N=33) received long course 
(chemo-) radiotherapy (CtRtx). There was no difference in administration of long course CtRtx 
between node positive versus node negative rectal primaries (N+: 19%, N0: 32%, P=0.74). In 
node positive rectal primaries, median survival did not differ between patients undergoing 
long course CtRtx (30 months, 95% CI 20-40) vs short CtRtx or no CtRtx (43 months, 95% 
CI 25-61, P=0,53). In all patients with CRLM from rectal primaries that received long course 
CtRtx, no median survival difference was found between node positive and node negative 
patients (N+: 30 months, 95% CI 20-40 vs. N0: median not reached at 5 years, P=0,325). 
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NEO-ADJUVANT CHEMOTHERAPY FOR CRLM
In our current protocol, perioperative chemotherapy is not considered as standard 
treatment for patients with CRLM. A large proportion of patients in this study received neo-
adjuvant chemotherapy in the referring hospital. The reason for administering one type of 
chemotherapy over another was based on local treatment protocols. All patients received 
a combination of 5-fluorouracil (5-FU)/Capecitabine and Oxaliplatin or Irinotecan, with or 
without Bevacizumab.
Neo-adjuvant systemic therapy for CRLM was administered in 25% of all patients. There was 
no difference in engagement of neo-adjuvant chemotherapy for CRLM between primary 
colon and rectal malignancies (28% vs. 22%, P=0.22). 
OVERALL AND DISEASE-FREE SURVIVAL
The median survival of all patients after resection of CRLM was 45 months (95% CI 39-51) 
with an estimated 5-year overall survival of 41%. The estimated median survival of patients 
with primary colon cancer was 47 months (95% CI 41-53) versus 43 months (95% CI 36-50) 
in primary rectal cancer. The estimated 5-year overall survival of colon cancer patients was 
42% and rectal cancer patients was 40%. This did not differ significantly (P=0.62) (Figure 1). 
The estimated median disease-free survival of patients with primary colon cancer was 16 
months (95% CI 11-21) and did not differ significantly from the median disease-free survival 
of patients with rectal cancer (13 months, 95% CI 7-19, P=0.36).
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Table 2: Patient characteristics by primary tumor’s nodal status
Variable Colon N0 (N=83) Colon N+ (N=82 ) P-value All patients (N=165)
Value % or IQR Value % or IQR p Value % or IQR
Male 53 64% 44 54% 0,183 97 59%
Age, median 66 59-74 64 57-71 0,48 65 58-73
Primary tumor
T3/T4 67 83% 73 89% 0,247 140 86%
Adjuvant CTx 3 0,04 69 0,9 < 0,001 72 45%
Liver metastases
DFI < 12 months 26 31% 31 38% 0,381 57 35%
Number metastases  > 1 42 51% 41 50% 0,938 83 50%
Diameter metastases > 5 23 28% 20 25% 0,627 43 26%
CEA > 200 μg/L 5 7% 4 6% 0,681 9 6%
Bilobair distribution 29 35% 23 28% 0,341 52 32%
Fong 3-5 6 0,08 31 0,38 < 0,001 32 22%
Neo-adjuvant CTx 28 34% 18 22% 0,091 46 28%
Variable Rectum N0 (N=58) Rectum N+ (N=63) P-value All patients (N=121)
Value % or IQR Value % or IQR p Value % or IQR
Male 38 66% 39 62 0,68 77 64
Age, median 65 63 0,536 64 60-69
Primary tumor
T3/T4 31 0,53 54 0,87 < 0,001 85 71%
Neo-adjuvant RTx, long course 17 32% 16 29% 0,74 33 30%
Adjuvant CTx 1 0,02 8 0,13 0,022 9 7%
Liver metastases
DFI  < 12 months 24 41% 24 38% 0,712 48 40%
Number metastases  > 1 24 41% 29 47% 0,552 53 44%
Diameter metastases > 5 16 28% 15 24% 0,671 31 26%
CEA > 200 μg/L 8 15% 5 9% 0,308 13 11%
Bilobair distribution 16 28% 22 35% 0,385 38 32%
Fong 3-5 7 0,12 19 0,31 0,012 26 22%
Neo-adjuvant CTx 8 0,14 18 0,29 0,048 26 22%
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Figure 1. Overall survival in all patients by primary tumor location and nodal status
OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL BY LYMPH NODE STATUS
For all patients, the estimated 5-year overall survival was 38% in lymph node positive patients 
versus 45% in lymph node negative patients (P=0.16) (figure 1). In patients with metastasis 
from a primary colon malignancy, the estimated 5-year overall survival was 42% in lymph 
node positive patients versus 41% in lymph node negative patients (P=0.991) (figure 2). In 
patients with liver metastases form a lymph node positive rectal tumor; the 5-year survival 
was 32% versus 49% in node negative rectal cancer (P=0.04) (figure 2). 
The estimated median disease-free survival for lymph node positive colon cancer (19 months 
95% CI 11-27) was similar to lymph node negative colon cancer (16 months 95% CI 13-19, 
P=0.54) (figure 2). In node positive rectal cancer estimated median disease-free survival was 9 
months (95%CI 6-12) versus 14 (95% CI 6-22) in node negative rectal cancer (P=0.05) (figure 2).
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Figure 2. Nodal status in patients with CRLM from colon primary and rectal primary malignancies: 
disease free survival and overall survival
PROGNOSTIC VALUE OF INDIVIDUAL PARAMETERS IN FONG’S CRS
None of Fong’s individual variables, other than nodal status of primary tumor, proved to 
be of prognostic value in the cohort of patients included in this study. However, adding up 
the points to Fong’s CRS, differentiating between patients with a high and low risk profile, 
confirmed its prognostic value: 5-year OS in low risk patients (CRS 0-2) 43% vs. 33% in high-
risk patients (CRS 3-5), P=0.03, (figure 3).
Figure 3. High and low clinical risk profile as described by Fong’s CRS: overall survival
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UNIVARIATE AND MULTIVARIATE ANALYSES 
In patients with liver metastases from a primary colon malignancy, the univariate analysis in 
relation to OS showed 7 factors with a P-value of less than 0.40 (table 3). Adjuvant CTx highly 
correlated with node positivity (Pearson product-moment correlation coefficient = 0,864) 
and could not be entered in the multivariate analysis. From the 6 variables in multivariate 
analysis, only age was prognostic for OS (Table 3). 
In patients with liver metastases from a primary rectal malignancy, the univariate analysis 
in relation to OS showed 5 factors with a P-value of less than 0.40. In multivariate analysis 
only the primary tumor’s nodal status was prognostic for OS: HR 1,942 (95% CI 1,105-3,412; 
P=0,021) (Table 3).
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Table 3: Univariate analysis, overall survival
Colon primary (N=165) Rectal primary (N=121)
Variable
Median
Survival
(95% CI)
Univariate 
HR (95%CI)
P-value*
Multivariate
HR (95% CI)
Median
Survival
(95% CI)
Univariate
HR (95% CI)
P-value*
Multivariate
HR (95% CI)
Gender
Male 45 (38-52) 1,175 (0,747-1,846) - 53 (35-71)
0,822 
(0,505-1,340) -
Female 51 (43-59) P=0,486 42 (35-49) P=0,433
Age (mean) - 1,017 (0,997-1,038)
1,022 
(1,002-1,042) -
0,999 
(0,973-1,026) -
P=0,103 P=0,033 P=0,962
Primary tumor
T-stage T 0-2 NR 0,516 (0,248-1,074)
0,816 
(0,443-1,505) NR
0,773 
(0,444-1,344)
0,915 
(0,498-1,168)
T 3-4 45 (35-55) P=0,077 P=0,516 42 (35-48) P=0,362  P=0,774
Lymph node Positive 49 (38-60) 0,998 (0,641-1,553)
0,761 
(0,466-1,243) 38 (26-50)
1,662 
(1,014-2,724)
1,942 
(1,105-3,412
Negative 45 (39-51) P=0,992  P=0,275 NR P=0,040  P=0,021
Adjuvant CTx Yes 37 (23-51) 1,458 (0,934-2,276) - 56 (0-138)
1,110 
(0,446-2,766) -
No 46 (39-53) 0,097 43 (36-50) P=0,823
Neo-adjuvant Yes - - - 39 (25-53) 1,314 (0,778-2,219)
1,359 
(0,768-2,404)
long CtRtx No - - - 52 (38-66) P=0,307 P=0,292
Liver Metastases
Disease free interval
< 12 
months 45 (35-60)
0,992 
(0,623-1,580) - 40 (32-48)
1,204 
(0,740-1,959) -
> 12 
months 48 (36-60) P=0,975 45 (30-60) P=0,454
Largest size metastases (cm)
> 5 37 (21-53) 1,238 (0,766-2,001)
1,169 
(0,735-1,861) 36 (21-51)
1,333 
(0,781-2,275)
1,572 
(0,860-2,873)
< 5 49 (43-55) P=0,384 P=0,509 44 (31-57) P=0,292 P=0,142
Number metastases
> 1 44 (36-52) 1,210 (0,776-1,885) - 40 (27-53)
1,219 
(0,747-1,990) -
1 NR P=0,400 45 (35-55) P=0,428
CEA level  µg/L
> 200 32 (12-52) 1,053 (0,424-2,614) - 38 (33-43)
1,309 
(0,644-2,661) -
< 200 47 (41-53) P=0,911 45 (33-57) P=0,456
Tumour distribution
Bilobar 38 (29-47) 1,289 (0,812-1,046)
1,244 
(0,745-2,077) 39 (27-51)
1,146 
(0,682-1,926) -
Unilobar 51 (44-58) P=0,281 P=0,404 45 (36-54) P=0,606
Clinical Risk Score
3-5 34 (30-38) 1,545 (0,950-2,511)
1,527 
(0,878-2,653) 38 (25-51)
1,425 
(0,819-2,480)
1,070 
(0,573-1,997)
0-2 51 (44-58 P=0,079 P=0,134 48 (35-61) P=0,210 P=0,901
Chemotherapy
Yes NR 0,680 (0,398-1,164)
0,663 
(0,386-1,138) 40 (30-50)
1,098 
(0,617-0,953) -
No 46 (36-56) P=0,160  P=0,136 44 (32-56) P=0,752
NR Not Reached, CEA Carcinoembryonic Antigen, Univariate p value < 0.40 included in Multivariate analysis with a 
maximum of 1 variable per 10 event
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DISCUSSION 
In this study, we specifically evaluated the prognostic value of primary tumor nodal status 
for survival after resection of CRLM. In different CRS’s, independent variables for survival 
after resection for CRLM have been established, however, before the current era of effective 
systemic therapy. The most widely used and validated CRS is Fong’s (1999). The relevance of 
CRS’s has already been questioned with respect to peri-operative chemotherapy for CRLM 
[17]. Ayez et al. showed that neo-adjuvant chemotherapy for CRLM downstaged tumor size 
and CEA levels, which in turn changes the CRS. Correspondingly, adjuvant systemic therapy 
for lymph node positive primary colorectal cancer might specifically affect the prognostic 
importance of the lymph node status. In this study, patients who underwent surgery for 
CRLM, and of whom the primary tumor was treated with effective systemic therapy, were 
analyzed. We showed that Fong’s CRS (high versus low risk) by itself still proved to be of 
prognostic value. However, lymph node status in patients with liver metastasis from a primary 
colon malignancy lost its prognostic value for OS, in contrast to lymph node status in patients 
with metastases of a rectal malignancy. This finding may be explained by the standard 
administration of adjuvant chemotherapy in lymph node positive primary colon cancer, in 
contrast to rectal cancer where no adjuvant treatment is adopted in the Netherlands.
Our findings are supported by a recently published study of Thomay et al. [18], which aimed 
to determine the prognostic value of the number of regional lymph node metastases in 
patients with stage IV colorectal cancer. The number of regional lymph node metastases 
correlated with survival among patients undergoing resection of CRLM, but lost prognostic 
significance in the subset of patients who underwent hepatectomy with peri-operative 
oxaliplatin- or irinotecan- based chemotherapy. As in our study, systemic treatment possibly 
devaluates the prognostic capacity of primary tumor lymph node status for survival after 
surgery for CRLM. The adjuvant treatment discrepancy between node positive colon and 
node positive rectal primaries in the Netherlands provided two different patient cohorts 
with liver metastases, in which the effect of modern multimodal therapy on the prognostic 
value of lymph nodes could be assessed. Our results suggest that modern chemotherapy in 
colon cancer nullifies the negative prognostic effect of lymph node status in these patients 
specifically. This difference cannot be explained by lower survival rates on basis of primary 
tumor localization: 5-year survival rates by primary tumor in our cohort are 42% for colon and 
40% for rectal cancer (P=0.62), in concordance with literature [19]. An alternative explanation 
for the difference in prognostic value of lymph node status between colon and rectal 
primary might be the effect of “stage migration” in rectal cancer, caused by neo-adjuvant 
(chemo-) radiotherapy. Long course (chemo-) radiotherapy leads to tumor downstaging 
and less positive lymph nodes [12, 13, 20]. Therefore, patients with positive lymph nodes 
after (chemo-) radiotherapy might have a more aggressive tumor biology than lymph node 
negative patients, which may result in a survival difference. However, in a subgroup analysis 
of lymph node positive rectal cancer patients, there was no survival difference between 
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patients who received “long course” neoadjuvant (chemo-) radiotherapy versus “short 
course” radiotherapy (5x5Gy) followed by surgery with a short interval or no neoadjuvant 
radiation at all. Moreover, the administration of long course (chemo-) radiotherapy, short 
course radiotherapy or no neoadjuvant treatment did not differ significantly between lymph 
node positive and node negative rectal cancer patients. Thus, the potential effect of stage 
migration by neo-adjuvant (chemo-) radiotherapy in rectal cancer patients seems limited. 
Fong’s study was conducted in a cohort of patients undergoing surgery for CRLM in a 
different era (1984-1998). In both colon and rectal cancer, (neo-) adjuvant therapies were 
developed over the years. The demonstration that postoperative adjuvant treatment with 
Fluorocouracil and Levamisole reduced mortality rate by 33 percent among patients with 
stage III colon cancer [21] prompted multiple trials which initially established Fluorouracil 
plus Leucovorin (FL) as the standard adjuvant treatment for stage III (lymph node positive) 
colon cancer [22-27]. Subsequently, the MOSAIC trial [15, 28] confirmed additional survival 
of 20% was obtained when adding Oxaliplatin to the chemotherapy regimen. Parallel to 
these developments, total mesorectal excision (TME) in rectal cancer was established which 
resulted in a drastic decrease in local recurrence rate. Neoadjuvant (chemo-) radiotherapy 
further decreased local recurrence [8, 29, 30]. In contrast to colon cancer, the effectiveness 
of adjuvant chemotherapy after rectal surgery is still under debate. Therefore, as mentioned 
before, no adjuvant chemotherapy is administered for lymph node positive rectal cancer 
in the Netherlands. Notably, in the literature, despite the difference in adjuvant treatment 
between colon and rectal cancer, 5 year survival is similar: 58% vs. 59% respectively, for all 
stages and ages [19].
Due to the retrospective nature of this analysis, this study has drawbacks. Only a selected 
group of patients was considered eligible for CRLM resection and different adjuvant 
chemotherapeutic regiments were used. Additionally, CRS’s might have lost their clinical 
value, as nowadays surgical resection will take place irrespective of patients risk classification. 
Nonetheless, CRS’s are still useful in clinical research, specifically for stratification of patients 
in prospective trials.
In conclusion, in patients who underwent resection of CRLM, lymph node status of the primary 
tumor was not of prognostic value in patients with primary colon cancer. Interestingly, in 
primary rectal cancer lymph node status was a prognostic factor. This difference may be 
caused by the administration of effective adjuvant chemotherapy in node positive colon 
cancer. 
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ABSTRACT
BACKGROUND
Increasing emphasis is put on the concept that inflammation is a key player in tumor 
progression. In the tumor microenvironment, inflammatory cells mediate tumor growth. 
Elevated C-reactive protein (CRP) levels are identified as being representative of a systemic 
inflammatory response. Therefore, studies have successfully linked peri-operative CRP levels 
to survival after surgery for primary colorectal cancer. The aim of this study was to investigate 
the prognostic value of the post-operative systemic inflammatory response as represented 
by serum CRP levels after resection of colorectal liver metastases (CRLM).
METHODS
Between January 2004 and December 2012, all patients who underwent resection for CRLM 
were analyzed. The total post-operative acute inflammatory response was objectified by the 
area under the curve (AUC, trapezium rule). Peak CRP concentrations were determined. The 
impact of peak CRP values and total CRP response on disease free survival (DFS) and overall 
survival (OS) was analyzed; patients were stratified by clinical risk score and/or administration 
of neo-adjuvant chemotherapy.
RESULTS
The final study population consisted of 403 patients. The OS of patients with a high CRP 
response (AUC, upper quartile) was equal to patients with intermediate (AUC, middle 
quartiles) or low (AUC, lower quartile) responses. Similarly, total post-operative CRP response 
did not impact survival when stratifying patients for CRS and/or administration of neo-
adjuvant chemotherapy. Peak CRP concentrations did not impact survival accordantly. 
CONCLUSION
Total post-operative inflammatory response, as evidenced by CRP serum levels, had no 
prognostic value for survival after surgery for CRLM.
ABBREVIATIONS
AUC:   Area Under the Curve
CEA:   CarcinoEmbryonic Antigen
CRP:   C-Reactive Protein
CRLM:   ColoRectal Liver Metastases
CRS:   Clinical Risk Score
CTx:   Chemotherapy
DFS:   Disease Free Survival
OS:   Overall Survival
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INTRODUCTION
Over the past decades, the concept that inflammation is fundamental for tumor development 
has been extended. Various studies describe the tumor microenvironment as a crucial 
partaker in the neoplastic process, where inflammatory cells nurture proliferation, survival 
and migration of tumor cells [1-3]. Given the link between inflammation and cancer, multiple 
studies investigated the importance of a systemic inflammatory response evidenced by 
elevated CRP levels in patients with advanced cancers [4-6], as well as patients undergoing 
resection of primary colorectal cancer. Several studies showed that a perioperative elevation 
in CRP, either at baseline or postoperatively, correlated with poor survival after resection of 
primary colorectal malignancies [7-12]. However other studies report conflicting evidence on 
the prognostic value of CRP [13], and little is known about the prognostic value of CRP serum 
levels in liver-only metastatic colorectal disease specifically. Elevated CRP levels at baseline 
(pre-operative) might be indicative of a chronic state of low-grade systemic inflammation 
nurturing the tumor cell microenvironment and therefore impacting overall survival [1, 14, 
15]. Alternatively it is suggested that post-operative changes in growth factor levels induced 
by resection of CRLM, or of other origin, might increase pathological cellular proliferation of 
occult micro metastases in the liver [16-18]. Some reports suggest that post-operative CRP 
levels play a role in prognostication after surgery for different types of malignancies. In our 
hospital, no pre-operative CRP levels are objectified standardly. However, post-operative CRP 
levels could be analyzed retrospectively, and therefore the aim of this study was to evaluate 
the effect of a post-operative acute inflammatory response, as represented by CRP levels, on 
survival after resection of CRLM. As part of the analysis, patients were stratified by clinical risk 
profile [19] and/or administration of neo-adjuvant chemotherapy. 
PATIENTS AND METHODS
PATIENT SELECTION, BLOOD PROCESSING
Between January 2004 and December 2012, all consecutive patients who underwent liver 
resection for CRLM were analyzed from a prospectively maintained database. Patients were 
assessed by availability of post-operative CRP levels, and excluded from the analysis if they 
had missing data to calculate a representative immune response. Since 2004, CRP levels 
were determined on a daily basis during the post-operative course. The total post-operative 
acute inflammatory response was objectified by the area under the curve (AUC, trapezium 
rule). The AUC calculation was based on 4 different post-operative time points between day 
1 and 7. In addition, post-operative peak serum CRP concentrations between days 1-7 were 
objectified. The impact of the total response and peak CRP concentrations on disease free 
survival (DFS) and overall survival (OS) was analyzed. Patients were stratified by clinical risk 
score and/or administration of neo-adjuvant chemotherapy. Differences in DFS and OS were 
compared between high (upper quartile), middle (middle quartiles) and low responders 
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(lower quartile). In our hospital, blood samples were taken between 0700 a.m. and 0800 a.m. 
daily, which rules out diurnal variations within this cohort. CRP serum levels were measured 
on a Cobas c701 modular analyzer by particle enhanced immunoturbidimetric assay. 
Patient characteristics were collected retrospectively from a prospectively maintained 
database. Data in our database comprises: gender, age, primary tumor site, primary tumor 
pathological and lymph node stage (pTN), carcinoembryonic antigen (CEA), interval between 
resection of primary tumor and detection of liver metastases, location, distribution, size and 
number of liver metastases. Furthermore, type of liver surgery, radicality of surgery (R1, R0), 
extrahepatic disease, adjuvant treatment of primary tumor, neo-adjuvant chemotherapy for 
CRLM, and neo-adjuvant (chemo) radiotherapy for primary rectal malignancies were listed. 
No patients received adjuvant chemotherapy for CRLM. 
SURGICAL METHODS
Liver resections were performed by a single or two-stage procedure and included wedge 
resections, segmental resections, hemihepatectomies and radiofrequency ablations (RFA). In 
case of a two-stage resection, vena porta embolization was performed between the first and 
second stage of resection. Hepatic parenchymal resection was performed with an ultrasonic 
surgical aspirator and a monopolar coagulator. R0-resections were defined by the absence of 
microscopic tumor invasion of the resection margins, and R1-resections were defined by the 
presence or microscopic tumor invasion of the resection margins.
FOLLOW-UP
During follow-up, patients visited the outpatient clinic every 3 months in the first 2 years 
after CRLM resection for clinical examination and CEA-determination. Thereafter, patients 
visited the outpatient clinic every 6 months and were discharged from follow up after 5 
years. Abdominal imaging (CT of thorax and abdomen) was performed biannually during 
the first 3 years and thereafter annually. If disease recurred, a decision on whether to 
initiate chemotherapy treatment (again) or to perform a second resection was made by the 
multidisciplinary team.
OUTCOME
Overall survival (OS) was defined as the interval in months between resection of CRLM and 
death, or the date of last follow-up. Disease-free survival (DFS) was defined as the interval in 
months between resection of CRLM and recurrence, death without recurrence, or date of last 
follow-up without recurrence. 
STATISTICS 
Descriptive values are expressed as median (interquartile range (IQR)). Variables were 
compared by means of chi-square analysis or Fischer’s exact test (depending on the sample 
size) or with the independent Student’s t test or Mann-Whitney U test when appropriate. 
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Survival analysis was performed by the Kaplan-Meier method. Comparison between survival 
curves was made by log-rank tests. The prognostic value of variables was calculated by Cox’s 
proportional hazard models. For the multivariate analysis, known prognostic factors and 
parameters with a P-value less than 0.10 in the univariate model were entered in the Cox 
regression model. 
As mentioned before, the total inflammatory response as represented by post-operative 
CRP levels was objectified by calculating the area under the curve, trapezium rule. This 
enables us to estimate the total exposure to CRP as a function of time, in a standardized 
time-frame, over a standardized number of time points. The SPSS statistical package (version 
21.0, Chicago, IL, USA) was used for statistical analysis; a p-value of ≤0.05 was considered 
statistically significant.
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RESULTS
CLINICOPATHOLOGICAL CHARACTERISTICS
632 patients were analyzed. 22 patients underwent an unfinished 2-staged liver resection due 
to progression of disease, 18 patients had an incomplete “liver-first” approach for synchronous 
disease for the same reason. These patients were excluded from analysis. From the remaining 
592 patients, 189 were excluded from the analysis due to missing data to calculate the AUC 
(missing or too few CRP levels). These missing values were a consequence of either a short 
hospital stay (<4 days) or, erroneously, at certain time points no serum was collected. The final 
study population consisted of 403 patients. Median follow up of all patients was 28 months (17-
51). 55% of patients (N=223) received neo-adjuvant chemotherapy for CRLM. 46% of patients 
(N=182) had a high clinical risk profile, as defined by Fong’s clinical risk score for liver metastases 
[19]. Patients’ clinicopathological characteristics are depicted for CRP as represented by the AUC 
(table 1a) and for CRP as represented by peak concentrations above or below 100 mg/L (table 
1b). Post-operative complications according to the Clavien-Dindo classification did not differ 
between patients with a high (AUC upper quartile) and low (AUC lower quartile) CRP serum 
response (table 1a). Median post-operative hospital stay was 7 days (5-8) for patients with a high 
serum CRP response versus 7 days (6-10) for patients with a low CRP serum response (P=0,054). 
Table 1a: Clinicopathological characteristics of patients by CRP serum response (AUC, lower versus upper quartile).
Variables CRP serum response (AUC)
Lower Quartile (N=103)
CRP serum response (AUC)
Upper Quartile (N=100)
All patients  (N=403)
(incl. middle Quartiles)
Value % or IQR Value % or IQR P-value Value % or IQR
Male 62 60% 76 76% 0,016 262 65%
Age Median 65 59-70 63 58-72 0,761 64 58-71
Primary tumor
Rectal cancer 45 44% 46 46% 0,741 165 41%
T3/T4 83 81% 70 73% 0,156 316 81%
Positive lymph node 61 60% 58 60% 0,999 235 60%
Liver metastases
CEA Median 21 7,36-65 11 5,85-49,25 0,084 19,10 6,70-65,00
Synchronous (≤ 3mo) 53 52% 59 59% 0,280 224 56%
Diameter (cm) Median 3,25 2,2-5,4 3 2-4 0,830 3 2,0-4,7
Number of metastases Median 2 1-4 2 1-3 0,408 2 1-4
Bilobar distribution 32 31% 37 37% 0,372 168 42%
Neo-adjuvant Ctx 62 60% 41 41% 0,006 223 55%
R1 resection 19 19% 18 18% 0,935 81 21%
Extrahepatic disease 11 11% 10 10% 0,874 42 10%
Clinical risk score 3-5 47 47% 44 47% 0,914 182 46%
Days of hospitalization Median 7 6-10 7 5-8 0,054 7 5-8
Clavien-Dindo Grade 1 8 8% 9 9% 0,463 36 9%
Grade 2 14 14% 15 16% 53 14%
Grade 3 9 9% 7 7% 24 6%
Grade 4 1 1% 1 1% 3 1%
Grade 5 0 0% 3 3% 5 1%
CEA = Carcinoembryonic Antigen; CRP = C-Reactive Protein; AUC = Area Under the Curve
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Table 1b: Clinicopathological characteristics of patients by peak CRP concentration (<100 mg/L versus >100 mg/mL).
Variables Peak CRP <100 mg/L 
(N=68)
Peak CRP >100 mg/L 
(N=335)
All patients  (N=403)
Value % or IQR Value % or IQR P-value Value % or IQR
Male 37 54% 225 67% 0,044 262 65%
Age Median 64 59-70 64 58-71 0,874 64 58-71
Primary tumor
Rectal cancer 33 49% 132 40% 0,169 165 41%
T3/T4 54 81% 262 81% 0,922 316 81%
Positive lymph node 42 62% 193 60% 0,695 235 60%
Liver metastases
CEA Median 22,5 8,51-79,5 18,44 6,16-64,5 0,546 19,10 6,70-65,00
Synchronous (≤ 3mo) 34 50% 190 57% 0,309 224 56%
Diameter (cm) Median 3,8 2,3-6,08 3,1 2,0-4,7 0,094 3 2,0-4,7
Number of metastases Median 2 1-4 2 1-4 0,548 2 1-4
Bilobar distribution 20 30% 148 44% 0,024 168 42%
Neo-adjuvant Ctx 44 65% 179 53% 0,088 223 55%
R1 resection 13 19% 68 21% 0,806 81 21%
Extrahepatic disease 10 15% 32 10% 0,205 42 10%
Clinical risk score 3-5 34 51% 148 47% 0,560 182 46%
Days of hospitalization Median 8 6-10 7 5-8 0,009 7 5-8
Clavien-Dindo Grade 1 6 9% 30 9% 0,516 36 9%
Grade 2 7 11% 46 14% 53 14%
Grade 3 6 9% 18 6% 24 6%
Grade 4 1 2% 2 1% 3 1%
Grade 5 0 0% 5 2% 5 1%
SURVIVAL AND TOTAL SERUM RESPONSE
The overall survival of patients with a high serum response of CRP (AUC, upper quartile) 
was equal to patients with intermediate (AUC, middle quartiles) or low (AUC, lower quartile) 
serum responses. Median OS was 55 (95% Confidence Interval (CI) 37-73), 54 (95% CI 26-82) 
and 52 months (95%CI 32-72) respectively (P=0,838 figure 1). Correspondingly, DFS was 9 
(95% CI 5-13), 12 (95% CI 9-15) and 13 months (95% CI 7-19) for high-, middle-, and lower- 
inflammatory response, respectively (P=0,368, figure 1). 
Overall survival did not differ between patients with a CRP concentration of >100 mg/L 
between days 1-7 post operatively versus patients without CRP levels <100 mg/L. Median 
OS for CRP >100 mg/L was 57 months (95%CI 38-76) versus 37 months in patients with CRP 
<100 mg/L, (95%CI 29-45), P=0,274. Univariate analysis of the prognostic value of peak CRP 
concentration, presented as quartiles and as a continuous variable, showed no significant 
impact on OS (table 2). 
Multivariate analysis was performed including known prognostic clinicopathologic 
variables for survival after surgery for CRLM. In this analysis, CRP was added to the model 
by 4 definitions. 1) CRP concentrations as defined by the AUC presented as quartiles; 2) CRP 
concentrations as defined by the AUC as a continuous variable; 3) CRP peak values between 
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days 1 and 7 post operatively; 4) CRP peak value as a continuous variable. In all 4 analyses, 
CRP did not impact OS significantly (table 2). 
Figure 1. Overall survival and disease free survival of patients after surgery for colorectal liver metastases 
stratified by post-operative C-reactive protein serum response. The response was calculated by the 
area under the curve (trapezium rule) from CRP serum levels on 4 different time points between day 
1 and day 7 post-operatively. Survival for patients in the upper, two middle, and lower quartiles of 
response was compared. 
Figure 1 
Overall survival and disease free survival of patients after surgery for colorectal liver metastases stratified by post-
operative C-reactive protein serum response. The response was calculated by the area under the curve (trapezium 
rule) from CRP serum levels on 4 different time points between day 1 and day 7 post-operatively. Survival for 
patients in the upper, two middle, and lower quartiles of response was compared.  
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Table 2: Multivariate analysis of known prognostic factors. All variables have been included in the 
multivariate analysis. Multivariate analysis was repeated 4 times: with 1) CRP AUC as quartiles, 2) CRP 
AUC as continuous variable, 3) CRP peak value as quartiles, 4) CRP peak value as continuous variable
Variable
Univariate HR (95%CI)
P-value
Multivariate HR (95% CI)
P-value
Gender Male 0,886 (0,653-1,203)P=0,438 -
Primary tumour Rectum 1,135 (0,843-1,529)P=0,404 -
T-stage T 3-4 1,493 (0,976-2,284)0,065 -
Lymph node Positive 1,619 (1,178-2,225)0,003 -
Liver Metastases
Disease free interval < 12 months
0,967 (0,702-1,332)
0,836 -
Largest size metastases (cm) > 5 1,363 (0,968-1,921)0,076 -
Number metastases > 1 1,117 (0,818-1,524)0,488 -
CEA level  µg/L > 200 1,167 (0,722-1,886)0,529 -
Tumour distribution Bilobar 1,249 (0,926-1,685)0,145 -
Resection margin R1 1,438 (1,018-2,032)0,039 -
Chemotherapy Yes 0,979 (0,727-1,318)0,889 -
1) CRP: AUC Quartiles Lower 1,0000,840
1,000
0,879
Middle (2) 1,063 (0,751-1,503)0,732
1,104 (0,737-1,654)
0,630
Upper 0,951 (0,627-1,444)0,815
0,102 (0,679-1,790)
0,694
2) CRP: AUC (continuous) 0,999 (0,998-1,000)0,245
1,000 (0,998-1,001)
0,808
3) CRP: peak value quartiles Lower 1,0000,555
1,000
0,428
Middle (2) 0,829 (0,583-1,178)0,294
0,842 (0,564-1,257)
0,400
Upper 0,937 (0,625-1,403)0,751
1,094 (0,681-1,755)
0,711
4) CRP: peak value 
                     (continuous)
0,999 (0,997-1,001)
0,415
1,000 (0,998-1,003)
0,917
CRP C-Reactive Protein; CEA Carcinoembryonic Antigen;  CRS Clinical Risk Score; AUC Area Under the Curve;
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TOTAL IMMUNE RESPONSE: STRATIFICATION BY CLINICAL RISK PROFILE
The clinical risk score described by Fong did correlate with overall survival: median OS for 
CRS 0-2 was 59 months (95% CI 40-78) versus 37 months (95% CI 29-45) in patients with 
a CRS 3-5 (P=0,004). The prognostic value of CRP levels was stratified for patients’ clinical 
risk score. Median OS (months) of patients with a high risk profile (CRS 3-5) that underwent 
resection was 41 (95% CI 32-50) for patients with a high inflammatory response versus 37 
(95% CI 24-50) in patients with a low inflammatory response (P=0,562). Median OS (months) 
of patients with a low risk profile (CRS 0-2) that underwent resection was 59 (95% CI 44-74) 
for patients with a high inflammatory response versus 71 (95% CI 37-105) in patients with a 
low inflammatory response (P=0,981).
In patients with a CRS of 3-5 with CRP concentration of >100 mg/L, median OS was 59 months 
(95% CI 39-79) versus 45 months (95% CI 12-78) in patients with CRP <100 mg/L (P=0,664). In 
patients with a CRS of 0-2, a CRP concentration of >100 mg/L resulted in a median OS of 38 
months (95% CI 10-66) versus 35 months (95% CI 25-45, P=0,333). 
TOTAL IMMUNE RESPONSE: STRATIFICATION BY NEO-ADJUVANT CHEMOTHERAPY
The prognostic value of CRP levels was stratified for use of neo-adjuvant chemotherapy. 
Median OS (months) of patients that underwent resection without neo-adjuvant 
chemotherapy was 51 (95% CI 29-73) for patients with a high inflammatory response versus 
58 (95% CI 14-102) in patients with a low inflammatory response (P=0,348). Median OS 
(months) of patients that underwent resection with neo-adjuvant chemotherapy was 55 
(95% CI 24-68) for patients with a high inflammatory response versus 43 (95% CI 14-72) in 
patients with a low inflammatory response (P=0,243).
All analyses were repeated using a CRP concentration cut-off of 100 mg/L. Only in patients 
receiving neo-adjuvant chemotherapy did CRP impact OS. Concentrations of CRP <100 mg/L 
had a protective effect on survival. With CRP <100 mg/L, OS was 78 months (95% CI 57-99) 
versus 35 months (95% CI 24-46, P=0,043). In a multivariate analysis with known prognostic 
factors this protective impact was insignificant (HR 0,645 95% CI 0,391-1,064; P=0,086).
TOTAL IMMUNE RESPONSE: STRATIFICATION BY CLINICAL RISK PROFILE AND NEO-
ADJUVANT CHEMOTHERAPY
In patients with a high clinical risk score (3-5), baseline characteristics between patients with 
a high CRP response versus a low CRP response differed on basis of administration of neo-
adjuvant chemotherapy: high CRP serum response 60% CTx (N=26), vs. low CRP response 
85% CTx (N=40), (P=0,005).
The prognostic value of CRP levels was stratified for both the use of neo-adjuvant 
chemotherapy as well as patient’s clinical risk profile. In concordance with results illustrated 
earlier in the total study population, there was no survival difference between patients with 
a high or low total CRP serum response (AUC, upper vs. middle vs. lower quartile), stratified 
by risk profile and by administration of neo-adjuvant chemotherapy. 
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All analyses were repeated using a CRP concentration cut-off of 100 mg/L. Only in high-risk 
patients receiving neo-adjuvant chemotherapy did CRP impact OS. Concentrations of CRP 
<100 mg/L had a protective effect on survival. With CRP <100 mg/L, OS was 85 months (95% 
CI 27-143) versus 35 months (95% CI 15-55, P=0,034). In a multivariate analysis with known 
prognostic factors this protective impact was insignificant (HR 0,644 95% CI 0,344-1,206; 
P=0,169).
DISCUSSION
In this study, total post-operative inflammatory response as evidenced by CRP serum levels 
(AUC, trapezium rule) did not prove to be of prognostic value for survival after surgery for 
CRLM. The inflammatory response represented by peak CRP levels had no significant impact 
on OS either. No prognostic value was found for CRP levels stratified by patient’s clinical risk 
score and/or administration of neo-adjuvant chemotherapy. This is the first study to stratify 
the prognostic value of post-operative CRP levels for administration of neo-adjuvant CTx and 
patients’ clinical risk profile. 
Tumor progression is a complex process that depends on both the intrinsic properties of the 
tumor as well as the interaction with its microenvironment. Within this microenvironment, 
inflammatory cells play an important role in promoting tumor growth through complex 
biological mechanisms [1-3]. It is only for the past two decades that these complex 
interactions are being recognized and understood. CRP is a classic acute phase reactant 
identified in 1930 [20], representative of a systemic inflammatory response. Given the link 
between inflammation and cancer, multiple studies have been conducted to evaluate 
the relationship between elevated serum levels of CRP and tumor stage or survival after 
resection of primary colorectal malignancies [7-12]. These studies analyzed either CRP alone 
or CRP as part of the Glasgow Prognostic Score, which includes serum albumin in addition 
to CRP [21]. Few studies objectified the prognostic value of pre-operative CRP levels as a 
component of the GPS for survival after resection of CRLM [22-24]. The limited studies that 
have investigated the relation between CRP alone and survival after surgery for CRLM, 
evaluated both pre-operative and/or post-operative CRP levels [25-28]. Wong et al. and 
Hamilton et al. found a pre-operative elevated serum level to be predictive of poor outcome 
after surgery for colorectal liver metastases (CRLM) [25, 28], and a study of de Jong et al. 
showed that the magnitude of post-operative immune response, as represented by systemic 
CRP levels, correlated with overall survival [26]. Overall, without substantive critical appraisal 
made, limited studies agree that for CRLM a high baseline CRP or a high peri-/post-operative 
response is indicative of poor prognosis. 
This study not only analyzed the potential effect on survival after resection in general, it 
also stratified for administration of neo-adjuvant chemotherapy and/or patients’ clinical risk 
score. No evidence was found suggesting that CRP levels do impact survival in any of these 
subgroups. The current analysis found no overall- or disease free survival disadvantage for 
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patients with an augmented post-operative immune response in general, which suggest 
the potential impact of CRP on survival after resection of CRLM is unlikely. In a review of 
literature [27], the prognostic value of CRP serum levels on cancer specific survival is 
already questioned. Although more patients undergoing resection without neo-adjuvant 
chemotherapy had an elevated immune response, this did not result in poorer survival 
outcomes. In fact: overall survival of patients with a high clinical risk score treated without 
neo-adjuvant chemotherapy and a high CRP response did not differ from low risk patients 
treated with neo-adjuvant chemotherapy. If there would be any influence of a post-
operative acute systemic inflammatory response on occult disease, as measured by CRP 
levels, it expectedly should have been measured in these subgroups. Our results support 
the hypothesis that an abrupt, non-specific post-operative inflammatory response does not 
drive occult tumor cell proliferation. 
Conceptually there is a difference between pre- and post-operative evidence of systemic 
inflammation. Pre-operative elevated CRP levels could be a surrogate for a chronic state of 
low-grade inflammation, reflecting the microenvironment and metastatic potential of the 
tumor [1, 14, 15]. Alternatively, this response could be nonspecific secondary to concurrent 
infections, tumor necrosis or local tissue damage. Evidently, tissue damage plays a major 
role in the post-operative inflammatory response. However, if occult micro-metastases are 
exposed to such an augmented post-operative inflammatory response, this could enhance 
pathologic tumor proliferation. In animal experiments, enhanced tumor growth during liver 
regeneration has been described and could be explained by local or systemic changes in 
growth factors [16, 29-32].
Naturally, this study has drawbacks. It might be biased by its retrospective, single-center 
nature. Also, there were insufficient data on CRP levels to be able to calculate an inflammatory 
response uniformly in all patients over a time period of more than 4 days. As mentioned 
before, this is a consequence of early discharge or missed serum collection (missing values). 
The patient group included might have had greater resections as compared to patients 
discharged early in the post-operative course. Still, in all included patients, the immune 
response was structurally objectified in a corresponding time frame by using the AUC 
trapezoid method. A hypothetical drawback of the AUC-method might be that significant 
peak CRP concentrations might not be accounted for. The AUC of a patient with a significant 
rise of CRP rapidly returning to normal might be similar to that of a patient whose CRP lingers 
around a lower value. Thus, the prognostic impact of peak CRP levels and CRP levels above a 
threshold of >100 mg/L was analyzed. Further, CRP was determined regardless of the post-
operative course. The post-operative course might influence CRP levels. Even if this would 
have been the case, it is hypothesized that a post-operative exposure of occult disease to 
an elevated inflammatory response triggers tumor proliferation, irrespective of the origin of 
that inflammatory response [16-18]. 
To our knowledge, this is the largest patient cohort assessing post-operative CRP levels with 
respect to survival after surgery for CRLM and the first study stratifying for known risk factors 
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and administration of neo-adjuvant chemotherapy. We hypothesize that abrupt, post-
operatively augmented CRP levels do not induce tumor proliferation, nor alter the tumor 
microenvironment of occult residual disease. Further research should focus on pre-operative 
markers for systemic inflammation. One may question the concept of a general, quantitative 
measurement of systemic inflammation (CRP levels) representing an enhanced state of 
inflammation at tumor site. Although other reports have objectified a relation between a 
general inflammatory response and oncological outcome, future research should focus on a 
more qualitative measurement of the inflammatory response in the tumor microenvironment 
in relation to survival. The characterization of such a specific immune infiltrate is of greater 
scientific and clinical interest, with respect to prognostication and development of tailor-
made systemic therapies.
To conclude, in this study post-operative CRP levels did not prove to be of prognostic value 
for survival after surgery for CRLM. 
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ABSTRACT
BACKGROUND
Identification of specific risk groups for recurrence after surgery for isolated colorectal liver 
metastases (CRLM) remains challenging due to the heterogeneity of the disease. Classical 
clinicopathologic parameters have limited prognostic value. The aim of this study was to 
identify a gene expression signature measured in CRLM discriminating early from late 
recurrence after partial hepatectomy. 
METHODS
CRLM from two patient groups were collected: I) with recurrent disease ≤12 months after 
surgery (N=33), and II) without recurrences and disease free for ≥36 months (N=30). The 
patients were clinically homogeneous; all had a low clinical risk score (0-2) and did not receive 
(neo-) adjuvant chemotherapy. Total RNA was hybridised to Illumina arrays, and processed 
for analysis. A leave-one-out cross validation (LOOCV) analysis was performed to identify a 
prognostic gene expression signature.  
RESULTS
LOOCV yielded an 11-gene profile with prognostic value in relation to recurrent disease ≤12 
months after partial hepatectomy. This signature had a sensitivity of 81.8%, with a specificity 
of 66.7% for predicting recurrences (≤12 months) versus no recurrences for at least 36 
months after surgery (X2 P<0.0001).
CONCLUSION
The current study yielded an 11-gene signature at mRNA level in CRLM discriminating early 
from late or no relapse after partial hepatectomy. 
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INTRODUCTION
Colorectal cancer is one of the most commonly diagnosed cancers worldwide [1]. 
Approximately 15-25% of patients with colorectal cancer (CRC) present with synchronous 
liver metastases and another 20% have a metachronous disease development [2]. For patients 
presenting with isolated liver metastases, partial hepatectomy is the only potentially curative 
treatment option. Reported 5-year survival rates are 40-60% [3-5]. A substantial number of 
patients develop recurrent disease after liver surgery, underlining the need for prognostic 
biomarkers [6-8]. Such prognostic biomarkers may allow a more personalised treatment 
strategy. In recent years, several clinicopathological prognostic variables in patients with 
isolated colorectal liver metastases (CRLM) have been identified predicting the risk of relapse 
after a metastasectomy [9]. These variables have been integrated in various clinical risk scores 
(CRS) [9-13]. The CRS according to Fong et al. is the most widely used and validated score, 
able to distinguish between high risk and low risk patients in terms of survival outcomes 
[10]. This score is composed of 5 prognostic variables: positive lymph node status of the 
primary tumour, diagnosis of liver metastases within 12 months after resection of primary 
tumour, serum CEA ≥200ng/ml, >1 liver metastases, a metastasis of >5cm diameter. Each 
variable accounts for 1 point. Patients with 0-2 points are categorised as low risk, patients 
with 3-5 points as high risk. Still, outcomes after surgery remain heterogeneous: low risk 
patients may develop early recurrences - approximately 50% of patients with a low CRS 
develop metastases within 12 months after surgery - while high risk patients may remain 
disease free [14, 15]. Unravelling the biological properties characterising tumours may be 
pivotal to designing individualised therapies, based on biological predictors of outcome 
rather than or in addition to clinical predictors. Various groups have established molecular 
subtypes in primary cancers with distinct biology, predictive and prognostic value [16-19] 
[20, 21]. Biological markers may improve patient selection for (neo-) adjuvant therapies in 
addition to surgical management or intensive surveillance schemes.
The ability to analyse tumours at DNA-, RNA-, and protein- level promises to revolutionize 
our understanding of the malignant disease process, and hopefully this will herald new 
(superior) biomarkers. The aim of the current study was to identify a prognostic gene 
signature at mRNA level in patients with a low CRS, effective in identifying patients at high 
risk of early recurrence after surgery for CRLM.
METHODS
PATIENTS AND TREATMENT
Erasmus MC Cancer Institute is a tertiary referral centre for liver surgery. In the current 
retrospective study, patient characteristics were collected from a prospectively maintained 
database. All patients undergoing resection for CRLM are prospectively entered into an 
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institutional database. This database includes standard clinicopathological variables. 
Patients selected for the current study had a low risk profile (Fong’s clinical risk score 0-2 [10]) 
and did not receive treatment with (neo-) adjuvant chemotherapy for the resectable CRLM in 
line with the Dutch guidelines that do not support routine administration of chemotherapy/
biologicals in the case of primary resectable colorectal liver-only metastases. Patients were 
further selected according to the following criteria: I) patients with recurrent disease within 
12 months after hepatectomy, and II) patients without recurrent disease and a disease free 
survival of at least 36 months after hepatectomy. Thus, “two extremes” were selected in 
terms of recurrent disease. All resections were performed between 2000 and 2009. Hepatic 
parenchymal resection was performed with an ultrasonic surgical aspirator and a monopolar 
coagulator. R0-resections were defined by the absence of microscopic tumour invasion 
of the resection margins, and R1-resections were defined by the presence or microscopic 
tumour invasion of the resection margins [22]. 
During follow-up, patients visited the outpatient clinic every 4 months in the first 2 years 
after CRLM resection for clinical examination and CEA-determination. Thereafter, patients 
visited the outpatient clinic every 6 months and were discharged from follow up after 5 
years. Abdominal imaging (CT of thorax and abdomen) was performed twice a year during 
the first 3 years and thereafter annually. If disease recurred, a decision on whether to initiate 
chemotherapy treatment or to perform local therapy was made by a multidisciplinary team. 
Disease free survival (DFS) was defined as the interval in months between resection of CRLM 
and recurrence.
TISSUE COLLECTION AND ASSESSMENT
After resection of CRLM, tumour tissue is standardly fixed on formalin and embedded in 
paraffin in the department of pathology according to standard protocols, and stored. For 
the current study, tumour samples (N=80) of CRLM were retrieved from the selected patient 
groups. In the case a patient had more than one metastasis, there were no additional selection 
criteria in terms of which tumour to analyse. The formalin fixed, paraffin embedded (FFPE) 
samples were evaluated by a pathologist for colon tumour cell content: only specimens with 
at least 30% tumour cells in the tissue block were included (N=63). The final study population 
consisted of 33 samples for group I with disease recurrence within 12 months and 30 samples 
for group II without disease recurrence and a DFS of 36 months. 
The established tumour growth patterns are assessed by a dedicated pathologist and at least 
one additional observer in all resected CRLM in Erasmus MC Cancer Institute [23, 24]. Three 
tumour growth patterns have been reported in literature, with a distinct growing pattern 
[23, 24]. These patterns consist of a pushing type, a replacing type and a desmoplastic type. 
Briefly, in the pushing type the metastasis has a displacing interaction with the normal 
liver parenchyma, and is separated from normal cells by a thin layer of reticulin fibres. The 
replacing type infiltrates the normal liver parenchyma. The desmoplastic type has a band of 
desmoplastic tissue that separates tumour cells from the liver parenchyma.
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On a patient level, the growth patterns were classified by two methods for analysis in relation 
to outcomes. First, when a pattern was expressed in >75% of the CRLM the patient was 
classified as such. If no pattern was expressed in >75%, the growth pattern was classified 
as a “mixed type”. Second, based on prognostic evidence reported in the literature, if any 
percentage of the pattern was a replacement type, the patient was classified as such [25-
28]. Tumour differentiation and inflammation at the leading edge of the tumour were also 
objectified, for the current study specifically. 
RNA EXTRACTION AND PURIFICATION
Depending on the size of the FFPE samples, total RNA was extracted from 3 to 6 x 20 μm 
sections. Following paraffin removal with xylene the high-pure RNA paraffin kit was used 
according the supplier’s instructions (Roche, Mannheim, Germany). Following isolation, RNA 
was stored in RNase/DNase-free water at -80°C. Quality control was performed as previously 
described [29].
GENE EXPRESSION PROFILES
Illumina Whole Genome- cDNA-mediated Annealing, Selection, Extension and Ligation 
(WG-DASL) V4 assay is an array-based method for expression profiling of partially degraded 
RNA molecules such as those isolated from Formalin-Fixed Paraffin-Embedded samples. In 
the HumanHT-12 v4 BeadChip assay 29,285 annotated transcripts corresponding to 27,253 
coding transcripts with well-established annotations are measured. The WG-DASL assay was 
performed according to the manufacturer’s instructions. In summary, 1,000 ng total RNA was 
used from the 63 FFPE samples. 500 ng of total RNA from a pool of fresh frozen tumour 
RNA samples (I-scan control) was included in each individual hybridisation experiment of 
11 to 23 samples to evaluate possible inter-assay differences (supplementary 1). Total RNA 
was converted to cDNA using biotinylated oligo-dT18 and random nonamer primers. The 
biotinylated cDNA was annealed to the DASL Assay Pool (DAP) probe groups, which contain 
oligonucleotides specifically designed to interrogate each target sequence of the transcript. 
The DAP was annealed to targeted cDNA during a 16 hours temperature gradient (70° to 
37°C) incubation. Hybridisation of these oligonucleotides to the targeted cDNA site, followed 
by enzymatic extension and ligation was used to create a Polymerase Chain Reaction (PCR) 
template that was amplified with a set of universal PCR primers [30]. Cy3-coupled primers 
were used to facilitate the precipitation of the single stranded labelled products, which 
were hybridised to the whole genome HumanHT-12 v4 BeadChips containing 12 identical 
microarrays each. The microarrays were scanned using a confocal type imaging system with 
Cy3 (532 nm) laser illumination Illumina I-scan reader (N0262). Fluorescent intensities were 
read and images were extracted using software version 1.8.13.5. Each sequence type is 
represented by an average of 30 beads on the array. 
Eight hybridisations did not meet our criteria of an average intensity signal of at least 500 
prior to background correction and normalisation and were re-measured at an input of 2,000 
ng total RNA.
Chapter 7 | Prognostic Value of mRNA Expression Profiles
124
DATA ANALYSIS
Scanned data were uploaded into GenomeStudio software version 2011.1 via the Whole 
Genome DASL gene expression module for further analysis. The average signal, detection 
P-value, Bead standard error and average beads were used to quantile normalise the data in 
the statistical language R (www.r-project.org) using the “lumi” package [31]. The expression 
raw data are available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/ 
entry nr.: GSE81423).
STATISTICS 
A leave-one-out cross validation (LOOCV) was performed using Biometric Research Branch 
ArrayTools (BRB-ArrayTools, http://linus.nci.nih.gov/BRB-ArrayTools.html), starting with the 
top 25% most variable genes (N=7,101) in all samples as input. Samples were classified in two 
classes: recurrences ≤12 months (class 1) or no recurrences and a disease free survival ≥36 
months (class 2). In each round of the LOOCV, genes with a univariate P-value <0.001 were 
selected to differentiate between class 1 and class 2 (patients with and without recurrent 
disease). The linear prediction rule was defined by the inner sum of the weights (Wi) and 
expression (Xi) of these significant genes. In the prediction model, a sample was classified 
to class 2 if the sum was greater than the established threshold (∑iWiXi >threshold). From 
the available prediction algorithms, the “Support Vector Machine” (SVM) proved the most 
accurate classifier (75% correct classification, supplementary 2), resulting in an 11-gene 
signature (Table 3). Through this algorithm, each patient could be classified as “high risk” or 
“low risk” on basis of the identified expression profile (molecular risk). 
Descriptive values are expressed as median (interquartile range (IQR)). Variables were 
compared by means of Chi-square analysis or Fischer’s exact test (depending on the sample 
size) or with the independent Student’s t test or Mann-Whitney U test when appropriate. The 
SPSS statistical package (version 21.0, Chicago, IL, USA) was used for statistical analysis; a 
two-sided P-value of ≤0.05 was considered statistically significant.
ETHICAL APPROVAL
Of all patients, an informed consent was available, to use residual tissue for research 
purposes. The data and tissue used in the current study was employed in an anonymous 
fashion. As prescribed by national regulations, the current study was not subject to the 
“Medical Research Involving Human Subjects Act”.
RESULTS
PATIENTS
Clinicopathological features of both patient groups (with recurrences ≤12 months and 
without recurrences and a DFS ≥36 months) are outlined in table 1. The groups were 
Chapter 7 | Prognostic Value of mRNA Expression Profiles
125
7
homogeneous in terms of clinicopathological characteristics, as expected since all patients 
were selected to have a low CRS according to Fong 9. There was no difference in tumour 
differentiation, histological growth pattern and inflammation (at the leading edge of 
the tumour). The respective molecular risk groups did not differ on basis of the assessed 
biological (pathological) characteristics.
GENES ASSOCIATED WITH EARLY RECURRENCE
Through a LOOCV analysis, an 11-gene profile was constructed capable of discriminating 
patients at high- from low risk of recurrence (Table 3 and supplementary 3). Clinicopathological 
features of patients by the identified molecular risk groups (low- and high-risk) are depicted 
in table 2. These groups differed on basis of location of primary tumour and, inherently, 
the administration of neo-adjuvant radiotherapy for primary CRC. Of the 37 patients with 
at high molecular risk, 27 developed recurrent disease within 12 months. This yielded 
a sensitivity of the signature of 81.8%, with a specificity of 66.7% (X2 P<0.0001, table 4a). 
From the group of patients with recurrences within 12 months, the subgroup of patients 
with hepatic recurrences was identified (N=17). All patients with hepatic recurrences were at 
high molecular risk based on the 11-gene signature, resulting in a 100% sensitivity and 56% 
specificity for hepatic recurrences specifically (X2 P<0.0001, table 4b).
In the KEGG Pathway Database (http://www.genome.jp/kegg/pathway.html) and Gene 
Ontology Consortium database (http://geneontology.org) the respective genes were 
searched and pathways in which they are known to be involved are depicted in supplementary 
4 (KEGG) and supplementary 5 (Gene Ontology). Two genes, CLRN3 and KIAA0219, have not 
been described and not been registered in both databases.
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Table 1: Clinicopathological characteristics of patients by recurrence
DFS ≤12 
Months (N=33)
DFS ≥36 + No Recur-
rence Months (N=30)
All patients 
(N=63)
Value % / IQR Value % or IQR P-value Value % / IQR
Male 19 58% 18 60% 0.845* 37 59%
Age Median 67  58-71  63.5  58-72 0.895^ 65 58-72
Primary tumour
Location (right sided) 6 18% 4 13% 0.599* 10 16%
Rectal cancer 17 52% 12 40% 0.360* 29 46%
T stage 3/4 25 76% 23 77% 0.933* 48 76%
Positive lymph node (pN+) 17 52% 14 47% 0.701* 31 49%
Adjuvant CTx 8 24% 6 20% 0.686* 14 22%
Neo-adjuvant RTx 10 32% 6 20% 0.277* 16 26%
Liver metastases
CEA > 200 2 6% 0 0% 0.164* 2 3%
Synchronous DFI < 12 11 33% 9 30% 0.777* 20 32%
Diameter > 5 (cm) 6 18% 3 10% 0.354* 9 14%
Number of mets > 1 7 21% 6 20% 0.905* 13 21%
Bilobar 6 18% 4 13% 0.599* 10 16%
R1 resection 5 15% 1 3% 0.110* 6 10%
Growth pattern 1 Replacement 23 70% 16 53% 0.284* 39 62%
Desmoplastic 3 9% 7 23% 10 16%
Pushing 1 3% 0 0% 1 2%
Mixed 6 18% 7 23% 13 21%
Growth pattern 2 Replacement (any) 28 85% 22 73% 0.259* 50 79%
Differentiation Good 4 13% 2 7% 0.657* 6 10%
Moderate/Good 3 10% 6 21% 9 15%
Moderate 6 19% 5 18% 11 19%
Poor/Moderate 11 36% 11 39% 22 37%
Poor 7 23% 4 14% 11 19%
Inflammation Increased 5 16% 5 18% 0.321* 10 17%
Moderate/
Increased 3 10% 8 29% 11 19%
Moderate 10 32% 8 29% 18 31%
Decreased/
Moderate 6 19% 2 7% 8 14%
Decreased 7 23% 5 18% 12 20%
DFS=Disease Free Survival; pN+=pathological node positivity; CTx=Chemotherapy; RTx=Radiotherapy; 
CEA=Carcinoembryonic Antigen; R1=microscopic irradical; *= Pearson X2; ^=Mann-Whitney U test;
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Table 2: Clinicopathological characteristics of patients by molecular risk
High Risk (N=37) Low Risk (N=26) All patients (N=63)
Value % / IQR Value % or IQR P-value Value % / IQR
Male 21 57% 16 62% 0.845* 37 59%
Age Median 64 57-70 68 60-72 0.895^ 65 58-72
Primary tumour
Location (right sided) 4 11% 6 23% 0.599* 10 16%
Rectal cancer 21 57% 8 31% 0.360* 29 46%
T stage 3/4 30 81% 18 69% 0.933* 48 76%
Positive lymph node (pN+) 20 54% 11 42% 0.701* 31 49%
Adjuvant CTx 7 19% 7 27% 0.686* 14 22%
Neo-adjuvant RTx 13 37% 3 12% 0.277* 16 26%
Liver metastases
CEA > 200 2 6% 0 0% 0.164* 2 3%
Synchronous DFI < 12 12 32% 8 31% 0.777* 20 32%
Diameter > 5 (cm) 7 19% 2 8% 0.354* 9 14%
Number of mets > 1 7 19% 6 23% 0.905* 13 21%
Bilobar 5 14% 5 19% 0.599* 10 16%
R1 resection 5 14% 1 4% 0.110* 6 10%
Growth pattern 1 Replacement 27 73% 12 46% 0.284* 39 62%
Desmoplastic 4 11% 6 23% 10 16%
Pushing 1 3% 0 0% 1 2%
Mixed 8 31% 5 14% 13 21%
Growth pattern 2 Replacement (any) 29 78% 21 81% 0.259* 50 79%
Differentiation Good 4 11% 2 9% 0.657* 6 10%
Moderate/Good 5 14% 4 17% 9 15%
Moderate 6 17% 5 22% 11 19%
Poor/Moderate 14 39% 8 35% 22 37%
Poor 7 19% 4 17% 11 19%
Inflammation Increased 5 14% 5 22% 0.321* 10 17%
Moderate/
Increased 5 14% 6 26% 11 19%
Moderate 11 31% 7 30% 18 31%
Decreased/
Moderate 6 17% 2 9% 8 14%
Decreased 9 25% 3 13% 12 20%
DFS=Disease Free Survival; pN+=pathological node positivity; CTx=Chemotherapy; RTx=Radiotherapy; 
CEA=Carcinoembryonic Antigen; R1=microscopic irradical; *= Pearson X2; ^=Mann-Whitney U test;
Table 3: The identified 11-gene signature
Nr. Parametric P-value Fold-change Unique ID Name
1 5.53e-05 0.55 ILMN_1786920 JARID1A
2 0.0003634 0.51 ILMN_1698404 ERN1
3 0.0004586 0.47 ILMN_1683082 RPUSD1
4 0.0004769 0.59 ILMN_2067408 CLRN3
5 0.0009447 0.53 ILMN_1668374 ITGB5
6 0.0007405 2.07 ILMN_1678061 CASS4
7 0.0006431 1.79 ILMN_1684183 RAD9A
8 0.0004545 1.8 ILMN_3238676 ULBP2
9 0.0002883 1.98 ILMN_2381758 G3BP2
10 0.0002758 2.03 ILMN_1783636 COX6A1
11 0.0002593 1.87 ILMN_1656042 KIAA0319
P-value, Relative fold change (DFS ≤12 months vs. no recurrence and DFS ≥36 months), ID , Names (annotations) of genes
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Table 4a: Prognostic impact of the molecular risk profile for all site recurrences
Molecular Risk
True Recurrence Low High Total  Sensitivity 81.8%
No 20 10 30  Specificity 66.7%
Yes 6 27 33  PPV 73%
Total 26 37 63  NPV 76.9%
Pearson X2: P<0.0001
PPV=Positive Predictive Value; NPV=Negative Predictive Value
Table 4b: Prognostic impact of the molecular risk profile for hepatic recurrences
Molecular Risk
True Recurrence Low High Total  Sensitivity 100%
No 26 20 46  Specificity 56%
Yes 0 17 17  PPV 46%
Total 26 37 63  NPV 100%
Pearson X2: P<0.0001
PPV=Positive Predictive Value; NPV=Negative Predictive Value
DISCUSSION
The clinical and biological diversity of CRLM urges the need for prognostic biomarkers and 
tailor-made treatment strategies [15]. Despite improvement of therapies for liver-only stage 
IV CRC resulting in improved survival rates, knowledge on treatment response and risks of 
relapse or progression is still scarce. A substantial number of patients develop recurrent 
disease following resection of CRLM, underlining the need for prognostic factors [6-8]. More 
insights into biological tumour behaviour may result in better understanding of treatment 
failure and may yield biomarkers for risks of relapse or prediction of response to therapy. 
This could improve identification of patients who will or will not benefit from tailored 
treatment strategies, e.g. more intensified (neo-) adjuvant treatments for those with a high 
risk for relapse and potentially less intensified approaches for those with a low risk profile. 
Currently, prognostication and prediction in resectable CRLM is solely based on clinical 
parameters, with sub-optimal performance. As an exception, KRAS/BRAF mutation status 
may impact response to treatment and outcome in CRLM as in primary colorectal cancer [32] 
[33-37]. Nevertheless, both clinical and the latter mutational status fails to impact clinical 
management of CRLM [38]. 
In the present study, mRNA expression profiles in CRLM were objectified in low risk patients 
who underwent hepatectomy with curative intent, without (neo-) adjuvant chemotherapy. 
All patients were homogeneous in terms of clinical risk, as defined by current standards 
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9. Within this homogeneous group with respect to clinical risk, we were still able to select 
two opposite ends of the clinical spectrum: patients with recurrences within 12 months 
after surgery and patients without recurrences for at least 36 months post-surgery. Analysis 
of differential gene expression of CRLM of these 2 adverse patient groups resulted in the 
identification of an 11-gene expression profile, able to discriminate between patients with 
early versus late or no recurrences after partial hepatectomy. 
The fact that we were still able to identify two extremes (in terms of time to recurrence) in a 
clinically homogeneous group confirms the shortcomings of classic clinical risk scoring. The 
selection of these specific groups provided the opportunity to find molecular differences 
involved in outcome in a cohort where clinical parameters are incapable to do so. As all 
patients were chemo naive, true prognostic impact (tumour biology) could be researched. 
Chemo-naivety ruled out potential influences of the systemic regimens on the RNA 
expression in the tumour samples. Comparable studies lack true focus on prognostics, since 
the majority of these patients underwent pre- or postoperative systemic treatment [39-41]. 
The current chemo naïve patient cohort is unique, and the molecular risk profile identified in 
the current study therefore promising. 
There is a strong potential for gene expression based-biomarkers such as the one identified 
in the current study. The 11-gene signature may serve as a novel blueprint for individualised 
therapies; either in combination with or without the classic clinical risk scores. Identification of 
patients for neo-adjuvant (preoperative) therapy is certainly possible since prognostic gene 
expression profiles may be detected in liquid biopsies before surgery [42, 43]. Currently the 
clinical risk scores do not impact clinical management, although some retrospective reports 
have suggested they may be effective [44, 45] (this is prospectively investigated at present 
in the CHARISMA trial [46]). There may be a synergistic effect between the clinical risk score 
and the molecular score of the current study. As all patients developing liver recurrences in 
the current study were at high molecular risk, the 11-gene signature may also play a role 
in identifying patients that benefit from regional chemotherapy specifically (e.g. hepatic 
arterial infusion pump [47]). Therefore, after thorough validation, the current biomarker may 
be effective in selecting patient groups for various treatment strategies. 
There was no clear link between the mRNA expression profiles and other previously identified 
pathological features in CRLM, such as the tumour growth patterns. As stated earlier, three 
types of CRLM growth patterns can be observed: a pushing type, a replacing type and a 
desmoplastic type [23, 24]. The clinical impact of these growth patterns is still under 
investigation as their pathological presence is widely recognised. The molecular risk groups 
of the current study may be associated with a corresponding distinctive phenotype, possibly 
in the form of any of the established growth patterns. If such apparent tumour phenotypes 
exist, one could hypothesise that obvious differences may be recognisable at molecular 
level accordingly. In the current study, there was a trend towards an association between 
the high molecular risk group and the replacing growth pattern. A replacing growth pattern 
has repeatedly been associated with worse outcomes as compared to the desmoplastic 
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growth pattern [28, 48, 49]. In the current study the association is argumentative. A possible 
explanation for the lack of significance may be that these growth patterns are a specific 
characteristic of the leading edge of tumours. The gene expression data from the tumour 
samples in the current study are not exclusively retrieved from tumour tissue present in the 
leading edge. Currently, gene expression profiles for each of the growth patterns are assessed 
in an on-going study through laser macro-dissection of representative parts of the tumour.
Some of the functional annotations of the 11 genes in the signature provided insight into 
underlying biological mechanisms involved in recurrence, yet no evident common pathways 
could be discerned (see supplementaries 4 and 5). JARID1A, one of the 11 genes, is part of 
the “KDM5 family” of histone demethylases removing tri- and di-methylation marks of lysine 
4 of histone H3 at transcription start site in actively transcribed genes. We find JARID1A 
upregulated in patients with early recurrences in the current study which is in line with 
growing evidence for a causal role of this marker in relation to cancer progression [50]. ERN1 
(endoplasmic reticulum to nucleus signalling 1) is an important endoplasmic reticulum (ER) 
stress sensor. ERN1 signalling is a pro-angiogenic mechanism 45 and since we found ERN1 
increased in patients with early recurrences, angiogenesis may be a contributing factor. 
Natural killer group 2, member D ligand ULBP2 and Ras-GAP binding protein G3BP2 are two 
extrinsic stress induced proteins contributing to progression. ULBP2, whose expression is low 
in patients having an early recurrence and whose receptor is on the surface of natural killer 
(NK) cells and specific T-cells, implies immune modulation 46 in recurrence. G3BP2 is known 
to affect matrix stiffness as does RPUSD1 (RNA pseudouridylate synthase domain containing 
1) by controlling lateral growth of collagen II fibrils. G3BP2 and RPUSD1, with decreased and 
increased expression in the current study respectively, suggest that extracellular remodelling 
may affect the occurrence of recurrences as well. Potentially connected to the latter we find 
integrin subunit beta 5 (ITGB5), which is overexpressed in higher stages of CRC 47 and which 
modulates adhesion phenomena, and CASS4 the less studied signalling scaffold of the 
CAS (Crk-associated substrate) family which affects motility. Expression of these genes was 
elevated (ITGB5) and decreased (CASS4) in patients with early recurrence in the current study 
implying a role for migration, invasion and possibly progenitor cell function 48 and inhibition 
of apoptosis in cancer recurrence as well. The barely studied KIAA0319L and transmembrane 
protein clarin 3 (CLRN3) as well as COX6A1, which is involved in oxidative phosphorylation, 
affect recurrence rate but for now we cannot connect these proteins mechanistically to 
disease progression. Finally, the RAD9A checkpoint protein is required for proper localization 
of topoisomerase II-binding protein 1 (TopBP1) regulating cell cycle checkpoints, DNA repair, 
telomere stability and apoptosis [51-53] thereby preserving genomic integrity in all types 
of DNA aberrations [51-53]. In the current study, RAD9A was relatively downregulated in 
patients with early recurrences suggesting loss of genomic integrity is another contributing 
factor to recurrence [52]. Overall, we can conclude that recurrence of metastatic colorectal 
cancer in the liver is influenced by multiple complementary factors. 
Limitations of the current study are its retrospective nature, the selection bias in terms of 
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DFS and a relatively small sample size. Based on the current study, it is challenging to provide 
advice regarding treatment management for the patient group 36>DFS>12. The present 
molecular marker profile therefore needs extensive validation in a larger independent cohort. 
This cohort should consist of patients representing the complete (continuous) spectrum in 
relation to recurrent disease, and possibly (but not necessarily) with both high- and low 
clinical risk scores. The current setting with two extremes in terms of recurrences was chosen 
as a first step in establishing a prognostic signature. If any relevant expression profiles exist 
in relation to recurrent disease, they are most likely to be identified within these extremes. 
KRAS and BRAF status would have been informative in terms of assessment of baseline risk 
for relapse. It is a timely topic of interest in CRLM. These molecular entities were not available 
in the current cohort. Ideally, in a validation study for the current molecular biomarker, 
all known prognostic molecular factors should be assessed (including other established 
signatures) such that all respective molecular markers can be put into context [32-37, 39-
41]. A general point of discussion related to this type of translational research is the impact 
of inter- and intra- tumour heterogeneity on the reproducibility of results. Multiple studies 
show that even within single tumours heterogeneity exists [54, 55]. Despite any consensus 
on what lesion to analyse (e.g.: the largest) or what area within a tumour (e.g.: leading edge 
or core), heterogeneity will affect the generated results. Interestingly, these features of 
heterogeneity are known to have prognostic associations by itself in resected colorectal liver 
metastases [56]. Future studies should possibly also address spatial and temporal tumour 
heterogeneity, in addition to identification of a new biomarker.
CONCLUSION
In summary, in the current study a prognostic signature was constructed with the mRNA 
expression profiles of tumour tissue from resected CRLM. The signature consists of 11 genes 
of which the expression-patterns were able to discriminate between patients with early 
recurrences (≤12 months) versus no recurrences (≥36 months) after partial hepatectomy. 
This biomarker requires validation in a larger cohort representative of the complete clinical 
spectrum in terms of relapse and treated without (neo-) adjuvant therapy, including any 
other established prognostic molecular markers. 
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APPENDIX A
Supplementary data 
Supplementary 1. 
Average signal references. In red: I-scan control samples (inter-assay), in blue: tumour samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary 1. Average signal references. In red: I-scan control samples (inter-assay), in blue: 
tumour samples.
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Supplementary 2: Raw data output from the “Leave-one-out-cross-validation” analysis
Sample Array ID
Class 
label
Nr of genes 
in classifier
SVM 
Correct? Sample
Array 
ID
Class 
label
Nr of genes 
in classifier
SVM 
Correct?
1 6812 No 9 YES 33 6744 Yes 12 YES
2 6740 No 12 YES 34 6746 Yes 12 YES
3 6803 No 10 YES 35 6748 Yes 10 YES
4 6743 No 13 NO 36 6749 Yes 11 NO
5 6752 No 11 YES 37 6751 Yes 12 YES
6 6759 No 11 YES 38 6761 Yes 10 YES
7 6760 No 13 NO 39 6762 Yes 12 YES
8 6767 No 10 YES 40 6770 Yes 11 YES
9 6777 No 10 YES 41 6771 Yes 9 YES
10 6755 No 12 YES 42 6784 Yes 14 NO
11 6769 No 10 YES 43 6789 Yes 12 YES
12 6773 No 11 YES 44 6790 Yes 9 YES
13 6779 No 10 YES 45 6791 Yes 12 NO
14 6782 No 11 NO 46 6792 Yes 9 YES
15 6783 No 12 NO 47 6793 Yes 9 YES
16 6787 No 12 NO 48 6745 Yes 15 NO
17 6799_r No 15 NO 49 6756 Yes 11 YES
18 6801 No 16 NO 50 6757 Yes 17 YES
19 6804 No 9 YES 51 6765_r Yes 12 YES
20 6805 No 11 YES 52 6778 Yes 16 NO
21 6763 No 12 YES 53 6780 Yes 12 YES
22 6798 No 13 YES 54 6786 Yes 10 YES
23 6802 No 10 NO 55 6808 Yes 12 YES
24 6809 No 13 YES 56 6794 Yes 11 YES
25 6814 No 10 YES 57 6811 Yes 11 YES
26 6818 No 10 YES 58 6795 Yes 11 YES
27 6775 No 15 NO 59 6797 Yes 11 YES
28 6816 No 15 NO 60 6810 Yes 11 YES
29 6768-r2 No 12 YES 61 6813 Yes 10 YES
30 6753-r2 No 10 YES 62 6806-r Yes 11 YES
31 6772_r Yes 13 NO 63 6800-r Yes 12 YES
32 6741 Yes 11 YES
Class label: No=no recurrence and DFS ≥36 months after hepatectomy, Yes=recurrence ≤12 months after 
hepatectomy; SVM=Support Vector Machine algorithm
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Supplementary 3. 
Expression heatmap of the 11 genes (vertical), in all analysed samples (horizontal). True recurrence and the 
prediction outcome of the currently established algorithm are depicted under the heatmap. 
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Supplementary 3. Expression heatmap of the 11 genes (vertical), in all analysed samples (horizontal). 
True recurrence and the prediction outcome of the currently established algorithm are depicted under 
the heatmap.
Supplementary 4: Pathways in which the identified genes are described to be involved in from the 
“KEGG Pathway Database”
ID Gene Name KEGG_PATHWAY
COX6A1 Cytochrome c oxidase subunit 6A1 Oxidative phosphorylation
Metabolic pathways
Cardiac muscle contraction
Non-alcoholic fatty liver disease (NAFLD)
Alzheimer’s disease
Parkinson’s disease
Huntington’s disease
Protein processing in endoplasmic reticulum
Non-alcoholic fatty liver disease (NAFLD)
Alzheimer’s disease
ITGB5 Integrin subunit beta 5 Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Regulation of actin cytoskeleton
Proteoglycans in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
ULBP2 UL16 binding protein 2 Natural killer cell mediated cytotoxicity
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Supplementary 5: Pathways in which the identified genes are described to be involved in from the “Gene 
Ontology Consortium”
ID Gene Name GOTERM_BP_DIRECT
CASS4 Cas scaffolding protein family member 4
Phosphorelay signal transduction system cell adhesion 
signal transduction by protein phosphorylation
Cell adhesion
Signal transduction by protein phosphorylation
COX6A1 Cytochrome c oxidase subunit 6A1 Generation of precursor metabolites and energy
Transcription initiation from RNA polymerase II promoter
Gene expression
Respiratory electron transport chain
Cellular metabolic process
Small molecule metabolic process
Hydrogen ion transmembrane transport
ERN1 Endoplasmic reticulum to nucleus signaling 1 Endothelial cell proliferation
Transcription, DNA-templated
Regulation of transcription, DNA-templated,
mRNA cleavage
mRNA catabolic process,
Protein phosphorylation
Activation of signaling protein activity involved in 
unfolded protein response
Cell cycle arrest
Activation of JUN kinase activity
Regulation of macroautophagy
Endoplasmic reticulum unfolded protein response
Positive regulation of RNA splicing
Response to endoplasmic reticulum stress
Cellular response to vascular endothelial growth factor 
stimulus
Peptidyl-serine autophosphorylation
IRE1-mediated unfolded protein response
Cellular protein metabolic process
Protein autophosphorylation
mRNA splicing, via endonucleolytic cleavage and ligation
mRNA endonucleolytic cleavage involved in unfolded 
protein response
Intrinsic apoptotic signaling pathway in response to endo-
plasmic reticulum stress
Cellular response to glucose stimulus
RNA phosphodiester bond hydrolysis, endonucleolytic
Positive regulation of endoplasmic reticulum unfolded 
protein response
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Supplementary 5: Pathways in which the identified genes are described to be involved in from the “Gene 
Ontology Consortium” (Continue)
ID Gene Name Insulin metabolic process
  Peptidyl-serine trans-autophosphorylation
G3BP2 G3BP stress granule assembly factor 2 Cytoplasmic sequestering of NF-kappaB
Ras protein signal transduction
mRNA transport
ITGB5 Integrin subunit beta 5 Antigen processing and presentation of peptide antigen via MHC class I
Antigen processing and presentation of exogenous 
peptide antigen via MHC class I, TAP-dependent
Muscle contraction
Cell-matrix adhesion
Transforming growth factor beta receptor signaling 
pathway
Integrin-mediated signaling pathway
Extracellular matrix organization
Endodermal cell differentiation
Antigen processing and presentation of exogenous 
peptide antigen via MHC class I
Stress fiber assembly
Viral entry into host cell
Epithelial cell-cell adhesion
KDM5A Lysine demethylase 5A Negative regulation of transcription from RNA polymerase II promoter
Chromatin organization,
Transcription from RNA polymerase II promoter,
Spermatogenesis
Male gonad development
Circadian regulation of gene expression
Histone H3-K4 demethylation
Positive regulation of transcription, DNA-templated
Oxidation-reduction process
Negative regulation of histone deacetylase activity
RAD9A RAD9 checkpoint clamp component A DNA replication checkpoint
DNA damage checkpoint
Double-strand break repair via homologous 
recombination
DNA repair
DNA replication
Double-strand break repair
Cellular response to DNA damage stimulus
Intra-S DNA damage checkpoint
Cellular response to ionizing radiation
Nucleic acid phosphodiester bond hydrolysis
Positive regulation of intrinsic apoptotic signaling 
pathway in response to DNA damage
RPUSD1 RNA pseudouridylate synthase domain 1 tRNA pseudouridine synthesis
ULBP2 UL16 binding protein 2 Antigen processing and presentation
Natural killer cell activation
Natural killer cell mediated cytotoxicity
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ABSTRACT
BACKGROUND
Liver metastases present with distinct histopathological growth patterns (HGPs), including 
the desmoplastic, pushing and replacement HGPs and two rare HGPs. The HGPs are defined 
owing to the distinct interface between the cancer cells and the adjacent normal liver 
parenchyma that is present in each pattern and can be scored from standard haematoxylin-
and-eosin-stained (H&E) tissue sections. The current study provides consensus guidelines for 
scoring these HGPs.
METHODS
Guidelines for defining the HGPs were established by a large international team. To assess the 
validity of these guidelines, 12 independent observers scored a set of 159 liver metastases 
and inter-observer variability was measured. In an independent cohort of 374 patients with 
colorectal liver metastases (CRCLM), the impact of HGPs on overall survival after hepatectomy 
was determined.
RESULTS
Good-to-excellent correlations (intraclass correlation coefficient >0.5) with the gold standard 
were obtained for the assessment of the replacement HGP and desmoplastic HGP. Overall 
survival was significantly superior in the desmoplastic HGP subgroup compared with the 
replacement or pushing HGP subgroup (P=0.006).
CONCLUSIONS
The current guidelines allow for reproducible determination of liver metastasis HGPs. As 
HGPs impact overall survival after surgery for CRCLM, they may serve as a novel biomarker 
for individualised therapies. 
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INTRODUCTION
Despite many years of basic and clinical research aimed at curbing tumour growth, 
metastasis still remains the principle cause of death in the majority of solid tumours. The 
liver is a frequent site of metastasis for tumours originating from the gastrointestinal tract, 
pancreas, breast and lung; the liver also hosts metastases of renal cell carcinoma, melanoma 
and sarcoma [1, 2]. For example, ±80% of all metastases from colorectal cancer (CRC) occur 
in the liver [3]. Approximately 20-25% of patients with CRC present with liver metastases at 
the time of diagnosis with a further 20-25% of patients expected to develop liver metastases 
at a later date. 
We and others have shown that the majority of metastases to the liver present in one of 
three common distinct histopathological growth patterns (HGPs), known as desmoplastic 
HGP, pushing HGP or replacement HGP, and two rare HGPs. These HGPs are distinguishable 
because the interface between the cancer cells of the metastasis and the surrounding 
normal liver is distinct in each growth pattern. Moreover, the HGPs are recognisable by 
light microscopy in standard haematoxylin-and-eosin (H&E)-stained tissue sections [2, 4, 
5]. The distinct topography of cancer cells in each HGP predicts HGP-specific interactions 
with parenchymal (hepatocytes and cholangiocytes) and non-parenchymal cells (sinusoidal 
endothelial cells, stellate cells and immune cells) of the liver. However, despite these clear 
differences in the biology of these metastases, the molecular drivers of the distinct HGPs 
remain unknown. It is also currently unclear whether these distinct HGPs require different 
clinical management strategies. 
An overview of previous reports where these HGPs have been studied is provided in Table 1. 
One of the most important observations made in these studies is that liver metastases with a 
replacement HGP do not rely on sprouting angiogenesis for a vascular supply but instead co-
opt the sinusoidal vasculature of the liver [4-6]. This is inferred from the specific morphology 
of replacement- type liver metastases [4-10] and is consistent with the small endothelial cell 
proliferation fraction reported in these metastases [4, 11-13]. This co-option of sinusoidal 
blood vessels and peri-sinusoidal space (space of Disse) in the replacement HGP is in 
contrast to the desmoplastic HGP where extensive stromal remodelling and angiogenesis 
are observed [5, 6]. Desmoplastic liver metastases have an upregulated uPA-uPAR-PAI-1 
proteolytic system and an elevated content of type I and type IV collagens [14-16]. 
Interestingly, there is some evidence that the HGP of CRC liver metastases may be predicted 
by the histology of the primary tumour. Primary CRC can be classified as having a pushing 
margin or an infiltrative margin as defined by Jass et al (1987) [17]. When liver metastases 
were classified as being ‘encapsulated’ (which probably corresponds to the desmoplastic 
HGP) or non-encapsulated (which probably corresponds to pushing HGP or replacement 
HGP), 69% of the primary CRCs with pushing margins, as defined by the Jass criteria (Jass et 
al, 1987), developed encapsulated liver metastases while only 17% of primary CRCs with an 
infiltrative margin developed encapsulated liver metastases [18]. The type of primary cancer 
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can also be predictive of the liver metastases HGP, as almost all breast cancer liver metastases 
adopt a replacement growth pattern, while liver metastases of CRC can present with any of 
the different HGPs described [4, 6]. 
Importantly, the HGPs of liver metastases were shown to have prognostic significance. Both 
Van den Eynden et al (2012) and Nielsen et al (2014) [12, 19] studied the impact of the HGPs 
on overall survival in patients with metastatic CRC. In both studies, the desmoplastic HGP 
represented superior overall survival. However, in these studies, the results regarding the 
relative incidence of the different HGPs and the prognostic values of the replacement and 
pushing HGPs were contradictory. These contradicting results may have been a consequence 
of differences in the treatment history of the patients in both studies or due to the low 
number of patient samples that were examined but were likely also due to differences in 
the methodology used to assess the HGPs. These disparities highlight the need to develop 
consensus guidelines for scoring the HGPs of liver metastases. 
A second important reason to develop such guidelines is the emerging prognostic or 
predictive value of the HGPs. The clinical and biological diversity of, for instance, CRC 
liver metastases indeed urges the need for predictive biomarkers to facilitate tailor-made 
treatment strategies [20, 21]. Frentzas et al (2016) [6] demonstrated that CRC liver metastases 
with a replacement HGP respond poorly to bevacizumab treatment, likely because these 
tumours utilise vessel co-option instead of angiogenesis. By contrast, desmoplastic liver 
metastases, which are angiogenic, showed a better response to bevacizumab [6]. These 
data strongly suggest that HGPs can be used to guide the choice of treatment for individual 
patients with liver metastases. 
Finally, guidelines for scoring the HGPs of liver metastases are important for future 
mechanistic studies that are aimed at elucidating the molecular drivers of each HGP. These 
studies will require the establishment of preclinical liver metastasis models that mimic the 
distinct growth patterns using established cell lines or patient-derived xenografts (PDXs). 
Studies using such models should lead to identification of novel targets to facilitate precision 
treatments for patients with liver metastases. 
The aims of the current manuscript are therefore to (a) propose consensus guidelines for 
scoring the HGPs of liver metastases, (b) test the analytical validity of these guidelines, (c) 
validate the prognostic significance of the HGPs of liver metastasis, (d) speculate on the 
molecular mechanisms that may underlie the differences in the growth patterns, and (e) 
highlight future research directions for growth pattern research.
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METHODS
CONSTRUCTING THE GUIDELINES
The team of experts responsible for the proposed guidelines consists of members of the 
Liver Metastasis Research Network (www.lmrn.org) all of whom have had experience in the 
assessment of the HGPs of liver metastases. Based on many observations in previous studies 
on HGPs [2, 5, 6, 11-13, 22], and consequently multiple discussions at annual meetings of 
the LMRN, consensus was reached on a systematic approach to assessing the HGPs. A draft 
manuscript was produced by a writing committee and was circulated to all the co-authors. 
Final approval of the guidelines occurred during the annual meeting of the LMRN on 16-17 
June 2016 in Umeå, Sweden. 
AGREEMENT IN HGP SCORE BETWEEN DIFFERENT SAMPLES FROM THE SAME METASTASIS
The extent of agreement in HGP score between different samples from the same lesion was 
addressed in 50 liver metastases of CRC for which ≥4 formalin-fixed-paraffin embedded 
(FFPE) blocks were available for scoring. The samples used for this analysis were obtained 
from the Department of Surgical Oncology of the Erasmus MC Cancer Institute (Rotterdam, 
The Netherlands). The total number of blocks included in the analysis was 234; median 
number of blocks available per lesion was 4 (range = 4-16 blocks per lesion). H&E-stained 
sections from all 234 blocks were scored for HGP by EPvdS, RRJCvdB, BG and PBV according 
to the proposed guidelines (a consensus score was agreed upon during multiple sessions at 
a multihead microscope). Each block was then assigned to an HGP category: those scored 
as >50% desmoplastic were categorised as predominant desmoplastic HGP (n = 121 blocks), 
those scored as >50% pushing were categorised as predominant pushing HGP (n = 7 blocks), 
and those scored as >50% replacement were categorised as predominant replacement HGP 
(n = 98 blocks). In the case that no predominant HGP was found, the block was categorised 
as having a mixed HGP (n = 8 blocks). In order to determine the extent of agreement in HGP 
score between different blocks derived from the same lesion, for each of the 50 lesions we 
calculated the percentage of blocks that fell into the same category. 
ANALYTICAL VALIDATION STUDY
For the analytical validation of the guidelines, representative H&E-stained sections from 159 
FFPE sections of CRC (n = 129) and breast cancer (BC) (n = 30) liver metastases (obtained from 
patients undergoing routine resection) were retrieved from the archives of the pathology 
laboratory of the St Augustinus Hospital (GZA Hospitals), Wilrijk-Antwerp, Belgium. This set 
was then divided into a training set of 60 metastases and a validation set of 99 metastases 
by PBV and GGvdE. The sections were scanned on a 3DHISTECH (3DHISTECH Ltd., Budapest, 
Hungary) scanning device. Explanatory notes were provided for each of the images in the 
training set. These notes included the ‘gold standard’ HGP score, that is, the consensus HGP 
score as agreed by two pathologists (PBV and GGvdE) with >10 years of experience in scoring 
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the HGPs. The images and the explanatory notes were then uploaded to the ‘Pathomation 
whole slide image viewer’ (Pathomation BVBA, Antwerp, Belgium) on the website of the Liver 
Metastasis Research Network (www.lmrn.org). The decision tree and the guidelines (Figure 1 
and Tables 2 and 3, respectively) were also published on this website. 
Twelve participants volunteered to take part in the validation study. Of these 12 participants, 
only 4 had prior experience of scoring liver metastasis growth patterns, while the remaining 
8 participants had no prior experience of scoring liver metastasis growth patterns. Of 
these 12 participants, only 3 were professionally trained pathologists, while the remaining 
9 participants were scientists with either a biological sciences or medical background. 
Participants were given access to the data on the website of the Liver Metastasis Research 
Network. The participants were first asked to study the decision tree and the guidelines so 
that they could understand how HGPs are to be scored. They were then asked to examine 
the training set and the explanatory notes. Once these tasks were completed, they were then 
given access to the validation set of 99 liver metastases and asked to record their HGP scores 
for each of the cases. The participants assessed the HGPs of each metastasis (percentage of 
interface occupied by a growth pattern for all growth patterns present in >5% of the length 
of the interface) and submitted their results electronically within the Pathomation image 
viewer. The submitted results were then compared with the pre-established ‘gold standard’. 
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Figure 1. Decision tree to assess the growth patterns of liver metastases based on the key 
histopathological characteristics.Figure 1. Decision tree to assess the growth patterns of liver metastases based on the key histopathological characteristics. 
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Table 3: standard method for histopathological growth pattern assessment of liver metastases
•     The growth pattern is a histological parameter assessed by light microscopy imaging of haematoxylin-and- 
      eosin sections of FFPE tissue of  liver metastases.
•   The histological growth patterns of liver metastases can be evaluated by a pathologist or by any other 
      investigator trained by a pathologist. A training set of H&E images is available as supplementary data. 
•    The growth pattern is a characteristic of the tumor-liver interface. The center of the metastasis does not 
      contribute to the classification of a growth pattern.
•   A histochemical silver impregnation staining of the sections (e.g. Gordon-Sweet’s reticulin staining) has 
    added value to discern fibrosis/preservation of the supportive tissue architecture of the spaces of Disse 
      and sinusoids.
•     The three common growth patterns are: desmoplastic, pushing and replacement (two types) 
•     Two rare growth patterns are: sinusoidal and portal
•      When more than one growth pattern is present in a metastasis: estimate the relative fraction of each growth 
      pattern with a length of ≥5% of the total length of the interface (e.g. 80% desmoplastic/20% pushing; 95% 
      replacement/5% pushing).
•     In case of multiple metastases/patient: assess the growth pattern(s) in every individual liver metastasis and 
      note the anatomical position.
•     Caveats: 
             o Portal tracts at the tumour-liver interface should not be evaluated as areas with a desmoplastic 
                     growth pattern.
             o Reactive ductular proliferation in the desmoplastic rim can simulate a replacement growth pattern.
             o Metastases with a replacement growth pattern usually have no or a very mild inflammatory 
                infiltrate. Exceptionally, these metastases can have a dense infiltrate obscuring the interface. This 
                     should not be misinterpreted as desmoplastic growth.
             o Metastases adjacent to the liver capsule should be assessed with caution to avoid overestimation of 
                     desmoplastic growth.
             o Tissue cores from needle biopsy procedures cannot be used to assess the growth pattern of liver 
                     metastases.
             o If less than 20% of the expected interface is present in the tissue section, a disclaimer stating 
                      ‘insufficient tumour-liver interface’ should be added.
             o Delayed fixation (e.g. autopsy cases) or Radiofrequency Ablation (RFA) can impair the quality of the 
                     tissue so that reliable assessment of growth patterns is not possible.
             o If no viable tumour tissue is present in the metastasis, this should be mentioned (treatment effect: 
                     fibrosis, infarct-type necrosis, acellular mucin lakes)
CLINICAL VALIDATION STUDY
The clinical validity was assessed by a survival analysis. For this we used representative 
H&E-stained tissue sections of FFPE CRC liver metastases from 374 patients who underwent 
surgical resection at the Department of Surgical Oncology of the Erasmus MC Cancer Institute 
(Rotterdam, The Netherlands) between 2000 and 2015. The HGPs were determined by EPvdS, 
RRJCvdB, BG and PBV according to the proposed guidelines (for patient details, see Table 4). 
A consensus score was agreed upon during multiple sessions at a multihead microscope. 
Patients for whom >50% of the tumour-liver interface was identified as exhibiting one of 
the three HGP were allocated to a group labelled as predominantly of this HGP (i.e., >50% 
desmoplastic were categorised as predominant desmoplastic
HGP; >50% pushing were categorised as predominant pushing HGP; >50% replacement were 
categorised as predominant replacement HGP). In cases of multiple sections per metastasis 
or multiple liver metastases per patient, the mean percentage was used. Overall survival was 
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considered the time interval between the date of liver metastasis resection and the date of 
death or last follow-up. 
OVERALL SURVIVAL ANALYSIS USING DIFFERENT HGP CUT-OFFS
Survival analyses were also performed using different cut points to define the predominant 
HGP. Owing to the low numbers of patients presenting with a predominant pushing HGP 
(only 3% of patients when using a cut-off of >50%), this analysis was limited to a comparison 
of replacement HGP patients with desmoplastic HGP patients. Cut points of >50%, >70%, 
>80%, >90% or 100% were used to define whether a tumour had a predominant replacement 
HGP or a predominant desmoplastic HGP. 
STATISTICAL ANALYSIS
Descriptive values are expressed as median (interquartile range). Variables were compared 
by chi-square analysis, Fisher’s exact test or with independent Student’s t-test or Mann-
Whitney U-test. The Kaplan-Meier method was used to generate survival estimates, which 
were compared by Log-rank test. Cox regression models were used to correct for potential 
confounders. Only parameters with a P-value <0.10 in the univariate model were entered 
in the multivariate Cox regression model. The SPSS statistical package (version 21.0, SPSS, 
Chicago, IL, USA) was used. A P-value ≤0.05 was considered statistically significant.
RESULTS
GUIDELINES FOR SCORING THE HGPS OF LIVER METASTASES
In these guidelines, three common (desmoplastic HGP, pushing HGP and replacement HGP) 
and two rare (sinusoidal HGP and portal HGP) growth patterns are described that can all 
be identified in H&E stained specimens of FFPE liver metastases. The key histopathological 
characteristics of the HGPs are summarised in Table 2. The consensus guidelines for scoring 
the HGPs are summarised in Table 3. In order to assist the observer in scoring the different 
HGPs, we have constructed a decision tree that can be easily followed to determine the 
growth pattern (Figure 1). 
In the desmoplastic HGP, the cancer cells of the metastasis are separated from the liver 
tissue by a rim of desmoplastic tissue (Figures 2A-D). The metastasis does not mimic the liver 
architecture and there is no direct contact between cancer cells and hepatocytes. New blood 
vessels in the desmoplastic rim are formed by sprouting angiogenesis. There is often a dense 
lymphocytic infiltrate at the interface of the desmoplastic and liver tissue that can sometimes 
obscure the interface (Figure 2E). A proliferation of bile ducts, often called ‘ductular reaction’, 
can sometimes be seen surrounding the desmoplastic metastasis (Figure 2E). It is important 
to note that portal tracts that lie directly adjacent to a metastasis should not be confused 
with the desmoplastic tissue (Figure 2F). Also, areas directly underneath the liver capsule 
should not be confused with desmoplastic tissue. 
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Figure 2. H&E images of the desmoplastic histopathological growth pattern. (A–C) Low magnification 
images of the desmoplastic histopathological growth pattern. (D) Higher magnification image of the 
desmoplastic histopathological growth pattern. (E) Desmoplastic histopathological growth pattern 
with ductular proliferation (also known as ductular reaction) and dense lymphocyte infiltrate. (F) Portal 
tracts at the tumour–liver interface. D, desmoplastic rim; DP, ductular proliferation; L, lymphocyte 
infiltrate; N, normal liver parenchyma; PT, portal tract; T, vital tumour tissue. Scale bar = 1000 mM (A–C 
and F), 100 mM (D and E).
Figure 2. H&E images of the desmoplastic histopathological growth pattern. (A–C) Low magnification images of 
the desmoplastic histopathological growth pattern. (D) Higher magnification image of the desmoplastic 
histopathological growth pattern. (E) Desmoplastic histopathological gr wth pattern with ductular proliferation 
(also known as ductular reaction) and dense lymphocyte infiltrate. (F) Portal tracts at the tumour–liver interface. D, 
desmoplastic rim; DP, ductular proliferation; L, lymphocyte infiltrate; N, normal liver parenchyma; PT, portal tract; 
T, vital tumour tissue. Scale bar = 1000 mM (A–C and F), 100 mM (D and E). 
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In the pushing HGP, the liver cell plates that surround the metastasis are pushed away and 
are compressed (Figures 3A-C). There is no desmoplastic rim surrounding the metastasis but 
also no direct contact between cancer cells and hepatocytes within the liver cell plates. As in 
the desmoplastic HGP, the metastasis does not mimic the liver architecture. 
In the replacement HGP, cancer cells form cell plates that are in continuity with the liver cell 
plates (Figures 4A-E). This permits the cancer cells to replace the hepatocytes within the 
liver cell plates and allows these metastases to co-opt the sinusoidal blood vessels at the 
tumour-liver interface, without inducing sprouting angiogenesis. There are two subtypes of 
the replacement HGP. In the first type (type 1) the liver cell plates used by the cancer cells 
are perpendicular to the tumour-liver interface (Figures 4B and C), and in the second type 
(type 2), the liver cell plates are pushed away while the cancer cells replace the hepatocytes 
(Figures 4D and E). The latter type of replacement HGP should not be confused with the 
pushing HGP (Figures 3A-C). 
There are two rare HGPs of liver metastases, namely, the sinusoidal HGP and the portal HGP. In 
the sinusoidal HGP, the cancer cells are present as emboli within the lumens of the sinusoidal 
blood vessels and/or grow in the peri-sinusoidal space (Figure 5). As the cancer cells do 
not exit the blood vessels or enter the liver cell plates, there is no cell-cell contact between 
the cancer cells and the hepatocytes in this sinusoidal HGP. As in the replacement HGP, the 
sinusoidal blood vessels are co-opted as a means of vascularisation. In our experience, the 
sinusoidal HGP occurs in patients with rapidly progressing liver metastases and is therefore 
often encountered in autopsy specimens (Allison et al, 2004; Simone et al, 2012). In the portal 
HGP, the growth of cancer is restricted to the connective tissue areas of the portal tracts, 
liver septa and liver capsule. The portal HGP has been detected in animal models of liver 
metastases by us and only very infrequently in human BC or CRC liver metastases. 
The current guidelines also address the fact that a liver metastasis may have more than one 
growth pattern. In order to collect all the available information for subsequent data analysis, 
the guidelines propose to estimate the relative fraction of each HGP that constitutes ≥5% of 
the total length of the interface. In the typical pathology archive, there may be either one 
tissue block available per liver lesion or multiple tissue blocks available per liver lesion. In the 
case where multiple blocks are available for a given lesion, we recommend that the HGP from 
each block is determined. The mean average HGP score should then be calculated to produce 
a single score for percentage of desmoplastic, percentage of pushing and percentage of 
replacement HGP for each lesion. In case of multiple liver metastases from a single patient, it 
is recommended that the HGPs of every individual single lesion be scored separately and the 
information saved together with the anatomical position of the respective lesion. 
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Figure 3. H&E images of the pushing histopathological growth pattern. (A) Low magnification image of 
the pushing histopathological growth pattern. (B and C) Higher magnification images of the pushing 
histopathological growth pattern. N, normal liver parenchyma; T, vital tumour tissue. Scale bar = 500 
mM (A), 100 mM (B), 50 mM (C).
Figure 3. H&E images of the pushing histopathological growth pattern. (A) Low magnification image of 
the pushing histopathological growth pattern. (B and C) Higher magnification images of the pushing 
histopathological growth pattern. N, normal liver parenchyma; T, vital tumour tissue. Scale bar = 500 
mM (A), 100 mM (B), 50 mM (C). 
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Figure 4. H&E images of the replacement histopathological growth pattern. (A) Low magnification 
image of the replacement histopathological growth pattern. (B and C) Higher magnification images of 
the type 1 replacement histopathological growth pattern. (D and E) Higher magnification images of the 
type 2 replacement histopathological growth pattern. N, normal liver parenchyma; T, vital tumour 
tissue. Scale bar = 2000 mM (A), 100 mM (B, D and E), 50mM (C).  
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Figure 4. H&E images of the replacement histopathological growth pattern. (A) Low magnification 
image of the replacement histopathological growth pattern. (B and C) Higher magnification images of 
the type 1 replacement histopathological growth pattern. (D and E) Higher magnification images of 
the type 2 replacement histopathological growth pattern. N, normal liver parenchyma; T, vital tumour 
tissue. Scale bar = 2000 mM (A), 100 mM (B, D and E), 50mM (C).
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Figure 5. H&E image of the sinusoidal histopathological growth pattern. Arrowheads indicate tumour 
cell emboli present within the lumen of liver sinusoidal vessels. N, normal liver parenchyma. Scale bar 
= 100 mM.
IMPORTANT CAVEATS FOR SCORING THE HGPS OF LIVER METASTASES
In order to score the HGPs correctly, there are issues of concern that are related to the 
amount of available tumour-liver interface (where the HGPs are assessed), the quality of the 
tissue and the process of data collection. These points of concern are summarized in Table 
3. First, tissue cores from needle biopsy procedures should not be used to assess the HGPs 
of liver metastases. The obvious reason is that the amount of interface present in a tissue 
core is minimal and insufficient to cover the possible heterogeneity of the HGPs within a 
single metastasis. Second, if <20% of the expected interface is present in the tissue section, 
a disclaimer stating ‘insufficient tumour-liver interface’ should be added. There are various 
circumstances that may cause <20% of the expected interface to be present in the tissue 
section. These include, but are not limited to, the following: (a) the presence of excessive 
damage to the tissue section or (b) when a considerable proportion of the tumour present 
in the section forms a border with the liver capsule rather than forming a border with the 
liver parenchyma. Third, if no viable tumour tissue is present in the metastasis, scoring the 
HGP is not possible. Often this is due to treatment before surgery that causes replacement of 
the cancerous tissue by areas of fibrosis, infarct-type necrosis or cell-free lakes of mucinous 
substance. Fourth, an adequate quality of the liver metastasis tissue is essential. Indeed, 
delayed fixation (e.g., autopsy cases) or radiofrequency ablation can impair the quality of the 
tissue so that reliable assessment of HGPs is not possible. 
 
Figure 5 H&E image of the sinusoidal histopathological growth pattern. Arrowheads indicate tumour 
cell emboli present within the lumen of liver sinusoidal vessels. N, normal liver parenchyma. Scale bar = 
100 mM. 
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AGREEMENT IN HGP SCORE BETWEEN DIFFERENT SAMPLES FROM THE SAME METASTASIS
When considering the diagnostic utility of the HGPs, one point of concern is whether a 
single tissue section adequately captures the growth pattern of the entire lesion. In order 
to address this issue, we examined whether scoring the HGP from a single tissue sample 
is as accurate as scoring the HGP from multiple tissue samples. To do this, we examined an 
unselected set of 50 liver metastases for which multiple (≥4) tissue blocks were available. The 
median number of blocks available per lesion in this set was four (range = 4-16 blocks per 
lesion). A single tissue section from each block was scored for the HGP and then assigned to 
an HGP category: predominant desmoplastic HGP, predominant pushing HGP, predominant 
replacement HGP, or mixed HGP (according to strictly defined criteria, as detailed in the 
Methods section). We then assessed the degree to which blocks from the same lesion fell 
into the same category. We found that, for 82% of the lesions examined (41 out of 50 lesions), 
the HGP category was in complete agreement (100% agreement) across all blocks tested. 
Among the 9 other lesions examined, we found agreement between: 4 out of 5 blocks (80% 
agreement) for two lesions, 3 out of 4 blocks (75% agreement) for 4 lesions, 3 out of 5 blocks 
for 2 lesions (60% agreement), and 2 out of 4 blocks for 1 lesion (50% agreement). There were 
no cases with an agreement <50%. 
ANALYTICAL VALIDATION OF THE GUIDELINES TO ASSESS THE HGPS OF LIVER METASTASIS
In order to assess the analytical validity of the current guidelines, a validation study was 
performed. In the first stage, 12 participants (a mixed group composed of 3 pathologists, 4 
clinicians and 5 basic scientists) underwent a training exercise, in which they were provided 
with a copy of the guidelines contained herein and were then asked to score a training 
set of whole slide digital images of 60 liver metastases. Subsequently, they were provided 
with a validation set comprising 99 additional whole slide digital images. The scores of this 
validation set were then used to compare the participants’ results with the gold standard. 
The results of the validation study were tabulated with rows representing the different 
participants (n = 12) and columns indicating the percentage of interface occupied by a HGP 
in the set of 99 metastases. Using an intraclass correlation coefficient (ICC), the participants’ 
scores were compared with the gold standard, (i.e., the consensus result of the pathologists 
GGvdE and PBV). This resulted in ICC coefficients for desmoplastic, pushing, replacement 
(type 1), replacement (type 2) and replacement (independent of type) HGP for each 
individual participant. ICC values >0.5 represent a good reproducibility and values >0.7 an 
excellent reproducibility. After colour coding and unsupervised hierarchical clustering of 
the ICC coefficients of each HGP for all participants, the heat map (Figure 6) shows that, for 
the majority of the participants, good-to-excellent correlations with the gold standard were 
obtained for replacement (independent of subtype), replacement (type 1) and desmoplastic 
HGP. This indicates that the key characteristics of the desmoplastic HGP and the replacement 
HGP were recognisable by most participants. The results also show that the participants 
found the pushing HGP and the type 2 replacement HGP more difficult to distinguish. 
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Figure 6. Heat-map of the unsupervised hierarchical clustering of the color-coded mean intra-class 
correlation coefficient of each growth pattern for all observers (n=12)
CLINICAL VALIDATION OF THE GUIDELINES TO ASSESS THE HGPS OF LIVER METASTASES: 
SURVIVAL ANALYSIS
In order to test the prognostic value of the growth patterns as scored according to our current 
guidelines, the HGPs were scored in CRC liver metastases resection specimens from a series of 
374 patients (Table 4). Correlation of the HGPs with overall survival was then analysed. For the 
analysis of overall survival, the 374 patients were stratified into one of the three subgroups. 
Patients for whom >50% of the tumour-liver interface was identified as desmoplastic HGP were 
classified as predominant desmoplastic HGP, while patients for whom >50% of the tumour-liver 
interface was identified as pushing HGP or replacement HGP were classified as predominant 
pushing HGP or predominant replacement HGP, respectively. According to these criteria, the 
desmoplastic HGP was predominant in 183 (49%) patients, the replacement HGP in 177 (47%) 
patients and the pushing HGP in 10 (3%) patients. No dominant HGP could be found in the liver 
metastases of 4 patients (1%) and so these patients were excluded from the survival analyses. 
Figure 7 shows the overall survival curves for each subgroup. The median time of follow-up was 
34 months (95% CI: 17-61 months). The median overall survival for the desmoplastic subgroup 
was 64 months (95% CI: 51-77 months). For the replacement subgroup median overall survival 
was 36 months (95% CI: 30-42 months). Median overall survival was not reached for the pushing 
subgroup. Overall survival was significantly superior in the desmoplastic subgroup as compared 
with the replacement or pushing subgroup (P = 0.006, Figure 7). 
According to Table 5, three parameters were significantly different between the distinct HGP 
Figure 6: Heat-map of the unsupervised hier rchical clustering of the color-coded mean intra-class 
correlation coefficient of each growth pattern for all observers (n=12). 
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Figure 7: Kaplan-Meier curves depicting overall survival of patients with colorectal liver metastases, 
stratified by predominant (>50%) HGP. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.006 
subgroups: lymph node status of the primary CRC, absence or presence of metastasis within 1 
year after resection of the primary CRC, and systemic treatment prior resection of liver metastasis. 
The effects on overall survival of these parameters were tested in a univariate Cox regression 
model. This was also carried out for the clinical risk score (CRS) according to Fong because of 
its established prognostic value [23] (Table 6). In a multivariate analysis, both a poor CRS (3–5) 
and the presence of a predominant replacement HGP resulted in a significantly shorter overall 
survival with respective HR of 1.97 (95% CI: 1.47-2.65) and 1.73 (95% CI: 1.28-2.33). 
We then repeated the overall survival analysis in order to determine whether using different cut-
offs to define the predominant HGP would affect the relationship between the HGP and overall 
survival. Owing to the low numbers of patients presenting with a predominantly pushing HGP 
(only 3% of patients when using a cut-off of >50%), we limited our analysis to a comparison of 
overall survival between the replacement HGP patients versus the desmoplastic HGP patients. 
Cut points of >50%, >70%, >80%, >90% or 100% were used to define whether a tumour had a 
predominant replacement HGP or a predominant desmoplastic HGP (Table 7). The first thing that 
emerges from this analysis is that, predictably, the use of higher cut-offs incrementally reduces 
the number of patients eligible for inclusion in the analysis. For example, while 360 patients are 
eligible using a cut point of >50%, this drops to 291 eligible patients using a cut point of >70% 
and drops to 134 patients using a cut point of 100%. However, overall survival was significantly 
superior in the desmoplastic HGP subgroup, as compared with the replacement HGP subgroup, 
at all cut-offs utilised (both by Kaplan-Meier analysis and in multivariate analysis, Table 7).
Figure 7. Kaplan-Meier curves depicting overall survival of patients with colorectal liver metastases, 
stratified by predominant (>50%) HGP
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Table 5: Clinicopathological characteristics in the final cohort used for clinical validation, excluding 4 
patients with a “mixed type”HGP
Variables
Desmoplastic 
(183)
Replacement 
(177) Pushing (10)
All patients 
(N=370)
Value % / IQR Value % or IQR Value % or IQR P-value Value % / IQR
Male 120 66% 112 63% 6 60% 0.865 238 64%
Age Median 63 56-71 64 59-70 63 58-73 0.591 63 57-70
Primary tumour
Rectal cancer 79 43% 84 48% 4 40% 0.758 167 45%
T stage 3/4 130 78% 132 79% 8 80% 0.982 270 79%
Positive lymph node 90 55% 113 68% 6 60% 0.049 209 61%
Liver metastases
CEA >200ng/ml 12 8% 11 8% 0 0% 0.892 23 8%
Synchronous (<1 year) 127 70% 102 58% 10 100% 0.004 239 65%
Diameter Largest >5cm 34 19% 30 17% 3 33% 0.484 67 19%
Number of metastases >1 122 67% 105 59% 4 44% 0.165 231 63%
Bilobar 85 46% 63 36% 4 40% 0.112 152 41%
Neo-adjuvant Ctx 110 60% 48 27% 5 50% <0.001 163 44%
R1 resection 49 27% 48 28% 1 10% 0.473 98 27%
Extrahepatic disease 25 14% 18 10% 0 0% 0.298 43 12%
CRS 3-5 64 36% 68 40% 5 50% 0.548 137 38%
Abbreviations: CEA = carcinoembryonic antigen; CRS = clinical risk score; CTx = chemotherapy; HGP = 
histopathological growth pattern; IQR = interquartile range.
Table 6: Univariate and multivariate analysis (overall survival)
Univariate HR (95%CI) P-value Multivariate HR (95%CI) P-value
Positive Lymph Node 1.267 (0.947-1.697) 0.111 Neo-adjuvant CTx 1.224 (0.893-1.678) 0.208
Synchronous (<1 year) 1.162 (0.878-1.537 0.294 CRS 3-5 (Fong) 1.971 (1.466-2.650) <0.001
Neo-adjuvant CTx 1.280 (0.974-1.681) 0.076 Desmoplastic HGP 1
CRS 3-5 (Fong) 2.005 (1.521-2.642) <0.001 Replacement HGP 1.729 (1.283-2.332) <0.001
Desmoplastic HGP 1 Pushing HGP 1.269 (0.553-2.908 0.574
Replacement HGP 1.556 (1.181-2.050) 0.019
Pushing HGP 1.435 (0.627-3.283) 0.392
Abbreviations: CI= confidence interval; CRS= clinical risk score; CTx= chemotherapy; HGP= histopathological 
growth pattern; HR= hazard ratio.
Table 7: Comparison of overall survival in patients with a predominant replacement HGP versus patients 
with a predominant desmoplastic HGP (using different % HGP cut-offs to determine the predominant HGP)
HGP Cut-off Total pts in analysis
No. of pts 
predominant 
replacement
No. of pts 
predominant 
desmoplastic
Kaplan-Meier 
P-value
Hazart ratio from multivariate 
analysis
>50% 360 177 183 P=0.001 1.79 (95% CI: 1.31–2.43) P<0.001
>70% 291 139 152 P=0.009 1.72 (95% CI: 1.21–2.46) P=0.003 
>80% 266 124 142 P=0.005 1.88 (95% CI: 1.29–2.73) P=0.001
>90% 233 108 125 P=0.003 2.13 (95% CI: 1.41–3.20) P=0.001 
100% 134 51 83 P<0.001 2.89 (95% CI: 1.66–5.02) P=0.001 
Abbreviations: pts = patients; CI = confidence interval; HGP = histopathological growth pattern.
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DISCUSSION
The current manuscript describes the first guidelines for scoring the HGPs of liver metastases, 
based on an international consensus among experts in the field. Furthermore, we show that, 
by applying these guidelines after adequate training, a reproducible assessment of the HGPs 
in human specimens of liver metastases is possible. In addition, it is demonstrated that the 
HGPs scored according to these guidelines determine overall survival in patients with liver 
metastases of CRC. 
Although the scoring can be performed reliably even by non-specialists and is reproducible 
between individuals as shown in our analytical validation study, some limitations were noted, 
among them the difficulty of distinguishing the pushing HGP from the type 2 replacement 
HGP. This distinction is important, given that the interaction of the cancer cells with the liver 
is completely different in the two HGPs. For example, the pushing growth pattern relies on 
sprouting angiogenesis for its vasculature while the replacement growth pattern co-opts the 
sinusoidal blood vessels of the liver [2, 5, 6]. 
In the current study, the HGPs scored according to the proposed guidelines predict outcome: 
patients with a predominant desmoplastic HGP have a significant overall survival advantage 
as compared with patients with a predominant replacement HGP or predominant pushing 
HGP. This is clearly in accordance with the studies in Table 1 that have addressed the 
prognostic value of the HGPs [6, 12, 16, 19, 22, 24-26]. However, there are some discrepancies 
in the reported impact of the replacement HGP and the pushing HGP on outcome (for 
details, see Table 1). These discrepancies may arise due to differences in the patient cohorts 
examined and/or due to differences in the way the HGPs were scored in different studies. For 
instance, the percentage of patients who received systemic treatment prior to the resection 
of liver metastases may influence the results, as suggested by the evidence that preoperative 
therapy may cause a conversion from a desmoplastic HGP to a replacement HGP [6, 27]. 
With regards to the methods in which the HGPs were scored, the cut-offs for classifying a 
metastasis as having a predominant HGP differ between different studies, ranging from 50% 
to 80% of the total length of the interface. Also, the distinction between the pushing HGP 
and the type 2 replacement HGP was not well defined in previous studies. Furthermore, all of 
these factors have impacted on the variability documented in the relative proportions of the 
different HGPs. Indeed, as an example, the pushing HGP was reported as the predominant 
HGP in ±7% of all samples in the study by Frentzas et al [6] and in ±3% of all samples in the 
survival study in this manuscript. However, in other studies, this fraction was as high as 16% 
[12], 33% [19], 34% [22] and even 50% [16]. These issues highlight the need for standardised 
and uniform criteria for HGP classification - a major aim of the present guidelines. 
Although we show here that scoring the HGPs of liver metastases is reproducible, in order 
to use the HGPs as a biomarker for treatment decisions it will be necessary to develop 
accurate non-invasive surrogate markers for this histopathological parameter. For example, 
medical imaging of the liver, such as MRI or CT scans that are performed routinely in clinical 
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practice, might eventually be utilised as a surrogate method to determine the HGPs of liver 
metastasis. We note that Semelka et al [28] found that the presence of transient perilesional 
enhancement on the MRI image is correlated with the presence of a desmoplastic reaction 
around the rim of liver metastases. However, transient perilesional enhancement was not 
present on the MRI image for liver metastases that lacked a desmoplastic reaction [28]. It is 
therefore possible that transient perilesional enhancement is a potential surrogate marker 
that distinguishes desmoplastic HGP liver metastases from pushing/replacement HGP liver 
metastases on MRI scans of the liver. However, a prospective imaging study performed in a 
large series of chemotherapy-naïve patients is necessary in order to validate whether this 
imaging feature (or other imaging features) can be successfully used to predict the HGPs of 
liver metastasis. A study of this sort is currently ongoing in Sweden (Hanna Nyström, personal 
communication). Furthermore, by longitudinal assessment of the HGPs, through repeated 
imaging of the same patients, it will also be possible to appreciate the dynamic nature of the 
HGPs. This is relevant because several studies suggest that the HGP of a tumour can change. 
For instance, there is evidence that, after systemic treatment with an antiangiogenic agent, 
liver metastases can switch from an angiogenic desmoplastic HGP to the non-angiogenic 
replacement HGP [6, 27]. Furthermore, a change from an angiogenic growth pattern to a 
non-angiogenic growth pattern upon treatment with antiangiogenic therapy has also 
been reported in preclinical models of hepatocellular carcinoma [29], lung metastasis [30], 
glioblastoma (GBM) [31]; and brain metastasis [32]. 
There is currently limited understanding of the biological mechanisms that underlie the 
different HGPs. Moreover, it is unclear why some tumours elicit a desmoplastic and angiogenic 
response while others grow in a non-angiogenic manner and adopt the replacement growth 
pattern. HGPs are, however, a broader phenomenon not restricted to liver metastases and 
have also been described in primary lung cancer [33] and lung metastases [30, 34, 35], 
primary brain tumours and brain metastases [36-39], lymph node metastases [13, 40, 41] and 
skin metastases [42]. Common biological themes, based on the interplay between cancer 
cells and the organ microenvironment, may thus be responsible for the HGPs in different 
organs. 
One working hypothesis to explain the biology of the different HGPs of liver metastases is that 
these HGPs recapitulate distinct reaction patterns of the liver to injury. Two reaction patterns 
to liver injury are known, liver fibrosis and liver regeneration, and they are characterised by 
specific cytokine profiles [43]. Fibrosis in the desmoplastic HGP may be mediated by the same 
biological mechanisms that drive liver fibrosis in response to injury. One hallmark of liver 
fibrosis is ductular reaction, which is a proliferation of activated cholangiocytes that form 
small nonfunctional bile ductular structures [44]. Indeed, ductular reaction is also present 
in the fibrotic rim of desmoplastic liver metastases (see Figure 2E). The replacement HGP, 
on the other hand, resembles liver regeneration, as cancer cells replace hepatocytes akin 
to the way that new hepatocytes replace older hepatocytes during liver regeneration [45, 
46]. Soluble angiocrine factors (which are secreted by endothelial cells in sinusoidal blood 
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vessels) have a major role during liver fibrosis, liver regeneration and in liver development 
[43, 47-49]. However, the role of these angiocrine factors in liver metastasis growth patterns 
is yet to be elucidated and is currently under investigation. 
Desmoplastic and pushing growth pattern tumours are associated with new vessel 
formation (via angiogenesis), while replacement growth pattern tumours are not dependent 
on angiogenesis and co-opt pre-existing sinusoidal blood vessels instead [2, 4-6]. Therefore, 
another significant question is: how are these different vascularization mechanisms co-
ordinated in the liver? Although this is yet to be elucidated, insight may come from studies 
performed in GBM. Similar to the liver metastasis scenario, GBM tumours displaying either an 
angiogenic growth pattern or a vessel co-opting growth pattern have also been described 
[38]. Sakariassen et al used PDX models of GBM to study what drives these different growth 
patterns in the brain. They showed that, while angiogenic GBMs and vessel co-opting GBMs 
are genetically similar (as determined by array CGH), marked differences in gene expression 
occur between these growth patterns. Notably, vessel co-opting GBMs had upregulated 
expression of genes associated with foetal development and cell motility when compared 
with angiogenic tumours. In contrast, angiogenic GBMs showed higher expression of 
angiogenic regulators, such as VEGF and angiopoetin-2, when compared with vessel co-
opting tumours [38]. These data suggest that tumour growth patterns are associated with 
differences in tumour gene expression, which may be drivers of the growth pattern. We are 
currently undertaking a transcriptomic analysis of human liver metastases to determine 
whether similar differences in gene expression can be found between liver metastases 
adopting different growth patterns (Van Laere et al, manuscript in preparation). 
Other studies, performed using preclinical brain metastasis models, have shown that cancer 
cells adhere to pre-existing brain vessels during vessel co-option in the brain and that this 
may be mediated by distinct cell adhesion molecules expressed by cancer cells, such as β1-
integrins or L1CAM [37, 39, 50, 51]. In the replacement growth pattern of liver metastases, 
our histopathological observations suggest that cancer cells also adhere to the sinusoidal 
blood vessels. Moreover, others have reported that ‘adhesive co-option’ of sinusoidal blood 
vessels by cancer cells, mediated by integrins, has a role in liver metastasis [52]. Taken 
together, these data suggest that the propensity for cancer cells to adopt a specific growth 
pattern may also involve important changes in the ability of cancer cells to adhere to pre-
existing blood vessels. 
In addition, the progression of cancer along pre-existing basement membranes (as observed 
in the replacement growth pattern) clearly resembles what pathologists recognise as in 
situ carcinoma, a presentation in which cancer cells respect the existing structure of the 
host organ. Although this is typically a feature that has been described to occur in primary 
tumours (i.e., occurring prior to invasion and subsequent metastasis), reversion of metastatic 
cancer to this in situ phase has indeed been documented in other sites, for instance, in lymph 
node metastases [53]. Therefore, the adoption of the replacement growth pattern may also 
represent a form of reversion to in situ tumour growth. 
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We find that, while approximately one-third of patients present with a ‘pure’ growth pattern 
(i.e., 100% desmoplastic, 100% pushing or 100% replacement HGP), approximately two-
thirds of patients present with a mixed growth pattern. Unfortunately, the biological basis 
for this heterogeneity of growth pattern within the same patient remains unclear. However, 
future studies aimed at addressing the molecular mechanisms that underlie the growth 
patterns should provide insight as to the basis for this heterogeneity. As for the practical 
significance of a mixed growth pattern, it is apparent that, even when a mixture of growth 
patterns is present, the predominant growth pattern can still have a significant effect on 
patient outcome. For example, around two thirds of the patients included in our overall 
survival analysis (using the >50% cut point) presented with a mixture of growth patterns, 
and yet the predominant growth pattern still had a statistically significant effect on overall 
survival. There is also evidence that treatment with standard therapies can alter the growth 
pattern of liver metastases from desmoplastic to replacement [6, 27]. It is therefore possible 
that, in some cases, liver metastases with a mixed growth pattern represent those tumours 
that are in a state of transition from one growth pattern to another. If it is the case that 
standard therapies can indeed drive a shift in growth pattern from a good prognosis pattern 
(i.e., desmoplastic) to a bad prognosis pattern (i.e., replacement), then it may be necessary to 
derive therapeutic strategies that can either prevent or combat this adverse transition. 
In conclusion, we provide clear and reproducible guidelines for scoring the HGPs of liver 
metastasis. The HGPs have a prognostic and predictive value for patients with liver metastatic 
CRC as demonstrated here and in other retrospective studies [6, 12, 16, 19, 22, 24-26]. 
Prospective studies based on large cohorts of patients, and preferably linked to clinical trials, 
are now needed to confirm the clinical value of the HGPs and to assess the value of medical 
imaging, or circulating molecular markers, as potential surrogate biomarkers for the HGPs. 
Moreover, further studies are now warranted to understand the molecular mechanisms that 
underlie the HGPs, because these may eventually lead to HGP-specific treatment strategies 
for liver metastases. This could pave the way for an improved selection strategy for the type 
of systemic treatment before and/or after liver surgery and for personalised risk-adapted 
follow-up strategies.
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ABSTRACT
BACKGROUND
Adjuvant systemic chemotherapy is widely administered in patients with colorectal 
liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent 
prognostic factor in patients with CRLM. This study evaluates whether HGPs can predict the 
effectiveness of adjuvant systemic chemotherapy in patients with resected CRLM.
METHODS
A multicenter cohort study, including patients from two centers, was conducted. Growth 
patterns were assessed according to the international concensus guidelines. 
RESULTS
In total, 816 consecutive patients were included in the study. Patients with desmoplastic 
type HGP (dHGP) had a superior overall survival (OS) of 87 months compared to 51 months 
in patients with non-desmoplastic type HGP (non-dHGP), p<0.001. Adjuvant systemic 
chemotherapy was administered in 173 patients (21%). Patients receiving adjuvant systemic 
chemotherapy had a superior median OS of 79 months (95%CI 61-97 months) compared to 
56 months for patients who did not receive adjuvant systemic chemotherapy (p=0.02). In 
patients with dHGP, OS did not improve with adjuvant systemic chemotherapy compared 
to resection only (adjusted Hazard Ratio (HR) 0.83, p=0.60). In patients with non-dHGP, OS 
did improve with adjuvant systemic chemotherapy compared to resection only (adjusted HR 
0.66, p=0.004). In subgroup analysis, superior OS was observed only for patients with non-
dHGP that did not receive preoperative chemotherapy (HR 0.51, p<0.001). No significant 
effect of adjuvant systemic chemotherapy was observed in patients after preoperative 
chemotherapy with either dHGP (HR 0.93, p=0.84) or non-dHGP (HR 0.93, p=0.68), or in 
patients with dHGP that were not pretreated (HR 2.50, p=0.07). 
CONCLUSION
Patients with non-dHGP have improved OS with adjuvant systemic chemotherapy after 
resection of CRLM; patients with dHGP do not.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cause of cancer related death worldwide [1]. 
About 25% of patients with CRC are diagnosed with synchronous colorectal liver metastases 
(CRLM), and another 20% of patients develop metachronous metastases, predominantly 
in the liver [2-4]. The 10-year survival after surgery for CRLM is approximately 25% [5]. The 
survival remains poor due to development of recurrent disease in up to 80% of all patients. 
In order to improve survival after resection of CRLM, several studies have evaluated the 
effect of (neo-)adjuvant treatments. Long-term follow-up of a phase 3 trial demonstrated 
no significant difference in overall survival (OS) for patients with and without perioperative 
systemic FOLFOX chemotherapy [6]. Some retrospective studies suggest that adjuvant 
systemic chemotherapy may only be effective in certain subgroups, such as patients with a 
high Clinical Risk Score (CRS) [7-9]. Better biomarkers are needed to improve patient selection 
for adjuvant systemic chemotherapy after hepatic resection of CRLM. 
The histopathological growth pattern (HGP) is a new independent prognostic factor in 
patients with  CRLM [10, 11]. Two main types of HGPs can be distinguished by a pathologist 
on microscopic examination (figure 1); a desmoplastic type (dHGP) and a non-desmoplastic 
type HGP (non-dHGP) [12]. In a previous study we found that 5-year OS was 78% in patients 
with dHGP versus 36% in months with non-dHGP (p<0.001) (submitted). The aim of the 
current study was to determine if HGPs can predict the effectiveness of adjuvant systemic 
chemotherapy after resection of CRLM.
Figure 1A-F. 1A-B: desmoplastic HGP low and high magnification; 1C-D: replacement HGP low and 
high magnification; 1E-F: pushing HGP low and high magnification. T: tumour; D: desmoplastic 
stroma; NL: normal liver parenchyma. 
 
 
 
 
Figure 2. Study flowchart 
Total group 
n = 2362
No adjuvant 
n = 643
Adjuvant SYS
n = 173
Excluded (n=1546)
• No complete liver resection (n = 88)
• Primary not resected (n = 25)
• EHD (n = 276)
• Ablation only (n = 14)
• Adjuvant HAIP (n = 488)
• No H&E sections (n = 621)
• Unusable H&E sections (n = 34)
 
 
Figure 1. 1A-B: desmoplastic HGP low and high magnification; 1C-D: replacement HGP low and high 
magnification; 1E-F: pushing HGP low and high magnification. T: tumour; D: desmoplastic stroma; NL: 
normal liver parenchyma.
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METHODS 
PATIENTS
All consecutive patients who underwent a complete resection of CRLM from 2000-2012 at 
two large centers, Memorial Sloan Kettering Cancer Center (MSKCC, New York, United States) 
and Erasmus MC (Rotterdam, the Netherlands), were evaluated for inclusion. In MSKCC, 
most patients received systemic adjuvant and/or preoperative chemotherapy. In Erasmus 
MC, adjuvant systemic chemotherapy is not the standard of care after resection of CRLM, 
according to the Dutch guidelines. Preoperative systemic chemotherapy however is regularly 
administered in patients with synchronous and unresectable CRLM. 
IN- AND EXCLUSION CRITERIA
Patients who did not undergo a complete resection for CRLM (i.e. not all lesions were 
resected or ablated), never had their primary tumour resected, or with extrahepatic disease 
before or at time of resection of CLRM were excluded. Patients who underwent ablative 
treatment without liver resection were also excluded. Patients receiving adjuvant Hepatic 
Arterial Infusion Pump (HAIP) chemotherapy were also excluded. Patients were also excluded 
if hematoxylin and eosin (H&E) stained tissue sections were not available or non-suitable 
for HGP evaluation. Non-suitable was defined as less than 20% tumor-liver interface, poor 
quality of the H&E tissue sections or when viable tumor tissue was absent [10]. 
Clinicopathological data and data on postoperative treatment were available from both 
prospectively maintained databases. Number and size of CRLM were derived from pathology 
reports. Any lesions treated with ablative therapies (Radio Frequency Ablation (RFA) or 
Microwave Ablation (MWA)) were added to the total number of CRLM treated. The Clinical Risk 
Score was calculated by assigning one point for the presence of each of the five components: 
nodal status of the primary tumour, disease-free interval between resection primary and 
diagnosis CRLM, number of CRLM, size largest CRLM, and serum carcinoembryonic antigen 
(CEA) level [9]. The CRS was subdivided into low risk (CRS 0-2) and high risk (CRS 3-5). A 
positive resection margin was defined as the presence of viable tumour at the resection 
margin. Preoperative chemotherapy was defined as any chemotherapy administered within 
6 months before liver resection. Adjuvant chemotherapy was defined as any chemotherapy 
administered within 6 months after liver resection. 
HGP CHARACTERIZATION 
HGPs on H&E stained tissue sections were evaluated according to international guidelines 
[10]. In order to determine HGP type, all available H&E stained tissue sections off all available 
metastases were evaluated using light microscopy. The interface between tumour border 
and normal liver tissue was evaluated for the type of HGP and scored using percentages of 
each HGP type. Average HGP percentages were calculated per metastasis and patient (in 
case of multiple CRLM). Patients were classified in two groups:  dHGP if all available slides 
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showed a 100% desmoplastic interface and non-dHGP if a replacement or pushing type HGP 
was found on one or more slides. 
STATISTICAL ANALYSIS
Differences between groups in baseline characteristics were evaluated using the Chi-
squared test for categorical variables and the Mann-Whitney U-test for continues variables. 
Median follow-up time was estimated using the reversed Kaplan-Meier method. No 
imputation of missing data was applied; complete case analysis for the regression analyses 
was performed. Survival was estimated by the Kaplan-Meier method and groups were 
compared using the log-rank test. OS was defined from the date of CRLM resection until the 
date of last follow-up or death. Uni- and multivariable analysis of OS was performed with 
Cox proportional hazard modeling. Results were reported as hazard ratios (HR) with 95% 
confidence intervals (CI). Subgroup analyses (Kaplan-Meier and univariable Cox regression) 
stratified for preoperative chemotherapy were performed, since previous studies showed 
a potential impact of preoperative chemotherapy on HGP type. A p-value of less than 0.05 
was considered statistically significant. All analyses were carried out using SPSS (IBM Corp, 
version 21, Armonk, NY).
RESULTS
PATIENTS
At MSKCC, 1620 patients were evaluated for inclusion after surgery of CRLM, of whom 1248 
patients (77.0%) received adjuvant chemotherapy. At Erasmus MC, 742 patients were evaluated 
for inclusion, of whom only 4 patients (0.5%) received adjuvant systemic chemotherapy. A total 
of 1546 patients (65%) were excluded; reasons for exclusion are listed in the flowchart of the 
study (figure 2). The most important reason for exclusion was missing H&E slides (n=621, 40%). 
The remaining 816 patients were included for analysis, of which 173 patients (21%) received 
adjuvant systemic chemotherapy, and 643 patients (89%) did not.
The baseline characteristics, comparing patients treated with and without adjuvant systemic 
chemotherapy, are displayed in table 1. Most patients treated with adjuvant systemic 
chemotherapy were from MSKCC (n=170, 98%), and patients without adjuvant systemic 
chemotherapy were mainly from the Erasmus MC (n=487, 76%). 
A dHGP was found in 183 patients (22%) and non-dHGP in 633 patients (78%). The distribution 
of HGP’s was similar among both adjuvant treatment groups (p= 0.65). 
The median follow-up for the survivors was 76 months (Interquartile Range (IQR) 55-112 
months). In total 453 patients (56%) died during follow-up. Patients receiving adjuvant systemic 
chemotherapy had a superior median OS of 79 months (95%CI 61-97 months) compared to 56 
months (95%CI 49-63 months) for patients who did not receive adjuvant systemic chemotherapy 
(p=0.02, figure 3). Patients with dHGP had a superior survival (87 months, 95%CI not reached) 
compared to patients with non-dHGP (51 months 95%CI 45-57 months, p<0.001) (figure 4).
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Figure 3. Kaplan-Meier curve for overall survival in patients with and without adjuvant systemic 
chemotherapy  
 
 
 
 
 
Figure 4. Kaplan-Meier curve for overall survival in patients with dHGP and non-dHGP 
 
 
 
 
 
Figure 1A-F. 1A-B: desmoplastic HGP low and high magnification; 1C-D: replacement HGP low and 
high magnification; 1E-F: pushing HGP low and high magnification. T: tumour; D: desmoplastic 
stroma; NL: normal liver parenchyma. 
 
 
 
 
Figure 2. Study flowchart 
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Figure 3. Kaplan-Meier curve for overall survival in patients with and without adjuvant systemic 
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Table 1: Overall patient characteristics
All patients No adjuvant CTx Adjuvant CTx P-value
Total 816 (100%) 643 (78.8%) 173 (21.2%) -
Age (median, IQR) 64.0 (57.0-71.0) 64.0 (57.0-72.0) 64.0 (55.5-71.0) 0.43
Gender 90 4-312
Male 136 4-312
Female 63 32-217
Nodal status 
primary tumour
0.17
N0 344 (42.5%) 263 (41.3%) 81 (47.1%)
 N+ 465 (57.5%) 374 (58.7%) 91 (52.9%)
Missing 7
Disease free 
interval
0.08
 < 12 months 528 (64.7%) 426 (66.3%) 102 (59.0%)
 ≥ 12 months 288 (35.3%) 217 (33.7%) 71 (41.0%)
Missing -
Number CRLM 
 solitary tumour 376 (46.3%) 293 (45.9%) 83 (48.0%)
0.62
 > 1 tumour 436 (53.7%) 346 (54.1%) 90 (52.0%)
Missing 4
Size largest tumour 0.22
 ≤ 5cm 643 (81.5%) 510 (82.4%) 133 (78.2%)
 > 5cm 146 (18.5%) 109 (17.6%) 37 (21.8%)
Missing 27
CEA 0.58
 < 200 705 (91.7%) 552 (91.4%) 153 (92.7%)
 ≥ 200 64 (8.3%) 52 (8.6%) 12 (7.3%)
Missing 47
Clinical risk score 0.28
Low 509 (65.5%) 395 (64.5%) 114 (69.1%)
High 268 (34.5%) 217 (35.5%) 51 (30.9%)
Missing 39
Preoperative CTx 0.97
No 378 (46.4%) 298 (46.4%) 80 (46.2%)
 Yes* 437 (53.6%) 344 (53.6%) 93 (53.8%)
Missing 1
Ablation at time of 
resection
0.92
No 672 (84.2%) 530 (82.4%) 142 (82.1%)
Yes 144 (17.6%) 113 (17.6%) 31 (17.9%)
Missing -
Resection margin 
involved
0.06
No 702 (86.5%) 545 (85.3%) 157 (90.8%)
Yes 110 (13.5%) 94 (14.7%) 16 (9.2%)
Missing 4
HGP 0.65
dHGP 183 (22.4%) 142 (22.1%) 41 (23.7%)
Non-dHGP 633 (77.6%) 501 (77.9%) 132 (76.3%)
* 31 patients (7.1%) received preoperative HAIP chemotherapy
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Figure 4. Kaplan-Meier curve for overall survival in patients with dHGP and non-dHGP
SURVIVAL OUTCOMES DHGP
The median OS in dHGP patients treated with adjuvant systemic chemotherapy was 79 
months (95% CI 46-112), compared to 91 months (95% CI not reached) in patients that did 
not receive adjuvant systemic chemotherapy (p=0.33, figure 5a). In multivariable analysis 
(table 2), no association between OS and adjuvant systemic chemotherapy was found for 
patients with dHGP (adjusted HR 0.83, 95%CI 0.42-1.65, p=0.60).  
Table 2: Uni- and multivariable Cox regression analysis for overall survival, dHGP
Univariable Multivariable
Covariate HR 95% CI p-value HR 95% CI p-value
Age 1.02 1.00-1.04 0.12 1.03 1.00-1.06 0.05
Node positive prim 1.06 0.66-1.72 0.80 1.25 0.71-2.21 0.44
DFI 1.01 1.00-1.02 0.14 1.01 1.00-1.02 0.16
Number CRLM 1.15 1.06-1.25 0.001 1.18 1.06-1.31 0.002
Diameter CRLM 1.04 0.96-1.11 0.34 1.02 0.94-1.11 0.60
CEA 1.00 1.00-1.00 0.19 1.00 1.00-1.00 0.40
R1 resection 1.49 0.68-3.26 0.32 1.22 0.49-3.06 0.6
Preoperative CTx 1.58 0.94-2.66 0.09 1.65 0.86-3.16 0.13
Adjuvant CTx 1.31 0.75-2.28 0.34 0.83 0.42-1.65 0.60
Figure 3. Kaplan-Meier curve for overall survival in patients with and without adjuvant systemic 
chemotherapy  
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Figure 5a. Kaplan-Meier for overall survival in dHGP patients with and without adjuvant systemic 
chemotherapy 
 
 
 
 
 
 
 
 
Figure 5b. Kaplan-Meier for OS in non-dHGP patients with and without adjuvant systemic 
chemotherapy 
 
 
 
 
Figure 5a. Kaplan-Meier for overall survival in dHGP patients with and without adjuvant systemic 
chemotherapy
SURVIVAL OUTCOMES NON-DHGP
The median OS in non-dHGP patients treated with adjuvant systemic chemotherapy was 74 
months (95%CI 53-96 months) compared to 45 months (95%CI 39-51 months) in patients not 
treated with adjuvant systemic chemotherapy (figure 5b, p=0.003). In multivariable analysis 
(table 3), adjuvant systemic chemotherapy remained significantly associated with improved 
survival (adjusted HR 0.66, 95%CI 0.50-0.88, p=0.004). 
Table 3: Uni- and multivariable Cox regression analysis for overall survival, non-dHGP
Univariable Multivariable
Covariate HR 95% CI p-value HR 95% CI p-value
Age 1.02 1.01-1.03 0.001 1.02 1.01-1.03 <0.001
Node positive prim 1.39 1.13-1.71 0.002 1.48 1.18-1.86 0.001
DFI 1.00 0.99-1.00 0.39 1.00 0.99-1.01 0.72
Number CRLM 1.07 1.01-1.12 0.01 1.10 1.04-1.16 0.001
Diameter CRLM 1.05 1.02-1.08 0.002 1.07 1.03-1.11 <0.001
CEA 1.00 1.00-1.00 0.05 1.00 1.00-1.00 0.20
R1 resection 1.44 1.10-1.87 0.008 1.22 0.91-1.63 0.19
Preoperative CTx 1.08 0.88-1.32 0.47 0.99 0.78-1.25 0.91
Adjuvant CTx 0.68 0.52-0.88 0.004 0.66 0.50-0.88 0.004
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Figure 5b.  Kaplan-Meier for OS in non-dHGP patients with and without adjuvant systemic chemotherapy
SUBGROUP ANALYSIS STRATIFIED BY PREOPERATIVE CHEMOTHERAPY 
Subgroup analyses stratified for preoperative chemotherapy were performed (figure 6). No 
benefit of adjuvant systemic chemotherapy was found in patients with dHGP treated with 
(HR 0.93; 95%CI 0.48-1.83, p=0.84) or without (HR 2.50, 95%CI 0.94-6.62, p=0.07) preoperative 
chemotherapy.  Also, no benefit of adjuvant systemic chemotherapy was found in patients 
with non-dHGP treated with preoperative chemotherapy (HR 0.93, 95%CI 0.64-1.34, p=0.68). 
Patients not pretreated with non-dHGP had superior survival outcomes with adjuvant 
systemic chemotherapy  (HR 0.51, 95%CI 0.34-0.74, p<0.001). 
Figure 5a. Kaplan-Meier for overall survival in dHGP patients with and without adjuvant systemic 
chemotherapy 
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Figure 6. Kaplan-Meier for overall survival stratified for preoperative chemotherapy
DISCUSSION
We found that HGPs predict the effectiveness of adjuvant systemic chemotherapy. Adjuvant 
systemic chemotherapy seemed to be effective in non-dHGP patients, reflected by improved 
OS (adjusted HR 0.66, p=0.004). No effect of adjuvant chemotherapy on OS (adjusted HR 
0.83, p=0.60) was observed in dHGP patients, suggesting that these patients may not benefit 
from adjuvant chemotherapy after resection of CRLM. Importantly, HGPs seemed to be only a 
predictive biomarker in patients that did not receive preoperative chemotherapy. 
In order to determine the effectiveness of perioperative systemic chemotherapy, several studies 
have been performed. A large randomized trial evaluated the effectiveness of perioperative 
FOLFOX in patients with resectable CRLM (EORTC 40983). Although OS was not the primary 
endpoint of the study, no significant OS benefit was found after long-term follow-up. However, 
there are several non-randomized studies available indicating that subgroups of patients may 
benefit from additional treatment with chemotherapy. These studies suggest that (neo-)
adjuvant systemic chemotherapy might be effective in patients at high risk of recurrence [7, 8]. 
Also, a subgroup analysis of the EORTC 40983 trial demonstrated beneficial progression free 
survival in patients with elevated CEA levels (>5 ng/ml) [13]. Furthermore, multiple previous 
studies have shown that the survival of patients with non-dHGP tumours is worse. Also, 
Figure 6. Kaplan-Meier for overall survival stratified for preoperative chemotherapy 
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non-dHGP is associated with several aggressive biological characteristics [14]. Therefore, the 
observed higher effectiveness of adjuvant chemotherapy in patients with non-dHGP tumours 
is in line with previous research, although validation of these findings is needed. 
The current study demonstrates that the predictive value of HGPs regarding the effect 
of systemic chemotherapy might be limited after preoperative chemotherapy. No clear 
explanation for this phenomenon is available yet. Patients with non-dHGP not responding 
to preoperative chemotherapy might remain non-dHGP, while the CRLM in those that do 
respond convert to dHGP. Patients that did not respond to preoperative chemotherapy 
remain non-dHGP after pretreatment, and consequently also might not benefit from adjuvant 
systemic chemotherapy. This could explain the limited value of HGPs in pretreated patients. 
Unfortunately, evaluation of HGPs is only possible after resection. 
Biological explanations of why only patients with non-dHGP appear to benefit from adjuvant 
systemic chemotherapy are lacking. One hypothesis is that a difference in tumour blood 
supply plays a role. Tumour cells in the non-dHGP use pre-existing liver vasculature from 
the surrounding liver parenchyma, instead of inducing the growth of new vessels through 
angiogenesis. However, in dHGP CRLM angiogenesis is observed [11]. This difference in tumour 
blood supply may also exist in occult micrometastases after curative-intent resection of CRLM, 
and could account for the fact that adjuvant systemic chemotherapy seems only effective in 
non-dHGP tumours due to a more effective supply of chemotherapy into the tumours. 
Since HGPs are determined after resection, this new biomarker can be used to guide the choice 
whether adjuvant systemic chemotherapy should be administered or not. However, future 
prospective studies should confirm the results of this study prior to clinical application. Future 
research should determine if pre-operative surrogate markers for HGPs can be identified (i.e., 
imaging [15], HGP gene expression in circulating tumour cells [16], or urine peptides [17]). 
Those surrogate markers may be helpful for predicting the effectiveness of preoperative 
systemic chemotherapy. 
The results of this study should be interpreted in the light of several limitations. Most 
importantly, the retrospective nature of this study and the fact that two different centers were 
involved with different treatment policies. Moreover, the administration of adjuvant systemic 
chemotherapy was not determined at random. In Erasmus MC, no standard adjuvant systemic 
chemotherapy is given, according to the national guidelines. Also, a large number of patients 
were excluded due to missing H&E sections. This is the first study that demonstrates the 
predictive value of HGPs for adjuvant systemic chemotherapy after resection of CRLM. Other 
studies should are needed to confirm our findings.
In conclusion, the current study demonstrated that HGPs can predict the effectiveness of 
adjuvant systemic chemotherapy after resection of CRLM. Patients with non-dHGP seem to 
benefit from adjuvant systemic chemotherapy, while patients with dHGP do not benefit. After 
preoperative  chemotherapy, adjuvant treatment seems not beneficial in either patient with 
dHGP or non-dHGP.
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ABSTRACT
OBJECTIVE
To evaluate and compare the overall survival (OS) in case-matched patient-groups treated 
either with systemic therapy or surgery for colorectal liver metastases (CRLM). 
METHODS
Patients with CRLM, without extra-hepatic disease, treated with chemotherapy with or 
without targeted therapy in two phase III studies (n=480) were selected and case-matched to 
patients who underwent liver resection (n=632). Matching criteria were sex, age, established 
prognostic factors for survival (clinical risk score (CRS)). Available CT scans of patients treated 
with systemic therapies were reviewed by three independent liver surgeons for resectability. 
Survival was compared between patients with resectable CRLM (based on CT scan review) 
who were treated with systemic therapy versus patients who underwent liver resection. 
RESULTS
A total of 96 patients treated with systemic therapy were included. Main reasons for excluding 
patients were missing data on the CRS, extra-hepatic disease, >10 CRLM and surgery after 
initial systemic therapy. Pre-treatment CT scans of the liver were available for review in 56 of 
the systemically treated patients, and metastases were unanimously considered (complex) 
resectable in 36 (64.3%) patients. These 36 patients were case matched with 36 patients who 
underwent liver resection. Median OS in the patient group treated with systemic therapy was 
26.5 months (range 0-81 months), which was significantly lower than the OS in case-matched 
patients who underwent liver resection (median OS 56 months; range 6-116) (p=0.027). 
CONCLUSIONS
In this case-matched control study, surgery provided superior overall survival rates compared 
to systemic therapy for CRLM. These findings suggest surgery remains the preferred treatment 
strategy for CRLM. Resection of CRLM should always be considered, preferably in a dedicated 
centre, since not all patients that qualify for resection are identified as such. 
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INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer-death world-wide [1]. CRC 
patients develop metastases in 30-40%, depending on various factors such as T stage, N stage 
or histological subtype of colorectal cancer (i.e. mucinous, signet ring cell or adenocarcinoma) 
[2]. Approximately 20% of patients present with synchronous distant metastases (stage IV 
disease) [3] and another 20% will develop metachronous metastases, predominantly located 
in the liver [4].
In terms of treatment, liver resection is considered the standard of care in patients with 
resectable colorectal liver metastases (CRLM), with 5-year survival rates ranging from 35-60% 
[5-7]. In recent years an increasing number of patients are considered eligible for surgical 
resection of CRLM due to improved treatment strategies, both surgical and non-surgical. 
These improvements include two-staged liver resections [8], portal vein embolization [9] and 
preoperative systemic therapy downsizing initially unresectable CRLM [10]. 
In order to predict prognosis of patients with CRLM considered for surgery, various groups have 
assessed risk factors [11, 12] and multiple prognostic scoring systems have been developed 
[13-17]. The clinical risk score (CRS) by Fong et al. [18] is the most used scoring system, and its 
prognostic value has been validated by several independent investigators [19-21]. According 
to this CRS the following items are assigned one point: positive nodal status of the primary 
tumour, tumour size >50mm, >1 metastases, CEA-level >200ng/ml and an interval between 
primary tumour and development of liver metastases <12 months. Patients with extrahepatic 
disease are excluded. The total sum of the CRS divides patients into ‘low risk’ (0-2 points), and 
‘high risk’ (3-5) of disease recurrence and overall survival after surgery [18]. 
Due to extra-hepatic disease and location, number or size of the liver metastases, only a 
minority of patients is, or will become, eligible for liver resection [13, 22]. Two issues play an 
important role in the treatment of patients with CRLM. First, there is no consensus on the 
criteria for resectability. Blinded retrospective reviews on this topic illustrated great variability 
in the assessment of resectability, even between dedicated liver surgeons [10, 23]. Second, 
chemotherapy regimens combining multiple drugs enriched with targeted agents, result 
in excellent median overall survival of >30 months in patients with initially unresectable 
colorectal metastases [24, 25]. Despite this, there is little doubt that surgical resection of CRLM 
offers the best chance for long-term survival [26] [27]. A randomized controlled trial on this 
topic is not considered to be ethical. Therefore, the challenge is to identify all patients who may 
be candidates for radical surgery of CRLM. Although the majority of cancer patients is currently 
being assessed in multidisciplinary teams, specific expertise in liver surgery is often lacking in 
these teams. 
Therefore, we investigated the baseline resectability status in the subgroup of patients with 
CRLM in two well-defined and prospectively established patient cohorts who were considered 
to have unresectable CRLM and received systemic therapy within a clinical trial. The survival 
of patients who were considered resectable at baseline was compared to a matched control 
group of patients who underwent surgical resection of CRLM during the same period.
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METHODS
PATIENT POPULATION AND DATA-COLLECTION
PATIENTS TREATED WITH SYSTEMIC THERAPY
We analysed patients with presumed unresectable CRLM at baseline who were included 
in two phase III randomized clinical trials from the Dutch Colorectal Cancer Group (DCCG). 
Starting in 2003, the CAIRO study randomized 820 metastatic colorectal cancer patients 
between first-line sequential or a combination treatment with capecitabine, irinotecan and 
oxaliplatin [28]. The CAIRO2 study included 755 metastatic colorectal cancer patients, who 
were randomly assigned to receive first-line treatment with capecitabine, oxaliplatin, and 
bevacizumab, or the same schedule with the addition of weekly cetuximab [29]. One of 
the inclusion criteria in both studies was that the metastases were unresectable. However 
a discussion of the individual patient in a multidisciplinary liver team was not mandatory 
for inclusion in both studies. Patients in the CAIRO study were required to have a WHO 
performance status of 0-2, and in the CAIRO2 study of 0-1. The details of both studies have 
been presented previously [28, 29]. 
Since patients with more than 10 CRLM are rarely candidates for curative surgery, CAIRO and 
CAIRO2 patients with less than 10 CRLM and without extra-hepatic disease were selected. 
Patients in both trials who underwent liver resection after initial systemic therapy were 
excluded as well as patients with the primary colorectal tumour still in situ. Another criterion 
for exclusion was incomplete data on the items of the CRS [18]. These criteria were pre-
operative CEA level, number of CRLM, size of the CRLM, lymph node status of the primary 
tumour, and the time between surgery of the primary tumour and ‘treatment’ (systemic 
therapy) of the metastases. These data were not necessary to be known for inclusion in the 
CAIRO and CAIRO2 studies, and therefore were not available in the majority of patients.
PATIENTS TREATED WITH LIVER RESECTION
Erasmus MC Cancer Institute Rotterdam and Radboud University Medical Centre Nijmegen 
are tertiary referral hospitals for CRLM surgery. Post-operative follow-up consisted of clinical 
examination, measurement of CEA-levels, and imaging using computed tomography (CT) 
imaging. In order to compare patients from similar time periods, all patients who underwent 
primary liver resection for CRLM between January 2003 (start of the CAIRO study) and September 
2011 were analysed in the present study. Patients who received induction, neo-adjuvant systemic 
therapy were excluded from the present analysis. Patients who underwent liver resection 
together with RFA of other lesions during the same operation were also excluded. Liver resection 
was considered to be complete (R0) when the pathologist assessed free resection margins. 
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DATA-COLLECTION AND MATCHING
Demographics and clinical-pathological factors of the primary tumour as well as the liver 
metastases were collected. Fong’s CRS[18] was used for matching patients’ oncological risk 
profiles. Thus, all 5 variables included in this CRS were collected: CEA level, tumour size and 
number of metastases recorded at baseline, the disease free interval between resection of 
the primary tumour and treatment of liver metastases (either surgery or randomization for 
systemic therapy) and nodal status of the primary tumour. Systemically treated patients 
were selected and case-matched to patients who underwent liver resection only, in terms of 
gender, age, CRS and the absence of extra-hepatic metastases. 
REVIEW OF RESECTABILITY 
In order to assess the potential surgical options and agreement on proposed treatment 
for CRLM, all baseline CT-scans of patients treated with systemic therapy were requested. 
Review of resectability, based on radiological images only, was performed by 3 dedicated 
liver surgeons. After reviewing the images of the CT scans, liver lesions were classified: 
 - resectable; 
 - complex resectable (e.g. two-staged procedures, including portal vein embolization, 
  resection in combination with radio frequent ablation, or the need for induction 
  chemo therapy); 
 - unresectable;
 - CT images were of insufficient quality for the assessment of resectability. Quality of 
  images was based on the system used by Jones et al. [23]. 
OUTCOME VARIABLES:
The primary endpoint of the current analysis was overall survival (OS). This was defined as 
the time from liver resection or from randomization to systemic therapy, until date of last 
follow up or death. As described in the protocols of CAIRO and CAIRO II, the maximum time 
from randomization to initiation of systemic treatment had to be within 7 days [28, 29].
STATISTICAL ANALYSIS: 
The comparison between categorical variables was performed using the Chi-square tests. 
Means and medians of the items from the CRS were compared using the Mann-Whitney-U 
test. Survival analysis was performed by using the Kaplan Meier survival analysis, and 
compared by using log-rank tests.  A p-value of <0.05 was considered statistically significant. 
All statistical analyses were performed using the Statistical Package for the Social Sciences 
version 18.0 (SPSS, Inc., Chicago, Illinois, USA).
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RESULTS
PATIENTS AND TREATMENT CHARACTERISTICS 
SYSTEMIC THERAPY
A total of 480 patients with CRLM without extra-hepatic metastases were treated with 
systemic therapy between January 2003-December 2004 (CAIRO, n=256) and between 
June 2005-December 2006 (CAIRO 2, n=224). The majority of patients (n=259; 54%) could 
not be included in the present study due to missing or incomplete data with respect to the 
CRS. Most frequently the pre-operative CEA-level was absent. Other reasons for exclusion 
are listed in figure 1a. Eventually 36 patients were eligible for inclusion from either the 
CAIRO (n=14), or CAIRO 2 (n=22). Of these 36 patients, 6 patients were treated with first-
line sequential chemotherapy, 8 patients received first-line combination therapy, 16 patients 
were treated with first-line chemotherapy with bevacizumab, and 6 patients received first-
line chemotherapy in combination with bevacizumab and cetuximab. Figure 1a. Selection 
process of patients with colorectal liver metastases treated with systemic therapy. tx: treatment. CRLM: 
colorectal liver metastases
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Figure 1a. Selection process of patients with colorectal liver metastases treated with systemic therapy. 
tx: treatment. CRLM: colorectal liver metastases
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Figure 1b: Selection process of patients with colorectal liver metastases treated with liver resection. 
Tx: treatment; CRS: clinical risk score.                        
Figure 1b. Selection process of patients with colorectal liver metastases treated with liver resection. Tx: 
treatment; CRS: clinical risk score. 
RETROSPECTIVE REVIEW OF RESECTABILITY
Baseline CT images of 57 patients out of 96 patients selected from the CAIRO studies could 
be retrieved from the different hospitals. These images were not available in 39 patients, 
because they were stored on microfilm only, or not stored digitally. In one patient, all three 
surgeons considered the CT images of “insufficient quality for review”, which left 56 patients 
(58.3%) eligible for analyses. In five patients one or more surgeons were unable to make 
a decision on resectability as a result of insufficient quality of the CT images. The majority 
of patients were considered (complex) resectable (n=36; 64.2%), while only 2 patients were 
considered unresectable by all three reviewers (Figure 2).
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Figure 2. Forrest plot showing decisions of 3 surgeons on resectability of colorectal liver metastases 
in 56 patients who were treated with systemic therapy, based on computer tomography images. The 
number of reviewers who made a decision is shown on the Y-axis and each bar on the X-axis represents 
one patient.  
Complex resectability was defined as the need for neo-adjuvant treatment or complex surgery (two-
staged procedures including portal vein embolization or resection in combination with radiofrequent 
ablation). 
LIVER RESECTION
Between January 2003 until September 2011 a total of 632 patients underwent liver 
resection. After excluding patients treated with neo-adjuvant systemic treatment (n=222), 
patients of whom data were missing on one of the items of the CRS (n=25), or patients with 
extra-hepatic disease (n=26), 358 patients were eligible and could be included in the current 
study. 
CASE-MATCHING
A total of 36 patients who were considered (complex) resectable by the liver surgeons were 
matched with patients who underwent liver surgery. The clinical-pathological characteristics 
used to case-match both treatment groups are summarized in Table 1. The types of performed 
liver resection were: wedge resection (n=15); segmental resection (n=11); hemihepatectomy 
(n=10). A microscopic incomplete resection (R1) seemed to be present in 6 patients (16.7%). 
After resection, 7 patients (19.4%) were treated with adjuvant systemic therapy 
(fluoropyrimidine only (n=1) and fluoropyrimidine plus oxaliplatin (n=6)). Of which, 1 patient 
was also treated with bevacizumab as part of a multicentre randomized clinical trial [30]. 
Figure 2: Forrest plot showing decisions of 3 surgeons on resectability of colorectal liver metastases 
in 56 patients who were treated with systemic therapy, based on computer tomography images. The 
number of reviewers who made a decision is shown on the Y-axis and each bar on the X-axis 
represents one patient.   
Complex resectability was defined as the need for neo-adjuvant treatment or complex surgery (two-
staged procedures including portal vein embolization or resection in combination with radiofrequent 
ablation).    
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Table 1: Demographic and tumour clinical-pathological factors of case-matched patients treated with 
systemic therapy or liver resection. CEA: carcinoembryonic antigen
Systemic therapy 
N=36
Surgery 
N=36 p-value
Gender Male 20 (55.6%) 20 (55.6%) -
Male Female 16 (44.4%) 16 (44.4%)
Median age in years (range) 66.5 (36-79) 66 (32-79) 0.813
Primary tumour
Colon 29 (80.6%) 22 (61.1%) 0.023**
Rectum 5 (13.9%) 14 (38.9%)
Unknown 2 (5.5%) 0
T-stage primary tumour
T1-3 26 (72.2%) 30 (83.3%) 0.257
T4 10 (27.8%) 6 (16.7%)
Lymph node Negative 16 (44.4%) 11 (30.6%) 0.224
Positive 20 (55.6%) 25(69.4%)
Liver metastases
Median CEA level  (range) 18.5 (1-635) 26.6 (1-910) 0.907
Median interval (range)* 4 (1-109) 3 (0-91) 0.907
Median number metastases (range) 4 (1-7) 3 (1-10) 0.009**
Median size largest metastasis in mm (range) 30 (12-160) 39 (12-120) 0.044**
Fong-score18 1 5 (13.9%) 4 (11.1%) 0.907
2 10 (27.8%) 12 (33.3%)
3 18 (50.0%) 16 (44.5%)
4 3 (8.3%) 4 (11.1%)
* interval between treatment of the primary tumour and the liver metastases (either systemic therapy or liver 
resection)
** significant with p<0.05
SURVIVAL
Median follow-up of all patients treated with systemic therapy was 43 months (range 0-81 
months) and 31 months (range 0-101) for patients who were surgically treated. 
Median overall survival (OS) in the total group of patients treated with systemic therapy 
(n=480) was 21 months (range 0-84 months) and 52 months (range 0-101 months) in the 
total group of patients who underwent liver resection (n=632). The 5-year OS was 11.9% in 
patients treated with systemic therapy only versus 45.6% in surgically treated patients.
In the matched cohort of patients treated with systemic therapy (n=36) median overall 
survival was 27 months (range 0-81 months), which was significantly higher (p=0.002) than 
in the total group of patients treated with systemic therapy (n=480). However, the OS in the 
matched cohort of patients treated with systemic therapy was significantly lower (p=0.027) 
compared to the median OS of 56 months (range 1-116 months) in case-matched patients 
treated with liver resection (n=36) (Figure 3).
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Figure 3. Overall survival in case-matched patients with colorectal liver metastases (considered 
resectable based on reviewing the computed tomography images) treated with either systemic 
therapy or liver resection (p=0.027). On the Y-axis the proportion of patients, on the X-axis survival in 
months. Tx: treatment. Nrs: numbers
DISCUSSION
This study showed that patients with CRLM are not always identified and offered surgery 
with curative intent. In the retrospective evaluation of CT-images performed by dedicated 
liver surgeons in a patient group treated with systemic, palliative regimens for CRLM, a 
significant number appeared to be resectable. The case-matched patient groups with 
resectable liver-only disease showed significant differences in overall survival after surgical 
or systemic treatment strategies. Patients undergoing surgery for CRLM had superior overall 
survival rates as compared to patients where systemic therapies were administered. Thus, 
the current study confirms surgery is the preferred treatment strategy in patients with CRLM. 
These findings emphasize the importance of adequate patient selection for surgery. 
Figure 3: Overall survival in case-matched patients with colorectal liver metastases (considered 
resectable based on reviewing the computed tomography images) treated with either systemic 
therapy or liver resection (p=0.027). On the Y-axis the proportion of patients, on the X-axis survival in 
months. Tx: treatment. Nrs: numbers  
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In the current study, patients were selected from two completed multicentre randomized 
clinical trials focusing on systemic therapy for CRLM, and from two large liver surgery 
databases. On ethical grounds, a true randomized clinical trial comparing both treatment 
strategies in patients with resectable CRLM has not been, and will not be performed. By case-
matching the patients for known prognostic factors, this study is the second best alternative 
to compare both treatment strategies in patients with resectable CRLM. 
After liver surgery patients showed a longer OS (median 56 months) compared to patients 
who were treated with systemic therapy for (retrospectively) resectable liver metastases 
(median 27 months).  
Kopetz et al. (2009) previously reported a survival benefit in patients with CRLM who 
underwent liver resection compared to patients treated with systemic therapy [26]. Patients 
undergoing liver surgery received pre-operative systemic therapy, suggestive of a selection 
bias in this study. Also, data were derived from unmatched patient cohorts, which could make 
the results susceptible for additional bias and should be interpreted cautiously. Brouquet 
et al. (2011) performed an intention-to-treat analysis to evaluate OS of “high risk patients” 
with CRLM (patients undergoing at least the first stage of a 2-staged surgical approach) after 
treatment with systemic agents versus patients treated with systemic therapy only [27]. In 
the surgery group, only non-progressors on systemic therapy were selected for comparison. 
In the group of patients treated with systemic therapy only, responders were selected, 
suggesting that only patients with a favourable tumour biology were used for comparison. 
This could induce a potential bias for the survival rates demonstrated in the group of patients 
receiving systemic therapy only (favourable tumour biology). However, even though patients 
with excellent response to systemic therapy were selected for comparison, surgery proved to 
yield superior overall survival. 
In the study of Brouquet et al. response to systemic therapy was accounted for in the 
analysis, in contrast to the study of Kopetz et al. [26, 27]. In the present study, only patients 
who underwent surgical treatment without neo-adjuvant/induction chemotherapy were 
selected in order to rule out a potential bias of selection of less aggressive cancers in resected 
patients. On the other hand, in the group treated with systemic therapy only, patients 
with favourable characteristics (< 10 liver only metastases) were selected from the CAIRO 
studies. This was demonstrated by a high median OS of 27 months, which was significantly 
better compared to the complete group of patients with treated with systemic therapy 
in both CAIRO studies (21 months; p=0.002) [28, 29]. Matching the surgical and systemic 
patient groups was performed using the CRS, age and gender. After case matching, the OS 
of systemically treated patients with resectable CRLM (based on reviewing the CT images, 
N=36), was compared to the OS of patients who underwent liver resection. Reviewing the 
CT scans with respect to resectability in the patient group treated with systemic therapy 
rules out the potential unfavourable effects of unresectability on survival. Median OS was 56 
months (range 1-101) in patients who were treated with liver resection, which was superior 
compared to systemically treated patients (median OS 27 months; range 0-81) (p=0.027). 
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Moreover, 5-year survival in the surgically treated group was 46.4% which is comparable to 
survival rates in the literature after liver resection with a median OS of 43-64 months and 
5-year OS rates of 51%-58% [7, 31]. The results of this study support the concept of a surgical 
treatment strategy as the gold standard for CRLM, although this has never been validated in 
a prospective randomized clinical trial. 
Unfortunately, there was no information available whether patients treated with systemic 
therapy were discussed in MDTs and evaluated for potential resectability in the CAIRO trials. 
Jones et al. reported the importance of MDTs and especially the involvement of specialist 
liver surgeons in those teams [23]. In their study, 63% of the patients with liver only colorectal 
metastases who were treated with palliative systemic treatment were retrospectively 
considered to have potentially resectable CRLM by a majority of the reviewing liver surgeons. 
In the present study the CT images of the systemically treated patients were reviewed and 
a majority of liver surgeons agreed on CRLM being resectable in 79% of cases, compared to 
63% in the study by Jones et al. [23]. 
In the CAIRO studies 4.8% (n=23) of all systemically treated patients with liver-only metastases 
underwent subsequent liver resection after a good response. For the comparison of survival 
in the present study, patients were only included if they continued systemic treatment and 
if they were not invited for surgery. Importantly, the decision on whether to perform a liver 
resection for CRLM is subject to bias as demonstrated by 13 of 56 patients (23.2%) in which 
at least one of the liver surgeons (being the expert panel of this study) considered lesions 
unresectable, while one of the other surgeons considered the same lesions (potentially) 
resectable. Folprecht et al. (2010) previously demonstrated critical disagreement between 
experienced liver surgeons in 7% of assessed patients, when they evaluated resectability on 
CT images of patients and deciding whether surgery or (induction) chemotherapy was the 
preferred treatment strategy [10]. 
The current study confirms that surgery yields superior survival rates in resectable, liver-only 
CRLM as compared to systemic treatment only. These results emphasize the importance of 
assessing each patient with CRLM by a dedicated MDT, including specialised liver surgeons. 
Furthermore, consensus on resectability between liver surgeons is essential. Standardised 
assessment of all patients with CRLM by specialist teams, might ensure that potentially all that 
qualify for surgery are identified accordingly, offering those patients the best prospects in 
terms of survival. A useful tool to assess resectability might be the Met-Assist program, which 
was developed to indicate the likelihood that experts in the field would judge surgery as 
feasible under given circumstances [32, 33]. Currently, the CAIRO5 trial is performed in which 
patients with potentially resectable CRLM are selected for different induction chemotherapy 
regimens [32]. This prospective trial uses a central panel consisting of one radiologist and 
three liver surgeons. Possibly, this trial will add to the definition of resectability of CRLM in 
the future. 
Separate from the (retrospective) observation that resection for CRLM yields superior survival 
rates as compared to systemic therapy, another point of interest is the cost effectiveness of 
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treatment strategies. Recently, Roberts et al. performed a cost-utility analysis of operative 
versus non-operative treatment for CRLM [34]. The results of their study show surgery is more 
effective and less costly than non-operative treatment for CRLM. Again, this emphasises the 
importance of patient selection for resection. 
A limitation of the present study may be that patients who underwent systemic therapy in 
the CAIRO and CAIRO2 trial underwent CT imaging demonstrating liver only disease, but 
did not all receive additional diagnostics for extra-hepatic metastases (e.g. FDG-PET scan). 
However, a recent randomized clinical trial evaluating the treatment changes in patients with 
CRLM scheduled for surgery after FDG-PET CT scan, reported cancellation of the suggested 
surgical procedure in only 2.7% of the patients [35]. Additionally, survival in patients who 
underwent liver surgery did not differ between patients who were selected with or without 
FDG-PET [36]. Because of the retrospective character of the current study and despite the 
thorough case matching, the performance status and co-morbidity may differ between 
surgery and systemically treated patients. However, the systemically treated patients all had 
a WHO performance status of 0-2 in the CAIRO study and WHO status of 0-1 in the CAIRO 2 
study, which is probably not inferior to the surgically treated patients. 
In conclusion, this case-matched controlled comparison of patients undergoing either 
systemic therapy or surgery for resectable CRLM demonstrate a significant survival benefit in 
patients treated with liver resection.  Surgery should remain the gold standard treatment for 
patients with CRLM. This finding emphasises the importance of adequate patient selection for 
surgery. Consensus on resectability and standardised assessment of all patients presenting 
with CRLM by dedicated liver surgeons in specialised MDTs optimises patient selection for 
surgery.  
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ABSTRACT 
BACKGROUND
The objective of this study was to map referral patterns in patients with synchronous 
colorectal liver metastases (SCLM) and to investigate if type, volume and location of the 
hospital of diagnosis are associated with whether or not patients underwent liver resection. 
METHODS
This population-based study includes all patients diagnosed with SCLM between 2008 
and 2012, based on the Netherlands Cancer Registry. To study inter-hospital variation, the 
proportion of patients undergoing liver surgery was calculated per hospital of diagnosis. 
Multivariable multilevel logistic regression analysis was used to investigate the association 
be- tween hospital characteristics and liver resection. 
RESULTS
Of 10,520 patients with SCLM, 12% (n = 1259) underwent liver surgery. Of these patients, 
58% (n = 733) were referred to another hospital to undergo liver surgery. In 53% of the 
patients (n = 647), liver resection was performed in a university hospital, in 39% (n = 482) 
in a dedicated liver centre and in 8% (n = 102) in a general hospital. There was a large inter-
hospital variation in the proportion of patients undergoing liver resection (2-26%). In a 
multi- level logistic regression model, the odds of undergoing liver surgery were higher 
when patients were diagnosed in hospitals where liver surgery was performed compared 
with the general hospitals (dedicated liver centre: odds ratio 1.36 [95% confidence intervals 
1.08-1.70], university hospital: odds ratio 1.69 [95% confidence intervals 1.22-2.34]). 
CONCLUSION
There is a large inter-hospital and inter-regional variation in the utilization of liver resection. 
Patients diagnosed with SCLM in expert centres had a higher chance of undergoing liver 
resection.
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common type of cancer worldwide. In 2014, more 
than 15,000 patients were diagnosed with CRC in the Netherlands. Metastases occur in a 
substantial number of patients, depending on the histological subtype of colorectal cancer 
(i.e. mucinous, signet ring cell or adenocarcinoma) [1]. Approximately, 20% of patients 
present with synchronous distant metastases (stage IV disease), and another 20% of patients 
develop metastases during follow-up (metachronous metastases) [2, 3]. Colorectal liver 
metastases (CLMs) are present in three out of four patients with stage IV disease and in the 
majority no extrahepatic metastases are found [3, 4]. 
Surgical resection of the primary tumour and all metastases offers a potential cure for 
patients with CLM; in particular for patients without extrahepatic metastases [5]. The five-
year survival rates for patients undergoing liver resection are nowadays between 20% and 
60%, depending on clinical risk factors [5-8]. As the criteria for resectability are evolving, the 
proportion of patients undergoing liver resection is increasing [9]. At present, metastasectomy 
is considered for patients with colorectal liver metastases if the patient is fit for surgery, if 
there is an expected remnant liver of at least 20-30% of the preoperative volume, if liver 
resection is anatomically possible with regard to vascular and biliary structures, and if no 
unresectable extrahepatic metastases are present [10, 11]. 
In the Netherlands, inter-hospital variation in the proportion of patients undergoing curative 
treatment has been demonstrated for various types of cancer [12-14]. A survey among 
surgeons showed a wide variety in the diagnostics and therapeutic workup for patients with 
metastatic CRC [15]. Recently, a regional study demonstrated variation in the utilization of 
liver resection in the south of the Netherlands [6]. This implies that substantial differences in 
the utilization of liver surgery might exist on a national level as well. Previous research has 
demonstrated that involvement of a hepatobiliary surgeon in the multidisciplinary colorectal 
cancer team improves overall survival [16-18]. Therefore, we hypothesize that patients with 
CLM diagnosed in a dedicated liver centre more often undergo liver surgery. 
The objective of this study was to determine the variation between hospitals in the 
proportion of patients with CLM undergoing liver resection, using the Netherlands Cancer 
Registry (NCR). Because only synchronous metastases can be identified by the NCR, we 
focused on stage IV patients only. Moreover, we analysed referral patterns for liver surgery 
and investigated if type, volume and region of the hospital of diagnosis were associated with 
the probability that a patient will undergo liver resection. 
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METHODS 
NETHERLANDS CANCER REGISTRY 
Nationwide population-based data were extracted from the NCR. This database registers 
all newly diagnosed cancers since 1989. Identification of patients is primarily based on 
notification by the national automated pathology archive and hospital discharge notes [19]. 
Patient, tumour and treatment characteristics were retrieved from patient files by specially 
trained registration employees of the Netherlands Comprehensive Cancer Organization. 
Classification of tumour characteristics occurs according to the current versions of the TNM 
Classification of Malignant Tumours [20] and the International Classification of Diseases 
for Oncology [21]. Information on metachronous metastases is not registered in the NCR. 
Follow-up of vital status is obtained by annually linking the Registry to the Municipal Personal 
Records Database, which contains information on vital status of all Dutch inhabitants.
DATA SELECTION 
All adult patients (18 years or older) who presented with SCLM between 2008 and 2012 
were selected for this study. Patients diagnosed with SCLM during autopsy were excluded. 
Synchronous metastases were defined as metastases detected before the start of initial 
treatment and/or during surgical exploration. The extracted data included patient, tumour 
and treatment characteristics, as well as overall survival (OS). OS was defined as the interval 
between date of diagnosis of the cancer until date of death from any cause, or censored 
at date of end of follow-up (December 2015). Year of diagnosis was defined as the year of 
first histological confirmation. Hospital of diagnosis was defined as the hospital where the 
first histological confirmation of malignant disease was obtained: most often as the result of 
endoscopic biopsy of the primary tumour. Liver resection was defined as any removal of liver 
metastases (including surgical diagnostic biopsies, not including percutaneous biopsies or 
percutaneous treatments such as radiofrequency ablation). 
ORGANIZATION OF DUTCH HOSPITAL HEALTH CARE 
Hospital health care in the Netherlands during the studied time period comprised of 91 
hospitals. These are commonly divided into general hospitals, teaching hospitals and 
university hospitals. University hospitals (n = 8) are allied with the Dutch universities and 
function as tertiary referral centres. There are 42 teaching hospitals that offer a surgical 
residency in collaboration with the university hospitals. General hospitals are often smaller 
and provide less complex care in high volume or diseases with a high incidence. 
However, because not all teaching hospitals provide liver surgery, within this article, we 
scored type of hospital as university hospital, dedicated liver centre (i.e. teaching hospitals 
where liver surgery in performed) and general hospital (i.e. teaching or general hospitals 
not providing liver surgery). In the Netherlands, liver surgery may be performed if a 
hospital meets specific requirements set by the medical professional associations. These 
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requirements state that a centre should employ at least two hepatobiliary surgeons, have 
access to specific interventions (e.g. radiofrequency ablation, endoscopic retrograde 
cholangiopancreatography) and meet a volume requirement of at least twenty oncologic liver 
resections annually [22]. The number of surgical procedures presented in this study does not 
include liver resections performed for metachronous colorectal metastases, non-colorectal 
metastases or primary liver tumours. Volume of hospital of diagnosis was divided in low (<20 
diagnoses), medium (20-35 diagnoses) and high (>35 diagnoses) according to the mean 
number of patients diagnosed with stage IV CRC annually in the studied time period. Regional 
differences were analysed using the nine regions of the Netherlands Comprehensive Cancer 
Organization. These nine regions, covering the whole of the Netherlands and all including 
rural and urban areas, are also the basis for regional collaboration between hospitals. 
DATA ANALYSIS 
Patient, tumour and treatment characteristics were presented for the total population. Any 
trend in the 
utilization of liver resection over time was studied using chi-square tests. The number of 
hospitals performing liver resections was calculated per year. For each type of hospital, the 
proportion of patients diagnosed with SCLM undergoing liver resection was calculated. To 
identify factors associated with liver resection, a multi-variable multilevel logistic regression 
analysis was per- formed, taking into account the hierarchical structure of patients clustered 
within hospitals of diagnosis. The multivariable analysis included those factors that showed 
a p-value below 0.1 on univariable analysis. Regions of diagnosis were alphabetically 
numbered to ensure anonymity. The region with the lowest rate of liver resection was taken 
as the reference value in multivariable analysis. For all statistical analyses, STATA version 12.0 
was used. 
RESULTS 
PATIENT CHARACTERISTICS 
Patient, tumour and treatment characteristics are presented in Table 1. A total of 10,520 
patients were diagnosed with SCLM in the Netherlands between 2008 and 2012. Over the 
years, there was a small increase in the number of diagnosed patients (from 1954 to 2173). The 
majority of patients were diagnosed in a general hospital (67%, n = 7036). Metastatic spread 
was limited to the liver in 60% (n = 6263) of the patients. Liver surgery was performed in 12% 
of patients (n = 1259). Most patients were treated with preoperative and/or postoperative 
systemic therapy (65%, n = 6869). Of 6263 patients with metastases confined to the liver, 19% 
underwent liver surgery (n = 1213). Over the years, the proportion of all patients undergoing 
liver resection increased from 9% to 15% (p < .001). Patients with colorectal liver metastases 
who underwent liver surgery had a 5-year OS of 46%, compared with 4% in patients who did 
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not undergo liver surgery. For patients with metastases confined to the liver specifically, this 
difference in 5-year OS was 47% versus 6%, respectively. 
CONCENTRATION OF CARE AND REFERRAL PATTERNS 
Between 2008 and 2012, there were a total of 91 hospitals in the Netherlands, divided into 9 
university hospitals, 16 dedicated liver centres and 66 general hospitals. Table 2 shows that 
there was some variation in the number of hospitals performing at least one liver resection 
for synchronous colorectal metastases. This was mainly due to a variation in the number of 
hospitals performing only one (incidental) resection per year (varying from 3 to 14). 
Table 3 shows the referral patterns for patients undergoing liver surgery. Of the 1259 patients 
who underwent liver surgery, 527 patients (42%) did so at the hospital of primary diagnosis. 
This number varied between the types of hospital of diagnosis: in university hospitals, only 
4% of patients were referred to another centre before undergoing liver surgery; in dedicated 
liver centres, 16% of patients underwent liver surgery at another hospital than the hospital 
of diagnosis; and in the general hospitals this number was 88%. 
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Table 1: Characteristics of patients with synchronous colorectal liver metastases (n=10 520).
Total Liver resection
N (%) N (%)
Year of diagnosis  
2008 1 954 (19) 172 (14)
2009 2 020 (19) 191 (15)
2010 2 178 (21) 269 (21)
2011 2 195 (21) 315 (25)
2012 2 173 (21) 312 (25)
Gender
Male 6 136 (58) 798 (63)
Female 4 384 (42) 461 (37)
Age
Mean 68 63
<60 2 347 (22) 398 (32)
60-75 5 316 (51) 714 (57)
75+ 2 857 (27) 147 (12)
Hospital of diagnosis
General hospital 7 036 (67) 720 (60)
Dedicated liver centre 2 869 (27) 402 (32)
University hospital 615 (6) 97 (8)
Location primary
Colon 7 402 (70) 787 (63)
Rectosigmoid 384 (4) 48 (4)
Rectum 2 734 (26) 424 (34)
Other metastatic locations
None (liver-only) 6 263 (60) 1 213 (96)
1 3 097 (29) 42 (3)
2 918 (9) 3 (0)
>2 242 (2) 1 (0)
Liver resection (+/- other treatment)
Yes 1 259 (12) 1 259 (100)
No 9 136 (87)
Unknown 125 (1)
Radiofrequency ablation (+/- other treatment)
Yes 302 (3) 147 (12)
No 10 218 (97) 1 112 (88)
Perioperative systemic therapy (+/- other treatment)
Chemotherapy 3 705 (35) 654 (52)
Targeted therapy 30 (0) 1 (0)
Combination therapy 3 134 (30) 357 (28)
None 3 651 (35) 247 (20)
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Table 2: Number of hospitals performing treatment in patients with SCLM
Total 2008 2009 2010 2011 2012
Hospitals where 
liver resection was 
performed
53 30 42 34 37 30
Number of liver 
resections per hospital 
per year (%)
      1 resection 4 (13%) 14(33%) 5(15%) 9(24%) 3(10%)
      2-10 resections 21(70%) 22(52%) 23(68%) 16(43%) 15(50%)
      >10 resections  5(17%) 6(14%) 6(18%) 12(32%) 12(40%)
Table 3: Referral patterns of patients undergoing liver resection (n = 1259) with type of hospital
Hospital of diagnosis Hospital of surgery (n, %)
Not referred Referred Total
General Dedicated University Foreign
General 95 (13) 4 (1) 136 (18) 499 (66) 26 (3) 760 (100)
Dedicated 339 (84) 3 (1) 4 (1) 54 (13) 2 (0) 402 (100)
University 93 (96) 0 (0) 3 (3) 0 (0) 1 (1) 97 (100)
Total  527 (42) 7 (1) 143 (11) 553 (44) 29 (2) 1259 (100)
UTILIZATION OF LIVER RESECTION 
Fig. 1 shows the proportion of patients undergoing liver resection for each hospital of 
diagnosis. Overall, 12% of patients with SCLM underwent a liver resection. This proportion 
varied between hospitals from 2% to 26%. The variation was largest in general hospitals (2-
26%), followed by the dedicated liver centres (4-24%) and the university hospitals (10-22%). 
The proportion was significantly higher in the university hospitals (16%) and the dedicated 
liver centres (14%), compared with the general hospitals (11%, p < .001). 
In univariable logistic regression analysis, no association was found between volume of 
hospital of diagnosis and liver resection (p = .12). Type and region of hospital, as well as several 
other clinicopathological factors were associated with liver resection and were thus included 
in the multivariable analysis. 
As shown in Fig. 2, patients diagnosed in a dedicated liver centre or in a university hospital 
were significantly more likely to undergo liver resection (odds ratio 1.36 [95% confidence 
intervals 1.14-1.62] and 1.64 [95% confidence intervals 1.25-2.14], respectively). There was an 
association between region of diagnosis and liver resection, with patients diagnosed in six out 
of nine regions (region B, C, F, G, H and I) being more likely to undergo liver resection compared 
with the reference region with the lowest probability of this treatment (region A). 
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With regard to chemotherapy, variation was smaller between type of hospital, as well as 
region. Only 6% of patients treated with chemotherapy were referred to another hospital for 
treatment. In the university hospital, 64% of patients were treated with chemotherapy, in the 
dedicated liver centres 65% and in the general hospitals 65%. Between regions, the percentage 
of patients treated with chemotherapy varied from 60% to 69%. 
Figure 1. Proportion of patients undergoing liver resection (whether or not after referral to another 
hospital) per hospital of primary diagnosis.
Figure 2. Forest plot of the probability to undergo liver resection, as found in a multilevel multivariable 
logistic regression analysis.
Figure 1. Proportion of patients undergoing liver resection (whether or not after referral to another 
hospital) per hospital of primary diagnosis. 
 
  
Figure 2. Forest plot of the probability to undergo liver resection, as found in a multilevel multivariable 
logistic regression analysis.  
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DISCUSSION 
This nationwide population-based study shows that the rate of liver resection in patients 
with synchronous colorectal liver metastases (SCLMs) varies considerably between hospitals 
in the Netherlands. Patients diagnosed in general hospitals were less likely to undergo liver 
surgery, compared with patients diagnosed in a dedicated liver centre or in a university 
hospital. Besides this inter-hospital variation, an inter-regional variation in the utilization of 
liver resection was also found, which was sustained after correction for several confounders 
in a multivariable analysis. 
Similar to these results, studies from the United Kingdom and Sweden showed considerable 
inter- hospital variation in the utilization of liver resection [8, 23]. Although patients included 
in the study by Morris et al. [8] 7] were diagnosed between 1998 and 2004, our study 
showed comparable results in more recent years, as did the study by Noren et al. [23]. In the 
Netherlands, inter-hospital variation was also found in the utilization of curative treatment 
for oesophageal cancer, lung cancer and gastric cancer [22, 24, 25]. Similar to the treatment 
of colorectal liver metastases, curative treatment for these cancer types is also concentrated 
in dedicated centres. 
According to The Dutch National Guidelines on Colorectal Cancer, all patients who are 
diagnosed with colorectal cancer should be discussed by a multidisciplinary team (MDT) 
[26]. In the general hospitals, this colorectal MDT also identifies patients who should be 
presented to a tertiary liver MDT at one of the dedicated liver centres or university hospitals. 
An explanation for the lower resection rate among patients diagnosed in the general 
hospitals could be that the local MDTs are less proficient in identifying all patients potentially 
eligible for curative treatment. Previous studies showed that a large number of patients, who 
were initially diagnosed with unresectable liver metastases, were still considered potentially 
resectable by a hepatobiliary surgeon [27, 28]. Therefore, an obvious solution to reduce inter-
hospital variation could be to involve a hepatobiliary surgeon in the local colorectal MDTs. 
As there was also a substantial inter-hospital variation in the hospitals where liver resection 
was performed with a range of 4-24% in the dedicated liver centres and 10-22% in the 
university hospitals involving a hepatobiliary surgeon in the local MDTs would not disperse 
these inter-hospital and inter-regional variations completely. Folprecht et al. [29] showed 
that even between hepatobiliary specialists considerable inter-individual variation in the 
decision of resectability existed. This could also account for the inter-hospital and inter- 
regional variation. 
The variation in treatment with chemotherapy was remarkably smaller, with an inter-regional 
variation of 60-69%. An important difference between chemotherapeutic treatment and liver 
surgery is that patients were seldom referred to another hospital, as there is no centralization 
of chemotherapeutic treatment in the Netherlands. 
A possible solution to this problem was recently put forth in the design of a new trial 
investigating treatment strategies in patients with initially unresectable colorectal liver-only 
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metastases: the CAIRO5 study and the CHARISMA study [30, 31]. To prevent bias caused 
by inter-individual variation, a nationwide expert panel was appointed, that first reached 
consensus on the criteria of resectability. Second, a web-based system was developed where 
physicians can upload diagnostic imaging, which are then assessed by a radiologist on 
quality, and subsequently evaluated by at least three expert liver surgeons on resectability 
[31]. Although this expert panel is currently only operating as part of a clinical trial, it shows 
that establishing a nationwide expert panel is logistically and financially possible. It should 
therefore be advocated that this panel will be maintained for daily practice as well, as this 
will probably contribute to more consensus on resectability, as well as a reduction in inter-
hospital and interregional variation. 
Besides type and region of hospital of diagnosis, other predictors to undergo liver resection 
included location of the primary tumour, the absence of extra- hepatic disease and the 
year of diagnosis. The latter shows that the utilization of liver resection is still increasing, 
implying that the rates of liver resection might increase even further in the nearby 
future [9]. The association between a more distal location of the primary tumour and an 
increased probability to receive curative treatment is remarkable and has been previously 
demonstrated; however, no clear explanation for this phenomenon is available [6] [8]. 
It might be that patients with distal tumours are more often eligible for resection of the 
primary tumour, due to the beneficial effect of neoadjuvant therapies; or that new strategies 
such as the ‘liver first’ resection are more suitable for rectal cancer patients [32]. 
Although it is tempting to consider the presented inter-hospital and inter-regional differences 
as a direct reflection of differences in quality of care, this would not be correct. Several other 
factors might attribute to these differences as well [33]. First, liver resection rates might 
vary simply because of chance. A variation in case-mix between the hospitals can also lead 
to a variation in treatment strategies [33]. To minimize this potential bias, a multivariable 
analysis including various clinicopathological factors was performed. Several factors, such as 
comorbidity, number and size of liver metastases, were not available. Because information 
on these prognostic factors was missing, multivariable analysis to investigate the influence 
of the inter-hospital and inter-regional variation in treatment utilization on overall survival 
could not be performed. Another limitation of this study is that no information is available 
on the accuracy of clinical staging. Recent studies demonstrate that PET- CT imaging does 
not have an impact on resectability or prognosis of patients with colorectal liver metastases 
[7, 34]. Hence, despite these possible differences, the variation shown in this study should at 
least be partially contributed to differences in (quality of ) care. This study does not include 
data on variation in overall survival, and future studies should investigate how inter-hospital 
and inter-regional differences influence survival. 
In conclusion, there is a considerable variation in the utilization of liver resection for patients 
with SCLM in the Netherlands. As liver resection offers the only potential cure, it is very 
important that all eligible patients are identified by dedicated specialists. The formation of 
a national expert panel, including hepatobiliary surgeons, dedicated radiologists as well 
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as dedicated medical oncologists, evaluating resectability in all patients with SCLM, will 
potentially lead to an important improvement in the identification of patients; and might 
even lead to an improvement in overall survival. 
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ABSTRACT
INTRODUCTION
Post-treatment surveillance protocols most often endure for 5 years after resection of 
colorectal liver metastasis (CRLM). Most recurrences occur within 3 years after surgical 
removal of the tumour. This study analyses the need of surveillance for patients with at least 
3 years of disease-free survival after potentially curative resection of CRLM.  
METHODS
A single-centre retrospective analysis of all consecutive patients who underwent treatment 
for CRLM with curative intent between 2000 and 2011.  
RESULTS
In total 152 out of 545 patient (28%) remained disease-free for 3 years after successful 
resection of the CRLM. The estimated recurrence rate after 10 years of follow-up in this 
group of 152 patients was 27%. More than half of these patients (55%) could be treated with 
curative intent for their recurrences. Multivariate analysis revealed that the nodal status of 
the primary tumour is of significant prognostic value for developing recurrences after 3 years 
of DFS. A disease-free interval (DFI) of less than 12 months between resection of primary 
tumour and detection of CRLM shows a trend towards significance. Both factors were used 
to create a risk score, showing that patients with a low-risk profile (node negative status 
and a DFI <12 months) have an estimated recurrence rate of 5% and might not benefit from 
intensive surveillance beyond three years of follow up without a recurrence.
CONCLUSION
The currently developed risk score shows that follow-up can be stopped in a specific 
subgroup, 3 years after treatment for their CRLM with curative intent.
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INTRODUCTION
Liver metastases are common in patients with colorectal cancer (CRC), developing in 
approximately half of patients with colorectal tumours [1, 2]. Surgical treatment of colorectal 
liver metastasis (CRLM) results in 5 years overall survival (OS) of 40-60% [3, 4]. Although the 
treatment of CRLM has improved, disease recurrence is seen in almost 70% of the patients. 
Most often recurrences develop during the first 3 years after surgery [5-7]. Both hepatic and 
pulmonary recurrences can be treated with local therapy repeatedly, thereby still offering 
the potential of cure [8-13]. The opportunity to control recurrent disease as a curable 
condition, increased interest in the surveillance of patients after hepatectomy. No consensus 
on the optimal follow-up protocol for curatively treated patients with stage IV CRC has been 
reached however. 
Patients treated with curative intent for CRLM enter a surveillance scheme, enduring for 5 
years in most centres. Research on the surveillance and prognosis of patients with CRLM 
mainly focuses on the first 3 years after surgery, as most recurrences occur in this period. 
Literature is scarce on the follow-up of patients with a disease-free survival (DFS) of 3 and 
more years [14]. The current study aims to analyse the need for surveillance in these patients, 
by determining the recurrence pattern, treatment for recurrences and oncological outcome. 
This study assesses the possibilities for a risk-based surveillance protocol in this highly 
selected but growing group of patients. 
PATIENTS AND METHODS
Patient data were extracted from a prospectively maintained database in Erasmus MC Cancer 
Institute. The database consists of perioperative and clinicopathological characteristics of 
primary CRC, CRLM and recurrent metastatic disease. In this retrospective analysis patients 
receiving surgical or ablative therapy for CRLM between January 2000 and November 2011 
were included. In this group all patients with a DFS of more than 3 years were identified. In 
case of relapsing disease after liver surgery, data on recurrence location, diagnosis and of 
treatment were collected.  
FOLLOW-UP OF PATIENTS WITH CRLM
Surveillance consists of physical examination, thoraco-abdominal Computed Tomography 
(CT) and regular serum Carcinoembryonic Antigen (CEA) level measurements. Patient 
surveillance was carried out for up to 5 years after treatment of CRLM. During this period 
serum CEA measurements and radiological imaging were performed every 3 to 6 months 
during the first 3 years after surgery and yearly thereafter. 
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RECURRENT DISEASE
In the present study, recurrences detected within 3 years of CRLM treatment with curative 
intent were categorized as early recurrences. All recurrences detected after 3 years were 
considered to be late recurrences. CEA blood levels above 5,00 µg/L were considered elevated. 
In case of normal CEA levels the absolute difference between baseline post-operative CEA 
levels and CEA levels at time of recurrence was calculated. 
Treatment of recurrent disease was assessed in a multidisciplinary tumour board for 
all patients. As long-term local control of metastatic CRC is achieved using surgery, 
radiofrequency ablation (RFA) or stereotactic radiotherapy (SRx), all of these modalities were 
considered to be potentially curative treatments for recurrent disease [15, 16]. 
Figure 1 Flowchart of the study 
 
 Figure 1. Flowchart of the study
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DISEASE-FREE AND OVERALL SURVIVAL
DFS was calculated as the time in months between the resection of CRLM and the diagnosis 
of recurrent disease (either by radiology, physical examination or endoscopy). When an 
elevated CEA level was the first sign of possible recurrence, this was followed by confirmative 
imaging or biopsies. The dates of the latter were used for survival calculations. 
OS was the time between treatment of CRLM and the date of death or last follow-up. For 
both patients with a DFS of 3 and 5 years, conditional OS and DFS curves were created, using 
36 and 60 months as the starting points (t0). In order to compare oncological outcome after 
potentially curative treatment for early and late recurrences, the survival estimate DFS2 
(from start treatment of recurrence until re-recurrence) was calculated. 
STATISTICAL ANALYSIS
The categorical data are presented as absolute numbers and percentages. Continuous 
variables were displayed as means (and standard deviations (SD)) or medians (and interquartile 
ranges (IQR)). Different proportions between groups were tested using the Chi-squared test. 
Univariable and multivariate regression models were created to identify factors related 
to late disease recurrence, for which Hazard Ratios (HR) and 95% confidence intervals (CI) 
were calculated. Prognostic factors were used to create a risk score. The score was internally 
validated for discrimination (concordance index) and calibration (calibration curve), using 
bootstrap resampling. The Kaplan-Meier method was used to estimate (conditional) survival. 
All (conditional) survival estimates were compared using the Log-Rank test. A p-value of less 
than 0,05 was considered significant. All analyses were performed using SPSS version 21.0 
(SPSS Inc., Chicago, Ill., USA) and R version 3.2.5 (http://www.r-project.org).
RESULTS
Of the 607 patients with a minimal potential follow-up of 3 years and potentially curative 
treatment for CRLM, 545 consecutive patients (90%) were eligible for analysis in this study. 
Exclusion criteria are presented in figure 1. One hundred fifty-two patients were disease-free 
after 3 years of follow-up (28%), of which 31 patients (20%) developed recurrences beyond 
3 years. Median follow-up time (t0=36 months after first hepatectomy) was 40 months (IQR: 
18-63 months) in this group. Twenty-four patients (16%) died during the follow-up period. In 
patients with 3 years of DFS the Kaplan-Meier analysis showed an estimated recurrence rate 
of 27% in the following 7 years of follow-up.  
Eighty-one patients were disease-free for more than 5 years (15%). Median follow-up time 
in this group of patients (t0=60 months after first hepatectomy) was 31 months (IQR: 20-
52 months). Seven recurrences (9%) and 6 deaths (7%) were observed and the estimated 
(Kaplan-Meier) probabilities of recurrence and mortality in the following 5 years were 11% 
and 12% respectively. Conditional OS and DFS curves are presented in figure 2, for both 
patients with 3 and 5 years of DFS. 
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Figure 2. Conditional DFS and OS for patients with 3- and 5 years of DFS
In total 393 patients (72%) had a DFS of less than 3 years. When comparing the recurrence 
pattern of early (< 3 years DFS) and late recurrences (> 3 years DFS), no significant differences 
in tumour location were seen (table 1). 
After evaluation of the late recurrences, 17 patients (55%) could be treated with curative 
treatment modalities, compared to 168 (45%) of the early recurrences (p=0,293). In patients 
with curatively treated early recurrences, re-recurrence occurred earlier than in patients 
with curatively treated late recurrences. Median time to relapse (DFS2) was 28 months (75th 
percentile at 12 months, 25th not reached) in patients with late recurrences and 8 months 
(IQR: 4-30 months) in patients with early recurrences (p=0,041). Table 1 displays treatment 
and surveillance results of early and late recurrences.  
In order to define which patients could potentially be excluded from follow-up, the chi-
squared test and univariable Cox regression analysis were performed. Factors associated 
with developing late disease recurrences were the nodal status of the primary tumour, 
the absence of neo-adjuvant chemotherapy for CRLM and the disease-free interval (DFI) 
between resection of the primary CRC and the detection of CRLM. The Clinical Risk Score 
(CRS) described by Fong et al. [17] showed no additional value in assessing the probability of 
developing late recurrence. 
After multivariate analysis, the nodal status remained a statistically significant prognostic 
factor for late disease recurrence after an initial DFS of 3 years. A DFI of more than 12 months 
between resection primary and development CRLM) shows a trend towards significance 
(table 2).
Risk categories for late recurrences were created, in which patients with node negative 
primary tumours and a DFI of less than 12 months (n=50, 33%) were considered at low-risk. 
All other patients (with either a N+ status, a DFI of more than 12 months or a combination 
of both characteristics) were considered at high-risk of late recurrence (n=101, 66%). In 1 
patient no risk score could be determined. In the low-risk group 2 patients (4%) developed 
recurrence during the 2 following years of surveillance (after the initial 3 disease-free years), 
Figure 2 Conditional DFS and OS for patients with 3- and 5 years of DFS 
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compared to 22 patients (22%) in the high-risk group. The estimated 10 years recurrence 
rate in the low risk group was 5% and 25% in the high risk group (p=0,005). The sensitivity 
of this risk score for prediction of late recurrences during the last 2 years of follow-up is 92%. 
The estimated difference in recurrence rate between the “high-risk” group and the complete 
group of patients with 3 years of DFS is 2%. This means that 50 patients with a DFS of 3 years 
need to remain in follow-up for another 2 years, in order to detect 1 “low-risk” patient with 
late recurrent disease. 
After 5 years of DFS one recurrence (3%) was observed in the low-risk group (n=32), 
compared to 6 recurrences (12%) in the high-risk group (n=49). The estimated 10 years 
recurrence rate in the following 5 years (after 5 years of DFS) is 3% in the low-risk group versus 
15% in the high-risk group (p=0,207). Kaplan-Meier curves after 3 and 5 years of DFS are 
presented in figure 3. The created risk model had a moderate capacity to predict late disease 
recurrence (bootstrap corrected concordance index: 0,707) and acceptable calibration (See 
Supplementary Material).
Table 1: Recurrence pattern, surveillance and treatment results
Recurrence < 3 years 
(N=373)
Recurrence > 3 years 
(N=31) P-value
Location recurrence:
Intrahepatic only 144 (39%) 9 (29%) 0.291
Extrahepatic location recurrences 229 (61%) 22 (71%) 0.904
Pulmonary recurrence 84 (23%) 11 (36%)
Local recurrence 15 (4%) 1 (3%)
Distant lymph nodes 21 (6%) 1 (3%)
Hepatic and pulmonary 35 (9%) 1 (3%)
Hepatic and other 28 (8%) 4 (13%)
Pulmonary and other 15 (4%) 2 (7%)
Multi-organ metastasis (≥3) 10 (3%) 1 (3%)
Other locations 21 (6%) 1 (3%)
Surveillance: 
Median CEA  (IQR) µg/L 7.0 (2.9-20.0) 7.1 (3.9-12.7) 0.849
Elevated CEA  (> 5,0 µg/L) 204 (55%) 22 (71%) 0.087
Non elevated CEA (≤ 5,0 µg/L) 152 (40%) 8 (26%)
Missing CEA values 17 (5%) 1 (3%)
Perc. increase (when normal CEA) 152 (40%) 8 (26%) 0.225
>25%  compared to baseline 49 (29%) 4 (50%)
1-25%  compared to baseline 25 (15%) 2 (25%)
Decreased compared to baseline 26 (16%) 2 (25%)
Not calculated 52 (34%) 0 (0%)
Treatment:
Curative 168 (45%) 17 (55%) 0.293
Non-curative 205 (55%) 14 (45%)
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Table 2: Baseline characteristics of patients with 3 years of DFS and the results of univariable and 
multivariable analysis
Variables: Total (N=152)
Recurrence  
>3 years 
(N=31)
Chi-squared       
p-value
Univariable 
[HR (95%CI) 
p-value]
Multivariable
[HR (95%CI)  
p-value]
Gender:
Male 94 19 (20.2%) 0.943 0.942 (0.456-1.943)
Female 58 12 (20.7%) 0.871
Age:
Median (range) 64 (30-86) 66 (30-86) 0.326 1.030 (0.994-1.067)
Mean ± SD 63.3 ± 11.1 65.9 ± 13.2 0.106
Primary CRC:
Location:
Colon 93 19 (20.4%) 0.989 0.978 (0.475-2.015)
Rectum 59 12 (20.3%) 0.952
T-stage:
T3-4 37 3 (8.1%) 0.086 3.250 (0.989-10.682)
T1-2 114 28 (24.6%) 0.052
Node status:
Positive 72 20 (27.8%) 0.035 2.316 (1.109-4.837) 2.279 (1.090 – 4.764)
Negative 79 11 (13.9%) 0.025 0.029
Adjuvant CTx:
Yes 31 9 (29.0%) 0.181 1.890 (0.868-4.116)
No 121 22 (18.2%) 0.109
CRLM:
DFI <12 months:
Yes 93 12 (12.9%) 0.004 0.372 (0.180-0.766) 0.471 (0.215 – 1.029)
No 59 19 (32.2%) 0.007 0.059
Number of CRLM:
1 77 17 (22.1%) 0.602 1.002 (4.94-2.033)
>1 75 14 (18.7%) 0.996
Size of tumours:
≤4,99 cm 124 24 (19.4%) 0.386 1.382 (0.595-3.210)
≥5,00 cm 26 7 (26.9%) 0.451
CEA preoperative:
≤199 µg/L 120 22 (18.3%) 0.305 0.045 (0.00- 46.585)
≥200 µg/L 8 1 (12.5%) 0.381
Bilobar metastases:
Yes 43 9 (20.9%) 0.918 1.218 (0.560-2.647)
No 109 22 (20.2%) 0.691
Neoadjuvant CTx:
Yes 70 8 (11.4%) 0.011 0.411 (0.184-0.920) 0.577 (0.241-1.380)
No 82 23 (28.0%) 0.03 0.216
Margin <1mm:
Yes 22 4 (18.2%) 0.743 0.985 (0.344-2.815)
No 127 27 (21.3%) 0.977
EHD:
Yes 3 0 (0.0%) 0.376 0.048 (0.00-8158.217)
No 149 31 (20.8%) 0.621
Clinical Risk Score:
LR (1-2) 102 23 (22.5%) 0.550 0.809 (0.347-1.886)
HR (3-5) 39 7 (17.9%) 0.624
Missing values were observed for T-stage (1), nodal status (1), tumour size (2), preoperative CEA (24), margin status 
(3 patients with RFA only) and the Clinical Risk  Score (11).
CTx = Chemotherapy; EHD = Extrahepatic disease; CEA = Carcinoembryonic antigen; LR = Low-risk; HR = High-risk
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Figure 3. Risk stratification for late recurrences. The graph on the left illustrates the DFS during the last 
2 years of follow-up (from 36 to 60 months after hepatectomy). The graph on the right illustrates the 
DFS after more than 60 months after hepatectomy.
DISCUSSION
The current study demonstrates that still a considerable proportion of patients with a DFS of 
more than 3 years develops recurrences, with an estimated 10 years recurrence rate of 27%. 
Patients with late recurrences received potentially curative treatment as often as patients 
with early recurrences did. This may justify surveillance in patients with CRLM, even after a 
DFS of 3 years. 
To date no prospective trials have been performed investigating the efficacy of long-term 
follow-up of patients with CRLM, nor curatively treated stage IV CRC in general. It is still 
unclear to what extend surveillance is useful. The primary target of this study was to objectify 
the necessity of surveillance in patients without evidence of disease 3 years after the first 
liver metastasectomy. Several groups have shown that repeat resections of recurrences 
offer survival benefit [18-20] and although the efficacy of RFA and SRx has been studied 
less intensively, results indicate that long-term disease control can be reached using these 
treatments [15, 16, 21, 22]. As more than half of the patients with late recurrences were 
treated with either one or a combination of local treatments, surveillance seems legitimate 
in this particular group of patients. 
Follow-up in the centre of the current study is carried out during 5 years for all patients 
after resection of CRLM, as is advised in the ASCRS and NCCN guidelines [23, 24]. Preferably 
cancer surveillance should only be performed in those patients benefiting from it. In order 
to decide in which patients follow-up is desirable, accurate prediction of outcome after 
metastasectomy is needed. Many efforts to determine prognosis of patients with CRLM have 
been made [4, 17, 25-27], of which the CRS is mostly practised [17]. Less evidence is available 
to predict the likelihood of late disease recurrence, which is demonstrated by the fact that 
patients with initially poor prognostic factors can still be cured from CRLM [28]. A study by Tan 
et al. shows that the currently used risk scores for CRLM have little predictive value in 3-years 
Figure 3 Risk stratification for late recurrences. The graph on the left illustrates the DFS during the 
last 2 years of follow-up (from 36 to 60 months after hepatectomy). The graph on the right illustrates 
the DFS after more than 60 months after hepatectomy. 
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survivors of CRLM with regards to the disease-specific survival and are therefore not suitable 
to decide whether long-term follow-up is appropriate [29]. In the current study the nodal 
status of the primary CRC showed to be the only significant prognostic factor with respect to 
developing late disease recurrence. The DFI was non-significant in multivariate analysis, but 
showed a trend towards significance. The interval between resection of the primary tumour 
and occurrence of CRLM has been used in most CRS, as a DFI of less than a year increases the 
chance of developing recurrent disease shortly after hepatectomy [4, 17, 25-27]. The results in 
this study indicate an opposite effect in patients with 3 years of DFS, as patients with a short 
interval (<12 months) between the primary CRC and the occurrence of CRLM had a favourable 
outcome in this particular group of patients.  Although counterintuitive, this finding might 
not be illogical. The included study group is highly selected as patients with early recurrence 
(< 3 years) have been excluded from the study. A short DFI between resection of primary 
CRC and development of CRLM is generally considered a sign of aggressive tumour biology, 
inducing recurrences shortly after partial hepatectomy rather than late [17]. This effect is still 
found in the current study: a short DFI makes it unlikely that a patient will recur after 3 years, 
but more likely a patient will recur within 3 years. The protective effect of a short DFI found in 
patients with 3 years of DFS after partial hepatectomy may well be explained by the selection 
criteria of this study. Further research in an external cohort of patients is needed to validate 
the currently obtained results. Nonetheless this study shows that the DFI might still be an 
important factor in a selected group of patients, when considering long-term surveillance in 
patients with CRLM.
In order to identify patients that could potentially be discharged from (intensive) surveillance, 
a stratification system was created using both the DFI and nodal status as variables. Patients 
with optimal prognostic factors (pN0-status and a DFI < 12 months) were considered to be at 
low-risk, resulting in an estimated recurrence probability of 5%. The results display that this is 
lower than the estimated 12% recurrence probability after 5 years of DFS, when it is generally 
accepted to discharge patients from follow-up. The risk score showed moderately good 
prediction capacity and acceptable calibration. Although this scoring system needs external 
validation and could potentially be extended with other variables, this study indicates that 
there may be patients with a low-risk profile that do not benefit from a surveillance protocol 
consisting of 5 years and can either be discharged from follow-up after 3 years or undergo 
less intensive surveillance by the general practitioner.
During the past decade several research groups have retrospectively evaluated the 
different aspects of follow-up after metastectomy, in order to define an optimal surveillance 
protocol [30-37]. Jones et al. [14] highlight the lack of evidence surrounding surveillance of 
patients with CRLM after reviewing all available literature on early intensive follow-up after 
metastasectomy and therefore remain inconclusive on how to perform optimal follow-up. 
In a review by Metcalfe et al. [38] 5 years of follow-up is proposed. As was shown in this and 
other studies, patients with a DFS of 5 years still have a probability of approximately 10% to 
develop recurrences after being discharged from surveillance. Recent literature states that 
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cure after resection of CRLM might only be achieved after 10 years of survival [28, 39]. This 
suggests that an extended follow-up protocol of more than 5 years could be worthwhile for 
some patients, again addressing the need for tailor-made follow-up schedules.
The current study has several limitations and its conclusions should therefore be interpreted 
with care. As a result of the retrospective nature of this study the obtained results might be 
biased, Due to the limited number of events after 3 years of DFS, only 3 factors could be 
evaluated in the multivariate analysis. It is likely that other factors are influential, although 
non-significant in this particular univariate analysis. The identified risk score has not been 
externally validated which impairs generalizability.  
Nevertheless, this study provides valuable insights regarding the follow-up of patients with 
3 years of DFS after surgery for CRLM. The data suggests that follow-up in patients surviving 
3 years without evidence of disease is useful and necessary in most patients. Patients with 
the currently developed low-risk profile might not benefit from the additional 2 years of 
surveillance, and patients with a high-risk profile should be followed beyond 5 years, which 
emphasizes the importance of a tailor-made long-term follow-up protocol after treatment of 
CRLM with curative intent.  
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ABSTRACT
Treatments for colorectal cancer (CRC) of all stages have evolved considerably over the past 
two decades, resulting in improved long-term outcomes. After curative treatment, 30% 
of patients with stage I–III and up to 65% of patients with stage IV CRC develop recurrent 
disease. Thus, patients are routinely offered surveillance in order to detect disease recurrence 
at an early, asymptomatic stage, with the intention of improving survival. Nevertheless, 
controversy continues to surround the optimal surveillance protocols. For patients with 
stage I–III CRC, more-intensive surveillance improves overall survival compared with less-
intensive or no surveillance, probably owing to improved outcomes after cancer recurrence, 
as well as proactive treatment of other conditions detected opportunistically. The benefit 
of surveillance after curative treatment of stage IV CRC is more controversial, but might be 
justified because repeat resection can improve overall survival and 20% of these patients are 
eligible for such treatment with curative intent. No trials have assessed the optimal follow-up 
approach after curative resection of metastatic CRC, and similarly to surveillance of patients 
with stage I–III disease, most programmes are more intensive during the first 3 years than at 
later time points. Herein, we provide a comprehensive overview of surveillance strategies 
for patients with CRC, and discuss the future development of patient-centred programmes. 
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INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer-related deaths [1]: CRC is the third most 
commonly diagnosed cancer worldwide, with an estimated 614,000 women (9.2% of all new 
cancer cases) and 746,000 men (10% of all new cancer cases) affected, and an estimated 
693,900 CRC-related deaths in 2012 [2]. Around 50% of patients with CRC present with 
localized disease (stage I–II), about 25% with locoregional advanced-stage disease (stage 
III), and the remainder with metastases in distant organs (stage IV) [3-5]. National screening 
programmes for CRC have been introduced in more than 50 countries, and this number is 
increasing [6]. Of note, screening increases the proportion of patients with CRCs that are 
diagnosed at an early disease stage [7], thereby increasing the potential for treatment 
with curative intent and improving patients outcomes. After treatment with curative 
intent, patients with CRC enter a surveillance programme that generally lasts for 5 years. 
Approximately 30% of patients with stage I–III disease develop recurrent disease after initial 
treatment [8, 9]; among patients with stage IV CRC, up to 65% have relapsed disease after 
treatment with curative intent [10-16].
The detection of local recurrent disease, metachronous lesions, and distant metastases at an 
early, asymptomatic, and treatable stage is the goal of surveillance after treatment of CRC 
with a curative intent. Indeed, early detection of recurrent CRC can increase patient eligibility 
for a range of effective treatments, reduce morbidity, and most importantly improve overall 
survival. In addition, treatment for early stage cancer tends to be less extensive than treatment 
for advanced-stage disease [17]. Modern curative treatments for locoregional and distant 
metastatic recurrences are increasingly successful, resulting in long-term survival [14, 18-22]. 
The early discovery of recurrent disease is only useful, however, if the patient’s condition 
— in terms of performance status — allows for repeated therapeutic intervention, and if 
the patient’s preference is to explore any opportunity for repeated treatment. Moreover, 
investigating whether treatment of asymptomatic recurrent disease ultimately provides 
an overall survival and/or quality-of-life benefit compared with treatment of patients only 
after they present with symptomatic disease is important. In addition, the total follow-up 
duration, the surveillance intervals, and the most-suitable diagnostic modalities must all be 
assessed in order to optimize the effectiveness of surveillance schemes. 
Herein, we review the established evidence on the effectiveness of surveillance programmes 
used after treatment of patients with CRC with curative intent. We have focused our 
discussion on surveillance of three specific patient groups: patients with stage I–III CRC who 
have received conventional curative treatment; those with stage IV CRC who have undergone 
local treatment with curative intent; and patients who have received curative organ-sparing 
treatment for CRC.
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KEY POINTS
 - Pooled analyses of prospective trials have demonstrated an overall survival benefit 
  of intensive postoperative surveillance in patients with stage I–III colorectal cancer 
  (CRC); however, individual studies used highly heterogeneous surveillance schemes 
 - The overall survival benefit of intensive surveillance is only partly due to improved 
  cancer-specific survival; other contributing factors include the treatment of 
  comorbidities owing to frequent contact with medical professionals 
 - For patients with stage I–III CRC, no optimal diagnostic tool or frequency of patient 
  visits has been established; regular follow-up assessment by a clinician seem to be 
  the most-important factor
 - Colonoscopies are generally performed at 6, 30 and 60 months after curative 
  treatment of patients with stage I–III CRC; performing additional colonoscopies does 
  not improve overall survival 
 - Limited evidence is available regarding surveillance after endoscopic resection of 
  early neoplasia, and after organ-sparing treatment for rectal cancer; prospective 
  randomized trials are needed 
 - Similarly, a lack of evidence exists on the effectiveness of surveillance after treatment 
  of patients with stage IV CRC with curative intent, and thus randomized trials are also 
  needed to address this issue 
DIAGNOSTIC MODALITIES FOR SURVEILLANCE
The diagnostic modalities used during follow-up assessments of patients are fundamental 
to the effectiveness of surveillance schemes. Detection of locally recurrent disease requires 
different diagnostics compared with those used to detect distant metastases: imaging and 
serum biomarker analyses are important for detection of non-luminal local recurrences and 
distant metastases, whereas endoscopic investigations enable diagnosis of intraluminal 
recurrent disease and metachronous (pre)malignant lesions. With every technique, 
patient burden, test accuracy (TABLE 1), optimal intervals, and cost effectiveness need to 
be considered in the design of surveillance strategies. Moreover, follow-up programmes 
should be based on anatomical and transitory patterns of tumour recurrence. In an efficient 
surveillance scheme, each specific modality is implemented at optimal time points.
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INTRALUMINAL RECURRENCES
Intraluminal locally recurrent disease and metachronous CRC occur after surgery in 
approximately 2–4% and 1.5–3% of patients, respectively [23-30]. In a long-term study 
of 10,283 Dutch patients with CRC [27], a mean 0.3% annual incidence of intraluminal 
metachronous cancer was observed, with a cumulative incidence of 1.1% at 3 years, rising 
to 2% at 6 years and 3.1% at 10 years after initial treatment. This incidence was significantly 
higher than the incidence of CRC in the age-matched and sex-matched general population 
(standardized incidence ratio 1.3, 95% CI 1.1–1.5) [27]. This finding is even more remarkable 
because most of the patients with metachronous lesions only had a hemicolon after previous 
surgical treatment to remove the primary CRC. The presence of synchronous intraluminal CRC 
at time of diagnosis was the most important risk factor for development of metachronous 
intraluminal CRC. Synchronous intraluminal lesions occur in ~4% of patients with CRC [27]. 
Table 1: Recurrence pattern, surveillance and treatment results
Anatomical location and 
modality
Test Sensitivity Specificity References
All-site recurrences
Laboratory tests CEA 50–90% 80–90%   [58, 66, 77, 80]
Circulating tumour DNA (methylation 
status) and/or circulating tumour cells 
(quantity, mRNA-expression profiles, 
KRAS and BRAF mutation status), and/
or tumour-derived RNA in platelets 
(RNA-expression profiles)
57–87% 90–96% [93-100]
Local recurrences
Laboratory tests Faecal tumour DNA (methylation 
analyses, mutation analyses, and 
immunoassays of various genes)
92% 90% [7, 91, 93]
FIT (for human haemoglobin) 74–88% (depending on cutoff used)
93–96% [7, 92, 214]
G-FOBT 51–100% 90–97% [89, 90]
Imaging CT 70–85% 50–92% [57-60]
MRI 66–95% 76–86% [58, 62, 63]
Endoscopy (colonoscopy) 95% 100% [31]
Endoscopic ultrasonography 67–95% 78–94% [62, 215]
18F-FDG-PET/CT 22–98% 93–98% [66, 69, 70]
CT-colonography 96–100% NR [48-55]
Liver metastasis  
Imaging Ultrasonography 50–76% 50–60% [58, 81, 82]
CT 85% 90–95% [81, 85]
MRI 85% 90–95% [81, 85]
18F-FDG-PET–CT 97% 97% [81, 85]
Urine collagen peptides 85% 92% [102]
Lung metastasis
Imaging CT 68–88% 87–97% [86-88]
18F-FDG-PET–CT 61–97% 95–96% [86]
Test characteristics as reported in studies of test use in screening, staging, and surveillance. 18F-FDG-PET–CT, 
2-[18F]fluoro-2-deoxy-D-glucose PET–CT; CEA, carcinoembryonic antigen; CRC, colorectal cancer; FIT, faecal 
immunochemical testing; G-FOBT, guaiac faecal occult blood test; NR, not reported.
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Colonoscopy 
Colonoscopy is considered the standard of care for detecting local or metachronous luminal 
recurrences of CRC, with a sensitivity of approximately 95% [31] (TABLE 1). Most guidelines 
recommend that colonoscopy is performed before initial surgery, or within 2–4 months of 
emergency surgery, to detect synchronous lesions, followed by repeat colonoscopy at 1 
year to detect metachronous tumours [32-37] (TABLE 2). In a range of studies reporting the 
yield of surveillance colonoscopy after CRC resection, approximately 65% of metachronous 
tumours were of stage I or II, of which 56% were asymptomatic, and 87% of patients with 
metachronous CRC underwent repeat surgery with curative intent [24, 38-45]. These 
findings are considered sufficient to warrant colonoscopy 1 year after initial resection. 
The effectiveness of colonoscopy surveillance in increasing overall survival after curative 
treatment for CRC has been assessed in a trial [46], in which 326 patients with CRC were 
randomly assigned to receive either intensive or ‘routine’ colonoscopy surveillance (see 
Supplementary S1 (table) for details of the test frequencies). During 5 years of follow-up 
monitoring, recurrent intraluminal CRC was detected in 8% and 11% of patients in the 
intensive versus routine surveillance groups, respectively (P = 0.32). Among the patients with 
intraluminal recurrence, more than two-thirds of those in the intensive colonoscopy group 
could be treated with curative intent versus one-third in the routine surveillance group (P = 
0.048; TABLE 3). Indeed, overall survival after CRC recurrence was significantly increased for 
patients in the intensive surveillance group (P = 0.03); however, this improvement had no 
statistically significant effect on 5-year overall survival for the intensive colonoscopy group 
as a whole (77% versus 72% in the routine surveillance group; P >0.05) [46]. These findings 
illustrate that intensive colonoscopy surveillance can improve outcomes for the subset of 
patients with locally recurrent and metachronous endoluminal CRC; altough, the effects of 
this approach on overall survival are limited because endoluminal recurrence only affects 
a minority of patients. Of note, the current emphasis on quality assurance in colonoscopy 
procedures and the improvements in endoscopic equipment since this study was conducted 
have substantially improved the diagnostic and therapeutic effectiveness of colonoscopy 
[47]. This progress, together with the biological behaviour of sporadic colorectal neoplasia 
and its anatomic location, probably make the use of colonoscopy surveillance intervals <1 
year irrelevant, even during the first 2 years after CRC resection.
CT-colonography
CT-colonography is an alternative to colonoscopy as a surveillance tool for the detection of 
intraluminal recurrent disease. In a Korean study that included 548 patients with CRC [48], 
of whom six (1%) developed intraluminal recurrences, the sensitivity of CT-colonography in 
the detection of intraluminal recurrence approximated to 100% (TABLE 1). Across a range 
of studies focused on surveillance monitoring of patients after CRC treatment [48-55], the 
negative predictive value (NPV) of CT-colonography for recurrent adenocarcinoma, advanced-
stage neoplasia, and any adenomatous lesions was 100%, 99%, and 97%, respectively. In 
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patients who are unwilling or unable to undergo colonoscopy, as well as in settings with 
limited colonoscopy resources, guidelines support the use of CT colonography as the best 
alternative tool for surveillance of intraluminal disease owing to the sensitivity and high NPV 
of this modality [48-55]. Notably, in a randomized trial that compared colonoscopy with CT-
colonography as screening modalities for the detection of primary CRC [56], participants 
scored the latter approach as the most burdensome, although this opinion did not affect 
their patients’ willingness to undergo repeat colonographic screening. 
LOCOREGIONAL EXTRALUMINAL RECURRENCES
Data on surveillance for local extraluminal disease after treatment of CRC with curative intent 
are scarce: most reports relate to disease staging prior to treatment. Detection of extraluminal 
locoregional disease, and differentiation between relapse and postoperative fibrosis can be 
achieved using CT, MRI, ultrasonography, and PET, with varying levels of accuracy reported in 
both surveillance and staging studies (TABLE 1). The approaches used to detect locoregional 
recurrence differ for colon and rectal cancer, as outlined in the following sections. 
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Table 2: Disease surveillance guidelines for patients with stage I–IV colorectal cancer
Modality ASCO 
2013[33]
ASCRS 2015 [36] ESMO (I–III: 2013; IV: 2014) 
[32] [37]
NCCN 2015 [34] UK 2011 
[35]
II–III I–IV: colon/rectum* I–III IV I–III IV I–IV
History and/or 
physical exam
Every 3–6 mo. 
for 5 yrs
Every 3–6 mo. for 
2 yrs
Every 6 mo. in 
yrs 3–5
Every 3–6 mo. 
for 3 yrs
Every 6–12 mo. 
in yrs 4–5
Every 3–6 
mo. for 3 yrs
Every 3–6 
mo. for 2 yrs
Every 6 mo. 
in yrs 3–5
Every 3–6 
mo. for 2 yrs
Every 6 mo. 
in yrs 3–5
NA
Serum CEA test Every 3–6 mo. 
for 5 yrs
Every 3–6 mo. for 
2 yrs
Every 6 mo. in 
yrs 3–5
Every 3–6 mo. 
for 3 yrs
Every 6–12 mo. 
in yrs 4–5
Every 3–6 
mo. for 3 yrs
Every 3–6 
mo. for 2 yrs
Every 6 mo. 
in yrs 3–5
Every 3–6 
mo. for 2 yrs
Every 6 mo. 
in yrs 3–5
Every 3–6 
mo. for 3 yrs
Chest CT Annually, or 
every 6–12 mo. 
for high-risk 
pts, for 3 yrs
Annually for 5 yrs Every 6–12 mo. 
for 3 yrs
Every 3–6 
mo. for 3 yrs
Annually for 
5 yrs
Every 3–6 
mo. for 2 yrs
Every 6–12 
mo. in yrs 
3–5
Two times in 
first 3 years
Abdominal CT Annually, or 
every 6–12 mo. 
for high-risk 
pts, for 3 yrs
Annually for 5 yrs Every 6–12 mo. 
for 3 yrs
Every 3–6 
mo. for 3 yrs
Annually for 
5 yrs
Every 3–6 
mo. for 2 yrs
Every 6–12 
mo. in yrs 
3–5
Two times in 
first 3 yrs
Pelvic CT Annually or 
every 6–12 mo. 
for high-risk 
pts, for up to 3 
yrs, or up to 5 
yrs for pts with 
rectal cancer
Annually for 5 yrs NA NA Annually for 
5 yrs
Every 3–6 
mo. for 2 yrs
Every 6–12 
mo. in yrs 
3–5
Two times in 
first 3 yrs
Liver CEUS NA NA Can substitute 
for abdominal 
CT
NA NA NA NA
Colonoscopy At 1 yr; every 5 
yrs thereafter
At 1 yr At 1 yr ; every 
3–5 yrs there-
after
NA At 1 and 4 
yrs, then 
every 5 yrs; 
annually if 
advanced 
adenoma is 
detected
At 1 and 4 
yrs, then 
every 5 yrs; 
annually if 
advanced 
adenoma is 
detected
At 1 yr; then 
every 5 yrs
Proctoscopy 
(+/- ERUS)
NA Colon cancer: NA 
Rectal cancer: 
Every 6–12 mo. 
for those with 
anastomosis, or 
every 6 mo. after 
local excision, for 
3–5 yrs
NA NA NA NA NA
ASCO, American Society of Clinical Oncology; ASCRS, American Society of Colon and Rectal Cancer Surgeons; 
CEA, carcinoembryonic antigen; CEUS, contrast-enhanced ultrasonography; ERUS, endorectal ultrasonography; 
ESMO, European Society for Medical Oncology; mo., months; NA, not applicable; NCCN, National Comprehensive 
Cancer Network; pts, patients; UK, United Kingdom; yr(s), year(s). *Same recommendations for colon and rectal 
cancer, unless noted.
CT scans
CT is the standard modality used to detect locoregional extraluminal disease during 
colon cancer staging. The sensitivity and specificity of CT for the detection of lymph-node 
metastases is approximately 70% and 78%, respectively, based on a meta-analysis of data 
from 674 patients [57] (TABLE 1). CT is also the most widely used imaging technique in the 
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Figure 1 | CT imaging surveillance for the diagnosis of colorectal liver metastases. An axial contrast-
enhanced CT image of a patient who was previously treated for a primary colorectal cancer with 
curative intent reveals three liver metastases (arrows).  
 
 
 
 
 
 
  
setting of follow-up surveillance for CRC recurrence. In a pooled analysis including 17 studies 
comprising a total of 1,226 patients, CT had a sensitivity of 85% and a specificity of 92% for 
detecting locally recurrent CRC when using pathological confirmation as the ‘gold standard’ 
diagnostic test [58]. Only limited data are available on the effectiveness of CT in the detection 
of recurrent rectal cancer specifically: two studies involving a total of 43 patients reported 
76% and 82% sensitivity, and a specificity of 50% [59, 60]; however, these studies were 
performed before the introduction of standardiz d surgical techniques and neoadjuvant 
therapies for rectal ca c r.
Figure 1. CT imaging surveillance for the diagnosis of colorectal liver metastases. An axial contrast-
enhanced CT image of a patient who was previously treated for a primary colorectal cancer with 
curative intent reveals three liver metastases (arrows).
MRI assessments
MRI is the modality of choice for rectal cancer staging [61]. With respect to lymph-node 
assessment in the setting of initial staging, a large meta-analysis has been performed to assess 
the accuracy of MRI (in a total of 1,003 patients), compared with endorectal ultrasonography 
(in 3,879 patients), and CT (in 1,123 patients). All three modalities had a moderate sensitivity 
of 66%, 67%, and 55%, respectively, which no statistically significant difference observed 
between the techniques in this regard[62]. Specificities were also similar: 76% for MRI, 78% 
for endorectal ultrasonography, and 74% for CT[62]. MRI is not used routinely for surveillance 
after colorectal cancer resection; however, the authors of one study[58] reported that the 
sensitivity of MRI for the detection of local recurrence is approximately 95%, with a specificity 
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of 82%. Routine surveillance of rectal or left-sided colon cancer using MRI has also been 
assessed in a study involving 226 patients [63]. Local recurrence was identified in 30 patients 
(13%) using colonoscopy, with 26 recurrences localized to perirectal tissue and the other four 
occurring at the anastomosis [63]. MRI enabled the diagnosis of 26 of these recurrences (87%); 
of note, three out of four anastomotic recurrences were not detected using MRI[63]. Only 
two patients had local recurrences that were deemed resectable [63]; therefore, routine MRI 
offered a potential survival advantage (via curative treatment of relapsed disease) for <1% of 
the patients included in this study. These findings raise important questions regarding the 
utility of routine MRI for rectal cancer surveillance, and support the notion that MRI should 
be reserved for staging of recurrent CRC after diagnosis by other means. MRI does have a role 
in intraluminal evaluation of complete clinical response after organ-sparing treatment for 
rectal cancer [64, 65], and will be discussed in this context later in this Review.
PET analysis
The use of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG)-PET–CT has been assessed for the 
detection of locoregional spread of CRC in several reports, with a sensitivity of 22–84% for nodal 
metastases [66-68](TABLE 1); the accuracy for detection of positive nodes in close vicinity to the 
primary tumour is lower owing to the limited spatial resolution of PET–CT [66]. 18F-FDG-PET-CT 
imaging is valuable, however, for the differentiation of post-treatment changes in nonmalignant 
tissue from a recurrent tumour. Indeed, in this context, PET with 18F FDG can have advantages 
over CT and MRI in terms of sensitivity and specificity for detection of tumour recurrence. A meta-
analysis of data from 336 patients indicated a 94% sensitivity with a 98% specificity for diagnosis 
of local and/or pelvic recurrences using 18F FDG-PET, when compared with the gold standard of 
histopathological confirmation [69] (TABLE 1). The performance of combined PET and CT (PET–
CT) was addressed in a retrospective study involving 62 patients [70], in which pelvic sites were 
rated separately using PET and PET–CT. PET alone had a sensitivity of 82% with a specificity of 
65% for the detection of malignant lesions, whereas PET–CT enabled greater accuracy with a 
sensitivity of 98% and a specificity of 96% [70]. This study emphasised the importance of careful 
evaluation of the data obtained using PET–CT. The use of CT alone resulted in the identification 
of 30 pelvic abnormalities, of which seven were recurrent tumours and 23 were benign lesions; 
PET–CT enabled the differentiation of these lesions with a sensitivity of 100% and a specificity 
of 96% [70]. The use of 18F-FDG-PET specifically in the follow-up surveillance of patients after 
curative treatment for stage III–IV CRC has been assessed in one prospective randomized trial 
[71]. The addition of two 18F-FDG-PET scans to a conventional surveillance scheme (used alone 
in the ‘control’ group) at 9 and 15 months after surgery was associated with a substantial increase 
in the number of recurrences that could be treated with curative intent (10 versus two) [71]. The 
study was not powered to detect survival differences, and only examined the surveillance period 
between 9 and 24 months after treatment of CRC with a curative intent. The value of PET-CT 
surveillance has also been evaluated a retrospective study that included a highly selected group 
of 88 patients with CRC who had been under surveillance for at least 5 years after treatment with 
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curative intent [72]. These patients had an elevated CEA and subsequent nonconclusive findings 
upon subsequent conventional imaging (with CT, ultrasonography, and/or colonoscopy). In 
this group, PET–CT enabled the diagnosis of recurrent disease with a sensitivity of 88% and a 
specificity of 88% [72]. These data suggest that PET–CT as ‘a last resort’ surveillance modality has 
a low specificity for detecting recurrent disease, raising the question of whether it should be used 
routinely in this setting.
PET-based surveillance has some inherent limitations. First, diagnosis of relapse is dependent on 
tumour size and 18F-FDG uptake [73]. Second, the specificity of PET is reduced in the first 12 
months after radiotherapy, owing to the presence of radiation-induced acute inflammatory and 
proliferative changes to tissues [74]. Finally, the sensitivity of 18F-FDG-PET is limited in patients 
receiving chemotherapy, which can reduce the metabolic activity of tumour cells [75]. In general, 
PET is not routinely used in surveillance after treatment for CRC with curative intent (TABLE 2).
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Figure 2. PET–CT imaging surveillance for the diagnosis of pulmonary metastases. The upper-left 
panel shows an axial CT image of a patient who was previously treated for a primary colorectal cancer 
with curative intent. A lesion that was later confirmed as a pulmonary metastasis of colorectal origin is 
evident in the inferior lobe of the left lung (arrow). The upper-right and lower-right panels are 2 [18F]
fluoro 2 deoxy-d-glucose (18F FDG) PET images from axial and coronal planes, respectively, with the 
same hypermetabolic lesion indicated (arrows). The lower-left panel shows a corresponding 18F FDG 
PET–CT fusion image demonstrating tracer accumulation and thus elevated metabolic activity in the 
pulmonary metastasis.
DISTANT RECURRENCES
Approximately 25% of patients with CRC have metastatic disease at presentation and another 
20% will subsequently develop metachronous metastases [3-5, 76]. Most distant metastases 
occur within the liver (FIG. 1), which is affected in 65% of patients with metachronous 
metastases [76]. The lungs are the second most-common site of metachronous metastasis 
(FIG. 2), and are affected in 43% of patients; in 12% of patients, liver and lung metastases are 
present simultaneously [76]. Biomarkers, such as CEA, can be indicative of distant, systemic 
disease; however, discovery of distant lesions requires a range of imaging techniques. 
Serum CEA testing
Serum CEA is the most widely used biomarker for the diagnosis of disseminated CRC. The 
sensitivity of CEA for identifying patients with distant metastases of CRC depends on the 
45 
 
Figure 2 | PET–CT imaging surveillance for the diagnosis of pulmonary metastases. The upper-left panel shows an 
axial CT image of a patient who was previously treated for a primary colorectal cancer with curative intent. A lesion 
that was later confirmed as a pulmonary metastasis of colorectal origin is evident in the inferior lobe of the left 
lung (arrow). The upper-right and lower-right panels are 2-[18F]fluoro-2-deoxy-d-glucose (18F-FDG)-PET images 
from axial and coronal planes, respectively, with the same hypermetabolic lesion indicated (arrows). The lower-left 
panel shows a corresponding 18F-FDG-PET–CT fusion image demonstrating tracer accumulation and thus elevated 
metabolic activity in the pulmonary metastasis.  
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cutoff level used, and ranges from 50–70%, with a specificity of 80–90% [58] . One meta-
analysis that included 4,285 patients with CRC established an optimal serum CEA cutoff 
of 2.2 ng/ml, which had a sensitivity of 64% and a specificity of 90% for detection of CRC 
metastases [77]. 
The diagnostic accuracy of CEA testing further depends on the algorithm used for 
interpretation of the findings [77-80]. After resection of colorectal liver metastases (CRLM), 
assessment of the extent of the increase in serum CEA levels (in particular, a slope ≥25%) 
rather than the absolute values can help to identify patients with recurrent disease, with 
a sensitivity of 69% [79]. Bimonthly surveillance with CEA slope analyses (and further 
investigation using imaging if serum CEA levels increase by ≥20%) after resection of CRLM 
resulted in increased detection of recurrences that could be treated with a curative intent, 
compared with standard surveillance with less frequent CEA testing according to Dutch 
guidelines (42% versus 30%; P = 0.0048) [80]; however, the increased opportunities for 
curative treatment of recurrent disease did not translate into an overall survival benefit. The 
latter study used a ‘stepped wedge’ randomization method, whereby most patients were at 
least partly covered by both the conventional and investigational surveillance schemes, thus 
introducing a potentially important confounding variable. 
Of note, surveillance for disease recurrence involving referral for targeted imaging based 
on CEA levels is less expensive than the use of intensive imaging without triage. In one 
study [79], the costs per detected recurrence using either CEA-directed or imaging-based 
surveillance schemes were estimated at €2,196 and €6,721, respectively. 
Imaging-based surveillance
Sensitivity for the detection of distant metastases from CRC differs between imaging 
techniques. Ultrasonography of the liver is inexpensive, non-burdensome and does not 
expose patients to radiation; however, this modality is not suitable for the detection of 
extrahepatic metastases, and has a lower sensitivity (approximately 60%) for the detection 
of CRLM than CT or MRI [58, 81, 82] (TABLE 1). The use of contrast-enhanced ultrasonography 
(CEUS) has improved the detection and characterization of liver lesions, compared with 
non-contrast-enhanced approaches [83]. Even with the use of contrast, limitations of 
ultrasonography remain, including: operator-dependency, low sensitivity for small lesions 
(<5 mm in diameter), difficulty in the evaluation of the subdiaphragmatic liver (especially 
segments VII and VIII), visual impairment by interposition of the intestine, and signal 
interference caused by steatosis and fibrosis. These various limitations of ultrasonography 
can increase the possibility of missing lesions [84]. Both CT and MRI overcome the mentioned 
drawbacks of ultrasonography, and both are associated with a sensitivity for CRLM of 
approximately 85% and a specificity of 90–95% [85] (TABLE 1). In addition, 18F-FDG-PET–CT 
enables detection of CRLM with a sensitivity of 97% and a specificity of 97% [81, 85]. 
The diagnostic value of CT scanning for the detection of extrahepatic abdominal metastases 
has not been systematically investigated. In a systematic review in which CT and 18F-FDG-
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PET–CT surveillance were compared in 178 patients, CT had a sensitivity of 64–88% with a 
specificity of 87–97% for the detection of pulmonary metastases [86]. Thus, the routine use of 
thoracic CT scans in patients with negative chest radiographs seems be of limited diagnostic 
value [87, 88]. In a retrospective analysis of the outcomes of 100 patients referred for resection 
of CRLM [88], all of whom had no signs of pulmonary metastasis on chest radiographs, 
additional assessments using chest CT revealed pulmonary lesions in 11 patients (11%); 
three patients had histologically confirmed pulmonary metastases, one patient had primary 
lung cancer, and the seven other patients had lesions were not malignant. Thus, in addition 
to negative findings of chest radiographs, the yield of a chest CT scan in the detection of 
malignant lesions was 4%, with a positive predictive value of 36% [88]. 18F-FDG-PET–CT has 
a sensitivity of 61–97% and a specificity of 95–96% for pulmonary metastases from CRC[88] 
(TABLE 1; FIG. 2); thus the specificity of 18F-FDG-PET–CT is comparable to that of CT.
NOVEL DIAGNOSTIC TOOLS
The field of screening and surveillance for CRC is evolving rapidly owing to the introduction 
of new tests. The novel approaches differ in character and scope, and comprise biomarker or 
imaging tests focused on the detection of intraluminal or systemic disease. Biomarker tests 
can be based on assessment of stools, blood, urine, or, potentially, breath.
Faecal immunochemical testing (FIT)
Faecal immunochemical testing (FIT) is aimed at the detection of faecal occult blood using 
antibodies specific to human globin, and is more sensitive than the traditional guaiac faecal 
occult blood tests (G-FOBT) [7, 89, 90] (TABLE 1). FIT enables the selective detection of the 
human globin-protein in stool, making it rather specific to colonic blood loss, as globin 
from blood lost proximal to the colon will mostly be degraded before entering the colon. 
FIT and G-FOBT are used primarily as a population screening tool for CRC, and the evidence 
supporting the use these methodologies to detect disease recurrence is less strong or non-
existant. In 1,244 patients with previous CRC undergoing surveillance colonoscopies, G-FOBT 
enabled the identification of only three of nine patients with local recurrence (33%) and two 
of 13 patients with metachronous intraluminal disease (15%) [91]. 
Faecal DNA testing
Quantification of tumour DNA in stool samples can enable the detection of intraluminal 
disease. In the setting of primary screening for CRC, stool DNA testing for changes in multiple 
genes, including quantitative molecular assays for KRAS mutations, NDRG4 and MBP3 
methylation, and ACTB (encoding β-actin), in combination with FIT has been compared with 
the use of FIT alone in 9,989 patients [92]; the combined stool DNA-testing plus FIT approach 
had a sensitivity of 92.3% and a specificity of 89.8% versus 73.8% and 96.4% for FIT alone (P 
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= 0.002) [92] (TABLE 1). These data support the conclusion that the inclusion of stool DNA 
testing improves on the accuracy of FIT alone, although the difference between both arms 
would have been reduced substantially if the investigators had achieved a similar rate of 
referral to colonoscopy in both arms by simply applying a lower FIT cutoff. 
Analysis of circulating tumour DNA and circulating tumour cells.
umour material can be shed from invasive CRCs into the circulation; therefore, interest in 
the use of blood-based tests — termed ‘liquid biopsies’ — to tailor treatment and evaluate 
therapy response is increasing. Such tests might also be helpful tools in surveillance 
for disease recurrence. Detection of mutations involving genes such as KRAS, as well as 
methylation markers, in circulating cell-free tumour DNA (ctDNA) can indicate the presence 
of metastatic disease with a sensitivity of 57–87% and a specificity of 90–96% in a primary 
screening setting [93-95] (TABLE 1). Other promising alternative liquid biopsy approaches, 
such as analysis of circulating tumour cells (and their gene-expression profiles) [96-98] and 
tumour RNA in thrombocytes [99, 100], and other serum biomarkers need to be further 
investigated in terms of their effectiveness as surveillance tools after treatment for CRC with 
curative intent. Novel biomarkers might be superior in terms of the prediction and detection 
of malignant spread at an earlier stage — that is, before symptoms occur, or long before 
disease recurrence can be detected using imaging modalities.
Urine peptides
The urinary proteome might also provide opportunities for the early detection of cancer 
[101]. Similar to stool and blood sampling, urine collection is noninvasive and can be 
performed in primary care. At present, data on this approach is limited, but urine collagen 
peptides have been used to diagnose CRC metastases [102]. 
PET–MRI
Lymph nodes with and without tumour metastases vary in size. In patients with lung cancer, 
up to 21% of lymph nodes <1 cm harbour metastases, while ~40% of those >1 cm do not 
[103, 104]. These findings are relevant to the assessment of lymph nodes with any imaging 
technique and for any cancer type. The combination of PET data with CT findings can result 
in superior accuracy of nodal staging compared with the use of MRI scans [105]. Similarly, 
the additional use of PET might improve the diagnostic accuracy of MRI. Indeed, no major 
differences in the accuracy of lymph-node staging would be expected when comparing 
PET–CT and PET–MRI [106], as differentiation of malignant and benign lesions is mainly 
based on functional information obtained using PET. With regard to distant metastases, 
studies comparing the effectiveness of 18F-FDG-PET–CT with that of whole-body MRI for the 
detection of pulmonary lesions demonstrated that the CT-based approach is more accurate 
[105, 107-109]; however, this advantage was attributable to the increased sensitivity of CT 
imaging for small pulmonary lesions (typically ≤3 mm) that are not detectable with MRI. 
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Thus, no additional benefit can be expected when adding PET to MRI in this setting [106]. 
Likewise, addition of functional PET imaging to classical morphological imaging is unlikely to 
increase the accuracy of detection of intraluminal lesions [106]. 
SURVEILLANCE INTERVALS
In patients with stage I–III CRC, approximately 60% of disease recurrences occur within the 
first 2 years, 80% within the first 3 years, and >90% within the first 5 years after resection of 
the primary tumour [110]. After 5 years, the recurrence rates are <1.5% per year, and after 
10 years, are <0.5% per year [110]. For patients with stage IV CRC who are treated with a 
curative intent, 80% of those with relapse develop recurrent disease within the first 2 years 
after metastasectomy [10, 13, 111]. Thus, as the majority of disease recurrences are within 
the first 3 years after treatment with curative intent, most surveillance programmes involve 
frequent, 3–6 monthly follow-up assessments during this period, with a decreased frequency 
of testing between years 3–5, and no further specified surveillance thereafter. These intervals 
are not evidence-based, however, and no level 1 evidence exists regarding the optimal total 
duration of surveillance after treatment for CRC. In a study that included 207 patients who 
had undergone resection of CRC [112], 121 patients were alive and disease free at 5 years. 
81 of these 121 patients (67%) had received a 5-year surveillance CT scan, and none of these 
scans had revealed recurrent CRC, although other malignancies were detected in six of the 
81 patients (7%) [112]. Notably, although fewer asymptomatic recurrences will be detected 
per additional year of surveillance beyond the traditional 5 years, a high proportion of these 
late recurrences are likely to have a relatively mild tumour biology and might, therefore, be 
curable.
SURVEILLANCE FOR STAGE I–III CRC 
After conventional curative treatment 
As can be distilled from the various international guidelines for surveillance after treatment of 
stage I–III CRC with curative intent (TABLE 2), no clear consensus has been reached regarding 
the frequency and modalities for intraluminal, extraluminal, and distant-organ evaluation. 
Over the past three decades, 14 randomized clinical trials examining different surveillance 
programmes after curative surgery for stage I–III CRC have been conducted [43, 44, 46, 113-
123] (TABLE 3 and Supplementary S1 (table), and one trial is ongoing [124]. The effectiveness of 
the various surveillance schemes was evaluated based primarily on 5-year overall survival rates. 
Intensive schemes applying frequent visits and/or the use of multiple diagnostic modalities 
were compared with less-intensive schemes or to a nihilistic approach of watchful waiting with 
diagnostic and therapeutic interventions based purely on the presence of symptoms. 
The FACS trial [118], published in 2014, evaluated the potential benefit of scheduled serum 
CEA measurement and/or CT of the chest and abdomen in the detection of recurrent disease, 
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compared with minimal surveillance (TABLE 3 and Supplementary S1 (table)). The original 
primary end point, overall survival, was abandoned owing to accrual issues, and was replaced 
with the detection rate of recurrent disease that could be treated with curative intent (from 
here on termed ‘treatable recurrence’). This rate was significantly higher in the CEA and/
or CT groups compared with the minimal surveillance group, with odds ratios of 3.0 (95% 
confidence interval (CI) 1.2–7.3) for CEA only and 3.6 (95% CI 1.5–8.7) for CT only. The odds 
ratio for combined CEA and CT surveillance was similar to those reported for CEA or CT alone. 
No significant difference in overall survival between the minimal surveillance group and 
the combined more-intensive surveillance groups was reported (81.8% versus 84.1% after a 
mean follow-up duration of 4.4 years). Mature results of the FACS trial were recently presented 
at the ESMO Congress 2016 [125]. At a median follow up duration of 8.7 years, use of the 
intensive surveillance strategies resulted in identification of recurrences that were amenable 
to treatment in a higher proportion of patients (7.5% versus 2.7%, P = 0.003); however, this 
apparent benefit in terms of earlier diagnosis had no effect on overall survival (P = 0.45) [125]. 
Subgroup analysis according to primary tumour location showed that the detection rate of 
treatable recurrences did not differ significantly between the various surveillance protocols 
among the patients with rectal cancer (9.8% versus 6.9%, P = 0.41) [125]. By contrast, in those 
with colon cancer, more patients had treatable recurrences detected with more-intensive 
than with minimal surveillance (left-sided tumours: 7.3% versus 0.9%, P = 0.01; right-sided: 
5% versus 0%, P = 0.02) [125]. Interestingly, an overall survival benefit was reported for a 
highly selected patient group: among the patients with recurrent disease from a left-sided 
primary colon cancer, those in the intensive surveillance group had a median overall survival 
of 4.4 years versus 3.1 years among those in the minimal surveillance protocol (P = 0.03) [125]. 
These findings suggest follow-up should be tailored based on the risk of recurrence, or more 
specifically, based on tumour biology. 
In 2016, the GILDA working group published the largest surveillance trial in patients with stage 
II–III CRC (n = 1,242) [120]. An interim analysis of this trial had been published previously, in 
2004 [114]. The final results showed that intensive surveillance imaging enabled the earlier 
diagnosis of disease recurrence than a protocol involving less-frequent imaging (but with 
CEA testing and physical examination at similar intervals), as demonstrated by differences in 
mean disease-free survival of 5.9 months (95% CI 2.71–9.11) between the groups [120]. This 
association with earlier diagnosis had no significantly effect on overall survival (hazard ratio 
(HR) 1.14, 95% CI 0.87–1.48; TABLE 3 and Supplementary S1 (table)) [120].
In one randomized trial [119], the costs associated with follow-up procedures and additional 
work-up for any suspected disease recurrence were estimated to be higher for use of ‘intensive’ 
surveillance including multiple imaging assessments versus ‘simple’ surveillance comprising 
only CEA testing and physical examinations (€300,315 versus €188,630). Among 132 patients 
undergoing simple surveillance, 34 recurrences were observed, of which 10 (29%) were 
treatable. During intensive surveillance of 127 patients, 36 recurrences were detected, of 
which 18 (51%) could be treated [119]. Thus, the costs per detected treatable recurrence were 
Chapter 13 | Surveillance After Treatment for Colorectal Cancer
259
13
€16,684 for the intensive scheme versus €18,863 for the simple scheme [119]. Nonetheless, 
total costs are increased with more-intensive surveillance. If the aim of surveillance is to detect 
treatable recurrence, more-intensive surveillance might be cost-effective compared with less-
intensive surveillance; however, whether intensive surveillance truly is cost-effective, when 
measured in terms of overall survival benefit (which is the ultimate end point for measuring 
cost-effectiveness), remains unknown. 
Of all randomized surveillance trials published to date, only two have demonstrated a statistically 
significant overall survival benefit from use of intensive surveillance (TABLE 3 and Supplementary 
S1 (table)) [117, 121]. In a meta-analysis based on 11 of the 13 published randomized trials 
[8], comprising 1,511 patients who underwent intensive surveillance versus 1,559 patients 
who received less-intensive or minimal surveillance, an overall survival difference of 3.3% was 
demonstrated in favour of intensive surveillance (25.8% versus 29.1%, with 5-year overall survival 
assessed in most of the trials included, but often without reporting of the median follow-up 
duration) [8]. This finding implies that 30 patients have to undergo an intensive surveillance 
programme to avoid one premature death (95% CI 16–458) [8]. The beneficial effect of intensive 
surveillance on overall survival expressed as hazard ratios have been confirmed in five other 
meta-analyses that included 5–8 of the same randomized prospective trials [126-130] (TABLE 
4). Another meta-analysis [131], published in 2016, included a marginally different selection of 
seven randomized trials; this study did not demonstrate any improvement in overall survival with 
intensified surveillance. Interestingly, the investigators also performed a subset analysis based on 
data from only the three most-recently published randomized trials, which confirmed this finding 
(HR 1.05, 95%CI 0.87–1.27) [131]. Further, none of the randomized trials, nor meta-analyses, 
demonstrated a CRC-specific survival benefit from intensive surveillance [8, 43, 46, 114, 116, 
118, 126, 131]. Thus, any influence of surveillance on overall survival might arise through various 
mechanisms other than improved detection and curative treatment of recurrent CRC. Indeed, in 
one meta-analysis [129], the authors estimated that only one-fifth of the overall survival benefit 
could be attributed directly to the curative treatment of disease relapse. The additional gain in 
overall survival is probably related to other factors, and thus trials only focusing on the number 
of asymptomatic recurrences detected and resected might underestimate the true potential 
of follow-up surveillance after curative-intent treatment of CRC [129]. In particular, effects 
associated with intensive surveillance that might contribute to overall survival improvements 
include increased psychological support and general wellbeing [132, 133], improvements in 
dietary and lifestyle factors [134, 135], and proactive treatment of other comorbidities [134].
The findings of six meta-analyses have confirmed that the use of intensive surveillance is 
associated with a shorter time to detection of relapse, although the total number of recurrences 
identified was not affected by the intensiveness of the surveillance programme [8, 126-130] 
(TABLE 4). Moreover, earlier detection can increase the frequency of treatment with curative 
intent, as demonstrated in seven trials and five meta-analyses [8, 43, 46, 71, 117-119, 121, 126, 
127, 129, 130]. Ultimately, these effects might translate into an overall survival benefit. 
The effect of different surveillance strategies on health-related quality of life (HRQoL) has 
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been assessed in five trials. The results of two of these trials demonstrated no difference in 
HRQoL between standard and intensive surveillance [16, 120]. Investigators of another two 
of these five trials assessed QoL, anxiety, depression, and patient satisfaction, and found no 
differences in outcomes between intramural (surgeon) or extramural (general practitioner) 
follow-up strategies [113, 123]. The findings of one trial indicated that intensive surveillance 
was associated with a marginal benefit in HRQoL [136]. Overall, intensive surveillance seems to 
have a limited, or even no effect on HRQoL. 
Table 4: Meta-analyses of prospective randomized trials on surveillance strategies for patients with 
stage I–III CRC
Study 
(year of 
publication)
Studies
included
Number of 
patients
OS
HR (95% CI)
Main conclusions regarding intensive follow-up 
surveillance
Renehan et al. 
[128] (2002) 5 1,342
0.81 
(0.70–0.94)
• Significantly improved OS (P = 0.007)
• Resulted in earlier detection of recurrences (P = 0.011)
Figueredo et al. 
[126] (2003) 6 1,679
0.80 
(0.70–0.91)
• Significantly improved OS (P = 0.0008)
• Rate of recurrence was similar between surveillance   
  schemes of different intensity
• Increased the detection of asymptomatic recurrences  
  and more often enabled attempted curative surgery,  
  compared with less-intensive schemes
Renehan et al. 
[129] (2005) 6 1,679
0.76 
(0.67–0.86)
• Significantly improved OS 
• Only ~2% of the total survival benefit was attributed  
  to treatment of recurrences detected through 
  follow-up surveillance specifically: other  factors are  
  involved 
Jeffery et al. 
[127] (2007) 8 2,141
0.73 
(0.59–0.91)
• Significantly improved OS 
• Absolute number of recurrences detected was similar    
  between different surveillance schemes; however,    
  more curative surgical procedures were attempted in  
  the intensive follow-up groups
• Survival benefit was associated with more tests versus 
  fewer tests, and with liver imaging versus no liver  
  imaging
Tjandra et al. 
[130] (2007) 8 2,923
0.74 
(0.59–0.93)
• Significantly improved OS (P = 0.01)
• No statistically significant difference in all-site  
  recurrence nor in local or distant recurrence between  
  follow-up schemes 
• Increased the detection of asymptomatic recurrences  
  (P = 0.00001) and the rate of attempted curative  
  surgery (P = 0.0002)
• No statistically significant difference, however, in DSS  
  between follow-up schemes 
Pita-Fernández 
et al. [8] (2014) 11 4,055
0.75 
(0.66–0.86)
• Significantly improved OS
• No statistically significant DSS benefit
• Absolute number of recurrences was similar between  
  follow-up schemes
• Increased the detection of asymptomatic recurrences  
  and the rate of attempted curative surgery 
• Shorter time to detection of recurrence
Mokhles et al. 
[131] (2016) 7 3,325
0.98 
(0.87–1.11)
• No improvement in OS
• Pooled subset analysis of the three most-recently  
  published randomized trials also showed no benefit in 
  terms of OS for intensified surveillance (HR 1.05, 95%  
  CI 0.87–1.27).
CI, confidence interval; CRC, colorectal cancer; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival.
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After organ-sparing treatment
In the past, surgery was the mainstay of treatment for all patients with stage I–III CRC; 
however, some patients are now treated with curative intent without surgery. This organ-
sparing approach pertains to two major groups of patients. 
The first group consists of patients diagnosed with a malignant colorectal polyp. The number 
of patients diagnosed with these lesions is increasing owing to implementation of CRC 
screening programmes [6]. Concurrently, the introduction of new endoscopic and surgical 
techniques has enabled these patients to be treated using organ-sparing techniques, such 
as endoscopic polypectomy, mucosal resection (EMR), and submucosal dissection (ESD), 
or transanal endoscopic microsurgery (TEM) for rectal tumours [137, 138]. Neoplastic 
polyps are classified as either malignant polyps, or T1 cancer when the lesion has invaded 
the submucosa [139]. Achieving cure via endoscopic resection of malignant polyps or T1 
CRC is dependent on complete resection of the lesion, and is only feasible in the absence 
of involved lymph nodes [140-143]. Even in the case of radical endoscopic resection of 
superficial T1 cancer, however, local recurrence — including lymph-node involvement — is 
an issue and should, therefore, be evaluated through surveillance schemes [143, 144]. The 
depth of tumour invasion within the submucosa is correlated with the rate of recurrence, 
including lymph-node metastasis: tumours that invade the upper, middle, and lower third 
of the submucosa are associated with a 2%, 9%, and 35% rate of lymph-node metastasis, 
respectively [143, 144]. Other prognostic factors predict the development of recurrences, 
including lymph-node metastases, after endoscopic resection of malignant polyps include 
tumour morphology, differentiation grade, and lymphovascular invasion [140-144] (TABLE 5). 
For example, preliminary evidence suggests that having T1-stage sessile lesions is associated 
with a higher risk of recurrence than T1-stage pedunculated polyps [145, 146]. Pedunculated 
polyps confined to the submucosa and without unfavourable histological characteristics, 
such as vascular and lymphatic invasion or poor differentiation, are associated with a 0.3% 
risk of cancer recurrence or lymph-node metastasis after complete endoscopic removal, 
whereas similar sessile polyps are associated with a 4.8% risk [147]. Of note, some studies 
have reported recurrence rates of up to 55% after piecemeal resection of malignant CRC 
polyps [144, 148-152]. When colon or rectal cancer is resected endoscopically and additional 
surgery is not planned (owing to complete resection of a lesion with a favourable histology, 
or to increased surgical risk as a result of comorbidities), endoscopic surveillance with 
inspection and biopsy sampling of the resection site is mandatory [140, 153, 154], and is 
typically performed 3–6 months after initial endoscopic resection [155]. Residual and/or 
recurrent neoplasia can be successfully treated via further endoscopic resection or ablation 
[149]. After endoscopic confirmation of the absence of residual disease, most guidelines 
recommend use of colonoscopy surveillance, according to adenoma surveillance guidelines 
[150, 156]. 
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Table 5: Estimated risk of pelvic rectal cancer recurrence at 3 years after organ-sparing treatment [144] 
Depth of invasion Lymphovascular 
invasion
Maximum tumour diameter (cm)
≤1 1.1–2 2.1–3 3.1–4 4.1–5 >5
pT1; sm1
No 3% 3.6% 4.4% 5.4% 6.6% 8.1%
Yes 5.2% 6.4% 7.7% 9.4% 11.4% 13.7%
pT1; sm2-3
No 10.5% 12.7% 15.3% 18.5% 22.1% 26.4%
Yes 17.8% 21.4% 25.5% 30.3% 35.7% 41.8%
pT2
No 9.8% 11.9% 14.3% 17.3% 20.7% 24.7%
Yes 16.7% 20% 23.9% 28.5% 33.7% 39.5%
pT3
No 19.7% 23.6% 28% 33.2% 39% 45.4%
Yes 32.2% 37.9% 44.1% 51% 58.3% 65.7%
pT, pathological T stage; sm, Kikuchi submucosal stage. Adapted with permission from John Wiley and Sons © 
Bach et al. Br. J. Surg. 96, 280–290 (2009).
The second group that is amenable to nonsurgical management of stage I–III disease 
comprises patients with rectal cancer and a clinical complete response to chemoradiotherapy 
(CRT). CRT for rectal cancer results in a pathological complete response in 9–24% of patients 
[157]. This finding has increased interest in rectum-conserving treatment strategies based on 
watchful waiting, as an alternative to immediate radical surgery that is inherently associated 
with morbidity [158, 159]. The presence of microscopic residual disease is a caveat of this ‘wait-
and-see’ approach in patients with a clinical (macroscopic) complete response. In two studies 
involving 109 and 488 patients undergoing CRT for rectal cancer [160, 161], concordance 
between achievement of a clinical and pathological complete response was only 22–25%. 
Moreover, in a detailed review of the outcomes of 509 patients with ypT0 rectal cancer (that 
is, a pathological complete response of the primary tumour to CRT), 26 patients (5%) had 
pathological lymph-node involvement confirmed by resection specimens [159]. In patients 
with rectal tumours invading the submucosa (ypT1) and muscularis propria (ypT2) after CRT, 
the rate of lymph-node involvement is increased to 15% and 17%, respectively [162].
In addition, definite confirmation of a clinical complete response to CRT for rectal cancer 
remains challenging, and similar complicating factors also pertain to the diagnosis of locally 
recurrent disease. For example, the identification of residual or recurrent viable tumour after 
CRT is hampered by the presence of post-treatment fibrosis. In general, the use of endoscopy 
leads to overestimation of the response of rectal cancer to CRT. The combination of diffusion-
weighted MRI, digital rectal examination (DRE), and endoscopy can enable confirmation of a 
clinical complete response with a sensitivity of up to 98% [163]. 
Seven published studies reporting outcomes of a wait-and-see strategy have described 
a systematic surveillance protocol (TABLE 6) [64, 65, 164-170]. These schemes consist of 
endoscopic examinations with targeted biopsy sampling of suspected neoplastic tissues, as 
well as DRE, MRI, CT or PET–CT, and CEA monitoring [64, 65, 164-170]. Surveillance is more 
intensive in the first 6–12 months after CRT, mainly to confirm a clinical complete response. In 
some protocols, patient visits are planned every 4 weeks during the first year, every 3 months 
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during the second year, and then biannually in the third, fourth, and fifth years after CRT [64, 
65, 164-170] (a detailed overview of these surveillance protocols is provided in TABLE 6). No 
prospective evidence is available to support these proposed surveillance schemes, and no 
national or international guidelines exist for surveillance of patients with a complete response 
to CRT for rectal cancer. 
The Dutch/UK/Danish phase II/III STAR-TREC trial (a successor to the CARTS study [138] discussed 
previously) has been approved by the Dutch Cancer Society (reference: KUN2014 7448). This 
trial will incorporate both wait-and-see and local excision as organ-sparing treatment options 
in patients with cT1sm3-T3N0M0 rectal cancer. This study will involve three-way randomization 
to treatment with either standard TME surgery; organ-sparing resection or ablation after long-
course CRT; or organ-sparing treatment after short-course preoperative radiation. For the latter 
two arms, secondary stratification to either wait-and-see organ-sparing local excision, or TME 
is being performed depending on the extent of treatment response: patients with a clinical 
complete response to radiation or CRT will undergo a wait-and-see follow up schedule (similar 
to that described at the end of this paragraph); those with limited residual disease will undergo 
local excision; and nonresponders will be treated with standard TME sur¬gery. In addition, a 
multicentre, prospective, observational and implementation study has also been approved 
by the Dutch Cancer Society (reference: UM2015-7738, a successor to the NCT00939666 
trial [171, 172]). The aim of this study is to set up a national network of dedicated centres for 
organ-preservation studies, in order to offer such treatment to all patients who are considered 
adequate candidates and to set up a national registry that will generate more evidence on the 
oncological and functional outcome of this approach. Patients with a complete response to 
CRT (as determined using endoscopy, diffusion-weighted MRI, digital rectal exam and lymph-
node imaging) will be offered organ-sparing treatment (using a wait-and-see policy). In the 
follow-up schedule of this study, patients will undergo clinical and physical evaluations, serum 
CEA testing, and pelvic MRI every 3 months for the first year, then at 18, 24, and 36 months, 
with sigmoidoscopy ± endorectal ultrasonography except at 36 months when colonoscopy 
with be performed instead; chest and abdominal CT scans will be conducted at 24 months. 
STAGE IV CRC
Treatment with curative intent 
For patients presenting with resectable stage IV CRC, surgery with or without systemic therapy 
offers the only potential for cure and is associated with better long-term outcomes than those 
of patients with unresectable metastatic CRC treated with palliative systemic therapy [21, 22, 76, 
173-176]; patients with unresectable stage IV CRC who are treated with modern chemotherapy 
with or without biologic agents have a median overall survival of approximately 30 months 
[174, 175]. Unfortunately, only 10–20% of patients with metastatic CRC are eligible for curative 
treatment strategies [21, 76]. Most of the literature on treatment for stage IV CRC with curative 
intent is focused on patients with CRLM and no extrahepatic disease. Partial hepatectomy offers 
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the potential for cure in these patients (FIG. 3), with various case series indicating 5-year survival 
rates of 30–60% [21, 22, 177-179], and 10-year survival of approximately 20% [21, 111, 180, 181].
Table 6: Surveillance in studies of organ-sparing ‘wait-and-see’ strategies after clinical CR of rectal 
cancer to CRT
Test Habr-Gama 
et al. [166] 
(2006)
Maas et al. 
[167] (2011) 
Dalton et al. 
[165] (2011) 
Yu et al. [170] 
(2011)
Yeo et al. [169] 
(2013)
Smith et al. 
[168] (2012) 
Araujo et al. 
[164] (2015) 
Physical
examination
Every 1–2 mo. 
in yr 1
NA NA NA Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5; then 
annually
Every 3 mo. 
in yr 1
Every 4–6 mo. 
thereafter
Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5
Complete 
blood counts
NA NA NA NA Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5; then 
annually 
NA NA
Serum CEA 
testing
NA Every 3 mo. in 
years 1–3 
Every 6 mo. in 
yrs 4–6 
NA At 1, 2, 3, 4, 
and 6 mo., then 
every 3 mo. 
until yr 3
Every 6 mo. in 
yrs 3–5; then 
annually until 
yr 10
Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5
Annually 
thereafter
NA Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5
Direct rectal 
examination
Every 1–2 mo. 
in yr 1
Every 3 mo. 
in yr 1 
Every 6 mo. in 
yrs 2–5 
NA At 1, 2, 3, 4, 
and 6 mo., then 
every 3 mo. 
until yr 3
Every 6 mo. in 
yrs 3–5; then 
annually until 
yr 10
Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5; then 
annually
NA NA
Endoscopy
(± biopsies)
Every 1–2 mo. 
in yr 1
Every 3 mo. 
in yr 1 
Every 6 mo. in 
yrs 2–5
At 3 and 12 
mo.
At 3, 6, 9, 18, 
and 24 mo.; 
then annually
Annual 
sigmoidoscopy 
or video 
colonoscopy
Every 3 mo. 
in yr 1 
Every 4–6 mo. 
thereafter
Every 3 mo. in 
yrs 1–2 
Every 6 mo. in 
yrs 3–5
Colonoscopy 
(± biopsies)
NA NA NA At 12, 24, 60 
and 120 mo.
NA NA NA
Pelvic MRI NA Every 3 mo. 
in yr 1
Every 6 mo. in 
yrs 2–5
Every 6 mo. in 
yr 1 Annually 
in yrs 2–5
At 1, 2, 3, 4, 6, 9, 
and 12 mo. 
Every 6 mo. 
in yr 2
Annually in yrs 
3–7 
NA NA NA
18F-FDG-PET–CT NA NA Every 6 mo. 
in yr 1
Annually in 
yrs 2–5
At 4, 16, and 52 
weeks
NA NA NA
Pelvic CT Every 6 mo. 
in yr 1
Annually 
thereafte
NA NA NA NA Not 
standardized
NA
Abdominal CT Every 6 mo. 
in yr 1; then 
annually
Every 6 mo. 
in yr 1 
Annually in 
yrs 2–5
NA NA Every 6 mo. in 
yrs 1–5; then 
annually
Not 
standardized
NA
Chest CT NA Every 6 mo. 
in yr 1
Annually in 
yrs 2–5
NA NA NA NA NA
Chest 
radiography
Every 6 mo. 
in yr 1; then 
annually
NA NA NA NA NA NA
CEA, carcinoembryonic antigen; CR, complete response; CRT, chemoradiotherapy; 18F-FDG-PET–CT; 2-[18F]
fluoro-2-deoxy-D-glucose-PET–CT; mo., months; NA, not applicable; yr(s), year(s).
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Figure 3. Resection of colorectal liver metastases. The photographs in the upper left and right frames 
show the appearance of the liver immediately before resection of a colorectal liver metastasis, with the 
metastasis clearly visible in segment IV (indicated by the surgeon’s finger in the upper-right image). This 
lesion was detected during follow up by CT imaging after treatment with curative intent for colorectal 
cancer. Lower-left and lower-right frames demonstrate the appearance of the liver immediately after 
resection of the metastasis.
Surgery with curative intent for isolated pulmonary metastases of colorectal origin is less well 
studied than resection of liver-limited disease, but such surgery is increasingly performed; 
the 5-year overall survival rates are around 40–50% [14, 16, 182, 183]. A randomized trial 
[184, 185] has been initiated to investigate the benefits of adding metastasectomy to 
active monitoring (with regular CT scans and CEA testing) in patients with pulmonary CRC 
metastases. 
At present, many patients with peritoneal carcinomatosis from CRC are also treated with 
curative intent. For such patients, cytoreductive surgery combined with use of perioperative 
hyperthermic intraperitoneal chemotherapy (HIPEC) can yield promising outcomes, with 
5-year survival rates of around 40% [11, 12, 15, 186-188]. Moreover, increasing evidence 
supports the use of surgery with curative intent for liver metastases and concurrent 
extrahepatic disease in selected patients, with reported 5-year overall survival rates of 
approximately 30% [19, 189]. The randomized ORCHESTRA trial that has opened in the 
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Netherlands is being conducted to assesses the value of maximal tumour debulking in 
patients with multiorgan CRC metastases (NCT 01792934) [190]. Yet more patients with stage 
IV CRC could become eligible for surgical treatment as the indications for use of curative 
therapies continue to expand.
Surveillance schemes
Follow-up schemes for patients with stage IV CRC treated with curative intent have been 
poorly studied, and few surveillance guidelines include protocols specifically for those with 
stage IV CRC (TABLE 2). For patients with CRLM specifically, clinical risk scores are based on 
surrogates of tumour load (including number of tumours, serum CEA, tumor size, and nodal 
status), which is an important prognostic factor for disease recurrence after resection [191]. 
Patients with high-risk disease (high tumour load) have a 5-year overall survival of around 
30% versus 60% for those with low-risk disease (low tumour load) [178]. In patients with 
pulmonary metastases, the number of metastases removed during metastasectomy or 
diagnosed using imaging is of prognostic value. One study demonstrated a higher mortality 
in patients who underwent resection of multiple pulmonary lesions versus patients with a 
solitary resected pulmonary lesion (HR 2.04, 95% CI 1.72–2.41) [182] — again tumour load 
dictates oncological outcome, representing aggressiveness of tumour biology. Likewise, the 
outcomes after maximal tumour debulking of peritoneal metastases combined with use 
of HIPEC or systemic therapy are related to peritoneal tumour load [11, 187]. One study in 
523 patients revealed 5-year overall survival rates between 10% and 50% depending on the 
peritoneal tumour load [11]. In general, tumour load influences the survival of patients with 
stage IV CRC after treatment with a curative intent; therefore, intensive follow-up surveillance 
is likely to be relevant to these patients because early detection of disease recurrence might 
increase the possibility of further treatment with curative intent. Indeed, accumulating 
evidence indicates that repeat resection of CRLM improves survival [10, 192-196]. Similarly, 
reports have described survival benefits of patients undergoing repeated resection of 
pulmonary metastases of colorectal origin [14, 16, 197]. Thus, the high recurrence rates 
in patients with stage IV CRC, and the fact that a considerable proportion of patients can 
nowadays be successfully treated for recurrent disease, might justify the use of intensive 
surveillance for patients with stage IV CRC treated with curative intent.
Most centres offer a more-intensive surveillance protocol for the first 3 years after partial 
hepatectomy in patients with CRLM. Surveillance during this initial period usually consists of 
CT of the thorax and abdomen, liver MRI, chest radiography, liver ultrasonography, and serum 
CEA testing every 3–6 months (TABLE 2). In the subsequent 2 years, the frequency of follow-
up assessments generally decreases to annual imaging combined with serum CEA testing. 
Studies evaluating follow-up schemes after surgery for those with stage IV CRC are limited to 
patients who underwent resection for CRLM [13, 198-203] (TABLE 7). In a meta-analysis based 
on data from a total of 7,330 patients, the effectiveness of surveillance schemes with uniform 
test intervals over the entire follow-up period of 5 years was compared to that of schemes 
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with more-intensive follow-up assessments in the early years after partial hepatectomy 
and then less-frequent testing thereafter. The meta-analysis did not demonstrate an overall 
survival benefit of initial more-intensive follow-up surveillance [13]. Of note, however, 
the studies included were heterogeneous in terms of patient characteristics, treatments 
used, surveillance protocols, and follow-up durations. The surveillance costs per operated 
recurrence after treatment with curative intent for stage IV CRC have been estimated to range 
from £23,338 to £31,000, depending on the scheme used (and excluding treatment costs) 
[198, 200]. No prospective data are available on cost-effectiveness. The limited available data 
on surveillance of patients with stage IV CRC after treatment with curative intent highlights 
the need for prospective randomized trials, in particular, to compare the effectiveness and 
cost-effectiveness of surveillance schemes of different intensities. 
Table 7: Overview of studies on patient follow-up surveillance after curative-intent treatment for stage 
IV CRC 
Authors (year 
of publication)
Study type Number of 
patients 
included
Main conclusions
Jones et al. [13] 
(2012)
Meta-analysis 7,330 Intensive early follow-up surveillance after resection of CRLM 
fails to improve 5-year OS (42% vs 40%; NS)
Metcalfe et al. 
[203] (2004)
Systematic 
review
5,745 •  Most surveillance protocols involved serum CEA  
   measurements combined with CT or US of the abdomen 
• Data relating to follow-up protocols used to detect  
  recurrence or record patient outcome were almost  
  completely absent 
Metcalfe et al. 
(2005) [202]
Retrospective 
cohort study
41 • Most recurrences were detected using CT
• Serum CEA testing did not result in earlier detection of  
  curable relapses than the use of CT or presentation of  
  symptoms
Langenhoff et 
al. [201] (2009)
Retrospective 
cohort study
103 • Resectable recurrent disease rate of 24% 
• Repeat resection resulted in superior OS compared with  
  patients treated with palliative chemotherapy for recurrent  
  disease (median 51 months versus 34 months, respectively;  
  P value not reported) 
• Serum CEA levels are not a sensitive maker for treatable  
  recurrence 
• 3 monthly CT scanning is too frequent: more pulmonary  
  recurrences were detected at 6 months interval than liver  
  recurrences at 3 month intervals
Bhattacharja et 
al. [198] (2006)
Prospective 
cohort study
76 • Relapses were predominantly hepatic, rather than extra  
  hepatic 
• Serum CEA levels before resection of the primary liver  
  metastases did not correlate with CEA levels at occurrence  
  of recurrent disease 
• Use of CT enabled detection of recurrences earlier than CEA  
  testing 
Connor et al. 
[199] (2007)
Retrospective 
cohort study
191 • Low rate of repeat resections for recurrent disease (9%)
• High rate of interval recurrences (58%)
Gomez et al. 
[200](2010)
Retrospective 
cohort study
705 Repeat resection of recurrent disease (liver or lung ± liver 
metastases) was superior to palliative systemic therapy in 
terms of 5-year OS (31% and 30% for patients who underwent 
resection, compared with 3.9% in the palliative systemic 
therapy group; P <0.001)
CEA, carcinoembryonic antigen; CRC, colorectal cancer; CRLM, colorectal liver metastases; NS, not significant; OS, 
overall survival; US, ultrasonography. 
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FUTURE DIRECTIONS 
The wide range of diagnostic modalities that can be used to detect disease recurrence after 
treatment of patients with CRC with a curative intent differ in terms of their invasiveness, 
accuracy, burden, costs as well as cost-effectiveness. Moreover, these modalities can be used 
in different combinations and at various intervals for surveillance after curative therapy. 
Thus, determining the optimal surveillance protocols for use among the diverse populations 
of patient who are eligible for curative treatment is extremely challenging. The numerous 
studies conducted to address this issue have varied in quality, cohort size, and the specific 
follow-up schemes investigated (in terms of diagnostic modalities, intervals, total duration). 
In addition, diagnostic and treatment modalities have evolved considerably during the 
timeframe in which these studies were conducted, raising further questions regarding the 
relevance and comparability of their results. The absence of strong conclusive evidence 
is reflected in the lack of consensus between surveillance guidelines (TABLE 2). Three 
decennia of meta-analyses, in some cases combining data from more than 5,000 patients, 
have therefore brought us only a little closer to defining the optimal surveillance protocol. 
Ongoing further meta-analytical evaluations of the available data will not add useful 
information: new prospective randomized trials are needed, in a risk-adapted setting aiming 
for tailored protocols [120]. 
Currently, patients with malignant colorectal polyps or early T1-stage cancers, and those 
with rectal cancer with a complete response to CRT are increasingly treated with organ-
sparing techniques, or even a watch-and-wait strategy for the latter group [64, 65, 137, 138]. 
In addition, local treatment of stage IV disease with curative intent is being performed at an 
increasing frequency for an expanding range of indications, owing to reports of improved 
survival in selected patients [21, 22, 76, 173-176]. Nevertheless, after organ-sparing treatment 
and metastasectomy, recurrence rates can be high, and evidence indicates that repeat 
resections might provide overall survival benefits [10, 14, 149, 194-197]. These findings 
emphasize the importance of surveillance for different patient populations. Clinicians should 
realize, however, that no prospective evidence supports the use of any of the surveillance 
schemes proposed to date. Thus, a clear need exists for prospective evaluation of the optimal 
surveillance strategy for these categories of patients, in particular, and for the development 
of evidence-based guidelines. 
Apart from an increased oncological risk of recurrence (according to clinical stage or 
molecular subgroup, for example), other factors are known to influence the risk of CRC 
recurrence [204]. These factors include tumour perforation [205, 206], obstructive tumours 
[207], anastomotic leakage and subsequent bacterial infection after resection of CRC 
[208], and perioperative blood transfusion [209]. The existing surveillance guidelines do 
not recommend use of specific surveillance protocols for these different risk subgroups. 
Disease recurrence has been investigated in patients at a high risk of developing colorectal 
peritoneal carcinomatosis, owing to tumour perforation, resected minimal synchronous 
Chapter 13 | Surveillance After Treatment for Colorectal Cancer
269
13
macroscopic peritoneal carcinomatosis, or synchronous ovarian metastases, via systematic 
‘second-look’ surgery performed 1 year after the initial surgery [210, 211]. In these patients, 
who had no signs of recurrence on imaging studies, the recurrence rate at second-look 
surgery was ~55% [210, 211]. These findings led to two prospective trials of mandatory 
second-look surgery for such patients, one in the USA [212] (NCT01095523) and the other 
in France [213] (NCT00005944). These studies provide examples of risk-adapted follow-
up protocols for patients with CRC. Future research on risk-adapted surveillance should 
implement considerations of the complete spectrum of risk factors for recurrence after 
curative treatment for CRC, including biological variance (clinical and molecular), radicality 
of surgery, anastomotic leakage, postoperative infection, and tumour perforation. Ideally, 
a nomogram integrating all of these risk factors should be developed, to direct the use of 
personalized surveillance.
Importantly, in future surveillance trials, attention should be paid to the design of the study 
arms in order to avoid ambiguity regarding the definition of ‘intensive’ surveillance. The 
heterogeneity between published randomized trials of surveillance for patients with stage 
I–III CRC impairs evidence-based selection of any of the protocols assessed, despite the fact 
that most meta-analyses have validated an overall survival benefit from ‘more-intensive 
surveillance’. Preferably, individual studies should be focused purely on comparing the 
efficacy of single diagnostic modalities, or the frequency of follow-up assessments, but not 
both. Computer-simulation modelling could then contribute to the development of more-
effective surveillance schemes via analysis of comprehensive information on patterns of 
disease recurrence, oncological risks (clinical and molecular), costs, sensitivity and specificity 
of diagnostic tests, follow-up intervals, follow-up duration, and survival outcomes gathered 
in the prospective trials. This approach would also facilitate further research on risk-adapted 
follow-up surveillance approaches for individual patients, preferably based on the intrinsic 
(molecular and clinical) characteristics of the disease.
CONCLUSIONS
Patients with stage I–IV CRC can benefit from surveillance after treatment with curative intent. 
The aim of surveillance is to detect recurrent disease at an early, asymptomatic, and treatable 
stage, with the ultimately goal of achieving an overall survival benefit. This approach is 
important because treatment for disease recurrence can nowadays be applied repeatedly 
in individual patients. The surveillance frequency and methods used partly depend on the 
location and stage of the primary tumour. Meta-analyses of data from a range of studies 
over the past two decades confirm that frequent patient visits improve overall survival after 
curative resection of stage I–III CRC, although most individual trials demonstrate minimal 
to no overall survival benefit. The effect of surveillance for stage I–III CRC on overall survival 
can only partly be explained by improved cancer-specific survival, with repeated clinical 
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assessment contributing to the overall survival benefit. Further (model-based) research on 
surveillance after CRC treatment should focus on risk-stratification and should incorporate 
current knowledge on risk of recurrence in relation to the biology of the tumour. Consensus 
guidelines and prospective research investigating the optimal follow-up protocols are 
urgently needed for surveillance of patients with stage IV CRC who are treated with curative 
intent, as well as patients treated according to a ‘wait and see’ strategy after a complete 
clinical response to CRT.
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CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES AND SURGERY FOR 
MULTI-ORGAN METASTASES
Systemic treatment for colorectal liver metastases (CRLM) is increasingly effective, with 
regains including oxaliplatin, irinotecan, and biologicals such as bevacizumab (monoclonal 
antibody against vascular endothelial growth factor) significantly improving overall survival 
(OS). Combining these regimens showed median overall survival of >30 months without 
local treatment in patients with metastasized colorectal cancer (mCRC) [2]. The high relapse 
rates after resection of CRLM, and the efficacy of modern systemic chemotherapy in the 
metastasized setting, have prompted investigators to perform studies to evaluate the role 
of systemic chemotherapy combined with liver resection. In four randomized trials, liver 
resection was followed by adjuvant systemic chemotherapy or observation [3-6]. Two 
of these trials included few patients and were inadequately powered [4, 5]. A Canadian/
European Intergroup study (ENG trial) closed early due to poor accrual [3]. In the other trial (a 
multicenter randomized trial) of 173 patients who received bolus FU/LV after liver resection 
vs. observation with median follow-up of 87.4 months, there was no survival benefit [6]. The 
small numbers accrued over 10 years and the outdated chemotherapy used, highlight the 
difficulties in conducting an adjuvant study after liver resection. The only successful trial 
is the EORTC 40983 trial that compared peri-operative FOLFOX-4 chemotherapy (6 cycles 
pre-operative and 6 cycles post-operative) in patients with resectable CRLM. Mature data 
showed no OS benefit from peri-operative chemotherapy in resectable patients [7].
In 2013 a questionnaire was sent to 27 Dutch hospitals with expertise in the area of 
hepatobiliary surgery [8]. The questionnaire focused on indications for (neo-) adjuvant 
chemotherapy for resectable colorectal liver metastases (CRLM) [8]. The results were striking: 
there was great variation in use of chemotherapy in resectable patients with great variation 
in indications for administration of chemotherapy. There seems to be no consensus, even 
though Dutch guidelines do not recommend standard administration of chemotherapy in 
resectable disease. However, various retrospective reports (including chapter 4), showed 
potential benefit in high-risk groups [9-11]. There was an obvious need for the CHARISMA 
trial, published in chapter 1. 
The CHARISMA multicenter randomized trial opened in 13 Dutch hospitals. The trial included 
14 patients in approximately 2 years. Main reasons for poor inclusion were patient preferences 
for surgical treatment without any delay; randomization for 6 cycles of chemotherapy would 
delay local treatment by 4 months. Another hurdle was the clinical risk score as an inclusion 
criterion. Very few patients present with a CEA>200ng/ml or a metastasis >5 cm. Patients 
with synchronous disease at presentation have no pathological lymph node status regarding 
their primary tumor (yet). Only a subset of patients would therefore become eligible (≥3 
points according to the CRS [12]) for randomization. To overcome these challenges, the 
CHARISMA protocol was amended and patients may be randomized in the future for 
adjuvant chemotherapy instead (resolving the issue with patient preference and nodal 
status of primary CRC). There is an urgent need for clarification regarding the dogma of 
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“chemotherapy for resectable CRLM”: even though (neo-) adjuvant randomized trials prove 
to be challenging we still need one.
For patients with a low-risk profile (Fong 0-2), a recent collaborative investigation (Erasmus 
MC & Memorial Sloan Kettering Cancer Center) objectified that this subgroup might benefit 
from hepatic arterial infusion (regional chemotherapy in addition to resection) [15]. The 
investigators initiated a randomized controlled trial in the Netherlands for this patient 
subgroup as well, randomizing between surgery alone versus adjuvant arterial infusion 
(PUMP trial). Results of both the CHARISMA-trial and the PUMP-trial will potentially enable 
us to tailor adjuvant systemic and regional treatment strategies for patients with CRLM.
In cases where patients present with multi-organ metastases of colorectal cancer, palliative 
systemic therapy is standard of care. The ORCHESTRA trial was initiated, randomizing patients 
for either systemic treatment or systemic treatment with additional tumor debulking. This 
is an ongoing trial, with significant logistic and safety implications. A safety and feasibility 
report was published in chapter 2. The protocol showed to be feasible and safe, now in place 
in over 30 hospitals in the Netherlands and including over 200 patients. In a few years we will 
see if additional tumor debulking of multi-organ metastases will lead to OS benefit.
MULTICENTER RESEARCH IN THE NETHERLANDS
The Netherlands ranks internationally among the countries with the highest scientific output, 
both in volume and quality [16, 17]. This reputation is at risk, as several reports produced by 
industry and academics on the initiation of trials show increasing delay and costs due to 
increasing complexity of procedures [18-23]. 
A recent evaluation of the procedure of obtaining local approval in individual hospitals of 
2 large multicenter oncological trials is outlined in chapter 3. This procedure is inherent to 
initiating multicenter clinical trials in the Netherlands and subject to significant complexity. 
This issue is recognized in other countries as well [16, 24-29]. Adding the time of initiation 
to actual accrual of patients and follow-up means that implementation of potential novel 
therapies is delayed. Trial logistics should be on a national agenda, to benefit all future trials. 
Procedures should be standardized, centralized and digitized. The latter will be implemented 
by 2019 on a European level by the central committee on Research Involving Human Subjects 
(CCMO) and the Dutch Clinical Research Foundation (DCRF). For other challenges, senior 
investigators should be involved on a national level, together with the central committee on 
Research Involving Human Subjects. Hospitals should be dedicated to solving the issue as 
well; a potential part of the solution may be to merge their research infrastructures (research 
personnel, funds, expertise, material) on a regional level. An individual principal investigator 
initiating a trial would only have to tap in on a regional level (instead of hospital level). 
BIOMARKERS FOR TAILORING TREATMENT STRATEGIES FOR COLORECTAL LIVER 
METASTASES
Currently, no biomarkers in patients with resectable colorectal liver metastases impact 
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clinical management [30]. The most widely used and validated marker would be the clinical 
risk score by Fong et al. established in 1999, but it is only used for scientific purposes [12]. 
Such scoring models permit comparisons of patient populations between studies, and 
provide prognostic information to the patient. Chapter 5 showed that some prognostic 
elements of these clinical scores might alter due to systemic therapies, making them even 
less valid in daily practice. Although previous reports established serum CRP as a prognostic 
marker, the current thesis describes the largest cohort assessing CRP in patients with CRLM 
(chapter 6). No prognostic power could be validated. The future development of clinically 
relevant biomarkers for patients with CRLM requires larger patient populations and should 
focus on other factors than (classic) clinical parameters. Genetic and pathological markers are 
needed to provide a more detailed picture of colorectal cancer and inherently more accurate 
stratification of patients. Hopefully novel biomarkers will be able to provide a blueprint for 
clinical management.
The current thesis describes two promising biomarkers in chapters 7, 8 and 9. The mRNA 
signature described in chapter 7 is currently being validated in ±100 chemo-naïve patients 
with resected CRLM, the “Winkelman II” study. Other prognostic signatures have been 
published, but these investigations remain scarce. This type of research remains expensive 
and technically challenging, with low yield in terms of clinically relevant markers.
The histopathological growth patterns (HGP) of CRLM published chapter 8 show to have 
prognostic impact. This biomarker can be determined irrespective of hospital resources; it 
can be easily assessed by trained pathologists and has been objectified/validated in various 
patient cohorts around the world. Chapter 9 involves an assessment of the predictive value 
of the histopathological growth patterns in relation to survival after hepatic arterial infusion 
therapy (PUMP); the patterns have been assessed in a cohort of patients in Memorial Sloan 
Kettering Cancer Center (MSKCC). HGP can be used to tailor treatment with hepatic arterial 
chemotherapy infusion, in this retrospective study. Future prospective studies, such as the 
PUMP-trial, should assess the relevance of HGP in clinical management of CRLM. Currently, 
the genetic background of the HGP’s is assessed to clarify how the different patterns 
originate, and HGP’s are related to recurrence patterns after resection of CRLM and their 
impact on radicality of surgery. All scored slides in MSKCC are digitized, and analyzed by 
machine learning (pathomics), in search of prognostic/predictive relevance.
Over recent years so called “liquid biopsies” have become increasingly relevant in the field of 
cancer [31]. By obtaining serum from patients, circulating biomarkers may represent more 
readily available methods to monitor, characterize and predict cancer biology. In addition to 
the abovementioned future studies, the MIRACLE study was initiated aiming to investigate 
whether circulating serum tumor DNA and circulating tumor cells (including their gene-
expression pattern) have prognostic or even predictive value in resectable CRLM. 
Possibly, for establishing relevant biomarkers in the complex setting of metastasized CRC, 
huge amounts of data from larger patient cohorts (preferably chemo naïve) should be 
analyzed with the help of artificial intelligence (AI) analysis [32]. Emergence of “Radiomics” 
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and “Pathomics”, where image features are extracted from routine diagnostic radiology and 
pathology studies, are also evolving as valuable biomarkers [33]. This information explosion 
provides new and complex opportunities for an integrated, multi-scale investigation of 
cancer. Information synthesis is required across a broad spectrum, from the host itself to 
the molecular level (clinical, pathological, radiological, genetic). Possibly, the only way to 
reliably establish a set of biomarkers with clinical impact is with the help of machine learning 
(AI), integrating all these types of complex information and relating those to patient and 
treatment outcome. New biomarkers are urgently needed [34].
SURGICAL MANAGEMENT OF COLORECTAL LIVER METASTASES
As delineated in chapters 10 and 11, all patients with stage IV disease should be presented 
in a multidisciplinary expert panel. Since inter-hospital variations in the use of curative local 
treatment exist, and with expanding indications for local curative treatment expert panels 
are needed. Stage IV colorectal cancer patients should also be evaluated for participation in 
studies within this field. Optimal assessment of patients with stage IV CRC can therefore only 
be achieved by specialized (regional/national) collaborative efforts. 
Chapter 13 outlines that for patients treated surgically for stage I-III colorectal cancer, some 
sort of surveillance should be organized. Literature does not support one specific follow-up 
scheme: there is no evidence for a specific frequency of follow-up visits nor for any kind of 
diagnostic modality. Meta-analyses have objectified a general health benefit from doctor’s 
visits during surveillance for cancer. Future research should focus on cancer specific survival 
effects of follow-up, instead of overall survival. In almost all studies assessing surveillance, 
investigators concluded a tailored approach was needed. Indeed, in chapter 12, a potential 
subgroup was identified with stage IV CRC that may not need intensive long-term surveillance 
after surgery. Follow-up should be tailored to patient and tumor characteristics. Studies 
assessing the impact of surveillance for organ sparing treatments for CRC and in stage IV 
CRC are urgently needed. The FUTURE trial was initiated, where patients after resection of 
CRLM will be randomized for intensive in-hospital surveillance versus less intensive tele-
surveillance.
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In chapter 1 a study protocol for a multicentre randomized trial is published, where patients 
with resectable colorectal liver metastases (CRLM) without extra hepatic disease and a 
clinical risk score of 3-5 will be included. The primary aim of this study, the CHARISMA trial, 
is to compare overall survival (OS) rates between patients randomized for treatment with 
chemotherapy followed by surgery, versus surgery alone. It is hypothesized that adding neo-
adjuvant chemotherapy to surgical resection of CRLM will provide an improvement in OS in 
patients with a high-risk profile.
In chapter 2 a report on safety and feasibility of the multicentre randomized ORCHESTRA 
trial is included, based on the first 100 included patients. This trial focuses on patients with 
multi-organ colorectal cancer metastases, and randomizes for palliative systemic treatment 
versus systemic treatment with maximal tumour debulking. Chapter 2 objectifies that the 
protocol is feasible as it operates in over 30 general and academic hospitals, and currently 
included over 200 patients. Complication rates from local treatment are comparable to 
literature. Patients in the intervention arm had an acceptable chemotherapy-free interval, 
and did not receive less cycles of chemotherapy compared to standard of care. 
In chapter 3 the logistics of initiating multicentre clinical trials in oncology were evaluated. 
Great variation exists in the procedures for obtaining approval for local feasibility of 
multicentre research in terms of time, content and costs. These variations are unpredictable 
and pose a serious obstacle in conducting scientific clinical research in The Netherlands. 
Delay in the process of initiation of studies decrease the chance of successful accrual of 
patients and thereby endanger their successful completion. Consensus on simplification 
of the procedure is urgently warranted. Collaboration with all stakeholders on further 
standardization, centralization and digitalization of the procedure would be of great value.  
In chapter 4 we demonstrate that stratifying patients with resectable colorectal liver 
metastases (CRLM) according to their clinical risk profile, as described by Fong et al, could 
provide a useful tool for selecting patients who are most likely to obtain survival benefit 
from neo-adjuvant chemotherapy. Although the indication for neo-adjuvant chemotherapy 
may not solely be based on overall survival benefit, we believe it should be included in the 
decision making process. Based on these findings and other retrospective evidence, the 
CHARISMA multicentre trial (chapter 1) was initiated.
Chapter 5 evaluated the prognostic value of lymph node status for overall survival after 
resection of colorectal liver. Patients who underwent resection of CRLM, lymph node status 
of the primary tumor was not of prognostic value in cases where the tumor was located in 
the colon. Interestingly, in primary rectal cancer lymph node status was a prognostic factor. 
This difference may be caused by the administration of effective adjuvant chemotherapy in 
node positive colon cancer. 
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In chapter 6, total post-operative inflammatory response as evidenced by CRP serum levels were 
evaluated as a prognostic marker in relation to overall survival after resection for colorectal liver 
metastases. To our knowledge, this is the largest patient cohort assessing post-operative CRP 
levels with respect to survival after surgery for CRLM and the first study stratifying for known 
risk factors and administration of neo-adjuvant chemotherapy. In the published study, post-
operative CRP levels did not prove to be of prognostic value for survival after surgery for CRLM. 
In chapter 7, a prognostic signature was constructed with the mRNA expression profiles 
of tumour tissue from resected CRLM. The signature consists of 11 genes of which the 
expression-patterns were able to discriminate between patients with early recurrences (≤12 
months) versus no recurrences (≥36 months) after partial hepatectomy. This biomarker 
requires validation in a larger cohort representative of the complete clinical spectrum in 
terms of relapse and treated without (neo-) adjuvant therapy, including any other established 
prognostic molecular markers. 
In chapter 8 the international consensus guidelines for assessing the prognostic 
histopathological growth patterns (HGP) in CRLM are published. These guidelines allow for 
reproducible determination of liver metastasis HGPs. As HGPs impact overall survival after 
surgery for CRLM, they may serve as a novel biomarker for tailor made therapies.
Chapter 9 demonstrated that HGPs could predict the effectiveness of adjuvant systemic 
chemotherapy after resection of CRLM. Patients with a non-desmoplastic type HGP seem to 
benefit from adjuvant systemic chemotherapy, while patients with a desmoplastic type HGP 
do not benefit.
Chapter 10 outlines a case-matched controlled comparison of patients undergoing either 
systemic therapy or surgery for resectable CRLM. It demonstrates a significant survival 
benefit in patients treated with liver resection. Surgery should remain the gold standard 
treatment for patients with CRLM. This finding emphasises the importance of adequate 
patient selection for surgery. Consensus on resectability and standardised assessment of all 
patients presenting with CRLM by dedicated liver surgeons in specialised MDTs optimises 
patient selection for surgery.  
Chapter 11 objectified a considerable variation in the utilization of liver resection for patients 
with synchronous CRLM in the Netherlands. As liver resection offers the only potential cure, it 
is important that dedicated specialists identify all potentially eligible patients. The formation 
of a national expert panel, including hepatobiliary surgeons, dedicated radiologists as well 
as dedicated medical oncologists, evaluating resectability in all patients with CRLM, will 
potentially lead to an important improvement outcome.
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Chapter 12 provides valuable insights regarding the follow-up of patients with 3 years of 
disease free survival after surgery for CRLM. The data suggests that follow-up in patients 
surviving 3 years without evidence of disease is useful and necessary in most patients. Some 
patients may not benefit from any additional surveillance after that period, as characterised 
by a risk profile. This chapter emphasizes the importance of a tailor-made long-term follow-
up protocol after treatment of CRLM with curative intent.
Chapter 13 provides a review of literature on surveillance after curative treatment for stage I-IV 
colorectal cancer. Patients with stage I–IV CRC can benefit from surveillance after treatment 
with curative intent. Meta-analyses of data from a range of studies over the past two decades 
confirm that frequent patient visits improve overall survival after curative resection of stage 
I–III CRC, although most individual trials demonstrate minimal to no overall survival benefit. 
The effect of surveillance for stage I–III CRC on overall survival can only partly be explained 
by improved cancer-specific survival, with repeated clinical assessment contributing to the 
overall survival benefit. Further (model-based) research on surveillance after CRC treatment 
should focus on risk-stratification and should incorporate current knowledge on risk of 
recurrence in relation to the biology of the tumour. Consensus guidelines and prospective 
research investigating the optimal follow-up protocols are urgently needed for surveillance 
of patients with stage IV CRC who are treated with curative intent, as well as patients treated 
according to a ‘wait and see’ strategy after a complete clinical response to CRT.
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In hoofdstuk 1 wordt een studieprotocol voor een multicenter gerandomiseerde studie 
gepubliceerd, waarin patiënten met resectabele colorectale levermetastasen (CRLM) zonder 
extra hepatische uitzaaiingen en een klinische risicoscore van 3-5 worden geïncludeerd. 
Het primaire doel van deze studie, de CHARISMA-studie, is om de algehele overleving te 
vergelijken tussen patiënten die gerandomiseerd zijn voor behandeling met chemotherapie 
gevolgd door een operatie, of alleen een operatie. Er wordt verondersteld dat toevoeging 
van neo-adjuvante chemotherapie aan chirurgische resectie een verbetering in algehele 
overleving zal geven. 
In hoofdstuk 2 is een rapport opgenomen over veiligheid en haalbaarheid van de multicenter 
gerandomiseerde ORCHESTRA studie, gebaseerd op de eerste 100 geïncludeerde patiënten. 
Deze studie richt zich op patiënten met uitzaaiingen van darmkanker in meerdere organen 
en randomiseert voor palliatieve systemische behandeling versus systemische behandeling 
met maximale tumor debulking. Hoofdstuk 2 objectiveert dat het protocol logistiek 
uitvoerbaar is met meer dan 30 participerende algemene en academische ziekenhuizen en 
200 geïncludeerde patiënten. Complicatie ratio’s van lokale behandeling zijn vergelijkbaar 
met de literatuur. Patiënten in de interventie arm hadden een aanvaardbaar chemotherapie-
vrij interval en kregen niet minder cycli van chemotherapie in vergelijking met de 
standaardbehandeling.
In hoofdstuk 3 werd de logistiek van het initiëren van oncologische, multicentrische klinische 
studies geëvalueerd. Er bestaat een grote variatie in de procedures voor het verkrijgen van 
goedkeuring voor lokale uitvoerbaarheid van multicenter onderzoek in termen van tijd, 
inhoud en kosten. Deze variaties zijn onvoorspelbaar en vormen een ernstig obstakel bij 
het uitvoeren van wetenschappelijk klinisch onderzoek in Nederland. Vertraging in het 
proces van initiatie van studies vermindert de kans op succesvolle inclusie van patiënten en 
brengt voltooiing in gevaar.  Een nationale agenda ter vereenvoudiging van de procedure is 
dringend nodig. Samenwerking met alle belanghebbenden omtrent verdere standaardisatie, 
centralisatie en digitalisering van de procedure zou van grote waarde zijn.
In hoofdstuk 4 laten we zien dat patiënten met reseceerbare colorectale levemetastasen 
(CRLM) op basis van hun klinische risicoprofiel, zoals beschreven door Fong et al., 
overlevingswinst hebben na behandeling met neo-adjuvante chemotherapie. Op basis 
van deze bevindingen en die uit ander retrospectief bewijsmateriaal werd de CHARISMA 
multicenter trial (hoofdstuk 1) geïnitieerd.
Hoofdstuk 5 evalueerde de prognostische waarde van de lymfeklierstatus van de primaire 
colorectale tumor ten aanzien van de algehele overleving na resectie van colorectale lever 
metastasen. Bij patiënten die resectie van CRLM ondergingen, was de lymfklierstatus van 
de primaire tumor niet prognostisch in gevallen waarbij de tumor zich in het colon bevond. 
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Interessant is dat lymfeklierstatus bij primaire rectumkanker wel prognostisch was. Dit 
verschil kan worden veroorzaakt door de toediening van adjuvante chemotherapie bij 
lymfeklier positief colon carcinoom.
In hoofdstuk 6 werd de totale postoperatieve inflammatoire respons, vertegenwoordigd 
door CRP-serumwaarden, geëvalueerd als prognostische marker in relatie tot de totale 
overleving na resectie voor colorectale levermetastasen. Voor zover ons bekend is dit het 
grootste patiënten cohort dat postoperatieve CRP-waarden beoordeelt met betrekking tot 
overleving na chirurgie voor CRLM en het eerste onderzoek dat stratificeert naar bekende 
risicofactoren en toediening van neo-adjuvante chemotherapie. In het gepubliceerde 
onderzoek bleken postoperatieve CRP-waarden geen prognostische waarde te hebben voor 
overleving na operatie voor CRLM.
In hoofdstuk 7 werd een prognostische signatuur geconstrueerd met de mRNA-
expressieprofielen van tumorweefsel van gereseceerde CRLM. De signatuur bestaat uit 11 
genen waarvan de expressiepatronen onderscheid konden maken tussen patiënten met 
vroege recidieven (≤12 maanden) versus geen recidieven (≥36 maanden) na chirurgie voor 
CRLM. Deze biomarker vereist validatie in een groter cohort dat representatief is voor het 
volledige klinische spectrum in termen van recidieven, dat chemo-naïef is, en tezamen met 
andere prognostische moleculaire markers.
In hoofdstuk 8 worden de internationale consensusrichtlijnen voor het beoordelen van 
de prognostische histopathologische groeipatronen (HGP) in CRLM gepubliceerd. Deze 
richtlijnen maken een universele, reproduceerbare bepaling van deze HGP’s mogelijk. 
Aangezien HGP’s van invloed zijn op de algehele overleving na een operatie voor CRLM, 
kunnen ze dienen als een nieuwe (veelbelovende) biomarker voor geïndividualiseerde 
therapieën.
Hoofdstuk 9 toonde aan dat HGP’s de effectiviteit van adjuvante systemische chemotherapie 
na resectie van CRLM kunnen voorspellen. Patiënten met een niet-desmoplastisch HGP 
lijken baat te hebben bij adjuvante systemische chemotherapie, terwijl patiënten met een 
desmoplastic type HGP niet profiteren in termen van algehele overleving.
Hoofdstuk 10 schetst een case-matched vergelijking van patiënten die alleen systemische 
therapie danwel een operatie ondergaan voor resectabele CRLM. Het vertoont een significant 
overlevingsvoordeel bij patiënten die worden behandeld met leverresectie. Chirurgie moet 
de gouden standaard behandeling blijven voor patiënten met CRLM. Deze bevinding 
benadrukt het belang van adequate selectie van patiënten voor chirurgie. Consensus over 
resectabiliteit en gestandaardiseerde beoordeling van alle patiënten die zich presenteren 
met CRLM door gespecialiseerde werkgroepen optimaliseert die patiënten selectie.
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Hoofdstuk 11 liet een aanzienlijke variatie in het gebruik van leverresectie voor patiënten 
met synchrone CRLM in Nederland zien. Aangezien leverresectie de enige mogelijke genezing 
biedt, is het belangrijk dat alle patiënten die mogelijk voor genezing in aanmerking komen 
geïdentificeerd worden. De vorming van een regionaal of nationaal panel van deskundigen, 
waaronder hepatobiliaire chirurgen, toegewijde radiologen en toegewijde medische 
oncologen, die de resectabiliteit evalueren bij alle patiënten met CRLM, kan mogelijk leiden 
tot een belangrijke verbetering van selectie.
Hoofdstuk 12 biedt waardevolle inzichten met betrekking tot de follow-up van patiënten 
met een ziektevrije overleving van minstens 3 jaar na chirurgie voor CRLM. De gepubliceerde 
data suggereren dat follow-up bij patiënten die 3 jaar overleven zonder bewijs van terugkeer 
van ziekte bij de meeste patiënten nuttig en noodzakelijk is. Sommige patiënten profiteren 
na die periode mogelijk niet van extra controles, en deze groep is te identificeren middels 
een klinisch risicoprofiel. Dit hoofdstuk benadrukt het belang van een op maat gemaakt 
follow-up protocol na behandeling van CRLM.
Hoofdstuk 13 geeft een overzicht van de literatuur omtrent follow-up na curatieve 
behandeling voor stadium I-IV colorectale kanker. Meta-analyses van gegevens uit een reeks 
onderzoeken in de afgelopen twee decennia bevestigen dat frequente patiënten bezoeken 
de algehele overleving verbeteren na curatieve resectie van stadium I-III-CRC, hoewel de 
meeste individuele onderzoeken minimale tot geen algehele overlevingswinst vertonen. Het 
effect van follow-up bij stadium I-III CRC op de algehele overleving kan slechts gedeeltelijk 
worden verklaard door een verbeterde kanker specifieke overleving, omdat blijkt dat 
herhaalde klinische beoordeling bijdraagt aan een algeheel overlevingsvoordeel. Verder 
(modelmatig, digitaal) onderzoek naar follow-up na CRC-behandeling moet zich richten 
op risicostratificatie en waarbij tumor biologie wordt betrokken. Consensusrichtlijnen en 
prospectief onderzoek naar de optimale follow-up protocollen zijn dringend nodig voor 
patiënten met stadium IV CRC die curatief worden behandeld, evenals patiënten die worden 
behandeld volgens orgaan sparende therapieën bij primair CRC.
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